485 search results for "risk stratification"

Screening Practices and Risk Stratification for Diabetic Foot Complications in South Africa



Prevalence, Screening Practices and Risk Stratification for Diabetic Foot Complications in Primary Healthcare Clinics: A Cross-Sectional Study in Gauteng Province, South Africa

Summary: This cross-sectional study in Gauteng, South Africa, involved 597 diabetic patients at five primary healthcare centers. Only 10% received diabetic foot assessments, with no risk stratification performed prior. Assessments revealed 30% very low risk, 17% high risk; 19% had active ulcers, 18% in remission; 33% neuropathy, 22% peripheral arterial disease, 17% history of amputation. Risk factors included multimorbidity (p=0.021), poor glycemic control (p=0.003), loss of sensation (p=0.017), and absent pulses (p=0.037). Barriers: inadequate protocols, limited training, high workloads. Implementing routine screening and stratification at PHC could prevent complications, reducing ulcers by up to 50% and amputations by 50-85%.

Key Highlights:

  • Prevalence: 19% active DFUs; 18% in remission; 33% neuropathy; 22% PAD; 17% amputation history.
  • Screening: 10% annual; 30% very low risk; 17% high risk; no prior stratification.
  • Risk: Multimorbidity (p=0.021); poor glycemic control (p=0.003); loss of sensation (p=0.017); absent pulses (p=0.037).
  • Barriers: Lack of protocols, insufficient training, high workloads (40-50 patients/day), limited resources.
  • Authors: Ntuli S et al.

Read full study

Keywords: diabetic foot, diabetic foot complications, diabetic foot screening, primary healthcare, risk factors, screening practices, South Africa

Digital Health Service for Diabetic Foot Ulcer Risk Stratification



Digital Health Service for Diabetic Foot Ulcer Risk Stratification: Usability Evaluation

Summary: Researchers developed and evaluated a digital health service designed to stratify risk of diabetic foot ulcers (DFU) and support preventive self-care. The platform integrates patient-reported data, education, and risk scoring. Usability testing showed strong user acceptance, ease of use, and potential to strengthen preventive efforts in high-risk diabetes populations, addressing the global need for scalable DFU prevention tools.

Key Highlights:

  • Digital tool combining risk assessment with patient education and monitoring
  • High usability scores from both patients and healthcare providers
  • Supports early identification and timely preventive interventions
  • Addresses lifetime DFU risk (up to 34%) through accessible technology

Read full open-access article

Keywords: DFU risk stratification, digital health DFU, diabetic foot prevention

Screening Practices and Risk Stratification for Diabetic Foot Complications in Saudi Arabia



Prevalence, Screening Practices and Risk Stratification for Diabetic Foot Complications in Primary Healthcare Settings in Saudi Arabia: A Cross-Sectional Study

Summary: This cross-sectional study (n=400 T2D patients in Saudi primary care) found 22.5% DFU prevalence, with only 18% receiving annual screening. High-risk factors included poor glycemic control (OR 3.2), neuropathy (OR 4.1), and peripheral artery disease (OR 5.6). Low awareness (45%) and screening barriers (time/staff) contributed; calls for standardized protocols and training to reduce 15% lifetime DFU risk.

Key Highlights:

  • Prevalence: 22.5% DFUs; 35% neuropathy; 28% PAD.
  • Screening: 18% annual; 45% unaware of risks.
  • Risk: Uncontrolled HbA1c OR 3.2; neuropathy OR 4.1; PAD OR 5.6.
  • Barriers: Time (60%), staff shortage (50%), lack of protocols (40%).
  • Authors: Alharbi AA, Alharbi AA, Alharbi AA et al.

Read full study

Keywords: DFU prevalence, primary care, screening practices, Saudi Arabia, risk stratification, AA Alharbi, AA Alharbi, AA Alharbi

Enhancing Diabetic Foot Prevention: Global Guidelines and Questionnaire Tools



Enhancing Diabetic Foot Prevention: Global Guidelines and Questionnaire Tools

Summary: This systematic review examines international guidelines and validated questionnaire tools for diabetic foot screening (DFS), highlighting their role in preventing diabetic foot ulcers amid rising diabetes prevalence. It synthesizes core screening elements like neuropathy, vascular, and visual assessments, along with risk stratification models and screening frequencies, while identifying variations across guidelines and the potential of tools like Q-DFD and MNSI for accessible, self-managed prevention.

Key Highlights:

  • Core DFS components include monofilament testing for neuropathy, pedal pulse palpation for vascular status, and visual inspection for early ulcer signs.
  • Risk stratification categorizes patients as low-, moderate-, or high-risk, with screening intervals from annual to quarterly based on IWGDF and ADA guidelines.
  • Questionnaire tools such as Q-DFD and DFSQ-UMA enhance self-assessment and accessibility in diverse settings, reducing amputation risks.
  • Challenges involve guideline standardization and implementation in resource-limited areas; broader adoption by general practitioners could lower healthcare costs.

Read full article

Keywords:
diabetic foot screening,
diabetic foot ulcers,
risk stratification,
questionnaire tools,
wound healing prevention

Charcot Neuro-Osteoarthropathy: A New Risk Class is Needed?



Charcot Neuro-Osteoarthropathy: A New Risk Class is Needed?

Summary: In this prospective single-centre observational study, researchers compared patients with chronic (post-remission) Charcot neuro-osteoarthropathy (CNO) to IWGDF high-risk (class 3) patients without CNO. Chronic CNO was associated with markedly higher re-ulceration (70.4% vs 33.1%) and amputation rates (18.5% vs 7.6%) during standard follow-up. When CNO patients received intensified surveillance (≤30-day intervals) in the second year, re-ulceration dropped dramatically to 18.5%. The authors propose that chronic CNO warrants its own dedicated high-risk category in future IWGDF stratification systems.

Key Highlights:

  • Chronic CNO identified as a distinct ultra-high-risk phenotype
  • Significantly higher ulcer recurrence and amputation rates vs standard IWGDF class 3
  • Intensified surveillance (≤30 days) reduced re-ulceration by ~74%
  • Supports adding CNO-specific risk class and more frequent monitoring

Read full article

Keywords: Charcot neuro osteoarthropathy, Charcot risk class, IWGDF risk stratification

Prediction of Diabetes Among Homeless Adults Using Artificial Intelligence

Prediction of Diabetes Among Homeless Adults Using Artificial Intelligence: Suggested Recommendations

Summary: Published March 22, 2026 in Healthcare (MDPI), this case-control study from Cairo University Faculty of Nursing, Beni-Suef University, and Saudi Electronic University applies machine learning-based diabetes prediction to a medically underserved population — homeless adults — using a hybrid stacking ensemble model. Led by Khadraa Mohamed Mousa and Manal Mohamed Elsawy (Community Health Nursing, Cairo University), the study enrolled 150 homeless adults at the Ma’ana Rescue Human Foundation (Giza, Egypt), including 99 confirmed diabetic cases (FBS ≥ 126 mg/dL or prior diagnosis) and 51 non-diabetic controls. Structured interviews collected demographic data, medical history, 15-item lifestyle questionnaire, and 7-item diabetes knowledge assessment; physiological measurements included weight, height, BMI, waist circumference, triceps skinfold thickness (TSF), fasting blood sugar, and blood pressure. From 43 initial variables, recursive feature elimination and correlation analysis reduced the predictor set to 13 variables: BMI, systolic blood pressure, triceps skinfold thickness, waist circumference, lifestyle score, presence of other diseases, diastolic blood pressure, age, regular medication use, educational level, marital status, duration of residence, and diabetes knowledge. SMOTE was applied exclusively to the training set (80/20 split) to address class imbalance without contaminating test evaluation. Six base classifiers were evaluated (logistic regression, SVM, random forest, decision tree, KNN, gradient boosting) before implementation of a hybrid stacking ensemble with XGBoost as the meta-learner using out-of-fold predicted probabilities from all six base models. The stacking ensemble achieved 95.45% accuracy, 100% precision, 93.75% recall, F1-score 0.968, and AUC-ROC 0.979 on the held-out test set — substantially outperforming all individual classifiers (accuracy 56.7–70%, F1 0.686–0.781). Wound care relevance: homeless adults with diabetes face substantially higher rates of lower limb amputations, less reliable wound care, inadequate nutritional status, and significantly higher rates of diabetes-related hospitalisations than housed populations — all of which converge on wound complications. The study explicitly references a 2021 AI-based DFU and amputation risk stratification study by Schäfer et al. as the broader clinical context. The authors recommend that healthcare institutions integrate AI-powered diagnostic support into community nursing workflows for early diabetes detection in vulnerable populations.

Key Highlights:

  • Stacking ensemble performance: hybrid XGBoost meta-learner achieved 95.45% accuracy, 100% precision, AUC 0.979 — substantially outperforming individual classifiers (best individual: 70% accuracy); feature selection improved hybrid model accuracy from 82% to 95% and AUC from 0.87 to 0.98
  • 13 key predictors identified: BMI, SBP, TSF, waist circumference, lifestyle score, comorbidities, DBP, age, medication adherence, educational level, marital status, duration of residence, and diabetes knowledge — a novel combination integrating psychosocial and contextual factors rarely included in conventional diabetes risk models
  • Homeless population vulnerability: diabetes in homeless adults associated with 5× higher ED visit and hospitalisation rates vs. housed counterparts; significantly higher rates of lower limb amputation (vs. 0.01% baseline mortality in same age group in general population); poor medication adherence; unreliable wound care; and low diabetes knowledge (82.8% had incorrect knowledge of diabetes definition)
  • Clinical wound care context: the study references Schäfer et al. (2021, Front Med) on ML-based DFU and amputation risk stratification as its broader framework — positioning early AI-assisted diabetes detection in homeless populations as an upstream prevention strategy for the DFU and amputation pipeline
  • Limitations: single-centre, n=150, purposive sample; case-control design reflects institutional prevalence rather than community prevalence; small test set (n=30) may inflate performance estimates; external validation in larger multi-centre samples is required before clinical deployment
  • Nursing recommendation: community and gerontological health nurses are positioned to implement AI-assisted screening alongside fingertip glucose testing in shelter and community settings — providing instant results and enabling same-encounter lifestyle counselling for high-risk homeless adults

Read full article

Keywords: diabetes prediction machine learninghomeless population diabetes wound riskAI diabetic foot amputation riskcommunity nursing diabetes screeningensemble machine learning healthcarehealth equity diabetes vulnerable population

Khadraa Mohamed Mousa, Farid Ali Mousa, Naglaa Mahmoud Abdelhamid, Mona Sayed Atress, Manal Mohamed Elsawy

Prevalence of Foot At-Risk and its Associated Characteristics among Outpatients with

Diabetes Mellitus in a Peruvian Public Hospital

Marlon Yovera-Aldana 1, Sonia Pérez-Cavero 2, Isabel Pinedo-Torres 3, Carlos Zubiate-López

This article was originally published here

 

ABSTRACT

 

OBJECTIVE: To assess the prevalence of patients at risk of developing diabetic foot complications(i.e.foot at-risk) and its clinical components according to the updated International Working Group on Diabetic Foot (IWGDF) criteria and to describe demographic and diabetes-related characteristics. METHODS: We conducted a cross-sectional study at María Auxiliadora Hospital between 2017 and 2018. The criteria for foot at-risk in the IWGDF 2019 risk stratification system are classified into four risk categories, R0-R3, ranging from no peripheral arterial disease (PAD) and no peripheral neuropathy (PN) to the presence of PAD or PN in combination with previous foot ulcer, amputation, or end- stage renal disease (R3). According to this system, we obtained prevalence ratios (PR) of foot at-risk categories dependent on sex, age, diabetes duration, and Total Symptom Score. A sample size of 402 subjects was included in the study. RESULTS: Subjects included had a mean age of 61 years, and 66% were female. There were no patients with type 1 diabetes, and 59% percent had a diabetes duration of less than ten years. The prevalence of foot at-risk was 54.3% defined by the IWGDF 2019 criteria, which gave prevalence17% higher than that defined with the previous 1999 criteria. PN and PAD frequency was 37.3% and 30.1%, respectively. Foot at-risk prevalence was 40% higher in those with severe Total Symptom Score (PR 1.40, 95% CI 1.09-1.80) and also 39% higher in men than in women (PR 1.39, 95% CI 1.17-1.64). Likewise, diabetes duration of more than ten years had a 25% higher prevalence of foot at-risk (PR 1.25, 95% CI 1.05-1.49), and those older than 60 years had a 20% higher presence of this condition (PR 1.20, 95% CI 1.0011.43). CONCLUSIONS: Our hospital faces a substantial burden of diabetic foot risk in men, patients with long diabetes duration, and those with painful neuropathy. More initiatives are required at primary or hospital level to detect this critical condition. Likewise, reference centers with multidisciplinary teams to apply prevention and therapeutic interventions are urgently needed.

 


If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

 

Development and Validation of a Diagnostic Nomogram for Wagner Grade ≥2 Diabetic Foot Ulcers



Development and Validation of a Diagnostic Nomogram for Wagner Grade ≥2 Diabetic Foot Ulcers in Patients with Diabetic Kidney Disease

Summary: Researchers developed and validated a practical nomogram to predict the risk of moderate-to-severe (Wagner grade ≥2) diabetic foot ulcers in patients with diabetic kidney disease (DKD). The model incorporates readily available admission parameters such as white blood cell count, hemoglobin, albumin, HbA1c, and clinical factors (hypertension, CAD, BMI). It demonstrates good discriminatory ability and calibration, providing clinicians with a bedside tool for early identification of high-risk patients. Early risk stratification can guide intensified preventive foot care, offloading, vascular assessment, and multidisciplinary intervention to reduce progression to severe ulcers, infection, and amputation.

Key Highlights:

  • Nomogram based on routine labs and comorbidities for Wagner ≥2 DFU prediction in DKD patients
  • Supports early risk stratification and targeted prevention
  • Addresses high amputation risk in combined diabetes + kidney disease population

Read full open-access article

Keywords: diabetic foot ulcer nomogram, Wagner grade DFU, diabetic kidney disease

Implementation Strategies for the Prevention and Management of Diabetes-Related Foot Disease


Implementation Strategies for the Prevention and Management of Diabetes-Related Foot Disease: A Consensus Document

Summary: This international consensus document translates evidence-based guidelines into actionable implementation strategies for diabetes-related foot disease. It covers systematic screening, risk stratification, patient education, therapeutic offloading, timely vascular intervention, infection management, and integrated multidisciplinary pathways. The document aims to bridge the gap between guidelines and real-world clinical practice to reduce ulcers, amputations, and mortality.

Key Highlights:

  • Clear pathways for annual screening and risk stratification
  • Practical offloading and footwear recommendations
  • Emphasis on rapid access to multidisciplinary teams
  • Strategies to overcome implementation barriers in different settings

Read full consensus document

Keywords: diabetes foot disease implementation, DFD prevention, international DFU guidelines

Could a Simple Blood Test Signal Diabetic Foot Ulcer Risk?



Could a Simple Blood Test Signal Diabetic Foot Ulcer Risk?

Summary: February 2026 article discusses promising research into blood-based biomarkers that could help identify patients at high risk of developing diabetic foot ulcers (DFUs) before clinical signs appear. Explores how specific inflammatory, metabolic, or vascular markers in routine blood tests might predict ulcer formation or poor healing. Highlights the potential for simple, non-invasive screening to complement current tools (monofilament, ABI, temperature monitoring). Early detection could enable timely preventive interventions (offloading, education, vascular care) and reduce amputation rates. Calls for further validation and integration into routine diabetes care protocols.

Key Highlights:

  • Blood biomarkers as potential early DFU risk indicators
  • Complement to traditional clinical assessments
  • Opportunity for proactive prevention and reduced amputations
  • Relevance: Advances risk stratification in diabetic foot care

Read full article (subscription may be required)

Keywords: DFU risk biomarkers, blood test DFU, diabetic foot ulcer, prevention screening

Development and Validation of a Wireless, Low-Cost Device for Dual Measurement of in-Shoe Plantar Pressure and ….



Development and Validation of a Wireless, Low-Cost Device for Dual Measurement of in-Shoe Plantar Pressure and Temperature in High-Risk Diabetic Feet

Summary: This study develops and validates a novel wireless, low-cost in-shoe sensing device that simultaneously measures plantar pressure and skin temperature—critical biomarkers for early detection of diabetic foot ulcer (DFU) risk in high-risk diabetic patients. Pressure performance was tested against the gold-standard F-Scan system across five trials, showing consistently strong correlations with peak pressure readings (r values: 0.801, 0.978, 0.813, 0.887, 0.944). Superimposed peak-pressure plots displayed highly similar waveform patterns, supported by low error metrics (e.g., Root Mean Squared Logarithmic Error). Temperature accuracy was compared to thermal camera measurements; the camera detected an average change of 3.7°C, while the in-shoe sensor recorded 0.67°C, with higher variability in the in-shoe device. Despite this difference, pressure and temperature measurements from the novel device were strongly correlated (r=0.87). The device addresses key limitations of current separate systems (cost, time, lack of real-time dual data) by providing site-specific, gait-based monitoring. Highlights potential for routine clinical use in high-risk foot surveillance to prevent DFUs through early identification of hotspots and temperature rises (pre-ulcer warning up to 1 week prior). Calls for larger-scale validation in real-world diabetic populations.

Key Highlights:

  • Pressure validation: Strong correlation (r=0.801–0.978) and waveform similarity vs. F-Scan
  • Temperature: Lower sensitivity than thermal camera but strong internal correlation with pressure (r=0.87)
  • Advantages: Wireless, low-cost, simultaneous dual measurement during gait
  • Clinical value: Enables proactive DFU risk stratification in high-risk diabetic feet
  • Next steps: Further real-world testing for routine monitoring and prevention

Read full article (open access)

Keywords: in-shoe pressure temperature, DFU risk assessment, plantar pressure, diabetic foot ulcer, prevention monitoring

From Molecules to Populations — Bridging Mechanistic and Clinical Insights in Diabetic Wound Healing

🔬 Spotlight: From Molecules to Populations — Bridging Mechanistic and Clinical Insights in Diabetic Wound Healing

Summary: Two recent publications highlight the full spectrum of diabetic wound research — from benchside mechanistic biology to population-level risk analysis. Together, they show how molecular targets and systemic biomarkers may eventually intersect to shape precision strategies for preventing and treating diabetic foot complications.

1. Molecular Focus — METTL3/GDF11 Pathway in Socket Healing

A study published in Diabetes, Metabolic Syndrome and Obesity explored how METTL3-mediated m6A modification regulates GDF11 expression, promoting extraction socket healing in diabetic rat models. Researchers demonstrated that overexpression of METTL3 improved trabecular bone formation, enhanced soft tissue healing, and restored angiogenesis. Mechanistically, the pathway hinges on stabilizing GDF11 transcripts via m6A methylation. When GDF11 was knocked down, much of METTL3’s benefit was reversed, underscoring this axis as a potential therapeutic target.

Notably, the use of micro-CT, histology, and gene expression assays confirmed both structural and molecular benefits. The translational implication is clear: modulating RNA methylation machinery could one day enhance oral and cutaneous wound repair in patients with diabetes, moving beyond symptomatic care toward biomaterial or gene-based interventions.

2. Population Focus — Inflammation and Nutrition Biomarkers in DFU Risk

In contrast, a large combined cross-sectional and retrospective study in Frontiers in Endocrinology examined over 31,000 NHANES participants plus clinical cohorts. The analysis revealed that composite indices linking inflammation and nutrition — such as the neutrophil-albumin ratio (NAR), monocyte-albumin ratio (MAR), red cell distribution width-albumin ratio (RAR), as well as the hemoglobin-albumin-lymphocyte-platelet (HALP) score and Prognostic Nutritional Index (PNI) — strongly associate with diabetic foot ulcer (DFU) prevalence.

High inflammatory ratios predicted greater odds of DFU, while better nutritional scores (HALP, PNI) were protective. These findings confirm what clinicians often see anecdotally: systemic inflammatory load and malnutrition compromise tissue repair, making individuals more vulnerable to chronic ulcers.

3. Connecting the Dots — Why Both Levels Matter

When viewed together, these studies illustrate the multi-layered nature of diabetic wound pathology. At the molecular level, disrupted post-transcriptional regulation (METTL3/GDF11) impairs local tissue repair. At the population level, imbalances in systemic inflammation and nutrition further compound risk. This dual perspective suggests that the future of diabetic wound care will not rest on one approach alone. Instead, clinicians may soon combine:

  • Molecular therapies — agents or biomaterials designed to enhance beneficial RNA modifications, boost angiogenesis, or support cellular repair pathways.
  • Risk stratification tools — composite blood indices (e.g., NAR, HALP, PNI) integrated into screening protocols to identify high-risk patients earlier.
  • Personalized care pathways — tailoring wound interventions not just by ulcer stage and location, but also by underlying molecular signatures and systemic biomarker profiles.

This convergence could redefine how diabetic wounds are prevented and treated: precision medicine approaches at the molecular level, layered onto predictive analytics at the population level.

Clinical Takeaway

For wound care teams, the practical message is twofold: support robust systemic health (nutrition, inflammation control) while staying attuned to emerging molecular targets like METTL3/GDF11 that may soon influence therapeutic options. By bridging scales — from gene regulation to bedside biomarkers — the field is moving toward a more holistic, integrated model of diabetic wound care.

Further Reading:

Keywords:
diabetic foot ulcers,
METTL3,
GDF11,
inflammation biomarkers,
nutritional indices,
precision medicine

Medial Arterial Calcification & Diabetic Foot Ulcer Management

Medial Arterial Calcification & Diabetic Foot Ulcer Management

Summary: Recent literature recognizes medial arterial calcification (MAC) in diabetic foot ulcer (DFU) patients, especially those with diabetic kidney disease (DKD), as more than a background finding—it’s now seen as a strong predictor of major amputation risk. Standard vascular assessment tools like the ankle-brachial index (ABI) are often unreliable in the presence of MAC, which makes imaging/radiographic scoring and clinical classification essential adjuncts.

Key Highlights:

  • Risk factor quantification: In DKD stages 3b-5, severe MAC (versus no MAC) confers ~4.5× greater odds of major amputation after adjusting for ulcer location and grade.
  • Ulcer location & grade matter: Ulcers in the mid- or hindfoot and higher Texas grades (2-3) also independently predict worse outcomes.
  • Limitations of ABI: Calcified arteries often render ABI readings unreliable; MAC should be considered as an alternative or adjunct measure.
  • Possible protective factor: Use of antiplatelet agents showed a trend toward lower major amputation risk, though results were borderline statistically.
  • Ease of detection: MAC scoring via foot radiographs is feasible and may be adopted in clinical practice to improve risk stratification.

Read the full letter/editorial on HMP Global Learning Network

Keywords:
medial arterial calcification,
diabetic foot ulcer,
diabetic kidney disease (DKD),
amputation risk,
ulcer location,
antiplatelet therapy

Toe Pressure Assessment in Lower Limb Wound Care



Toe Pressure Assessment in Lower Limb Wound Care

Summary: 2025 document from Wound Canada provides guidelines for toe pressure assessment in lower limb wound care. Technique: Photoplethysmography (PPG) or strain-gauge; measures systolic pressure in great toe. Interpretation: Normal >60 mmHg; 30–60 mmHg moderate ischemia; <30 mmHg critical (high amputation risk). Role: Complements ABI (less affected by calcification), detects distal disease in diabetes/PAD, stratifies DFU/CLI risk, guides referral (vascular specialist if low). Benefits: Non-invasive, bedside, reliable in calcified vessels. Recommendations: Routine in high-risk patients, serial monitoring, integration into multidisciplinary pathways. Supports timely intervention to preserve limbs.

Read document

Keywords: toe pressure, lower limb wounds, CLI risk, vascular assessment

C-Reactive Protein-to-Albumin Ratio Improves Prediction of 6-Month Major Adverse Limb Events in Patients with Diabetic Foot Ulcers



C-Reactive Protein-to-Albumin Ratio Improves Prediction of 6-Month Major Adverse Limb Events in Patients with Diabetic Foot Ulcers

Summary: This retrospective study evaluated the prognostic value of the C-reactive protein-to-albumin ratio (CAR) in patients with diabetic foot ulcers (DFU). CAR, a readily available inflammatory biomarker, demonstrated strong independent predictive power for 6-month major adverse limb events (MALE), including major amputation and revascularization. Adding CAR to traditional risk models significantly improved discrimination and reclassification. The authors conclude that CAR is a simple, inexpensive tool that can help clinicians better stratify risk and guide intensified interventions in high-risk DFU patients.

Key Highlights:

  • CAR independently predicts 6-month MALE in DFU patients
  • Improves model performance when added to conventional risk factors
  • Low-cost, routinely available biomarker from standard labs
  • Useful for early risk stratification and personalized care

Read full open-access article

Keywords: CRP albumin ratio, DFU prognosis, major adverse limb events

Trends and Healthcare Innovations in Plantar Pressure Management for Diabetic Foot Ulcers

Global Research Trends and Healthcare Innovations in Plantar Pressure Management for Diabetic Foot Ulcers: A 25-Year Bibliometric and Visual Analysis

Summary: Published March 19, 2026 in Healthcare (MDPI), this comprehensive bibliometric and visual analysis from Capital Medical University Affiliated Beijing Shijitan Hospital (China), led by Dehua Wei, Boya Li, Jiangning Wang, and Lei Gao (Orthopedic Department), maps the global landscape of plantar pressure research in the context of diabetic foot ulcers across 2000–2024. Using Web of Science Core Collection data (2,110 articles after screening from 2,518 initial records), and analysis tools including VOSviewer, CiteSpace, and Scimago Graphica, the study provides the first dedicated bibliometric synthesis of this specific subdomain. Key findings: the United States led in both publication volume (678 articles) and H-index, followed by the United Kingdom and China, with the Netherlands achieving the highest average citations per article. David G. Armstrong ranked as the most prolific and highest H-index author (76 publications), followed by Sicco A. Bus (52) and Lawrence A. Lavery (40). The University of Amsterdam led institutional output (68 publications). The Journal of Wound Care had the highest publication count; Diabetes Care ranked first in both citation frequency and impact factor (IF 14.8). Keyword co-occurrence analysis identified 12 major clusters spanning: diabetic foot pathophysiology and amputation risk, microcirculation and vascular management, evidence-based management and guidelines, ischemia and regenerative repair, biomechanical risk factors, foot biomechanics and modeling, prevention and offloading interventions, NPWT and therapeutic technology, wound nursing and efficacy evaluation, chronic wounds and biofilm, ulcer classification and regenerative medicine, and population-level epidemiology. A keyword time zone map reveals three distinct research phases: a foundational phase (2000–2005) establishing neuropathy and plantar pressure as core DFU risk factors; a clinical technology expansion phase (2006–2015) advancing total contact casting, NPWT, and RCT methodology; and an innovation and refinement phase (2016–2024) integrating smart wearables (intelligent insoles, temperature monitoring), customised footwear (peak plantar pressure below 200 kPa target), and emerging regenerative approaches (extracellular matrix, hyaluronic acid). A key bibliometric finding of clinical significance: despite high publication frequency, “plantar pressure” exhibits low betweenness centrality (0.06), indicating it functions as a local biomechanical focus rather than a cross-domain network hub — a translational gap suggesting plantar pressure data is not being systematically integrated into multidimensional clinical management frameworks alongside vascular evaluation, neuropathy screening, and glycaemic control. The most co-cited reference is the Armstrong, Boulton, and Bus 2017 NEJM review (co-citation count n=150).

Key Highlights:

  • 25-year dataset: 2,110 articles (WoS, 2000–2024); sustained growth from ~50 publications/year (2000) toward 150+/year (2024); US, UK, and Netherlands as dominant contributors; China and India showing rapid recent acceleration
  • Key opinion leaders: David G. Armstrong (76 publications, highest H-index), Sicco A. Bus (52), Lawrence A. Lavery (40), Andrew J.M. Boulton; Armstrong 2017 NEJM review is the most co-cited document (n=150) in the entire corpus
  • Translational gap identified: plantar pressure has high publication frequency but low betweenness centrality (0.06) in the co-occurrence network — meaning it functions as a local biomechanics topic rather than bridging to broader clinical outcome, vascular, or care-coordination frameworks; the authors call for integration of pressure data with comprehensive risk stratification tools
  • Offloading evidence: total contact casting remains gold standard for healing neuropathic plantar DFUs; custom diabetic footwear reduces 18-month recurrence by ~50%; Achilles tendon lengthening reduces forefoot ulcer recurrence by 75% in selected cases; peak in-shoe pressure target of <200 kPa for recurrence prevention
  • Smart technology trends (2016–2024 burst terms): custom-made footwear (burst 2019–2020), wound care (burst 2021–2024), epidemiology (burst 2022–2024); emerging: continuous plantar temperature monitoring, intelligent insole pressure feedback systems, remote monitoring platforms — all gaining publication volume but still limited by patient acceptance, alert fatigue, and adherence barriers
  • Global health equity gap: US and European institutions lead publication output and establish most guidelines; China and India are rapidly expanding contributions; but access to smart insoles, custom footwear, and multidisciplinary foot teams remains inequitable globally — the authors call for locally adaptable, cost-effective offloading solutions

Read full article

Keywords: plantar pressure diabetic footdiabetic foot offloadingDFU bibliometric analysissmart insole wound caretotal contact casting DFUfoot biomechanics ulcer prevention

Dehua Wei, Boya Li, Jiangning Wang, Lei Gao

C-Reactive Protein-to-Albumin Ratio Improves Prediction of 6-Month Major Adverse Limb Events in Patients with Diabetic Foot Ulcers



C-Reactive Protein-to-Albumin Ratio Improves Prediction of 6-Month Major Adverse Limb Events in Patients with Diabetic Foot Ulcers

Summary: This retrospective study evaluated the prognostic utility of the C-reactive protein-to-albumin ratio (CAR) in patients with diabetic foot ulcers (DFU). CAR, a simple and inexpensive inflammatory biomarker calculated from routine labs, emerged as a strong independent predictor of 6-month major adverse limb events (MALE), including major amputation and revascularization. Incorporating CAR into existing risk models significantly improved discrimination and net reclassification. The authors propose CAR as a practical tool for early identification of high-risk DFU patients who may benefit from more aggressive multidisciplinary intervention.

Key Highlights:

  • CAR independently predicts 6-month MALE in DFU patients
  • Improves predictive performance of traditional risk models
  • Low-cost biomarker readily available from standard bloodwork
  • Potential for better risk stratification and timely limb-preservation strategies

Read full open-access article

Keywords: CRP albumin ratio DFU, major adverse limb events, DFU prognosis

From a Pragmatic Clinical Staging of Distal Symmetrical Polyneuropathy to a Continuum of Diabetes Severity



From a Pragmatic Clinical Staging of Distal Symmetrical Polyneuropathy to a Continuum of Diabetes Severity: New Ideas, New Challenges

Summary: In this editorial, Anastasios Tentolouris and Péter Kempler discuss two emerging frameworks: a pragmatic five-stage clinical staging system for distal symmetrical polyneuropathy (DSPN) and the broader Diabetes Severity Classification (DSC). These tools move beyond binary diabetes classification toward a continuum model that better reflects complication risk, enabling earlier identification of high-risk patients for intensified foot care and prevention strategies.

Key Highlights:

  • New pragmatic DSPN staging system from early vulnerability to advanced ulceration risk
  • Diabetes Severity Classification (DSC) as a multi-axial continuum model
  • Strong potential to improve risk stratification and foot ulcer prevention
  • Calls for validation and integration into routine clinical practice

Read full editorial

Keywords: DSPN staging, diabetes severity classification, diabetic neuropathy staging

Management of Early-Onset Type 2 Diabetes in Adults

Management of Early-Onset Type 2 Diabetes in Adults

Summary: A 2025 review in the Diabetes & Metabolism Journal explores strategies for managing early-onset type 2 diabetes (EOT2D) in adults. The article emphasizes the importance of early intervention, weight reduction, and preserving β-cell function to delay complications and improve long-term outcomes.

Key Highlights:

  • Weight reduction: Lifestyle modification, structured dietary plans, and when appropriate, pharmacologic or surgical interventions are recommended to achieve sustained weight loss.
  • Preserving β-cell function: Early initiation of therapies that reduce β-cell stress and maintain tight glycemic control helps slow disease progression.
  • Therapeutic escalation: Clinicians are encouraged to move beyond metformin monotherapy sooner when patients are not meeting glycemic targets, incorporating newer agents with cardiovascular and renal benefits.
  • Risk stratification: Assess patients based on age at onset, baseline insulin resistance, comorbidities, and family history to guide individualized management.
  • Monitoring complications: Early screening for retinopathy, nephropathy, and cardiovascular disease is advised from diagnosis, alongside aggressive risk-factor management.

Read the full review in Diabetes & Metabolism Journal

Keywords:
early-onset type 2 diabetes,
weight reduction,
β-cell preservation,
therapeutic escalation,
cardiovascular risk,
diabetes complications

Diabetic Neuropathy vs Peripheral Artery Disease

Diabetic Neuropathy vs Peripheral Artery Disease

Summary: Both diabetic neuropathy and peripheral artery disease (PAD) are common in patients with diabetes and contribute to foot complications, but they differ in causes, symptoms, diagnosis, and management. Understanding the distinctions helps in risk stratification, preventing non-healing ulcers, and tailoring treatment.

Key Highlights:

  • Causes & physiology:
    • Diabetic neuropathy results from nerve damage due to prolonged hyperglycemia, impacting sensory, motor, and autonomic nerves.
    • PAD is caused by atherosclerosis and arterial narrowing/blockage, reducing blood supply to the limbs.
  • Symptoms:
    • Neuropathy: numbness, tingling, burning sensations, loss of protective feeling, sometimes pain.
    • PAD: intermittent claudication (leg pain with walking), cold feet or limbs, slow wound healing, possible tissue loss.
  • Overlap and impact on wounds: Neuropathy can mask symptoms of PAD (like pain), delaying diagnosis. Both conditions increase risk of ulceration, infection, and in severe cases amputation.
  • Diagnosis tools:
    • Neuropathy: vibration perception threshold (e.g., biothesiometer), monofilament testing, nerve conduction studies.
    • PAD: ankle-brachial index (ABI), toe-brachial index (TBI), Doppler ultrasound, imaging when needed.
  • Management approaches:
    • For neuropathy: tight glycemic control, patient education, protective foot care, offloading, treating pain when present.
    • For PAD: lifestyle modification (smoking cessation, exercise), medical therapies (lipids, antiplatelets), revascularization when necessary, optimizing perfusion for wound healing.
  • Screening & prevention: Regular screening in diabetic patients for both neuropathy and PAD is essential. Early detection allows earlier intervention, which can improve healing, reduce costs, and prevent complications.

See full review: “Peripheral Arterial Disease and the Diabetic Foot Syndrome: Neuropathy Makes the Difference!” (Journal of Clinical Medicine)

Keywords:
diabetic neuropathy,
peripheral arterial disease,
ABI screening,
ulcer prevention,
glycemic control,
offloading

Karnataka Launches PRAIAS Initiative to Combat Diabetic Foot Complications



Karnataka Launches PRAIAS Initiative to Combat Diabetic Foot Complications

Summary: On March 30, 2026, Karnataka launched the PRAIAS initiative (Podiatry Reach Across India for Awareness and Screening) at the Gulbarga Institute of Medical Sciences in Kalaburagi. The program aims to tackle India’s massive diabetic foot burden—where a new diabetic foot ulcer develops every 12 seconds and a limb is lost globally every 20 seconds—through prevention, early detection, and public awareness. Key component: a Digital Podiatry Screening Van equipped with advanced tools to assess foot pressure, neuropathy, and circulation. The initiative follows a structured outreach model across cities, integrating technology and data analysis for risk stratification and timely intervention. Goal: achieve zero preventable amputations through education, screening, and clinical support in collaboration with diabetic foot specialists and healthcare organizations.

Key Highlights:

  • Launch of mobile screening van with advanced diagnostic tools
  • Focus on early detection of neuropathy, pressure issues, and vascular risk
  • Structured awareness and outreach to reduce amputations
  • Relevance: Scalable public health model for high-burden diabetic foot care

Read full article

Keywords: PRAIAS initiative, diabetic foot prevention, Karnataka diabetic foot, mobile screening

Supporting Closure: Therapeutic Interventions for Diabetic Foot Ulcers

Diabetic foot ulcers (DFUs) are arguably among the most difficult types of wounds to manage; the etiology of these wounds poses some of the greatest clinical challenges for healing, considering the multifaceted nature of diabetes mellitus (DM). Multiple patient-related factors must be addressed and controlled through faithful adherence to the prescribed plan of care, which is developed by both the patient and clinicians to ensure success … Treatment of DFUs requires multidisciplinary provider involvement (podiatry, vascular, infectious disease, internal medicine or family practice, endocrinology, cardiology, nephrology, and physical therapy). The standard of care for patients with DFUs includes medical management of chronic disease, including nutrition and glucose control, routine wound assessments with ulcer grading and risk stratification, topical wound management with attention to serial debridements and moist wound healing … read more

Characteristics of Diabetic Foot Ulcer Patients

Characteristics of Diabetic Foot Ulcer Patients

Summary: This clinical study is designed to describe the demographic, clinical, and laboratory features of patients living with diabetic foot ulcers (DFUs). By analyzing data from approximately 200 participants, the trial seeks to better understand the patient population and inform future strategies for prognosis and treatment.

Key Details:

  • Study type: Cross-sectional, descriptive-analytical study.
  • Participants: About 200 adult patients diagnosed with diabetic foot ulcers.
  • Data collection: Demographics, ulcer characteristics (size, duration, grade), associated comorbidities, and laboratory parameters.
  • Status: Currently recruiting.
  • Objective: To generate a clearer clinical and laboratory profile of DFU patients, supporting improved risk stratification and therapeutic planning.

View the full study record on ClinicalTrials.gov

Keywords:
diabetic foot ulcer,
patient characteristics,
comorbidities,
laboratory data,
clinical study

Lymphocyte-to-monocyte ratio is associated with all-cause and cardiovascular mortality among ….

Lymphocyte-to-monocyte ratio is associated with all-cause and cardiovascular mortality among individuals with diabetes mellitus in the National Health and Nutrition Examination Survey 2003-2018 cohort

Summary: Using data from NHANES (2003–2018), this study explored the prognostic value of the lymphocyte-to-monocyte ratio (LMR) in people with diabetes. Among 2,327 participants followed for a median of 76 months, a higher LMR (>2.62) was linked to significantly lower risks of all-cause and cardiovascular mortality after adjusting for demographics, comorbidities, and laboratory measures.

Key Highlights:

  • Population & design: 2,327 diabetic participants, stratified into low (≤2.62) vs high (>2.62) LMR groups.
  • Mortality outcomes: High LMR group showed reduced all-cause mortality (HR ~0.64) and cardiovascular mortality (HR ~0.55).
  • Predictive accuracy: AUC values ranged ~0.80–0.86 across 1–10 year follow-up, demonstrating strong prognostic performance.
  • Nonlinear relationship: Benefits plateaued at higher LMR levels, suggesting diminishing returns.
  • Clinical value: LMR is a simple, inexpensive biomarker that could enhance cardiovascular and overall risk stratification in diabetic patients.
  • Limitations: Observational design, U.S.-based cohort, and reliance on single blood measurements limit causality claims.

Read the full article in BMC Cardiovascular Disorders

Keywords:
Anmin Ren,
Shanshan Cao,
Donghuo Gong,
Xinkai Qu,
lymphocyte-to-monocyte ratio,
all-cause mortality,
cardiovascular mortality,
diabetes mellitus,
NHANES

The US Wound Registry’s Guide to Bias-Free Data in Wound Care



Unlocking Real-World Insights: The US Wound Registry’s Guide to Bias-Free Data in Wound Care

Summary: This white paper from the US Wound Registry (USWR), a non-profit patient registry since 2005 and CMS-recognized Qualified Clinical Data Registry since 2014, introduces the ABCs (Analysis of Bias Criteria) Checklist for minimizing bias in wound care registries and EHRs. It addresses the challenges of chronic wounds affecting 8.2 million Medicare patients at a cost of up to $96.8 billion annually, emphasizing real-world data from complex patients excluded from trials. The checklist, adapted from STROBE and wound-specific guidelines, standardizes reporting on study design, data collection, participant selection, variables, statistical methods, results, and discussion to improve outcome accuracy, support quality care, and inform policy. By ensuring transparent, ethical data handling, it aims to “Find What Works for Chronic Wounds” through reliable EHR-derived insights.

Key Highlights:

  • Prevalence and Costs: Chronic wounds impact 15% of Medicare patients (8.2 million), costing $96.8 billion yearly, with surgical dehiscence and unnamed wounds from comorbidities being most common, as wounds are symptoms rather than diseases.
  • Registry Role: USWR collects real-world EHR data since 2005 to evaluate treatments for patients with 6+ comorbidities and 10 medications, excluded from RCTs, enabling evidence-based improvements in wound care outcomes.
  • Bias Minimization in Methods: Checklist requires detailing settings, EHR types (e.g., certification levels), participant inclusion (e.g., % of patients/wounds captured), wound types via ICD codes, and data sources to limit selection and systematic errors.
  • Variables and Outcomes: Defines outcomes like healing rates (e.g., 1-year timeframe), confounders (e.g., ischemia, amputations), and standard-of-care factors (e.g., offloading frequency) to ensure fair comparisons and control for care variations.
  • Data Reporting and Ethics: Mandates structured data entry, IRB oversight, deidentification protocols, and methods to prevent recall bias, ensuring contemporaneous clinician-assessed outcomes over post-hoc imputation.
  • Statistical and Results Standards: Includes risk stratification models, cohort matching, sensitivity analyses, flow diagrams, and adjusted estimates (e.g., 95% CI) with confounder details for unbiased healing and patient outcome reporting.
  • Implications for Care: Promotes generalizable, reliable findings to enhance clinical decision-making, benchmarking, and policy, with limitations discussed to maintain ethical standards in real-world wound research.

Read full article

Keywords: wound registry, EHR data, bias criteria, real-world evidence, chronic wound outcomes

Endocrine and Metabolic Modulation of Vascular Dysfunction in the Diabetic Foot



Endocrine and Metabolic Modulation of Vascular Dysfunction in the Diabetic Foot: A Narrative Review

Summary: January 25, 2026 narrative review synthesizes evidence on the endocrine-vascular axis in diabetic foot ulcers (DFUs). Beyond traditional risks (hyperglycemia, dyslipidemia), endocrine alterations (impaired insulin signaling, glucagon excess, adipokine imbalance, stress hormones, thyroid dysfunction) interact with mitochondrial issues and inflammation to impair endothelial function, reduce nitric oxide, promote oxidative stress/pro-ischemic environment, and hinder angiogenesis, ECM remodeling, immune response, and repair. Draws from PubMed/Embase/Scopus studies; highlights potential biomarkers for risk stratification and emerging therapies targeting hormonal/metabolic optimization. Identifies gaps and priorities for translational research to improve DFU outcomes and limb preservation.

Key Highlights:

  • Mechanisms: Endocrine dysregulation exacerbates microvascular compromise in diabetes.
  • Implications: Limits effective wound repair; pro-inflammatory/ischemic tissue milieu.
  • Perspectives: Biomarkers, endocrine modulation for prevention/healing.
  • Relevance: Deepens understanding of DFU pathophysiology; supports integrated strategies beyond local wound care.

Read full review

Keywords: endocrine vascular axis, diabetic foot ulcer, vascular dysfunction, DFU prevention

Simplified and Comprehensive Diabetic Foot Ulcer Guidelines



Simplified and Comprehensive Diabetic Foot Ulcer Guidelines

Summary: March 2026 article presents simplified yet comprehensive guidelines for diabetic foot ulcer (DFU) management. Key areas: Risk stratification (IWGDF/IPAD screening), offloading (total contact casts, removable devices), debridement (sharp/autolytic), infection management (topical/systemic, biofilm disruption), vascular evaluation (ABI, toe pressures, revascularization), wound bed preparation (moisture balance, advanced dressings), patient education/adherence. Highlights multidisciplinary teams, timely referral, evidence-based advanced therapies (synthetics, biologics, NPWT). Simplified for primary care use; comprehensive for specialists. Emphasizes prevention, early intervention, and amputation reduction through standardized pathways and patient-centered care.

Read abstract (subscription may be required)

Keywords: DFU guidelines, diabetic foot ulcer, offloading, multidisciplinary DFU

Liraglutide Lowers Risk for Amputation in Patients with Type 2 Diabetes and CV Risk

Liraglutide lowers risk for amputation: investigators find patients treated with GLP-1 drug had significantly lower number of amputations compared to placebo group.

 

The word may still be out on whether certain oral diabetes medications puts patients at risk for lower limb complications, but a new study has shown that liraglutide is not one of them. A post hoc review analysis of the LEADER trial published in Diabetes Care examined the effects of Liraglutide on rates of foot ulceration and amputation in patients at high risk for cardiovascular (CV) events.

 

Liraglutide, a GLP-1 agonist, is an injectable glucose-lowering medication used in patients with type 2 diabetes. GLP-1 agonists act by mimicking the effects of the hormone GLP-1, which increases insulin secretion and lowers glucagon release. This, in effect, causes increased satiety and slowed gastric emptying, with one of the main benefits of GLP-1 agonists being weight loss in patients with diabetes … read more

Conducting Your HIPAA-Required Security Risk Assessment

A company based in the state of Pennsylvania that develops wireless technology that’s used to assist physicians in the care of their cardiology patients was recently fined in excess of $2 million for a HIPAA breach that occurred when the protected health information (PHI) belonging to nearly 1,400 individuals was compromised after a company employee’s laptop was stolen.  The Office for Civil Rights (OCR), the body within the U.S. Department of Health & Human Services (HHS) tasked with enforcing HIPAA’s privacy and security rules, found, specifically, that “[the company] had insufficient risk analysis and risk management processes in place at the time the theft occurred; failed to conduct an accurate and thorough risk analysis to assess the potential risks and vulnerabilities to the confidentiality, integrity, and availability of [electronic] PHI (ePHI); and failed to plan for and implement security measures sufficient to reduce those risks and vulnerabilities. (Code of Federal Regulations [CFR] 45 164.308(a)(1)).”  This article will discuss the processes of HIPAA risk analysis and risk management to educate providers in the outpatient wound clinic setting on how to better protect their patients’ PHI and ePHI. The authors will also describe the general process of the security risk assessment (SRA) and offer direction and resources for providers to utilize … read more

 

Amputation-free survival in 17,353 people at high risk for foot ulceration

     in diabetes: a national observational study

 

Using data from the Scottish Care Information-Diabetes register (N=247,278), researchers analyzed 17,353 individuals with diabetes and at high risk for foot ulceration (“high-risk foot”) from January 2008 to December 2011 to determine amputation-free survival and to compare different subcategories of high-risk foot. According to findings, for those with diabetes and at high risk for foot ulceration, the risk of death was up to nine times the risk of amputation. In addition, those with diabetes who had healed ulcers displayed higher death rates than those with active ulcers. However, the highest risk of amputation was noted for people with active ulcers.

 

Read the full article on Diabetologia – Clinical and Experimental Diabetes and Metabolism

Podimetrics Secures $45 Million Series C To Help At-Risk Providers and Health Plans Prevent

Diabetic Amputations in High-Risk Patients

Every 4 minutes in the U.S., a patient loses a limb due to diabetes complications
Black Americans face diabetes-related amputations 3x as often as white Americans
Podimetrics strives to reduce disparities in diabetes care and unnecessary limb loss
SOMERVILLE, Mass., March 24, 2022 — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced a $45 million Series C round led by D1 Capital Partners, along with two new investors, the Medtech Convergence Fund and an undisclosed strategic investor. Existing investors, Polaris Partners and Scientific Health Development, also participated in the financing. Prior to their Series C, Podimetrics had raised $28.3 million in funding to fuel development and distribution of their SmartMat.

 

With this latest round of funding, Podimetrics plans to focus on hiring to build out their product development and research teams, while also expanding the breadth of services delivered by their nurse support team. This new funding will help even more at-risk providers and health plans drive broader adoption of Podimetrics’ SmartMat so they can improve care outcomes for at-risk patients dealing with diabetic foot ulcers (DFUs) that often lead to amputations.

 

Podimetrics, founded in 2011, developed the SmartMat — the only easy-to-use, at-home mat that a patient steps on for 20 seconds per day. The mat detects temperature changes in the foot, which are associated with early signs of inflammation, often a precursor to DFUs. The FDA-cleared and HIPAA-compliant SmartMat is remotely monitored by Podimetrics’ in-house nurse support team. If the data from the mat are indicative of potential health issues, Podimetrics’ nursing team connects with the patient and the patients’ provider in as close to real time as possible. The SmartMat, which also has the Seal of Approval from the American Podiatric Medical Association, has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans, such as the Veterans Health Administration.

 

“The patients we serve at Podimetrics are extremely complex and have been largely ignored by our healthcare system,” said Jon Bloom, MD, CEO and Co-founder of Podimetrics. “With our SmartMat and this latest funding, we have the chance to put an end to ‘Civil War’–era amputations with early, home-based detection. We also have the opportunity to improve the overall health and well-being for patients dealing with diabetes because of the close relationship we’ve built through our trusted technology and clinical services.”

 

In a previous multi-center trial, diabetic foot complications were shown to be detected up to five weeks before they presented clinically. Even after one full year, about 70% of patients continued to use the SmartMat regularly. Early detection and related preventive care actions often result in significant cost-savings, too, anywhere from $8,000–$13,000 in savings per member per year (savings estimates based on customer research and analysis). In addition, considering Black Americans and Hispanics are two to three times more likely to require a diabetic amputation than others, Podimetrics’ SmartMat holds the power to help support health equity advancements over time.

 

Recent peer-reviewed research has also suggested the following benefits among patients using the SmartMat at home: 71% elimination of amputations; 52% reduction in all-cause hospitalizations; 40% reduction in emergency department visits; and a 26% reduction in outpatient visits.

 

Building on these notable data-driven findings, most recently Podimetrics published peer-reviewed research in Diabetes Research and Clinical Practice, the journal of the International Diabetes Federation. This research found that during episodes-of-care for DFUs, patients are 50% more likely to die and nearly three times more likely to be hospitalized. What this research shows is that patients with a DFU tend to have multiple other chronic health conditions, putting them at higher risk for hospitalization and even death. In addition, these medically complex patients are often among the costliest patients within a healthcare system. As a result of this research, diabetic foot complications can and should be viewed as indicators of other costly chronic conditions not commonly associated with DFUs.

 

In addition to this research, which was published in January 2022, Podimetrics has already gotten off to a strong start in 2022. The company doubled its revenue for the third year in a row, and also doubled the size of its team.

 

“We are proud to partner with Podimetrics and to support its efforts to save lives and limbs,” said James Rogers, Investment Partner with D1 Capital Partners. “Our growth capital will expand commercialization of the SmartMat which we believe has demonstrated the ability to reduce unnecessary healthcare costs through preventive, risk-based strategies that prioritize high-quality outcomes for vulnerable patients. We believe that Podimetrics is building a strong team and are honored to support its worthy mission.”

 

For more information on Podimetrics and how its FDA-cleared SmartMat and clinical care services can help prevent diabetic foot ulcers and improve patient outcomes, please visit Podimetrics.com.

 

About Podimetrics

Podimetrics is the creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex diabetic patients. Through partnerships with health plans and at-risk providers, such as the Veterans Health Administration and Independence Blue Cross, Podimetrics has helped prevent amputations associated with complex diabetes. By combining cutting-edge technology with best-in-class clinical care services, Podimetrics earns high engagement rates from patients and allows clinicians to save limbs, lives, and money — all while keeping vulnerable populations healthy in their own homes. For more information, visit podimetrics.com or follow us on LinkedIn and Twitter.

 

About D1 Capital Partners

D1 Capital Partners is a global investment firm that operates across public and private markets. The firm combines the talent and operational excellence of a large, premier asset management firm with the flexible mandate and long-term time horizon of a family office. Founded in 2018 by Dan Sundheim, D1 focuses on investing in the global internet, technology, telecom, media, consumer, healthcare, financial, industrial and real estate sectors.

Assessing Patients for Pressure Injury Risk



Assessing Patients for Pressure Injury Risk

Summary: This blog reviews pressure injury (PI) risk assessment tools like Braden (now paid via bradenscale.com), Norton, and Waterlow, noting >40 options with varying sensitivity by setting (e.g., ICU vs home). Emphasizes subscale analysis over totals for targeted interventions (e.g., moisture subscale for incontinence). Prevention bundles include exams, friction reduction, nutrition; emerging infrared/ultrasound detect early damage, with AI promising predictive algorithms. Comorbidities like diabetes (>65% risk) and low hemoglobin amplify threats.

Key Highlights:

  • Tools: Braden (subscales for moisture/mobility); Norton/Waterlow for specificity.
  • Limitations: Braden no longer free; high totals mask risks like incontinence.
  • Bundles: Risk assessment + physical exams, nutrition (albumin >3g/dL), offloading.
  • Comorbidities: Diabetes, age >65, vasopressors increase risk 2-5x.
  • Tech: Infrared/ultrasound for subclinical detection; AI for predictions.

Read full guide

Keywords: pressure injury risk, Braden scale, prevention bundles, comorbidities, AI detection, Cathy Milne

Dipeptidyl Peptidase-4 Inhibitors and Risk of Diabetic Foot Ulcers



Dipeptidyl Peptidase-4 Inhibitors and Risk of Diabetic Foot Ulcers: A Nationwide Cohort Study

Summary: This Korean cohort (n=1.2M T2D patients, 2013-2020) found DPP4 inhibitors associated with higher DFU risk (HR 1.23, 95% CI 1.10-1.37) vs sulfonylureas, after PSM matching. Adjusted for comorbidities, the risk persisted, suggesting DPP4i may impair wound healing via immune modulation. Calls for monitoring in high-risk patients.

Key Highlights:

  • Cohort: 1.2M; DPP4i vs SU; PSM for age/sex/comorbidities.
  • Risk: HR 1.23 for DFU; dose-response trend.
  • Mechanisms: DPP4i alters inflammation/fibroblast function.
  • Implications: Prefer SUs in DFU-prone; further RCTs needed.
  • Authors: Kim Y, Lee H, Park S et al.
  • Read cohort study

    Keywords: DPP4i, DFU risk, Korean cohort, sulfonylureas, wound healing, Y Kim, H Lee, S Park

    From Screening to Full Risk Assessment in Pressure Injury Prevention



    From Screening to Full Risk Assessment in Pressure Injury Prevention

    Summary: Article outlines 2019 International Guideline’s two-step PI prevention: screening (quick, on admission for mobility/friction/Stage 1) then full assessment if risk not ruled out (scales like Braden + clinical judgment, head-to-toe skin check). PURPOSE-T tool supports both; high-risk settings may skip screening. Emphasizes modifiable factors, interprofessional input, reassessment; examples from Australia/Germany policies.

    Key Highlights:

    • Screening: Dichotomous (risk/no risk); fast, no full skin exam.
    • Full: Scales + judgment; factors like perfusion/nutrition.
    • Tools: Braden/Norton/Waterlow; PURPOSE-T qualitative.
    • Best Practices: Structured, population-specific, ongoing evaluation.

    Read full article

    Keywords: PI risk assessment, screening, full assessment, PURPOSE-T, prevention

    Epidemiology and Risk of Amputation in Patients With Diabetes Mellitus and Peripheral Artery Disease

    Peripheral artery disease (PAD) stems from atherosclerosis of lower extremity arteries with resultant arterial narrowing or occlusion. The most severe form of PAD is termed chronic limb-threatening ischemia and carries a significant risk of limb loss and cardiovascular mortality. Diabetes mellitus is known to increase the incidence of PAD, accelerate disease progression, and increase disease severity. Patients with concomitant diabetes mellitus and PAD are at high risk for major complications, such as amputation. Despite a decrease in the overall number of amputations performed annually in the United States, amputation rates among those with both diabetes mellitus and PAD have remained stable or even increased in high-risk subgroups. Within this cohort, there is significant regional, racial/ethnic, and socioeconomic variation in amputation risk. Specifically, residents of rural areas, African-American and Native American patients, and those of low socioeconomic status carry the highest risk of amputation … read more

    Understanding the Link Between Sitting and Pressure Ulcer Risk

    Understanding the Link Between Sitting and Pressure Ulcer Risk: New Seating Guidelines

    The Society of Tissue Viability has launched the third edition of its Seating Guidelines, spotlighting the often-overlooked connection between prolonged sitting and the development of pressure ulcers. These evidence-based recommendations are designed to help clinicians, caregivers, and patients reduce risk and improve outcomes—especially for adults with limited mobility.

    Key Highlights:

    • Guideline Launch: The new guidelines were introduced during a free webinar held on 25 June 2025, offering practical tools for health and social care professionals working in hospitals, home settings, and long-term care facilities.
    • Scale of the Problem: Pressure ulcers affect over 700,000 people annually in the UK and cost the NHS an estimated £3.8 million per day. Many cases are preventable with proper seating assessment and interventions.
    • Seating as a Risk Factor: Prolonged sitting places excessive pressure on high-risk areas such as the sacrum and ischial tuberosities. The updated guidelines explain how these pressure points contribute to tissue damage over time.
    • Prevention Strategies: Recommendations include frequent repositioning, daily skin inspections, use of pressure-relieving cushions, good posture, appropriate chair fit, moisture management, and proper nutrition to support skin integrity.
    • Collaborative Development: The guidelines were created with input from clinicians, carers, and individuals with lived experience, ensuring the content is accessible, relevant, and grounded in real-world care settings.

    This update serves as a critical reminder that seating matters—and that evidence-based positioning and equipment can significantly reduce preventable pressure injuries, particularly in at-risk populations.

    Source: Society of Tissue Viability – June 2025

    Keywords: pressure ulcers, seating guidelines, pressure management, mobility, caregivers

    Read more on the Society of Tissue Viability website

    Risk Management Is Important to Healthcare Facilities in Order to Prevent Pressure Ulcers



    Risk Management Is Important to Healthcare Facilities in Order to Prevent Pressure Ulcers

    Summary: This article discusses the critical role of risk management in healthcare to mitigate pressure ulcers (bedsores), a common complication in nursing homes and hospitals from prolonged immobility. It highlights prevention programs including regular skin assessments, repositioning schedules, and specialized mattresses to redistribute pressure, alongside staff training and documentation to avoid legal and financial liabilities. By addressing root causes like poor nutrition and incontinence, facilities can reduce incidence, enhance patient outcomes, and comply with regulations, ultimately lowering waste from extended stays and treatments.

    Key Highlights:

    • Pressure ulcers form from sustained pressure on bony prominences, leading to tissue damage and infection risks in immobile patients.
    • Prevention strategies: Hourly turning, barrier creams for incontinence, high-protein diets, and Braden Scale assessments for early risk detection.
    • Specialized equipment: Alternating air mattresses or foam overlays reduce shear and friction for high-risk individuals.
    • Legal implications: Proper documentation defends against negligence claims; failure to prevent can result in lawsuits and fines.
    • Overall benefits: Proactive management cuts readmissions, shortens healing time, and improves quality of life for vulnerable patients.

    Read full article

    Keywords: pressure ulcers, risk management, nursing home care, skin assessment, repositioning schedules

    Identifying Risk Factors Associated with the Severity of Foot Ulcers in Type 2 Diabetic Patients



    Identifying Risk Factors Associated with the Severity of Foot Ulcers in Type 2 Diabetic Patients: Evidence from a Hospital-Based Study in Rajshahi, Bangladesh

    Summary: This 2026 cross-sectional study of 159 type 2 diabetes patients with foot ulcers at Rajshahi Diabetic Association General Hospital (Bangladesh) found that 63.5% had severe DFU (Wagner grades 3–5). Severe cases showed higher rates of peripheral arterial disease (PAD), peripheral neuropathy (PN), poor glycemic control, prior amputation, longer ulcer duration, and greater treatment costs. Firth’s penalized logistic regression identified independent predictors: older age, poor glycemic control, PN, PAD, and prior amputation. The predictive model demonstrated strong performance (AUC 0.924, accuracy 85.5%). Findings underscore the need for early screening and aggressive management of modifiable risk factors to prevent progression to severe ulcers and reduce amputation risk in resource-limited settings.

    Key Highlights:

    • 63.5% of DFU cases were severe (Wagner 3–5); higher costs and complications in severe group
    • Independent risk factors: older age (aOR 1.08), poor glycemic control (aOR 3.90), PN (aOR 3.41), PAD (aOR 7.54), prior amputation (aOR 13.67)
    • Strong model performance with good calibration and clinical utility
    • Authors: Shah Tanzen Jahan, Durga H. Kutal, Anicha Akter, Md. Selim Reza, Md. Kabirul Islam, Md. Monimul Huq

    Read full article (open access)

    Keywords: diabetic foot ulcer severity, risk factors DFU, peripheral neuropathy, peripheral arterial disease, Shah Tanzen Jahan

    Identifying Risk Factors Associated with the Severity of Foot Ulcers in Type 2 Diabetic Patients



    Identifying Risk Factors Associated with the Severity of Foot Ulcers in Type 2 Diabetic Patients: Evidence from a Hospital-Based Study in Rajshahi, Bangladesh

    Summary: This 2026 cross-sectional study analyzed 159 type 2 diabetes patients with foot ulcers at Rajshahi Diabetic Association General Hospital. Severe ulcers (Wagner grades 3–5) occurred in 63.5% of cases and were associated with higher BMI, longer ulcer duration, greater treatment costs, and increased prevalence of peripheral arterial disease (PAD), peripheral neuropathy (PN), poor glycemic control, and prior amputation. Using Firth’s penalized logistic regression, independent predictors of severity were older age, poor glycemic control, PN, PAD, and prior amputation. The predictive model showed excellent performance (AUC 0.924, accuracy 85.5%). The findings emphasize the importance of early screening and aggressive management of modifiable risk factors to prevent progression to severe diabetic foot ulcers and reduce amputation risk in similar settings.

    Key Highlights:

    • 63.5% of DFU cases classified as severe (Wagner 3–5)
    • Independent risk factors: older age, poor glycemic control, PN, PAD, prior amputation
    • Strong predictive model (AUC 0.924) with good clinical utility
    • Authors: Shah Tanzen Jahan, Durga H. Kutal, Anicha Akter, Md. Selim Reza, Md. Kabirul Islam

    Read full article (open access)

    Keywords: DFU severity, risk factors diabetic foot, peripheral neuropathy, peripheral arterial disease, Shah Tanzen Jahan

    Advancing Clinical Trial Design in Chronic Wounds: WCCC Proposes Modernized FDA Guidance


    Advancing Clinical Trial Design in Chronic Wounds: WCCC Proposes Modernized FDA Guidance

    Summary: WoundSource reports on the Wound Care Collaborative Community (WCCC) proposals to modernize FDA guidance for chronic wound trials. The piece highlights recommended changes to endpoints, control arms, patient selection, and real-world methodology to speed innovation while maintaining rigor.

    Key Highlights:

    • Calls for clinically meaningful endpoints beyond complete closure alone (e.g., durable closure, infection control, pain, function).
    • Encourages pragmatic and adaptive designs, leveraging real-world evidence and standardized care pathways.
    • Recommends clearer definitions for “standard of care,” stratification by wound etiology/severity, and consistent offloading/compression.
    • Supports composite outcomes and longer follow-up to assess durability and recurrence.

    Read the full post on WoundSource

    Keywords:
    WCCC,
    FDA guidance,
    clinical trial design,
    chronic wounds

    Some Diabetes Drugs, Higher Amputation Risk Linked

    A specific class of diabetes medication appears to double the risk of losing a leg or foot to amputation, a new study reports … People on sodium-glucose cotransporter2 (SGLT2) inhibitors were twice as likely to require a lower limb amputation as people taking another type of diabetes medication, Scandinavian researchers found … Patients also had a doubled risk of diabetic ketoacidosis, a life-threatening complication in which acids called ketones build up in the bloodstream … “Patients at high risk of amputation, for example those with peripheral artery disease or foot ulcers, might be monitored more closely if SGLT2 inhibitors are used, and the risk of this adverse event may be considered when deciding on which drugs to use,” said lead researcher Dr. Peter Ueda, a postdoctoral researcher with Karolinska University Hospital in Stockholm, Sweden … read more

    Amputation-free survival in 17,353 people at high risk for foot ulceration

         in diabetes: A national observational study

     

    Diabetic foot ulcers and amputations are devastating and much feared complications of diabetes. Between 15% and 34% of people with diabetes develop a foot ulcer during their lifetime, with more than half acquiring infections that may result in lower extremity amputations causing disability, extensive periods of hospitalisation, and premature mortality. The incidence of major amputation ranges from 0·2 to 2·0 per 1000 people in those with diabetes. Major or minor amputation also increases the risk of additional subsequent amputations. Foot ulcers are the costliest microvascular complication of diabetes … Amputations in people with diabetes have a significant impact on ambulation, body care, movement and mobility, resulting in an inability to perform daily tasks and often a loss of employment impacting on the wider family. Clinical epidemiology studies suggest that foot ulcers precede around 85% of non-traumatic lower extremity amputations in individuals with diabetes [8] and hence ulcer prevention is important. Previous studies have reported that apart from severity of ulcer, age [9], low socioeconomic status, smoking, sex, renal impairment, ischaemic heart disease, diabetic neuropathy, glucose levels and peripheral arterial disease are some of the important factors associated with the risk of amputation. Identifying a person’s risk of foot ulceration helps in directing scarce resources to those most at need. Assessment of individual risk factors … read more

    Risk Factors for *Candida auris* Colonization in Riyadh ICU Patients

    Risk Factors for *Candida auris* Colonization in Riyadh ICU Patients

    A prospective observational study from a Riyadh intensive care unit (published in *Infection and Drug Resistance*, July 2025) investigates risk factors associated with *Candida auris* colonization among hospitalized adults. The research team led by Faris Altrafi and Mohammed Obeid evaluated clinical associations linked to this emerging multidrug-resistant pathogen.

    Study Highlights:

    • Patient Population: Over 250 adult ICU patients were screened using body site swabs to identify colonization with *C. auris*.
    • Major Risk Factors: Statistical analysis found prior broad-spectrum antibiotic use, central venous catheter presence, mechanical ventilation, and diabetes mellitus were significant independent predictors of colonization.
    • Colonization Rates: Approximately 13% of screened patients tested positive for *C. auris* colonization at one or more body sites.
    • Clinical Implications: Colonized patients faced higher risks of subsequent bloodstream infections and associated morbidity. The authors emphasized the need for early detection protocols and strict infection control measures in ICU settings.

    Conclusion: This study supports targeted surveillance for *C. auris* using risk-based screening in ICU patients, combined with robust antimicrobial stewardship and infection prevention strategies to curb its spread.

    Keywords:
    Faris Altrafi,
    Mohammed Obeid,
    Candida auris,
    ICU colonization,
    broad-spectrum antibiotics,
    central venous catheter,
    mechanical ventilation,
    infection control

    Read the full study on Dove Press

    What Patient Populations Are at Higher Risk for Wounds?

    What Patient Populations Are at Higher Risk for Wounds?

    Summary: Experts in wound care highlight patient populations most at risk for developing wounds that fail to heal within 1–3 weeks. Factors such as advanced age, diabetes, vascular disease, immobility, and unrecognized underlying conditions contribute significantly to poor healing outcomes. The discussion stresses that wound care requires a holistic, multidisciplinary approach.

    Key Highlights:

    • Older adults: Patients aged 65 and above face increased risk due to thinning skin, comorbidities, and reduced tissue perfusion.
    • Diabetes and vascular disease: Diabetes and peripheral arterial disease impair circulation and delay healing, raising complication risks.
    • Immobility and ICU patients: Bedridden, post-surgical, or intensive care patients are vulnerable to pressure injuries and delayed healing.
    • Undiagnosed conditions: Non-healing wounds can be the first sign of previously unrecognized diabetes or vascular disease.
    • Systemic approach: Healing requires evaluating vascular health, mobility, nutrition, and overall patient condition, not just wound appearance.
    • Team-based care: Effective management depends on collaboration among wound specialists, vascular experts, primary care providers, and nursing teams.

    Read the full article on AJMC

    Keywords:
    higher risk populations,
    older adults,
    diabetes,
    immobility,
    vascular disease,
    non-healing wounds

    A Machine-Learning-Based Clinical Decision Model for Predicting Amputation Risk



    A Machine-Learning-Based Clinical Decision Model for Predicting Amputation Risk in Patients with Diabetic Foot Ulcers

    Summary: Retrospective study (n=149 hospitalized DFU patients) developed a support vector machine (SVM) model to predict lower-limb amputation risk using CRP and Wagner grade as key predictors. Model achieved AUC 0.89, accuracy 82.4%, sensitivity 79.6%, specificity 86.5%; outperformed LDA/KNN. Decision curve analysis showed net benefit at 30% threshold. Provides quantitative tool for early intervention, individualized strategies, and multidisciplinary care in high-risk DFUs.

    Key Highlights:

    • Predictors: CRP and Wagner grade (independent via LASSO, p<0.05).
    • Performance: AUC 0.89; moderate calibration (p=0.012); net benefit 0.351.
    • Validation: 5-fold cross-validation; 82.4% correct classification.
    • Implications: Identifies high-risk patients for aggressive management; external validation needed.
    • Authors: Lei Gao, Zixuan Liu, Siyang Han et al.

    Read full open-access article

    Keywords: DFU amputation, machine learning, SVM, CRP, Wagner grade, Lei Gao, Zixuan Liu, Siyang Han

    Amputation Risk in Veterans with DFUs: What’s Driving Differences in Care and Outcomes



    Amputation Risk in Veterans with DFUs: What’s Driving Differences in Care and Outcomes

    Summary: Recent research highlights two major drivers of amputation risk in Veterans with diabetic foot ulcers (DFUs). First, developing a DFU is the strongest independent predictor of lower-extremity amputation — increasing risk nearly 10-fold. Second, a large JAMA Network Open study of over 86,000 Veterans found significant facility-level variation across VA centers: the odds of major leg amputation within one year were 1.85 times higher between two randomly selected facilities for an otherwise average patient. While mortality rates were relatively consistent, amputation rates varied widely (facility odds ratios ranging from 0.29 to 3.53), suggesting differences in care delivery, rather than patient factors alone, play a critical role.

    Key Highlights:

    • DFU development increases amputation risk nearly 10-fold in Veterans
    • Significant VA facility-level variation in amputation rates (MOR 1.85) despite similar patient populations
    • Variation in care processes (early intervention, offloading, vascular assessment, multidisciplinary coordination) likely drives outcome differences
    • Emphasizes need for standardized, high-quality DFU protocols across all facilities
    • Source: Podimetrics analysis of recent VA studies

    Read full LinkedIn post

    Keywords: veterans DFU amputation, VA facility variation, limb salvage veterans

    Study Shows Increased Risk For Foot Infection-Related Hospitalizations In People With Diabetes

    According to a recent publication in Diabetologia, there is an increased risk of infection-related hospitalization in patients with diabetes.1 This includes foot infections, for which the risk of hospitalization was nearly six times greater in patients with diabetes than those without. Remarkably, the risk for hospitalization in patients with diabetes for all infection types, including foot infection, respiratory infection, urinary tract infection, GI infection, sepsis, and post-operative infection was 67 percent higher than the non-diabetic group. In addition, the study authors noted a stronger association between diabetes and hospitalization related to infection in younger participants and Black patients … read more

    Developing a foot ulcer risk model

         what is needed to do this in a real‐world primary care setting?

     

    To determine how routinely collected data can inform a risk model to predict de novofoot ulcer presentation in the primary care setting … Data were available on 15 727 individuals without foot ulcers and 1125 individuals with new foot ulcers over a 12‐year follow‐up in UK primary care. We examined known risk factors and added putative risk factors in our logistic model … read more

    Lipid Profiling Can Predict the Risk of Diabetes and CVD Years Before Onset

    Janet Falade, PharmD Candidate, South College School of Pharmacy

     

    The increased risk of having type 2 diabetes (T2D) and cardiovascular disease (CVD) has been a significant concern in the health care sector worldwide. Also, it has been regularly reported by the World Health Organization (WHO) that cardiovascular diseases (CVDs) and diabetes mellitus are part of the ten major leading causes of death globally. Some changes, such as increased blood pressure, cholesterol, and blood sugar level, are usually apparent before the onset of these diseases. Therefore, early detection of individuals at increased risk of having this disease is essential in preventing the disease Incidence. Furthermore, these diseases can influence specific measures like lifestyle changes such as healthy diet and exercise. In addition, machine learning models can help predict the risk of having T2D and CVD. Other factors such as lipid level and blood sugar levels, particularly evaluation of gene variations, protein complements, and metabolome, which includes lipidome, may aid in identifying physiopathology pathways that might be … read more


    If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

     

    Interpretable Machine Learning for the Prediction of Amputation Risk Following

    Lower Extremity Infrainguinal Endovascular Interventions for Peripheral Arterial Disease

     

    Abstract
    Purpose: Severe peripheral artery disease (PAD) may result in lower extremity amputation or require multiple procedures to achieve limb salvage. Current prediction models for major amputation risk have had limited performance at the individual level. We developed an interpretable machine learning model that will allow clinicians to identify patients at risk of amputation and optimize treatment decisions for PAD patients.

     

    Methods: We utilized the American College of Surgeons National Surgical Quality Improvement Program database to collect preoperative clinical and laboratory information on 14,444 patients who underwent lower extremity endovascular procedures for PAD from 2011 to 2018. Using data from 2011 to 2017 for training and data from 2018 for testing, we developed a machine learning model to predict 30 day amputation in this patient population. We present performance metrics overall and stratified by race, sex, and age. We also demonstrate model interpretability using Gini importance and SHapley Additive exPlanations.

     

    Results: A random forest machine learning model achieved an area under the receiver-operator curve (AU-ROC) of 0.81. The most important features of the model were elective surgery designation, claudication, open wound/wound infection, white blood cell count, and albumin. The model performed equally well on white and non-white patients (Delong p-value = 0.189), males and females (Delong p-value = 0.572), and patients under age 65 and patients age 65 and older (Delong p-value = 0.704).

     

    Conclusion: We present a machine learning model that predicts 30 day major amputation events in PAD patients undergoing lower extremity endovascular procedures. This model can optimize clinical decision-making for patients with PAD.

     

    Keywords: Endovascular intervention; Machine learning; Peripheral artery disease; Risk assessment.

    from PubMed


    If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

     

    UT Health San Antonio study uncovers key risk factors ….

    UT Health San Antonio Study Uncovers Key Risk Factors for Diabetic Foot Infection Recurrence

    A recent study conducted by researchers at UT Health San Antonio has identified significant risk factors contributing to the recurrence of diabetic foot infections. Published in the International Wound Journal in November 2024, the study analyzed eight years of patient data to understand why nearly half of patients treated for diabetic foot infections experience reinfection within a year.

    Led by Dr. Lawrence A. Lavery, DPM, MPH, a specialist in diabetic foot complications and professor of orthopaedics, the research reviewed records of 294 patients hospitalized for moderate to severe diabetic foot infections. The findings revealed that patients with wounds unhealed after three months were three times more likely to experience reinfection. Additionally, those with bone infections had more than twice the risk compared to patients with only soft tissue infections.

    Dr. Lavery emphasized the importance of wound healing in preventing reinfections, stating, “When your wound fails to heal or you develop another wound, the clock starts ticking.” The study also highlighted that patients with unhealed wounds faced longer healing times, increased hospital readmissions, and extended hospital stays, underscoring the need for early intervention and comprehensive care strategies.

    Read the full article on the UT Health San Antonio Newsroom.

    Keywords:
    Diabetic foot infection,
    Infection recurrence,
    Wound healing,
    Bone infection,
    Peripheral neuropathy,
    UT Health San Antonio,
    Lawrence A. Lavery

     

    Note: The above synopsis is based on the article’s content and available information. For a comprehensive understanding, please refer to the full article.

    Custom-Made Footwear Boosts Adherence in High-Risk Diabetes Patients

    Custom-Made Footwear Boosts Adherence in High-Risk Diabetes Patients

    An early report from the DIASSIST trial, published June 21, 2025 on DiabeticFootOnline, explores whether a multi-modal intervention can improve adherence to custom-made footwear in individuals at high risk for diabetic foot ulceration.

    Key Highlights:

    • Behavioural Strategy: The intervention paired structured education (using the Fragile Feet–Trivial Trauma model), motivational interviewing via phone, and custom-made indoor footwear.
    • Study Participants: 53 people with healed ulcers and prescribed custom footwear were monitored for usage via embedded sensors; 57% had low adherence at baseline (<8 hours/day).
    • Education Boost: Structured education led to a clinically meaningful increase in wear time (~+1 hr/day), though this did not reach statistical significance.
    • Limited MI Impact: Motivational interviewing did not significantly affect adherence in this short-term evaluation.
    • Footwear Matters: Custom indoor footwear produced a significant jump in wear time—+2.7 h/day for low adherence users and +2.0 h/day for high adherence users (p < 0.01).

    Although the combined approach didn’t yield statistically significant overall changes at 3 months, the immediate and meaningful increase from indoor footwear highlights its potential as an effective, easy-to-implement measure in ulcer prevention protocols.

    Based on Van Netten et al., “Short‑Term Efficacy of a Multi‑Modal Intervention Program to Improve Custom‑Made Footwear Use in People at High Risk of Diabetes‑Related Foot Ulceration,” J Clin Med, 2025;14(11):3635.

    Keywords: custom footwear, footwear adherence, diabetic foot ulcer, education intervention, indoor footwear

    Read the full article on DiabeticFootOnline

    Obstructive Sleep Apnea: An Independent Risk Factor for Split-Thickness Skin Graft Failure

    Obstructive Sleep Apnea: An Independent Risk Factor for Split-Thickness Skin Graft Failure

    A recent original research article published in Wounds highlights the significant impact of obstructive sleep apnea (OSA) on outcomes of split-thickness skin graft (STSG) procedures. The retrospective study evaluated whether a diagnosis of OSA is independently associated with increased graft failure rates in surgical wound management.

    Study Overview:

    • Population Studied: 259 patients who underwent STSG procedures at a tertiary wound care center between January 2017 and December 2020.
    • Primary Finding: Graft failure occurred in 23.7% of patients with OSA versus only 12.7% in patients without OSA.
    • Independent Risk: After controlling for confounding factors such as age, diabetes, smoking status, and BMI, OSA remained an independent predictor of graft failure (adjusted odds ratio 2.33).
    • Pathophysiology: The authors speculate that hypoxia, intermittent airway obstruction, and systemic inflammation associated with untreated OSA may impair tissue oxygenation and compromise graft viability.

    Clinical Implications: The study emphasizes the need for screening and potential preoperative optimization of patients with known or suspected OSA undergoing STSG procedures. Greater interdisciplinary collaboration between sleep medicine and wound care teams may be warranted to improve outcomes.

    Keywords: obstructive sleep apnea, split-thickness skin graft, wound healing risk factors, graft failure, surgical wound care

    Read the full article at Wounds Journal

    High Relapse Risk in Diabetic Foot Ulcers

    High Relapse Risk in Diabetic Foot Ulcers

    Summary: A Medscape view article published in 2025 highlights striking new data showing that diabetic foot ulcers (DFUs) carry relapse risks at levels that match or exceed those of aggressive cancers. By pulling together recent studies on ulcer recurrence and limb preservation, the authors call for more vigilant follow-up and structured surveillance after remission.

    Key Highlights:

    • At 3 years after healing (remission), approximately **58%** of patients with DFUs experience recurrence.
    • Similarly, about **50%** of patients who had chronic limb-threatening ischemia (CLTI) treated via endovascular intervention require reintervention within 3 years.
    • Those relapse and reintervention rates are comparable to—or even higher than—those for many advanced cancers such as breast, colorectal, or prostate when considering a 3-year window.
    • These findings underscore that “healed” DFUs should not be treated as endpoints but signals for ongoing risk; patients in remission need structured monitoring similar to post-cancer care protocols.

    Read the full article on Medscape

    Keywords:
    diabetic foot ulcer recurrence,
    chronic limb-threatening ischemia (CLTI),
    relapse risk,
    three-year rate

    Total-Contact Casts: Healing Ulcers Fast—with Remarkably Low Reported Thrombosis Risk



    Total-Contact Casts: Healing Ulcers Fast—with Remarkably Low Reported Thrombosis Risk

    Summary: Total-contact casts (TCCs) remain the gold standard for offloading diabetic foot ulcers in tolerant patients, alongside irremovable devices, but concerns about immobility-related venous thrombosis have limited use. A recent systematic review reports remarkably low DVT rates (~0.7%, 1 in 136 cases) with TCCs, compared to up to 40% in general lower-limb immobilization, attributing protection to frequent recasting and partial mobility. This reinforces TCCs’ role in accelerating ulcer healing while minimizing vascular risks, calling for broader adoption in diabetic wound care.

    Key Highlights:

    • TCCs or irremovable casts are top for offloading diabetic foot ulcers in suitable patients.
    • DVT prevalence with TCCs: ~0.7% (1/136 cases), far below 40% in standard immobilization.
    • Factors reducing risk: Regular recasting, partial weight-bearing during therapy.
    • Implications: Addresses thrombosis fears, promoting faster healing without heightened vascular concerns.
    • Authors: Tsai R, Bazikian S, Shin L, Woelfel S, Armstrong DG.

    Read full article

    Keywords: total contact cast, diabetic ulcer, DVT risk, offloading, thrombosis

    Predictive Model of Chronic Wounds Identifies Risk Factors for Amputation and Death



    Predictive Model of Chronic Wounds Identifies Risk Factors for Amputation and Death

    Summary: Multistate model from Regenstrief Chronic Wound Registry/INPC (n=52,916 Indiana lower-extremity chronic wound patients, 2011-2021) predicts progression to amputation/death. Key: DFUs ↑ minor amputation risk; venous ulcers ↓ amputation/death; pressure ulcers ↑ death but ↓ minor amputation; osteomyelitis ↑ amputation but ↓ death pre-major; sepsis ↑ death pre-major. 3-year mortality: >10% post-diagnosis, ~13% post-minor, 19% post-major. Model supports proactive decisions; registry expansion planned for ML on notes/socioeconomics.

    Key Highlights:

    • Population: 52,916 patients; lower-extremity chronic wounds.
    • Risks: DFU ↑ minor amp; venous ↓ overall; pressure ↑ death; sepsis/osteomyelitis modifiers.
    • Mortality: 3-year >10% diagnosis, 13% minor amp, 19% major amp.
    • Quotes: Schleyer/Choi on real-world data for earlier intervention.
    • Source: Annals of Surgery (DOI: 10.1097/sla.0000000000006761).

    Read full news

    Keywords: chronic wounds, amputation risk, mortality, multistate model, Regenstrief

    High Mortality Following Major Amputation in Diabetes: An Analysis of Risk Factors and Causes of Death



    High Mortality Following Major Amputation in Diabetes: An Analysis of Risk Factors and Causes of Death (2024)

    Summary: Summary of 2024 Diabetes UK conference abstract (published in Diabetic Medicine): Analyzed 48 major non-traumatic lower-limb amputations (2022–2023); 31% died within 1 year (mostly in-hospital). Risk factors: age >40 at diabetes diagnosis, advanced nephropathy, retinopathy; common profile includes long-duration T2DM, neuropathy/PAD. Causes: cardiorespiratory (40%), sepsis (DFU-related 13%, unrelated 20%). Implications: Emphasize managing comorbidities for better outcomes/prevention in diabetic wound/amputation cases.

    Key Highlights:

    • Mortality: 31% at 1 year; similar for BKA/AKA.
    • Risks: Nephropathy/retinopathy predictors; high comorbidities (neuropathy 80%, PAD 80%).
    • Causes: Cardiorespiratory dominant; sepsis notable.
    • Amputation reasons: Ischaemia (56%), sepsis/gangrene (36%).

    Read summary

    Keywords: amputation mortality, diabetic amputation, risk factors, nephropathy

    Increasing SBP variability is associated with an increased risk of

         developing incident diabetic foot ulcers

     

    Researchers assessed the link between increased SBP variability and incident diabetic foot ulceration risk in 51,111 cases and 129,247 controls. Cases were patients diagnosed with diabetes and treated by the US Department of Veterans Affairs Healthcare system for development of a diabetic foot ulcer (event) between 2006 and 2010; on the basis of age, sex, race/ethnicity, and calendar time, each case was randomly matched to up to five controls. Higher adjusted odds ratios for diabetic foot ulcer development were observed in patients in quartiles 2-4 vs those in quartile 1 (lowest variability). In adjusted subgroup analyses, reduced risks of ulceration were observed in association with calcium channel blockers for those without peripheral vascular disease or neuropathy. Overall, a graded link between SBP variability and diabetic foot ulceration risk was shown.

    Read the full article on Journal of Hypertension (subscription required)

    The Miller-Newgent Amputation Scale

    A comprehensive scoring system to evaluate patient-centered risk factors regarding lower extremity amputation

     

    Abstract: Care of the patient with a presumed life- or limb-threatening lower extremity wound poses many challenges. The mindset regarding potential outcomes of such conditions is mostly driven by the experiences and expertise of those providing the care. This mindset generally appears as two primary actions presented to the afflicted patient: attempted resolution of the problem via medical, surgical or combination treatment, with the hope of low recurrence risk, or exacerbation and amputation—amputations at a level sufficient to, at least in the mind of the surgeon, eliminate the problem. Achieving the former outcome is dependent on a number of factors associated with both patient and caregiver. If healing is achieved, the secondary goal of prevention of recurrence may be no less arduous, with failure most likely resulting in amputation. Clearly, these considerations appear to be based more on the health professionals perception, of the patient’s physical and medical status rather than on patient-centered considerations. This article will review considerations and recommendations for lower extremity amputation, and the short- and long-term implications. Based on our research, there is clear need for a set of criteria against which to weigh not just the medical issues, but also definitive patient-centered issues when considering a lower extremity amputation. We offer a set of patient-centered, easily verified and recognized criteria that we believe addresses this need. The goal of the Miller-Newgent Amputation Scale (MENACE) is to provide a decision base from which to consider and evaluate all factors in determining the need for a lower extremity amputation. This involves identification of patient-centered issues, which are likely to produce satisfactory short- and long-term physical and quality-of-life outcomes if the amputation does proceed.

     

    Declaration of interest: The authors have no conflict of interest to declare. The lead author, as a Board Certified general surgeon with 23 years’ experience in the field of advanced wound care, has been involved in the different aspects to amputation and its considerations and a common thread my colleagues and I have identified is that the expertise of those attempting to heal and salvage limbs was largely ineffectual. More often than not, the progression of high-risk conditions mandated lower extremity amputation. The progression of technology, science and products to promote healing is thought to improve limb salvage rates; however, there has not been an appreciable reduction in amputations. The thought is that those possessing the skill, knowledge and desire to promote limb salvage (which entails greater time and effort with considerably lower compensation) are few and far between. Despite advances in medical care, the rates of lower extremity amputation are unchanged at best or are even increasing.

     

    Despite educational programmes touting the newest technologies for vascular intervention and advanced wound healing to mitigate those conditions commonly leading to amputation, there has been minimal change in the willingness of health professionals to consider limb salvage and indications for amputation have changed minimally. There is a clear need for a matrix against which to compare and contrast the clinical and non-clinical considerations for amputation. Since the patient is the one undergoing this potentially horrific procedure, it is only fair that all aspects of the procedure must be considered as an integral part of the decisionmaking process. The Miller-Newgent Amputation Scale (MENACE) scale was created to provide a patientcentred guide using simple, easily identified information that directly impacts on all aspects of the amputation decision process.

     

    Background Considerations for the intentional removal of a body part have their roots in antiquity. Matthew 5:29–30, 18:8–9 and Mark 9:43–47 are commonly recognised biblical references to amputation. Lower extremity amputation is one of the oldest known surgical practices with Hippocrates among others providing insights.

     

    In the US, 30,000–40,000 amputations are performed annually. In 2005, there were an estimated 1.6 million individuals living with the loss of a limb; by 2050, this figure is expected to rise to 3.6 million.

     

    In 1954, Silbert and Hamiovici published an article recommending that lower extremity amputation be avoided, preferring more conservative surgeries such as supracondylar amputations as opposed to mid-leg amputations. In the paper they cited the Handbook on Amputations, published in 1942 by the Council on Physical Therapy of the American Medical Association, which expressed the opinion of most surgeons, when it advised the use of supracondylar amputations and warned against mid-leg amputations: an opinion justifiable at the time before the advent of antibiotics.

     

    The Netherlands Society of Physical and Rehabilitation Medicine in October 2012 published its guideline on Amputation and Prosthetics of the Lower Extremities in which it recommended that the interventional radiologist, vascular internist and rehabilitation physician collectively identify and resolve those clinical issues before proceeding with a lower extremity amputation. Further, the guidelines state that treatment by a multidisciplinary team (MDT) involving a surgeon, anaesthesiologist, pain specialist, rehabilitation specialist, and possibly an internist is necessary for treatment of pain, cardiovascular risks, comorbidity and the co-determination of the level of amputation. The article identified many of the clinical indications for lower extremity amputation found in the literature; however, there is the same omission of any patient-centred, non-clinical concerns.

    Table 1. Estimated change in metabolic energy expenditure based on level of amputation

    Table 1. Estimated change in metabolic energy expenditure based on level of amputation

     

    Reyzelman and Kim presented their idea of acceptable considerations for partial tissue removal (digital amputation) based on presenting conditions including: osteomyelitis, septic arthritis, gas gangrene, ischaemia/ gangrene and an advancing soft tissue infection. The authors concluded that early digital amputation in the appropriate patient allowed patients a return to normal activity with minimal disability.

     

    Kalapatapu attempted to provide a compendium of indications for lower extremity amputation by providing an exhaustive listing of essentially all lower extremity morbidities. He stated:

     

       ‘Primary amputation may be the only option for
       patients without an anatomic option for
       revascularisation or those with medical risk factors that
       contraindicate revascularisation.’

     

    Recognising that the spectrum of surgical and medical skills is considerable, and that there are an almost limitless number of non-medical factors, even attempting to define specific conditions as the basis for amputations is extremely problematic and potentially precludes the surgeon and thus the patient from any consideration of limb salvage.

     

    A patient presenting with a condition prompting even the slightest consideration for lower extremity amputation likely has other issues related directly or indirectly to the presenting condition itself. It is a small leap of faith to recognise that an increase in metabolic demand places greater stress systemically on the patient with a concurrent risk of exacerbating current comorbidities as well as promoting new ones. These increased energy expenditures clearly mandate the highest scrutiny of a patient’s physical condition, both pre- and postoperatively, before undertaking any surgical consideration including lower extremity amputation. Recognising that the loss of an extremity means a dramatic change in the metabolic as well as mental status of the body, the failure to include these considerations potentially impacts on the ability of the patient to engage in activities of daily living. Estimates of the changes in metabolic energy expenditure based on the level of the amputation are shown in Table 1.

     

    However, the definitive consideration must be the effect of survival from a lower extremity amputation since this takes all factors together under a single irreversible endpoint. Survival rates for individuals with dysvascular pathology undergoing major lower extremity amputations including (above the knee amputation) AKA and BKA (below the knee amputation) have been reported as 69.7% and 34.7% at 1 and 5 years, respectively.12 Mortality was found to be significantly higher for patients who underwent AKA (50.6% and 22.5% at 1 and 5 years) as compared with BKA (74.5% and 37.8% at 1 and 5 years).

     

    Although amputation can be considered a failure of treatment, the actual considerations must be based on a number of factors, even when the initial impression is that salvage of the limb is untenable. There are still general categories of lower extremity conditions in which limb salvage is not appropriate. These would include traumatic limb loss or significant tissue deformation from motor vehicle or industrial accidents, malignancies whose location or dissemination precluded salvage, and congenital malformations precluding use of prosthetics or achieving a functional end result. Excluding the majority of these still leaves a considerable number of lower extremity conditions, in which the end result, amputation, unquestionably puts the patient at a higher risk of morbidity and mortality than before the decision to perform the procedure.

     

    At present, the decision to recommend lower extremity amputation appears to be universally based on objective medical issues. Without recognising and attending to the equally important and pervasive, nonclinical, patient-centred issues, the decision is usually made based on the surgeon’s tunnel vision. The most basic tenet becomes that of removing the problem as the key to resolving the problem. As Ertl aptly stated:

     

    ‘The only contraindication for amputation is poor
    health that impairs the patient’s ability to tolerate
    anaesthesia and surgery. However, the diseased limb is
    often at the centre of the patient’s illness, leading to a
    compromised medical status. The removal of the
    diseased limb is necessary to eliminate systemic toxins
    and save the patient’s life.’

     

    Unfortunately, the mere removal of an afflicted lower extremity under the guise of resolving the issue takes on a ‘low-hanging fruit’ mentality as it fails to address equally important patient-centred issues that often define the progress and ultimate outcome.

     

    The identification of any criteria regarding the appropriateness of a lower extremity amputation based on patient-centered, non-clinical criteria has been found to be nonexistent despite an exhaustive literature search. This covered 70 years and approximately 200 citations. Brigham and Women’s Hospital in Boston uses a Pre-Amputation Assessment Checklist that, while comprehensively identifying specific patient expectations and information, does not consider any patient-centered criteria for amputation. Therefore, the Brigham tool does not recognize the potential issues and ultimate outcomes surrounding amputation. In contrast, the MENACE SCALE and its patent-centered components focus the attention on those issues related to non-clinical outcomes when lower extremity amputation is considered.

     

    Table 2

    The MENACE scale

    It is not enough to objectively quantify only the clinical considerations for lower extremity amputation. The resulting amputation and the effect on quality-oflife must be taken into account. For that reason, there must be a combination of clinical factors together with non-clinical factors. The impact of these patientcentred, non-clinical factors cannot be overstated. The loss of all or part of a limb has a major psychological impact on the patient’s mental status. The psychological effects of amputation can be related to postoperative pain, cosmetic appearance, cultural and social effects, all potentially causing or exacerbating anxiety and depression.

     

    We believe that any initial consideration for lower extremity amputation, regardless of the presenting issues, can be based on two primary factors. Those two factors are intractable pain and functionality in the presence of a potentially life- or limb-threatening condition. While these factors may at first appear to be objective they are equally dependent on the patient’s subjective impressions of their condition.

     

    In considering the issues that ‘open the door’ to amputation, the authors felt that this process is analogous to ‘looking through a keyhole’ from which only a narrowed view is possible. We chose the term ‘keyhole criteria’ to represent this process as initial consideration regarding amputation. The two criteria (Table 2) establish a platform that forms the basis for the critical decision of amputation. These criteria move the decision from one that is based solely on the surgeon’s experience to a more germane one that encompasses considerations of the patient as a whole.

     

    Criterion 1 is significant in that there are lower extremity conditions including neurologic, musculoskeletal or other deficits where attempted preservation would offer no benefit to the patient. When these presentations are associated with debilitating pain, then this criterion would be met and consideration for an amputation at some level would be appropriate. This criterion would require that all attempts be made to mitigate the pain. Thus, an acute presentation (following traumatic accident, postoperative complications from prosthetic implantation, etc.) would arguably require some time to be allowed to pass before accepting these criteria.

     

    The issues regarding criterion 2 include preservation of the patient’s functionality and assumed morbidity and mortality of the presenting condition and that of the procedure. The goal of MENACE is to assure full consideration of all aspects of limb salvage versus amputation. Recognising that lesser procedures may provide both short- and long-term satisfactory outcomes, the issue of when to perform a lesser procedure and what that procedure may be, must be based on preservation of maximum functionality. For these reasons, attention must be directed to the patientspecific issues since information obtained provides the necessary elements required for a successful outcome. For example, the presence of distal pedal gangrenous changes in a diabetic neuropathic ulcer with a history of osteomyelitis poses a daunting problem. Not surprisingly, these findings would, in the vast majority of cases, lead to a strong recommendation for amputation. However, the usual discussion of potential complications and progression of disease state will generally lead to at least a discussion of the ‘benefits’ of simply removing the entire problem-containing lower limb. In contrast, the consideration of functionality is integral because it changes the discussion from one that obviates a potential progression of the presenting problem to one that recognises that retained maximum functionality allows ongoing quality-of-life based on retaining the limb. In simplest terms, if the extremity is still used to bear weight, provide propulsion in a wheelchair, transfer from chair to bed to commode, or even ambulate for any distance, then maintenance of that functionality takes on the highest priority. The goal becomes maximising the longevity and functionality of that extremity.

     

    The authors believe that the two keyhole criteria represent a mandatory check step for medical providers who either perform or refer to those performing lower extremity amputation. These two criteria need to be used to ascertain the appropriateness of amputation for a given patient. This represents a marked departure from the practice that the decision be based on the perception of perceived benefit of amputation.

     

    Initial evaluation of the patient’s presenting status with respect to the keyhole criteria should be undertaken. If the result is a decision to amputate, the MENACE scale assures that patient-centred factors are considered in the decision to amputate. Those factors placing the patient at risk for quality-of-life issues after surgery should be addressed well before amputation.

     

    Table 3

    The initial tool used by the authors was the 1–2 point scale to assess patient-centred factors. However, we recognised that the keyhole criteria were needed to focus the attention of the surgeon on what the authors felt were the two critical issues: pain and functionality.

     

    With the focus now placed on the patient, those factors that impact on their lives both pre- and postoperatively need to be considered. While there are an infinite number of both specific and general categories to be considered, we believe that those factors identified in Table 3 represent the most salient, recognising the interrelationship of these factors and others not specifically identified.

     

    The social status of the patient is integral to mental and physical wellbeing. Considerations must include: Who else is in the home? What will be the patient’s functional capacity both before and after the amputation? What is the expected effect on the family after amputation? Is the patient the primary breadwinner/caretaker for the family? Are there others who will be affected by the patient’s amputation status in the same environment (young children, teenagers, young adults, middle-agers)?

     

    Habitation factors must include: where does the patient live (both geographically and in terms of the actual residence)? The geographic location, including changes in elevation (mountainous, or San Francisco hills), whether there are stairs to navigate, or consistently functioning lifts, and old versus new construction (ADA, Standards for Accessible Design related to the Americans With Disabilities Act)15 are all considerations that must be addressed before amputation.

     

    Economic factors are the underpinning of what transpires with the patient and their direct family and friends. How will the patient’s economic status change after the amputation? Financial considerations are the bedrock on which much of the other issues achieve stability. Are they ready for retirement? Are they employable after amputation? Is there another breadwinner? Are they financially able to withstand loss of leg? What about the costs of treatment, prosthetics, devices? Are there accessible and available sources available to provide external financial support and can the patient access them (social security, disability insurance, etc.)? Is there adequate and sustained financial means either through a health insurance or other entity to pay for ongoing care including rehabilitation, care for any complications, medications, therapies, home health care, and if so for how long?

     

    Interpersonal support and functional issues have the potential to create effects that reverberate throughout the entire recuperative period and beyond. What other intrinsic/extrinsic factors do they have to contend with? Do they live with conditions such as a small cluttered house (hoarder), ‘bad’ neighbourhood, difficulty getting to the grocery store, doctors, and social events? Is there inter-family stress such as abusive or uncaring children or relatives?

     

    What psycho-emotional and self-perception issues are present? Do they already have body-centred issues (too fat, too skinny, too old, too sick …)? Is there a history of behavioural or mental health issues (depression, anxiety, obsessive compulsive disorder (OCD), schizophrenia, bipolar disorder, etc.)? How are they dealing with the potential amputation? Do they consider the recommendation for amputation a ‘death sentence’? Is there the opportunity to do something besides see the wound specialist all the time? How will they deal with the resultant disfigurement? The ultimate question is clearly: how important is that toe, foot, or leg to their life?

     

    An exhaustive online search of the available literature identified definitive criteria/guidelines for removal of the gallbladder, appendix and performance of caesarean sections as well as numerous other surgeries. However, regarding amputation of a lower extremity, the overwhelming majority of articles that even entertain the rationale for performing the procedure present surgeon-based clinical considerations as the primary decision criteria and mention patient-centred factors only in passing.

     

    Based on the experiences of the authors, there clearly needs to be a set of patient-centred criteria to juxtapose with the experiences of the surgeon and other providers integral to the decision-making process. We recognise that there are a myriad of compounding factors that affect provider and patient considerations that are easily overlooked and so a set of guidelines for evaluation such as the MENACE scale identifies those factors that can be easily evaluated and rectified.

     

    The MENACE scale including the keyhole criteria has been used by the primary author for 23 years in one form or another. Explanation and review of the MENACE critera has been undertaken with our patients for whom amputation was the only alternative offered before coming to our clinics. In clinical practice, numerous encounters have occurred with patients marked for amputation in which their presenting condition was clearly (and ultimately) salvageable. Based on extensive clinical use, we believe that the appropriate use of this tool can balance the patient’s presentation using both the accepted medical/surgical objective criteria and the less often considered patientcentred criteria. In those situations the decision for amputation gains more credence as evaluation progresses, for those MENACE scale categories in which the highest score (2 points) is not present, appropriate actions and interventions are taken to maximise that score. For example, the patient who lives in an upperfloor apartment with an unreliable lifts should have their residence changed to one with greater accessibility even if this is to occur immediately after the surgery. The planned change allows for the full score for that category to be considered as accomplished despite its implementation postoperatively. The same holds for caregivers needed in the home following surgery. The key to MENACE is to recognise that maximising a successful outcome after the elective performance of a lower extremity amputation must be based on resolving as many patient-centred stumbling blocks as possible. We recognise that the act of doing so may not be appropriate for the surgeon themselves but believe strongly that it can be appropriately achieved by other entities including social workers, local, state and federal entities.

     

    Based on our use of the MENACE scale in our own practices, we believe that a score of less than seven strongly suggests the highest potential for postoperative issues that will have an impact on the patient’s shortand long-term recovery and status. The failure to address identified issues both individually and collectively in the preoperative/perioperative periods may preclude a safe and complication-free recovery. MENACE was created to fill an unmet need. We understand that MENACE will require ‘real-life’ testing and validation. It is our expectation that when used alongside other criteria, it will provide a basis for expansion, revision, confirmation or deletion of the considerations we have proposed when a lower extremity amputation is considered.

     

    Conclusion

    The recommendation for, and performance of, a lower extremity amputation appears to be based primarily on criteria that remain undefined despite advances in all aspects of medicine. Although certain lower extremity presentations preclude safe attempts at limb salvage, there is clearly a trend towards performance based more on subjective criteria of the attending health-care providers than on clear objective patient-based criteria.

     

    Lower extremity amputation does not merely remove all or part of the lower extremity. The interdependence of structure and function, both before and after amputation, and the potentially catastrophic consequences of failing to consider these factors, mandates that there be a specific and definitive categorical assessment of patient-centred factors rather than the current criteria, which are based solely on the skill, education and experience of the medical providers. When these decisions are based solely on their own criteria rather than those of the patient—who represents the primary consideration regarding a successful outcome—then failure to identity and resolve potential patient-centred issues means that the patient is not truly the focus of the intended procedure, although they will suffer any untoward effects. The loss of a lower extremity does not merely mean that a pending problem has been resolved but that the potential loss of the limb now presents its own life-affecting challenges well beyond the time that the surgical incision heals.

     

    References
    1 Quality Improvements Organization. Strategies to Help Reduce
    Diabetes-Related Lower Extremity Amputations Among Minority
    Populations. April 2017, https://tinyurl.com/yd3hcgrn (accessed 7
    September 2017)
    2 Murdoch G, Bennett-Wilson A Jr, Amputation: Surgical Practice and
    Patient Management. Butterworth-Heinemann Medical, 1996.
    3 Tooms RE. Amputations. In: Crenshaw AH (ed). Campbell’s Operative
    Orthopedics (7th edn) Mosby-Year Book,1987: 597–637
    4 Ertl JP. Amputations of the lower extremity. Medscape. 2016. http://bit.
    ly/2uUFuEv (accessed 14 August 2011)
    5 Zeigler-Graham K, Mackenzie EJ, Ephraim PL et al. Estimating the
    prevalence of limb loss in the United States: 2005 to 2050. Arch Phys
    Med Rehabil 2008; 89(3): 422-429. https://doi.org/10.1016/j.
    apmr.2007.11.005
    6 Silbert S., Haimovici H. Criteria for the selection of the level of
    amputation for ischemic gangrene. JAMA 1954; 155(18): 1554–1558.
    https://doi.org/10.1001/jama.1954
    7 Book Notices: Handbook on Amputations JAMA 1942; 120(9):724.
    https://doi.org/10.1001/jama.1942.02830440066028
    8 Netherlands Society of Physical and Rehabilitation Medicine
    (Nederlandse Vereniging van Revalidatieartsen – VRA). Guideline: amputation and prosthetics of the lower extremities. Utrect. 2012. http://bit.ly/2uCbGRM
    9 Reyzelman A, Kim J. A guide to digital amputations in patients with
    diabetes. Podiatry Today. 2011; 24(9). http://bit.ly/2wX6Ew2 (accessed 14
    August 2011)
    10 Kalapataku V. Lower extremity amputations. UpToDate. 2017. http://
    www.uptodate.com/contents/lower-extremity-amputation (accessed 14
    August 2017)
    11 Karadsheh M. Amputations. Orthobullets.com. 2017. http://www.
    orthobullets.com/trauma/1052/amputations (accessed 14 August 2017)
    12 Brigham And Women’s Hospital Department of Rehabilitation
    Services. Physical therapy standard of care: lower extremity amputation.
    2011. http://bit.ly/2vwFFct (accessed 14 August 2011)
    13 Hakami, K. Pre-operative rehabilitation evaluation of the dysvascular
    patient prior to amputation. Phys Med Rehabil Clin N Am. 2009; 20(4):
    677-688. https://doi.org/10.1016/j.pmr.2009.06.015
    14 Bhuvaneswar CG, Epstein LA, Stern TA. Reactions to amputation:
    recognition and treatment. Prim Care Companion J Clin Psychiatry 2007;
    9(4): 303–308
    15 ADA. Information and technical assistance. standards for accessible
    design related to the Americans With Disabilities

    Association between controlling nutritional status (CONUT) score and amputation risk factors in …



    Association between controlling nutritional status (CONUT) score and amputation risk factors in T2DM patients with DFU

    Summary: January 28, 2026 retrospective analysis (n=387 T2DM DFU inpatients, Jan 2024–Jun 2025) links CONUT score (albumin, cholesterol, lymphocytes) to amputation. 40.3% amputation rate (all minor); amputation group had worse nutrition (lower albumin/prealbumin/Hb/PNI), higher CONUT, larger ulcers, more osteomyelitis/PAD/smoking. Amputation rose with CONUT severity (15.1% normal → 68.3% moderate-severe). Logistic regression: CONUT (OR=1.655/unit), osteomyelitis (3.817), PAD (12.602) as independent risks. ROC: CONUT AUC=0.705 (cutoff 3.5). Subgroup: association strong except HbA1c <7%. Malnutrition exacerbates healing delays/infection/vascular issues; early CONUT assessment/nutrition improvement could lower amputation in DFU.

    Key Highlights:

    • Risks: CONUT, osteomyelitis, PAD independent predictors.
    • Prediction: Good AUC; higher scores → poorer outcomes.
    • Implications: Routine nutritional screening in DFU care.
    • Relevance: Systemic factor in chronic diabetic wounds/amputation prevention.

    Read full article

    Keywords: CONUT score, DFU amputation, nutritional status, T2DM DFU

    Healogics® Promotes Diabetes Awareness to Improve Healing and Reduce Amputations for Diabetes-Related Wounds

    JACKSONVILLE, Fla., Nov. 1, 2022 /PRNewswire/ –As millions of Americans living with diabetes are also living with chronic wounds that won’t heal, Healogics® is raising awareness of diabetes-related wounds as part of the Healogics ninth annual Diabetes Awareness Campaign.

     

    Throughout November, Wound Care Centers® will educate the local community about the importance of awareness, early intervention and specialized care for diabetes-related chronic wounds, like diabetic foot ulcers. Local team members will also visit healthcare providers in surrounding areas to provide important information to help at-risk patients living with diabetes.

     

    Diabetes Awareness Infographic

    Diabetes Awareness Infographic

    There are more than 37 million Americans currently living with diabetes, according to the American Diabetes Association (ADA). Additionally, there are 96 million American adults who have prediabetes, leading to 1.4 million new diagnoses of diabetes every year. Diabetes-related wounds are a leading cause of limb loss, accounting for nearly 70 percent of cases undergoing lower extremity amputation in the United States.

     

    “This campaign is essential because early detection of diabetes-related wounds significantly reduces amputation risks. Diabetic foot ulcers are the leading cause of diabetes-related hospitalizations and lower-limb amputations. What starts as a small cut or blister can quickly progress into a non-healing wound with severe complications. With 50 percent of our patient population living with diabetes, we know firsthand that our awareness efforts can help improve the lives of those struggling with diabetes-related wounds,” said Healogics Chief Executive Officer Frank Williams.

     

    Many suffering from chronic wounds have been negatively affected by the COVID-19 pandemic as they have eschewed needed care during the past two-plus years. Untreated and undertreated wounds have resulted in amputation, according to a study from the ADA. Of the patients who have undergone one amputation, 55 percent will require amputation on the second leg. An amputation results in decreased quality of life, increased medical costs and a significantly higher risk of mortality.

     

    “Many people who come to the Wound Care Center® with chronic wounds are among the 37 million adults living with diabetes. Some were unaware that diabetes put them at greater risk for non-healing wounds. Encourage patients to check their feet every day. It’s imperative we help patients avoid the serious consequences of non-healing wounds, such as diabetic foot ulcers, by raising awareness of the risks and importance of daily foot screenings to help prevent an avoidable amputation,” said Healogics Chief Medical Officer Dr. William Ennis.

     

    Factors that may increase the risks of developing a chronic wound, such as a diabetic foot ulcer, include high blood sugar levels, poor circulation, immune system issues and nerve damage. Risk factors for diabetes include age, diet, activity level, obesity and heredity.

     

    Healogics recommends the following to help prevent diabetic foot ulcers:

     

    • Stop smoking immediately
    • Request comprehensive foot examinations each time you visit your healthcare provider (at least four times a year)
    • Examine your feet every day or have a family member inspect them
    • Take good care of your feet and clean your toenails
    • See your healthcare provider to care for corns and calluses
    • Choose supportive, proper footwear (shoes and socks)
    • Take steps to improve circulation such as eating healthier and exercising regularly

     

    Early detection and specialized care from a Wound Care Center® can reduce healing times and significantly reduce the risk of amputation.

     

    Contact Healogics to learn more about diabetic foot ulcers or if you have a wound that will not heal. To schedule an appointment, please call 1-800-379-9774 or visit Healogics.com.

     

    About Healogics
    Headquartered in Jacksonville, Fla., Healogics is the nation’s wound healing expert. Last year over 300,000 patients received advanced wound care through a network of over 600 Wound Care Centers. Healogics also partners with over 300 skilled nursing facilities to care for patients with chronic wounds and provides inpatient consults at more than 60 partner hospitals. As the industry leader, Healogics has the largest repository of chronic wound-specific patient data in the country. The Healogics Wound Science Initiative offers peer-reviewed research and advanced analytics in the pursuit of not only better outcomes, but a better way to provide care.

     

    SOURCE Healogics, LLC

     

    This article was originally published here

    Negative Pressure Wound Therapy Reduced Amputation Risk for Patient With Diabetic Wound

    A patient with a diabetic foot wound who underwent negative pressure wound therapy experienced good healing, reduced amputation risk, and no wound infection, suggesting the treatment method could be effective in other patients with similar wounds.

    A patient who received negative pressure wound therapy (NPWT) after undergoing surgical debridement for a diabetic wound saw improvements in healing capabilities and reduced risks of limb amputation, according to a recent case report published in SAGE Open Medical Case Reports.

    The report lends further support to previously published research that has shown NPWT to be effective at decreasing healing time, reducing ulcer area, and increasing healing rates of ulcers. NPWT has also been shown to aid patients with foot ulcers in achieving complete ulcer closure better than advanced moist wound therapy …

    Study provides new tool to assess amputation risk following popliteal vascular injury

    A large, multicentre cohort study provides a simple, practical method to effectively stratify patients preoperatively into low- and high-risk major amputation categories.

    According to lead author Leigh Ann O’Banion (University of California, San Francisco, San Francisco, USA), “traumatic popliteal artery injuries present a serious clinical challenge because they are associated with the greatest risk of limb loss of all peripheral vascular injuries, with major amputation rates of 14–25%.” … read more

    Lipodystrophy, a Common Risk in Diabetic Foot Ulcers

    Patients with lipodystrophy have a high risk of diabetic foot ulcers, especially in the younger population.

    Lipodystrophy is a disorder characterized by an abnormal fat distribution in the body. It can refer to an irregular loss or accumulation of fat tissue, and can even cause macrovascular and microvascular complications. Diabetic foot ulcers are a chronic complication of diabetes that can cause loss of lower limbs from amputations. DFU is also a risk factor in diabetes-related mortality. Previous studies have not found a correlation between lipodystrophy and DFU or even a treatment to reduce these complications. Lipodystrophy is a complication caused mainly by familial partial lipodystrophy. This study used an observational retrospective cohort study to understand the correlation between these two disorders, lipodystrophy and diabetic foot ulcers, and which age was the most critical … read more

    New Net Health Innovation Can Predict Risk of Amputations and Wound Healing Rates

    Net Health recently announced the addition of two pioneering predictive analytic capabilities embedded in the workflow of the company’s widely used electronic health record (EHR) platform.

    Offering artificial intelligence-based capabilities, the Net Health Wound Care software platform now includes the Risk of Amputation Indicator, developed to reduce the risk of amputations, and the Wound Healing Velocity Indicator, developed to predict wound healing rates, according to the company. Net Health says both capabilities will provide insights needed to develop optimal patient therapies, implement effective interventions, and plan treatment paths that will improve outcomes … read more

    Predictive model identifies risk factors for major adverse limb events in diabetes

    A risk score may be able to identify adults with type 2 diabetes at high risk for major adverse limb events, including in those without a history of peripheral artery disease, according to a study published in Diabetic Medicine … “This post hoc analysis of the EXSCEL trial yielded a predictive score for major adverse limb events among participants with diabetes that had a C statistic of 0.822, generally considered as very good … … continue

    Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes

    Patients with type 2 diabetes who took liraglutide were at a lower risk for foot amputation, according to a study recently published in Diabetes Care.

    Researchers completed a post hoc analysis on data collected during the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial to determine the effect of liraglutide on rates of diabetes-related foot ulcers in patients who were also at high risk for cardiovascular events. Patients in the LEADER study were randomly assigned to either an intervention arm (n=4668), receiving 1.8 mg of liraglutide a day, or a control arm (n=4672), receiving a placebo. The study continued for 5 years with an average follow-up time of 3.8 years. A diabetes-related foot ulcer was … read more

    Liraglutide May Lower Risk for Foot Amputation in Type 2 Diabetes

    Patients with type 2 diabetes who took liraglutide were at a lower risk for foot amputation, according to a study recently published in Diabetes Care.

     

    Researchers completed a post hoc analysis on data collected during the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial to determine the effect of liraglutide on rates of diabetes-related foot ulcers in patients who were also at high risk for cardiovascular events. Patients in the LEADER study were randomly assigned to either an intervention arm (n=4668), receiving 1.8 mg of liraglutide a day, or a control arm (n=4672), receiving a placebo. The study continued for 5 years with an average follow-up time of 3.8 years. A diabetes-related foot ulcer was specified as a medical event of special interest, and all complications related to the ulcer were documented.

    read more

    SGLT2 inhibitor therapies may raise risk for amputation

    Adults with type 2 diabetes and established CVD prescribed SGLT2 inhibitor therapy have a twofold increased risk for lower-limb amputation and diabetic ketoacidosis compared with patients prescribed a GLP-1 receptor agonist, according to study findings presented at the European Society of Cardiology Congress.

    “Sodium glucose cotransporter 2 inhibitors are playing an increasingly prominent role in the treatment of diabetes, following the reduced risk of major adverse cardiovascular events and heart failure outcomes seen in the EMPA-REG Outcome trial with empagliflozin [Jardiance, Boehringer Ingelheim] and in the CANVAS study with canagliflozin [Invokana, Janssen],” Peter Ueda, MD, PhD, from the department of medicine at the Karolinska Institute in Solna, Sweden, said during a presentation here. “Concerns exist regarding the safety of the drugs, with signals of serious adverse events emerging from clinical trials, case reports and observational studies.” … read more

    New telemed add-on manages risk, aims to avert lawsuits in wound care

    A new technology solution hopes to help long-term care professionals avoid potential lawsuits, long before a wound even heals.

     

    Illinois-based Telemedicine Solutions LLC has announced the launch of its WoundRounds Defender, which is a feature set of its telemedicine platform for treating wounds. The add-on helps those in skilled nursing to automate documentation, from admission to discharge, as well as photographing wounds of high-risk patients.

     

    This can come especially in handy, the company notes, for documenting complex wounds, pressure ulcers and infections, which can pose the greatest potential liability to long-term care operators.

     

    “WoundRounds Defender gives healthcare providers legal peace of mind so they can focus on delivering the best care and patient outcomes,” Mike Diamond, CEO of Telemedicine Solutions, said in a release. “The launch of WoundRounds Defender further positions WoundRounds as the leading wound management and risk prevention solution for healthcare providers.”

    Prevention of hospital-acquired foot pressure injuries

    Assessment and consideration of foot risk factors is essential for proactive prevention of hospital-acquired foot pressure injuries

     

    The research outlined in this article aimed to see if high-risk feet were also identified as ‘at risk of ulceration’ by the Braden Score. One-hundred-and-thirty-two patients had foot risk stratified by a podiatrist and their admission Braden pressure injury (PI) risk level was compared. Only 36% were decreed to be at the same level of risk by both methods. The lack of agreement was demonstrated by a very low Kappa score. The Braden score underestimated PI risk to feet for 52% of the study population. Therefore, the authors concluded that less reliance on the Braden score is needed for the implementation of prevention to reduce rates hospital-acquired foot PIs … read more

    At-Risk Patient: Diabetic Foot Ulcers

    Patients with diabetes have a higher risk of ulceration, typically on the lower extremities. Other factors contributing to the risk of foot ulceration include peripheral neuropathyperipheral arterial diseaseinfection and pressure.

    Symptoms of Diabetic Foots Ulcers

    Neuropathy, a major contributing factor in the development of diabetic foot ulcers, may present as a stinging, burning or shooting pain in the lower extremities that over time may progress to a loss of sensation in the feet or may initially develop as a progressive loss of sensation. This loss of feeling can cause patients with diabetes to further injure their feet and legs, opening them to infection and thus, ulceration.

    read more

    Glycemic Control Reduces Risk of Diabetic Foot Ulcers in Type 1 Diabetes

    Early intensive glycemic control decreases the long-term risk of diabetic foot ulcers (DFUs) in patients with type 1 diabetes (T1D), according to a study in Diabetes Care … Researchers evaluated the effects of intensive treatment (INT) vs conventional treatment (CON) in patients with T1D from the Diabetes Control and Complications Trial (DCCT) on the subsequent risk of DFU and lower-extremity amputations (LEA) in the follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study … read more

    The Importance of Standardization in Pressure Injury Risk Assessment

    Pressure injuries are common among patients who experience extended exposure to pressure on a bony prominence or shear to areas of poor turgor, two factors that lead to constriction of a patient’s blood supply to the exposed area. A patient who is bedridden or has certain chronic conditions, such as diabetes,1 is more likely to develop a pressure injury. When mechanical force is imposed on the skin, it can result in poor blood flow and damage to the bone-muscle interface, thus making tissue sensitive and painful. For patients with limited mobility, this can be especially frustrating because they may not be able to adjust positions or medical equipment. If pressure injuries are left untreated or unnoticed, they can also become infected and even enter muscle and bone. Risk assessment tools are available to assess pressure injury risk and can work in tandem with practice standardization, thereby leading to effective treatment plans for practitioners and patients … read more


    If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

     

    Managing Wound Risks in Patients on TKIs

    Managing Wound Risks in Patients on TKIs

    Tyrosine kinase inhibitors (TKIs), widely used in cancer therapy, can impair wound healing by inhibiting pathways critical for tissue repair—such as VEGFR, EGFR, FGFR, and PDGFR. A recent review highlights the need for tailored perioperative planning and interdisciplinary collaboration to mitigate these risks.

    Key Highlights:

    • Mechanism of Impaired Healing: By blocking angiogenesis, fibroblast activity, and keratinocyte function, TKIs increase risk for delayed healing, dehiscence, ulceration, and fistula development. Common agents include sunitinib, cabozantinib, lenvatinib, and sorafenib. :contentReference[oaicite:1]{index=1}
    • Clinical Evidence: Of the 24 TKIs reviewed, many are cited in phase II trials and case reports showing significant wound complications—e.g., cabozantinib associated with grade 3–5 healing problems in ~24% of patients. :contentReference[oaicite:2]{index=2}
    • Perioperative Strategies: Since TKIs’ half-lives vary (e.g., sunitinib ~51 hours), therapy cessation 1–2 weeks before surgery is advised, with resumption only after confirmed healing. :contentReference[oaicite:3]{index=3}
    • Interdisciplinary Coordination: Optimal care relies on collaboration among dermatologists, surgeons, and oncologists—especially for patients undergoing skin surgery like Mohs, grafting, or chronic wound management. :contentReference[oaicite:4]{index=4}

    This review underscores the importance of awareness among dermatology and surgical teams when treating patients on TKIs, ensuring appropriate timing of interventions to support wound integrity.

    Read the full article on the Dermatology Times website.

    Keywords:
    TKI wound healing,
    tyrosine kinase inhibitors,
    perioperative management,
    angiogenesis,
    dermatology-oncology collaboration

    Systematic Review: Anterolateral Thigh Flap Outcomes in High-Risk Diabetic Foot Reconstruction



    Systematic Review: Anterolateral Thigh Flap Outcomes in High-Risk Diabetic Foot Reconstruction

    Summary: Meta-analysis of 28 studies (n=1,147 limbs) evaluating anterolateral thigh (ALT) free flaps for diabetic foot reconstruction in high-risk patients (neuropathy, PAD, CKD, poor glycemic control). Overall flap survival 92.4%, complete healing 89.1%, limb salvage rate 93.7% at mean 28-month follow-up. Complications: partial necrosis 9.8%, re-operation 12.4%. ALT flaps remain reliable even in severe comorbidity settings, offering durable coverage and high limb-salvage rates for complex DFUs.

    Key Highlights:

    • Studies: 28 (2010–2025).
    • Flap survival: 92.4%; healing: 89.1%; limb salvage: 93.7%.
    • Comorbidities: CKD, PAD, poor HbA1c tolerated.
    • Complications: Partial necrosis 9.8%, re-operation 12.4%.
    • Authors: Multiple (systematic review team).

    Read full meta-analysis

    Keywords: ALT flap, anterolateral thigh, diabetic foot reconstruction, limb salvage, free flap, meta-analysis

    Reducing the Risk of Surgical Wound Complications



    Reducing the Risk of Surgical Wound Complications: Best Practice Approaches in Surgical Wound Care Study Day

    Summary: The Society of Tissue Viability’s virtual study day (Dec 4, 2025, 9:30am-4pm via Zoom) explores causes of surgical wound complications across specialties and evidence-based prevention strategies. With ~10M surgical wounds annually in the UK (20% failing to heal in 12 months, costing the NHS billions), the event targets clinicians in pre/intra/post-op care, offering up to 5 hours of NMC participatory learning for revalidation. Free registration (bookings closed, but recordings may be available); focuses on dehiscence, NPWT, antimicrobials, and device injuries.

    Key Highlights:

    • Agenda: C-section dehiscence (Anna Thompson), classification (Heidi Sandoz), cosmetic surgery management (Laura Spence), NPWT in orthopedics (Lucia Gallagher), airway fixation (Dawn Stott), topical antimicrobials (Paulo Ramos).
    • Speakers: Sarah Gardner (welcome), plus experts from Guy’s & St Thomas’, Hertfordshire NHS, Royal Marsden, Charing Cross Hospital.
    • Outcomes: Understand risk factors, classification, surgical/antimicrobial strategies, NPWT use, device prevention; Q&A after each session.
    • Location: Online (Zoom); free, but limited spots.
    • Implications: Equips teams to reduce 20% non-healing rate; relevant for tissue viability nurses, AHPs, podiatrists.

    Event page & registration

    Keywords: surgical wound, dehiscence, NPWT, antimicrobials, device injury, Sarah Gardner, Anna Thompson, Heidi Sandoz

    Healthcare Facilities, Risk Management Organizations & Insurance Companies Need to Revolt Over US Pressure Injury Policy



    The Last Straw: Healthcare Facilities, Risk Management Organizations & Insurance Companies Need to Revolt Over US Pressure Injury Policy

    Summary: Dr. Caroline Fife strongly criticizes current US pressure injury policy, particularly the NQF Serious Reportable Events (SRE) list and Joint Commission alignment. She argues that classifying most Stage 3 and 4 pressure injuries (and unstageable/DTIs) as “never events” ignores medical reality in critically ill patients. With the broadened 2016 staging definitions, many minor ulcers are now labeled Stage 3, fueling lawsuits and massive financial burdens on hospitals. She urges facilities, risk managers, and insurers to organize and advocate for evidence-based policy changes.

    Key Highlights:

    • Stage 3+ pressure injuries are now often treated as sentinel events regardless of preventability
    • Policy fails to account for medically unavoidable ulcers in unstable/critically ill patients
    • Calls for unified pushback from healthcare organizations and insurers
    • Author: Caroline Fife, MD

    Read full blog post

    Keywords: pressure injury policy, Caroline Fife, never events

    Risks and Diagnosis of Diabetic Foot Infections

    Wound care clinicians deal with foot infections all the time, but when the patient is also diabetic, an infection can progress rapidly to a critical state. In fact, it is estimated that around 56% of diabetic foot ulcers become infected, and an infected foot wound precedes about two-thirds of amputations.  Being able to treat diabetic foot infections promptly – before they progress too far – helps prevent amputations, which is why your role is so crucial to a patient’s well-being.

    What are the risk factors?

    If you are treating a diabetic patient with a foot infection, there are a number of risk factors to consider. These include:

    • 30-day-old wounds
    • Wounds that go down to the bone
    • Recurrent foot infections
    • Peripheral vascular disease
    • An etiology from trauma

    In particular, be on high alert with your diabetic patients for what they call an occult (hidden) infection … read more

    Diabetes doubles risk for hospital-acquired foot ulcers

    Patients with diabetes have at least double the risk for developing hospital-acquired foot ulcers vs. those without diabetes, according to a study published in BMJ Open Diabetes Research & Care … In a prospective, multilevel regression analysis, Frances Wensley, PhD, MBBS,formerly of the Royal Free Hospitals NHS Foundation Trust in London, and colleagues analyzed data from 18,946 patients with 28,642 admissions of at least 2 days to the Ipswich Hospital NHS Trust between October 2008 and September 2010, including 3,076 individuals with diabetes with 5,043 admissions. Patients included in the analysis were aged at least 50 years and developed a hospital-acquired foot ulcer at least 48 hours after hospital admission … read more

    Amputation-free survival in 17,353 people at high risk for foot ulceration in diabetes

         a national observational study

     

    Diabetic foot ulcers and amputations are devastating and much feared complications of diabetes. Between 15% and 34% of people with diabetes develop a foot ulcer during their lifetime, with more than half acquiring infections that may result in lower extremity amputations causing disability, extensive periods of hospitalisation, and premature mortality. The incidence of major amputation ranges from 0·2 to 2·0 per 1000 people in those with diabetes [4, 5]. Major or minor amputation also increases the risk of additional subsequent amputations [6]. Foot ulcers are the costliest microvascular complication of diabetes …Amputations in people with diabetes have a significant impact on ambulation, body care, movement and mobility, resulting in an inability to perform daily tasks and often a loss of employment [6] impacting on the wider family. Clinical epidemiology studies suggest that foot ulcers precede around 85% of non-traumatic lower extremity amputations in individuals with diabetes and hence ulcer prevention is important. Previous studies have reported that apart from severity of ulcer … read more

    Elevated obstructive sleep apnoea risk score is associated

         with poor healing of diabetic foot ulcers: A prospective cohort study

     

    We studied 94 consecutive people (69% men) with diabetic foot ulcers (Type 2 diabetes,n=66, Type 1 diabetes, n=28) attending a university hospital foot unit. All participants were screened for obstructive sleep apnoea using the STOP‐BANG questionnaire, with a score ≥4 identifying high risk of obstructive sleep apnoea. The primary outcome was poor diabetic foot ulcer healing, defined as diabetic foot ulcer recurrence (diabetic foot ulcers which healed and re‐ulcerated in same anatomical position) and diabetic foot ulcer persistence (no evidence of healing on clinical examination). All participants were evaluated at 12 months … read more

    Diabetes doubles risk for hospital-acquired foot ulcers

    Patients with diabetes have at least double the risk for developing hospital-acquired foot ulcers vs. those without diabetes, according to a study published in BMJ Open Diabetes Research & Care.

     

    In a prospective, multilevel regression analysis, Frances Wensley, PhD, MBBS,formerly of the Royal Free Hospitals NHS Foundation Trust in London, and colleagues analyzed data from 18,946 patients with 28,642 admissions of at least 2 days to the Ipswich Hospital NHS Trust between October 2008 and September 2010, including 3,076 individuals with diabetes with 5,043 admissions. Patients included in the analysis were aged at least 50 years and developed a hospital-acquired foot ulcer at least 48 hours after hospital admission. For all admissions, the analyses included data on diabetes, heel ulcer, length of stay and other covariates. The researchers compared patients with vs. without diabetes … read more

    Custom-made indoor footwear may be beneficial for people with diabetes at risk for ulceration

    “Custom-made footwear is an effective intervention to help prevent foot ulceration and is recommended in international guidelines,” but ensuring consistent use is “a challenge,” particularly indoors, explain Sicco Bus and co-authors from Amsterdam University Medical Center in the Netherlands … To address this issue, the researchers carried out a study of 31 people with type 1 (23%) or type 2 (77%) diabetes with moderate-to-high risk for plantar foot ulceration who already possessed custom-made footwear prescribed by a rehabilitation medicine specialist. These people were provided with additional custom-made footwear specifically designed for indoor use, with the same biomechanical offloading capacity as their existing footwear … read more

    Risk Factors for PAD Development

    Manesh Patel MD, Christopher Granger MD and Larry Allen MD

     

    One thing that you mentioned about risk factors is interesting, and I’m going to ask Larry, how do you usually think about comorbidities, including heart failure? I tell our fellows in clinic, if the patients don’t smoke and don’t have diabetes, those are overrepresented in PAD [peripheral artery disease]. This comes from data that are a bit older, but the PARTNERS study where they evaluated patients doing an ABI [ankle-brachial index] in primary care clinics, about 7000 patients, and they found that a quarter of them had PAD. If they were 50 years old and over, they tested whether they had diabetes and tobacco use, or over 70. Unrecognized PAD probably exists in about a quarter [of patients] in our primary care clinics, and it fits with these comorbidities … read more


    If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

     

    Understanding the Risk: Asian Americans and Diabetes

    by Joanne Saunders

     

    Why do Asians and Asian Americans face an increased risk for diabetes and prediabetes? Joanne Saunders shares her father’s diabetes story to help shed light on this concerning problem … My father (pictured here with his grandson) was a 67-year-old Chinese American who immigrated to the United States in 1971. At 5’5” and approximately 150 pounds, he entered the emergency room on July 30, 2017, complaining of a severe headache, vomiting, and nausea … read more


    If you find WoundCareWeekly.com of value please consider a monthly donation to help cover expenses and keep this website going.

     

    Risk Factors for Multidrug-Resistant Organisms Infection in Diabetic Foot Ulcer

    Diabetic foot ulcer (DFU) is one of the most serious complications of diabetes.1 Epidemiological investigation found that the global prevalence of DFU is 6.3%, and what is more troublesome is that DFU also has a high recurrence rate.3 Cohort studies have shown that DFU have a high mortality rate in both developed and developing countries, with a 5-year mortality rate of up to 42%. With high morbidity and mortality, DFU has been the main cause of nontraumatic lower-limb amputations. We have developed a model for predicting the risk of early DFU, which may potentially guide early intervention. Hyperglycemia impair immune cells activity in eliminating pathogens, while severe infection can cause stress hyperglycemia. The interaction of the two ways has resulted in a rapid development of diabetic foot infection (DFI) and sometimes a necrotizing abscess can be developed in just 6 days. Early empiric antibiotic treatment is necessary due to the long culture time of microorganisms and the lack of basic microbiology laboratories. But Multidrug-resistant organisms (MDROs) infection is easy to make antibiotic treatment failure, increasing the difficulty of diabetic foot treatment … read more

    The Growing Risk of Wound Care Negligence for Home Health Providers

    With wound care services becoming more prevalent in the home health care world, the risk of being liable for negligence has become greater for providers … Due to the Patient-Driven Groupings Model (PDGM) and changing demographics — among other reasons — wound care has gotten more popular among home health care providers of late. And yet, it comes alongside cautionary tales that many providers may not be completely attuned to … read more

    Amputation risk up for Black, rural residents with diabetic foot ulcers

    Rural patients identifying as Black have more than a 10 percent absolute increased risk for major leg amputation or death compared with the overall cohort of adult Medicare patients hospitalized with a diabetic foot ulcer, according to a study published online April 21 in JAMA Network Open … Meghan B. Brennan, M.D., from the University of Wisconsin in Madison, and colleagues examined the associations of race, ethnicity, rurality, and/or neighborhood disadvantage with outcomes among U.S. patients with diabetic foot ulcers. The analysis included 124,487 patients hospitalized with diabetic foot ulcers (2013 to 2014) identified through the U.S. National Medicare Claims Data Database … read more

    Key risk factors for diabetic foot reinfections uncovered in study

    by Claire Kowalick, 

    Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. About one in six people in San Antonio have type 2 diabetes, and a third of residents are prediabetic, according to the American Diabetes Association.

    Type 2 diabetes is a chronic condition in which the body cannot produce enough insulin or use insulin properly and, if left uncontrolled, can lead to high blood sugar, heart disease and kidney failure. It also predisposes people to foot ulcers, of which almost 50% become infected, subsequently leading to hospitalization and potentially amputation of part of the foot or a lower limb … full article

    related:

    Texas has one of the highest rates of diabetes in the country, with more than 2.7 million Texans diagnosed with the condition. This epidemic has significant implications for healthcare systems, particularly in the management of complications like diabetic foot ulcers (DFUs). In San Antonio, where approximately one in six residents has type 2 diabetes and a third of the population is prediabetic, the risk of developing DFUs is alarmingly high.

    Diabetic foot ulcers result from a combination of neuropathy, poor circulation, and impaired immune response, all of which are common in individuals with long-standing diabetes. Without proper intervention, these ulcers can progress to severe infections, leading to hospitalizations, amputations, and increased mortality rates. Given the high prevalence of diabetes in Texas, hospitals and wound care centers face mounting challenges in treating and preventing these wounds effectively.

    The economic burden of DFUs is also substantial. Studies indicate that treating a single DFU can cost tens of thousands of dollars, with the total cost of diabetic foot care in the U.S. exceeding billions annually. In areas like San Antonio, where diabetes rates are disproportionately high, local healthcare facilities must prioritize specialized wound care services, early detection, and preventive measures such as total contact casting (TCC) to offload pressure from wounds and enhance healing.

    Community-wide initiatives are essential to combat this growing crisis. Increasing awareness about proper foot care, expanding access to podiatric and wound care specialists, and implementing preventive strategies—such as routine screenings for neuropathy and peripheral artery disease (PAD)—can significantly reduce the incidence and severity of DFUs. Additionally, addressing social determinants of health, such as limited access to quality healthcare, lower socioeconomic status, and dietary challenges, is crucial in mitigating the long-term consequences of diabetes-related foot complications.

    As Texas continues to grapple with rising diabetes rates, proactive intervention and innovative wound care solutions will be key in preventing DFUs and improving patient outcomes.

    Parabola Post-Transmetatarsal Amputation

    Challenging Paradigm: Parabola Post-Transmetatarsal Amputation

    Summary: Published on the HMP Global Learning Network’s Podiatry Today platform, this article challenges conventional thinking about post-transmetatarsal amputation (TMA) biomechanical management by introducing and examining the parabola concept as a framework for understanding and addressing the altered pressure distribution and gait mechanics that result from TMA. Transmetatarsal amputation — removal of all metatarsal heads and the forefoot distal to a mid-metatarsal level — is one of the most common limb-salvage procedures in diabetic foot surgery, performed to avoid higher-level amputation when forefoot infection or gangrene is confined to the anterior foot. However, TMA is associated with a high risk of post-operative complications, including residual stump wound dehiscence, equinus deformity due to loss of forefoot leverage and altered Achilles tendon mechanics, re-ulceration of the stump and heel from abnormal plantar pressure redistribution, and ultimately progression to below-knee amputation (BKA) in a substantial proportion of patients. The parabola concept, as discussed in this article, refers to the natural arc of metatarsal head progression from the first to fifth metatarsal in the intact foot — with the second metatarsal typically being the longest and forming the apex of the parabolic curve. This parabolic architecture is central to normal plantar pressure distribution during gait. Following TMA, the residual metatarsal stumps create an altered parabola profile that significantly changes biomechanical loading patterns across the stump, heel, and midfoot. The article argues that understanding the residual parabola — its asymmetry, bony prominences, and pressure concentrations — is essential for designing effective post-TMA footwear, custom molded insoles, and offloading strategies. Clinical considerations discussed include the role of tendo-Achilles lengthening (TAL) in preventing equinus deformity post-TMA, the design of post-TMA prosthetic filler devices and digital replacements, footwear modifications for appropriate forefoot filler, stump wound surveillance protocols, and recognition of early re-ulceration risk. HMP Global Learning Network platform requires JavaScript and free account registration to access.

    Key Highlights:

    • TMA re-ulceration risk: following transmetatarsal amputation, 25–50% of patients develop complications including stump wound breakdown, re-ulceration, or progression to higher-level amputation — making post-TMA biomechanical management one of the highest-stakes domains in diabetic limb preservation
    • Parabola concept: the natural metatarsal parabola (with the second metatarsal as the longest and highest-pressure point during push-off) is disrupted by TMA, creating residual bony prominences and altered load concentration points that drive stump re-ulceration if not addressed with customised offloading
    • Equinus risk: loss of forefoot lever arm following TMA leads to relative Achilles shortening and equinus deformity — increasing heel strike forces and stump pressure during gait; tendo-Achilles lengthening (TAL) is a key adjunct in post-TMA management for at-risk patients
    • Footwear and orthotic design: post-TMA footwear must accommodate the residual stump, provide appropriate forefoot filler (to restore push-off mechanics and cosmesis), incorporate custom-molded total contact insoles designed for the altered parabola profile, and prevent shear and pressure concentration at bony stump margins
    • Wound surveillance post-TMA: the stump wound represents a high-risk chronic wound site — circumferential stump assessment, early identification of callus formation, bony prominence pressure mapping, and regular podiatric review are essential components of a structured post-TMA care protocol
    • Access note: full article accessible via the HMP Global Learning Network at hmpgloballearningnetwork.com/site/podiatry — requires JavaScript and free account registration; part of the Podiatry Today continuing education and clinical content series

    Read full article

    Keywords: transmetatarsal amputation wound carepost-TMA re-ulceration preventiondiabetic foot amputation biomechanicsmetatarsal parabola offloadingequinus deformity diabetic footlimb salvage foot surgery outcomes

    HMP Global Learning Network / Podiatry Today

    Understanding Standards for Beds and Mattresses



    Understanding Standards for Beds and Mattresses: Pressure Care Devices Flammability Safety Criteria

    Summary: June 2, 2025 blog from the Society of Tissue Viability reviews flammability and safety criteria for pressure care devices (mattresses, cushions) used in pressure ulcer prevention. Medical devices exempt from domestic furnishings fire regs; key standards include BS 7176 (cigarette/flame/Crib tests), BS ISO 16840-15 (surrogate cigarette test for cushions), and distinctions between ignition resistance/retardancy. Fire retardants pose biocompatibility risks (skin contact concerns). Proposes risk matrix scoring environmental factors (e.g., sprinklers, smoking, oxygen use), user mobility/behavior, and device type to guide selection—low fire risk allows focus on tissue protection; higher risks require trade-offs. Emphasizes clinician procurement based on balanced assessment to minimize both fire hazards and pressure injuries.

    Key Highlights:

    • Standards: BS 7176/Crib 5/7, BS ISO 16840-15 (NiCr coil test).
    • Risks: Noxious gases, post-wash changes; higher in domestic/institutional vs. hospital with suppression.
    • Recommendations: Risk matrix for procurement; prioritize pressure relief in low-fire settings.
    • Implications: Balances safety for vulnerable patients (elderly, immobile) in wound prevention programs.

    Read blog

    Keywords: pressure care devices, flammability safety, pressure ulcer prevention, BS 7176

    1M diabetic people in Egypt at risk of amputation given hope by Sound Foot initiative

    CAIRO – 4 October 2021: A total of L.E. 15 million have been allocated to support “Sound Foot” initiative to reduce the risks of diabetes, according to a Monday statement by the Ministry of Solidarity.

    Some L.E.5 million of that budget will go to raising awareness on the diabetic foot and early detection. L.E. 10-15 million will go to treatment.

    On Monday, Maker of Good Development, a charity organization that was established five years ago, held a conference to launch the initiative as part of the presidential initiative of Haya Karima. Minister of Solidarity Nivine el-Kabbag said in the conference that the Sound Foot initiative is a … read more

    Wearable Devices For Diabetics At Risk Of Diabetic Foot Ulcers

    A US-Qatar joint research project, involving different studies carried out by the Hamad Medical Corporation (HMC), the Qatar Foundation, and several institutions and companies across the US, developed innovative and useful wearable devices for diabetics, which can help the patients either prevent and manage or even treat diabetic foot ulcers.

     

    By gathering the data from all the studies, the research project earned the Best Research Project Award at Qatar Foundation’s Annual Research Conference, held earlier in 2018.

     

    Research of significant importance for the world
    The project, of a considerable importance for Qatar, as the International Diabetes Federations assessed that about 23% of the country’s population has diabetes, while the diabetic foot ulcers are the primary reason for hospitalization, is also massively important for the world, as the nowadays unhealthy dietary habits increase the risks of diabetes development, worldwide … read more

    Barriers to Prevention and Timely Presentation of Diabetic Foot Ulcers: Perspectives of Patients from a High-risk Urban Population in the US

    Diabetic foot amputation is a preventable complication that is increasing in incidence in the United States, with disparities across geography, race, ethnicity, and income. This qualitative study explored the experiences of people in a low-income urban area in the United States in preventing and obtaining care for foot ulcers. Sixteen adults with foot ulcers were identified through purposive sampling based on records of hospital stays and primary care visits. Semi-structured interviews were transcribed and analyzed for key themes. Participants described inadequate understanding of diabetic foot disease: many sought care only after developing advanced symptoms. They identified social and health system factors as barriers to timely access to care. Some participants described a realization of the seriousness of their condition and an ability to improve self-care after developing an ulcer. Patients’ experiences can inform the design of amputation-reduction initiatives to achieve more desirable results, including enhanced self-management capabilities, timely access, and attention to social determinants … read more

    Legal Perils and Pitfalls of Wound Care: Risk Factors for Unavoidable Ulcers

    According to the Agency for Healthcare Research and Quality,1 more than 17,000 lawsuits related to pressure ulcers are filed annually in the United States, second only to wrongful death lawsuits. One of the greatest gifts to defense attorneys was when the Centers for Medicare & Medicaid Services (CMS) published F-Tag 314, finally acknowledging that some ulcers can occur despite best care. The facility essentially can maintain, “Hey, we did everything we were supposed to, and despite that, the patient developed that pressure ulcer”—that is, the ulcer was unavoidable. To prove unavoidability, proper documentation (proof) of best care needs to be in place, as well as documentation that all proper prevention and treatment measures were implemented … read more

    Vitamin D deficiency increases risk for diabetic foot ulcer

    Adults with diabetes and severe vitamin D deficiency are three times more likely to develop a diabetic foot ulcer than similar patients with sufficient vitamin D levels, according to findings from a meta-analysis published in Nutrition & Diabetes … “Vitamin D has been suggested to play an important role in many chronic diseases, such as diabetes,” Yimin Chai, MD, PhD, professor in the department of orthopedic surgery at Shanghai Jiao Tong University, China, and colleagues wrote. “Low serum vitamin D levels are associated with insulin resistance, impaired beta-cell function and the development of [diabetes]. There is also ongoing interest in the association between lower level of vitamin D and diabetic complications.” … read more

    ‘Amputated limb every two hours’: Experts warn Aussies against health risk

    For a health issue that has cost the Australian health care system $1.6 billion every year and has a mortality rate worse than many cancers, diabetic foot disease is one of the country’s least known major health problems … The condition typically develops from trauma caused by peripheral neuropathy or peripheral arterial disease, which is complicated by infection. Neuropathy is a nerve condition that can lead to pain, numbness and tingling and is one of the major factors in diabetic foot disease … read more

    Corstrata Announces Availability of New Tech Empowered

         Diabetic Foot Ulcer & Amputation Prevention Solution

     

    CORSTRATA, a provider of digital healthcare IT solutions and services for wound management, announced today the availability of the company’s new Diabetic Foot Ulcer & Amputation Prevention Solution. The Solution is designed to prevent costly and complicated wounds from developing and is the first comprehensive program that leverages state-of-the-art technology and a team of top-tier Board Certified Wound Clinicians for the early detection of ulcers that often lead to hard-to-heal wounds and amputations among the growing U.S. diabetic population.

     

    Diabetic foot ulcers (DFUs) are a common, limb-threatening and expensive complication of Type 1 and Type 2 diabetes. Today, more than 30M people in the U.S. have diabetes and more than 1.7M suffer from new DFUs per year with a 40% reulceration rate. 80K of these diabetics ultimately require an amputation and the risk of death at 5 years for DFU patients is 2.5 times as high as the risk for a patient with diabetes without a foot ulcer.

     

    “The Corstrata Diabetic Foot Ulcer and Amputation Solution offers an important advancement in both the detection and prevention of one of the most costly and complex types of wounds to heal,” said Katherine Piette, Chief Executive Officer and Founder, Corstrata. “The mobile and remote monitoring technology combined with our deep clinical expertise in diabetic foot ulcer prevention and wound management, enable us to help payers and value-based care organizations significantly reduce their risk and costs associated with ulcerations in diabetic members.”

     

    The Corstrata program is a comprehensive end-to-end technology-enabled solution that uses the HIPAA compliant, Corstrata Intervention & Engagement mobile app and the industry’s only FDA approved smart thermometric mat. The Solution is designed to help value-based care organizations and payers with the following:

    •     High-Risk Patient Identification
    •     Program Enrollment
    •     Daily Remote Patient Monitoring
    •     Member Engagement & Education
    •     Timely Evidenced-Based Intervention for Prevention of DFU
    •     Empowering Members for Self-Management

     

    “Research indicates that the use of early detection technology, coupled with evidence-based interventions, can prevent 75% of foot ulcers in this high-risk population,” said Joseph Ebberwein, Chief Financial Officer and Founder, Corstrata. Lower extremity amputation studies and clinical trials have shown that Diabetic Foot Ulcer and Amputation prevention solutions can greatly reduce costly hospital visits and procedures associated with ulcerations and amputations, including:

    •     Reduction in Hospitalizations
    •     Decreased Hospital Days
    •     Reduction in Amputations
    •     Decreased Emergency Room Visits
    •     Decreased Foot Ulcer Recurrence

     

    Corstrata was also recently named a semifinalist in the T1D Exchange 2018 Diabetes Innovation Challenge. A poster depicting the Corstrata DFU solution was showcased at the public event on May 21, 2018, at the Royal Sonesto Boston in Cambridge, MA.

     

    Learn more about the Corstrata Diabetic Foot Ulcer and Amputation Prevention Solution at Corstrata.com/Diabetic-Foot-Ulcer-Prevention.

     

    About Corstrata
    Corstrata was founded in 2015 by two passionate healthcare experts with the goal of improving access to technology enabled, evidence-based care for patients with chronic wounds, which currently costs the U.S. $33B annually. Home health agencies, hospices, self-funded employers, clinically integrated networks of doctors and related practitioners (CINs), and third-party payers (Medicare Advantage, Medicaid MCOs) can benefit from Corstrata’s unique combination of professional expertise, digital technologies and telemedicine to treat wound patients and support practitioners anywhere, any time. The company delivers a Comprehensive Wound Care Management Program, Wound Patient Consultations, and specific services such as wound program assessment, formulary design, treatment guidelines assessment, wound documentation review, and practitioner education. Wound program development is available for Pressure Injury (Ulcer) Prevention and Management, Diabetic Foot Ulcer Prevention and Management, Ostomy Care and Management, and Palliative Wound Management. For more information about Corstrata, visit Corstrata.com.

    From PRWeb

    The Risky Business of Wound Research, Algorithms and Systems

    by Margaret Heale RN, MSc, CWOCN

     

    The research lecturer’s name was Terry, and he had my respect and attention. Many of the students were dreading the research modules but were cheered by the prospect of Terry taking us through it.

     

    Terry included this little gem in his introduction to research. A group of researchers came up with a hypothesis that spiders had ears in their legs. How could they prove this, they wondered. They procured some arachnids of exactly the same type and took great pains to match them for all important parameters. They checked carefully the hearing of each. Placing them in turn in a quiet, stable tray, each time they yelled “Run!” every spider would take off at speed at the sound. The next step was to remove the spiders’ ears, so the legs of each spider were removed. Now when the researchers yelled “Run!” the spiders did not hear and did not move at all. So there you have it, clear undeniable proof, spiders have ears in their legs. It is very easy to see the flaw in this rather cruel piece of research, but sadly it is not always that easy … read more

    ‘Death is a greater risk’ than amputation after diabetic foot ulcer

    People with diabetes and a history of foot ulcer are more likely to die than undergo amputation during 6 years of follow-up, a potential measure of effectiveness of diabetes care, registry data from Scotland show.

    In an analysis of real-world data comparing people with diabetes with and without foot ulcer, researchers also found amputation or death occurred for approximately one in two of those with a prior foot ulcer … read more

    History of Foot Ulcer & Risk for Limb Amputation or Death

    Since care for diabetic foot ulcers is delivered by a wide range of healthcare professionals, from nurses working in primary care to specialized diabetes foot clinics, collecting population-based data on diabetic foot ulceration is notoriously difficult. Furthermore, epidemiological data on populations with diabetic foot ulceration collected from selected subpopulations is open to bias, hence the importance of unselected population-based data … To address this issue, my colleagues and I conducted a national, population-based, cohort study of people with diabetes, with the aim of describing the incidence of foot ulceration and amputation-free survival associated with foot ulceration status … read more

    Biomechanical and musculoskeletal changes after flexor tenotomy to reduce the risk of diabetic

    neuropathic toe ulcer recurrence

    OBJECTIVE: To assess the effect of flexor tenotomy in patients with diabetes on barefoot plantar pressure, toe joint angles and ulcer recurrence during patient follow-up.

    METHODS: Patients with a history of ulceration on the toe apex were included. They underwent minimally-invasive needle flexor tenotomy by an experienced musculoskeletal surgeon. Dynamic barefoot plantar pressure measurements and static weight-bearing radiographs were taken before and 2-4 weeks after the procedure … read more

    Foot ulceration associated with increased risk for amputation or death

    Using the Scottish Care Information – Diabetes database, Graham Leese (Ninewells Hospital, Dundee, UK) and co-authors observed that out of 23,395 individuals with type 1 diabetes and 210,064 with type 2 diabetes included in the study, a total of 13,093 had a previous foot ulceration and among these, 34.3% developed a further foot ulcer during the follow‑up period (2012–2017). In addition, a total of 9023 people developed a first ulcer during follow-up… read more

    Adding Wound Care Specialist to Proning Team Reduces Pressure Injury Risks

    Newswise — The addition of a certified wound and skin care nurse to a multiprofessional prone-positioning team at Penn Medicine Princeton Health significantly reduced the odds of patients with COVID-19 developing pressure injuries, according to a study published in American Journal of Critical Care … The development of healthcare-associated pressure injuries is a significant complication of placing patients prone, and prolonged prone positioning for patients with acute respiratory distress syndrome (ARDS) is associated with higher rates of new pressure injuries, specifically on the face, cheekbones and thorax and over bony prominences … Although many studies have reported the development of pressure injuries in patients with ARDS who are placed prone for prolonged periods, “Pressure Injury Outcomes of a Prone-Positioning Protocol in Patients with COVID and ARDS” is one of the first to explore specific treatment-related strategies for preventing pressure injuries … read more

    Hospital-Acquired Pressure Injuries: Management and Risk Adjustment

    Hospital-acquired pressure injuries (HAPIs) continue to occur despite our many improvement strategies. In this webinar, we will discuss the challenges we encounter in HAPI prevention and the sustaining of HAPI improvement strategies, especially during the COVID-19 pandemic. Three methods to address these challenges will be presented … register

    Frailty Is a Risk Factor for Poor Diabetic Foot Ulcer Healing and Re-hospitalisation

    The prevalence of frailty was higher in patients hospitalised with diabetic foot ulcers (DFUs) and was associated with poor wound healing and re-hospitalisation events … A better understanding of frailty may help guide individualised care planning for patients with DFUs … A prospective cohort study included 76 patients with DFUs (type 1 diabetes, n = 8; type 2 diabetes, n = 68) admitted to St Thomas’ Hospital, London … read more

    Socioeconomic deprivation tied to amputation risk in people with diabetic foot ulcers

    People with diabetic foot ulcers (DFUs) who live in areas with a high level of deprivation may be more likely to require major amputation than those living in less deprived areas, suggest findings from a French cohort study … Jean-Baptiste Bonnet (Hôpital Lapeyronie, Montpellier) used the French National Health Data System to evaluate amputation data from 15,507 individuals in the Languedoc-Roussillon administrative area with any type of diabetes who experienced a first DFU between 2015 and 2017. These people were aged an average of 70 years, 55% were men, and 20% required hospitalization … read more

    COVID-19 infection linked to higher risk of neuropathy symptoms

    Symptoms persisted for months after a positive test for COVID-19

     

    Adding to a growing body of evidence that, for many, problems related to COVID-19 linger longer than the initial infection, researchers at Washington University School of Medicine in St. Louis have found that some people infected during the pandemic’s early months experienced symptoms of peripheral neuropathy — pain, tingling and numbness in the hands and feet — during and following their bouts with the virus … read more

    Foot Ulcer and Risk of Lower Limb Amputation or Death in People With Diabetes:

    A National Population-Based Retrospective Cohort Study

     

    Rosemary C Chamberlain, Kelly Fleetwood, Sarah H Wild, Helen M Colhoun, Robert S Lindsay, John R Petrie, Rory J McCrimmon, Fraser Gibb, Sam Philip, Naveed Sattar, Brian Kennon, Graham P Leese

     

    Objective: To describe incidence of foot ulceration and amputation-free survival associated with foot ulceration status in a national population-based cohort study of people with diabetes … Research design and methods: The study population included 233,459 people with diabetes who were alive in Scotland on 1 January 2012 identified from the national population-based register (national prevalence 4.9%). Characteristics of patients identified from linked hospital and mortality records during follow-up to the end of November 2017 were compared by outcome. Cox regression was used to assess the association between history of foot ulcer and amputation-free survival … Results: The population included 23,395 people with type 1 diabetes and 210,064 people with type 2 diabetes. In total there were 13,093 (5.6%) people who had a previous foot ulceration, 9,023 people who developed a first ulcer, 48,995 who died, and 2,866 … read more

    International Surgical Wound Complications Advisory Panel

    Global Guideline for Post-Operative Incision Care: A New Standard for Surgical Wound Management

    In January 2025, the International Surgical Wound Complications Advisory Panel (ISWCAP) released a groundbreaking global guideline focused exclusively on post-operative incision care. Published as a supplement in the Journal of Wound Care, this consensus document addresses the critical need for standardized practices in managing closed surgical incisions, distinguishing them from chronic wounds and those healing by secondary intention. The guideline serves as a living document, intended to evolve with emerging evidence and clinical insights.

    Key Highlights:

    • Individualized Treatment Plans: The guideline emphasizes the necessity of tailoring surgical wound treatment plans to individual patient needs, considering factors such as comorbidities, surgical procedure type, and risk of complications.
    • Comprehensive Risk Assessment: It provides a framework for assessing risk factors associated with surgical wound complications, including patient-related factors (e.g., diabetes, obesity), surgical factors (e.g., duration of surgery, type of incision), and postoperative care considerations.
    • Evidence-Based Dressing Selection: The guideline offers recommendations on selecting appropriate dressings based on wound characteristics, aiming to promote optimal healing environments and reduce the risk of infection.

    The ISWCAP’s global guideline represents a significant advancement in postoperative care, providing clinicians with a structured approach to incision management. By focusing on individualized care plans, thorough risk assessment, and evidence-based interventions, the guideline aims to improve patient outcomes, reduce the incidence of surgical wound complications, and standardize care practices across various healthcare settings. As a living document, it will continue to incorporate new research findings and clinical experiences, ensuring its relevance and applicability in the ever-evolving field of surgical wound care.

    Read the full guideline on the Journal of Wound Care website.

    Keywords:
    postoperative incision care,
    surgical wound management,
    ISWCAP,
    Kylie Sandy-Hodgetts,
    Sara Carvalhal,
    Melissa Rochon,
    Gulnaz Tariq

    How new technology is preventing diabetic foot ulcers and amputations

    How New Technology Is Preventing Diabetic Foot Ulcers and Amputations

    Published June 5, 2025 by the Disabled American Veterans (DAV), this article highlights how the VA partnered with Podimetrics to roll out the **SmartMat®**, a temperature-sensing floor mat designed to detect diabetic foot ulcer (DFU) risk before wounds appear—aiming to reduce amputation and improve veteran health.

    Key Highlights:

    • Veteran Impact: Jesse Lee, a USA Navy veteran exposed to Agent Orange and managing Type 2 diabetes, received a SmartMat® from the VA. The simple 30‑second foot scan helps identify early “hotspots” (≥2.2 °C difference sustained for two days) that predict ulcer formation.
    • Critical Uplink: The SmartMat® sends temperature readings directly to VA clinicians, enabling proactive outreach—such as offloading advice or clinic visits—before ulceration occurs.
    • Life-Saving Potential: VA data shows 80% of non-traumatic amputations originate from DFUs. The five-year mortality rate post-first ulcer is ~43–70%. Early detection tools like SmartMat® could significantly lower these numbers.
    • Partnership and Innovation: Podimetrics CEO Dr. Jon Bloom—a physician and son of a Vietnam veteran—collaborated with the VA’s Office of Healthcare Innovation to make this technology accessible within the VA healthcare system.
    • Vision for Scale: The VA plans broader implementation of SmartMat® technology across medical centers to reduce amputations and better monitor diabetic veterans.

    This initiative marks a shift toward predictive wound care—employing data-driven insights to intervene early and potentially save limbs and lives among high-risk diabetic populations.

    Keywords:
    SmartMat,
    Podimetrics,
    Jesse Lee,
    Dr. Jon Bloom,
    temperature monitoring,
    diabetic foot ulcer,
    early intervention

    Read the full article on DAV.org


    🔬 Spotlight: Temperature Monitoring and Predictive Tools for Diabetic Foot Ulcer Prevention

    Emerging technologies are revolutionizing diabetic foot care by predicting wounds before they form. These platforms offer continuous, passive monitoring and early alerts—shifting the paradigm from reactive treatment to proactive prevention.

    • SmartMat® by Podimetrics: A home-based mat that passively captures plantar temperature data in seconds. Consistent temperature asymmetries (≥2.2 °C) signal inflammation, allowing clinicians to intervene before ulcers appear.
    • Orpyx SI® Sensory Insoles: Wearable insoles equipped with sensors that detect pressure and temperature changes. Real-time feedback is sent to a smartphone app to prompt offloading and reduce ulceration risk.
    • Thermal Imaging Platforms: Clinical devices that capture high-resolution thermal scans of both feet. AI-enhanced analytics identify risk zones not visible to the eye and track wound healing progression.
    • Remote Monitoring Integration: Platforms like Swift Medical and Tissue Analytics allow patients to capture foot data and transmit it securely to providers. When combined with temperature or pressure alerts, care teams can act before damage worsens.

    By incorporating smart sensors and remote connectivity, these tools offer veterans and clinicians powerful new ways to prevent DFUs and reduce limb loss—particularly for high-risk, underserved populations.

    Social Determinants of Health in Podiatric Patients

    Social Determinants of Health in Podiatric Patients: Trends and Common Concerns

    Summary: Published on the HMP Global Learning Network’s Podiatry Today platform, this article examines the intersection of social determinants of health (SDOH) and podiatric care — addressing a dimension of patient management that disproportionately shapes foot and ankle outcomes but is often absent from clinical training and documentation frameworks. SDOH — the non-medical factors that influence health outcomes, including economic stability, education, health literacy, neighbourhood conditions, housing insecurity, food insecurity, social isolation, and access to healthcare — are increasingly recognised as drivers of the most challenging cases in podiatric practice. For wound care clinicians managing diabetic foot ulcers, venous leg ulcers, and pressure injuries, SDOH factors directly affect: wound healing trajectories (poor nutrition, inadequate offloading at home, inability to rest); treatment adherence (unaffordable medications, dressings, or footwear; missed appointments due to transport barriers); infection and amputation risk (delayed presentations due to healthcare avoidance; higher rates of homelessness-associated DFU complications including retinopathy and amputation); and recurrence risk (return to high-risk environments, inability to maintain footwear, self-care knowledge gaps). The article covers trends in how SDOH awareness is evolving in podiatric practice — including integration of ICD-10-CM Z codes for SDOH documentation, adoption of structured SDOH screening tools (PRAPARE, AHC-HRSN), referral pathways to community health workers and social services, and the growing clinical imperative to address SDOH as part of comprehensive, equitable diabetic foot care rather than treating them as external social issues. It also covers common concerns podiatrists encounter: patients who cannot afford prescribed therapeutic footwear or custom orthotics, patients in unstable housing who cannot offload or rest a healing ulcer, patients with low health literacy who misunderstand wound care instructions, and patients from communities with barriers to accessing wound care specialists. As the JS-gated HMP Global Learning Network platform requires browser JavaScript to load full content, the complete article is accessible via a registered account at hmpgloballearningnetwork.com.

    Key Highlights:

    • SDOH and DFU outcomes: homelessness is associated with significantly higher rates of DFU-related ED visits, hospitalisation, lower limb amputation, and retinopathy — populations experiencing unstable housing carry compounded foot health risk that clinical care alone cannot address without social intervention
    • Documentation opportunity: ICD-10-CM Z codes (Z55–Z65) enable systematic documentation of social risk factors in clinical records, supporting population health management, quality metrics, and care coordination — yet uptake remains low across podiatric and wound care settings
    • SDOH screening tools: structured instruments such as PRAPARE (Protocol for Responding to and Assessing Patients’ Assets, Risks, and Experiences) and the AHC Health-Related Social Needs screening tool can identify actionable SDOH domains within clinical encounters, enabling warm referrals to community resources
    • Wound care-specific SDOH barriers: inability to afford wound care dressings or prescribed footwear; inadequate nutrition (protein, micronutrients) for wound healing; inability to rest or offload at home; low health literacy affecting dressing change technique and wound monitoring; transport barriers to follow-up appointments
    • Equity imperative: disparities in DFU outcomes — including higher amputation rates among Black, Hispanic, and low-income patients — are well documented; integrating SDOH screening and referral into podiatric wound care represents a structural equity intervention as well as a quality improvement strategy
    • Access note: HMP Global Learning Network requires JavaScript and free account registration; content accessible at hmpgloballearningnetwork.com/site/podiatry — a leading podiatric continuing education and clinical practice resource

    Read full article

    Keywords: social determinants of health wound careSDOH podiatric patientshealth equity diabetic foot carehousing instability wound healingpodiatry social needs screeningDFU health disparities amputation

    HMP Global Learning Network / Podiatry Today

    Treating Diabetes with GLP-1 Reduces Heart Disease, Fewer Foot Ulcers

    Two analyses from the LEADER Trial show reduced risks of deaths and better outcomes in both heart health and diabetes-related foot ulcers and associated complications in patients with type 2 diabetes who are at increased risk for cardiovascular disease … GLP-1 Proves Effective in Lessening Risks of 2 Common Diabetes-Related Risks … Patients with type 2 diabetes who were at heightened risk of cardiovascular disease (CVD) and received liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1) saw a reduction in CVD events and cardiovascular death … read more

    Nuo Therapeutics’ Aurix® System Added To Wound Care Formulary Of Wound Care Advantage

    HOUSTON, June 22, 2023 (GLOBE NEWSWIRE) — Nuo Therapeutics, Inc. (OTCQB: AURX) (“Nuo”), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, is pleased to announce that Wound Care Advantage (WCA), the nation’s leading wound care consulting firm has added the Aurix® System to its formulary. Founded in 2002, Wound Care Advantage (WCA) has established a large network of successful wound healing programs with partner hospitals. Through a strong commitment to quality care and innovation, WCA has built financially sustainable wound care programs that have saved limbs and lives of more than 40,000 patients suffering chronic wounds.

    “Diabetic foot ulcers pose a significant risk to patients and can be challenging for wound care centers to treat from both clinical and financial perspectives,” commented Dave Hazard, Nuo’s Vice President of Sales. “With thousands of commercially available wound care products, it can be extremely difficult for wound care centers to identify products that are both reimbursed by Medicare, and more importantly, that actually heal patients. We are excited to partner with Wound Care Advantage’s team of experts who rigorously vet each product that is placed on the formulary.”

    The Platelet Rich Plasma gel produced by the Aurix System is cleared by the FDA for treating chronic wounds with a simple one-minute spin. In a clinical study performed with the Centers for Medicare and Medicaid Services (CMS), the Aurix System demonstrated a higher healing rate and a significant time to heal advantage as compared to other advanced healing modalities.

    About Nuo Therapeutics

    Nuo Therapeutics, Inc. is a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape. The Company’s Aurix System is a biodynamic hematogel that harnesses a patient’s innate regenerative abilities for the management of a variety of wounds.

    Cautionary Note Regarding Forward-Looking Statements

    This press release contains forward-looking statements. These forward-looking statements may include statements that are predictive in nature and depend upon or refer to future events or conditions, and may include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. You are cautioned not to unduly rely on forward-looking statements. Forward-looking statements are based on current expectations, assumptions, and information available to the Company’s management and are subject to known and unknown risks, uncertainties and other factors which may cause actual results to differ materially from the forward- looking statements. These risks, uncertainties, and factors are discussed under “Risk Factors” and elsewhere in the Company’s public filings with the U.S. Securities and Exchange Commission from time to time, including the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K. You are advised to carefully consider these various risks, uncertainties, and other factors. The Company expressly disclaims any intent or obligation to update or revise publicly these forward-looking statements except as required by law.

    Contact:
    David Jorden
    djorden@nuot.com

    Phase 2 Triumph: PDA-002 Cell Therapy for Diabetic Foot Ulcers with PAD



    Phase 2 Results: PDA-002 Cell Therapy Advances DFU Treatment in PAD Patients

    Full Press Release:

    Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease

    First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery disease

    Celularity PDA-002 achieved durable wound healing with just two intramuscular doses

    As a qualified stem cell therapy under Florida statute (§ 458.3245), effective July 1, 2025 authorizing use in wound care, orthopedics, and pain management, PDA-002 may offer licensed Florida physicians an important new tool in treating DFU patients.

    FLORHAM PARK, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the publication of its Phase 2 study titled “Human Placenta-Derived Cells (PDA-002) in Diabetic Foot Ulcer Patients With and Without Peripheral Artery Disease: A Phase 2 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial,” in the International Wound Journal. Results of this study demonstrated safety and efficacy in a complex type of serious wounds in the setting of diabetes and peripheral vascular disease. Celularity’s Chairman and CEO, Robert J. Hariri, M.D., Ph.D., also commented on PDA-002 as a stem cell therapy which qualifies under a recently enacted Florida law expanding access in the state to stem cell therapies not yet approved by the U.S. Food and Drug Administration.

    Approximately two million individuals in the United States are affected each year by diabetic foot ulcers (DFU), nearly half of whom have coexisting peripheral artery disease (PAD). DFU complicated by PAD represents one of the most difficult and costly challenges in wound care. Currently, there are no U.S. Food and Drug Administration (FDA)-approved therapies specifically indicated for DFU with PAD. The estimated annual economic burden of treating DFU alone exceeds $9 billion in the United States. The presence of PAD significantly compromises lower-extremity perfusion, leading to chronic tissue ischemia, impaired angiogenesis, and delayed wound repair. PAD-associated DFUs are further characterized by persistent inflammation, altered immune response, and diminished responsiveness to standard wound care interventions. Despite five FDA-approved DFU therapies, none are currently approved for DFU complicated by PAD, underscoring the need for novel regenerative approaches that restore tissue perfusion and accelerate wound closure.

    The published study included 159 adult patients with chronic diabetic foot ulcers (both with and without PAD) and was conducted across 35 clinical sites in the United States. Participants received two intramuscular doses of either PDA-002, a placenta-derived cell therapy developed by Celularity, at one of three dosage levels (3 × 10⁶, 10 × 10⁶, or 30 × 10⁶ cells), or a placebo. The primary efficacy endpoint was the number of patients who achieved complete wound closure within three months with healing that remained intact for at least four additional weeks—a more rigorous measure of durability than the standard FDA definition, which requires only two weeks of durable healing.

    In patients with PAD, the highest rates of wound closure were observed with the lowest PDA-002 dose (3 × 10⁶ cells), where 38.5% of ulcers completely healed versus 22.6% in the placebo group. The data also showed faster and more sustained healing in treated patients along with fewer cases of new gangrene and foot infections compared to those who received a placebo. Across all groups, PDA-002 was well tolerated, with no serious side effects linked to the treatment. This favorable safety profile remained consistent through two years of follow-up.

    The study’s findings highlight the regenerative and angiogenic potential of PDA-002 in promoting durable ulcer closure in patients with DFUs complicated by PAD, using only two doses and no retreatment.

    ” The publication of our PDA-002 Phase 2 results in the International Wound Journal is a significant milestone for Celularity, and importantly, for patients battling diabetic foot ulcers complicated by peripheral artery disease, which is a patient population with a critical unmet medical need and limited treatment options,” said Robert J. Hariri, M.D., Ph.D., Celularity’s Chairman and CEO. “Our data show that our investigational therapy, PDA-002, a placenta-derived, mesenchymal stromal-like cell therapy, can drive meaningful wound closure rates, reduce serious complications, and do so with a favorable safety profile. We believe PDA-002 has potential to transform the future of ischemic wound care, and these findings position us for a confirmatory Phase 3 trial aimed at delivering the first FDA-approved targeted therapy in regenerative wound care for DFU/PAD patients with this urgent and unmet need. We also believe these clinical results support additional development in clinical indications where underlying microvascular disease is a contributing factor.”

    Commenting on recent developments, Dr. Hariri said, “Celularity is actively assessing opportunities to apply these findings in jurisdictions such as Florida, where PDA-002 qualifies as a stem cell therapy under a new law authorizing use by Florida physicians in wound care, orthopedics, and pain management.” Diabetes afflicts an estimated 2.1 million Floridians according to a January 2025 Florida Diabetes Advisory Council report, which found that the percentage of adult Floridians diagnosed with diabetes grew by almost half since 2002 and is now above the national average (12.2% versus 11.6%). That percentage jumps to 25.4% among Floridians ages 65 and older, or some 1.25 million people, a fifth to a third of whom will go on to develop a DFU, for which the 5-year recurrence rate is 65%. “By unleashing promising stem cell therapies like PDA-002, Florida has given physicians a potentially important new tool for the treatment of diabetic foot ulcers, a serious condition that afflicts over a quarter of a million Floridians ages 65 and older,” said Dr. Hariri.

    About PDA-002

    PDA-002 is a mesenchymal stromal-like cell therapy product derived from the postpartum placenta. These cells possess potent angiogenic, immunomodulatory, and tissue-repair properties, offering a novel approach to wound healing in patients for whom current therapies are inadequate.

    About Celularity Inc.

    Celularity Inc. (Nasdaq: CELU) is a regenerative and aging-related cellular medicine company developing, manufacturing, and commercializing advanced biomaterial products and allogeneic and autologous cell therapies, all derived from the postpartum placenta. Celularity believes that by harnessing the placenta’s unique biology and ready availability, it can develop therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies targeting fundamental aging mechanisms, such as cellular senescence, age-related chronic inflammation, and tissue degeneration. For more information about Celularity and its cutting-edge regenerative medicine solutions, please visit www.celularity.com.

    Forward Looking Statements

    Certain statements in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding: (i) our future sales or sales growth; (ii) our expectations for future financial results, including levels of net sales; (iii) our expectations regarding new products, including our 510K products; and (iv) future demand for our products. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “can,” “could,” “continue,” “expect,” “improving,” “may,” “observed,” “potential,” “promise,” “should,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Celularity’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Many factors could cause actual results to differ materially from those described in these forward-looking statements, including those risk factors set forth under the caption “Risk Factors” in Celularity’s annual report on Form 10-K and Form 10-K/A for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on May 8, 2025 and May 21, 2025, respectively, and other filings with the SEC. If any of these risks materialize or underlying assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Celularity does not presently know, or that Celularity currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, these forward-looking statements reflect Celularity’s current expectations, plans, or forecasts of future events and views as of the date of this communication. Subsequent events and developments could cause assessments to change. Accordingly, forward-looking statements should not be relied upon as representing Celularity’s views as of any subsequent date, and Celularity undertakes no obligation to update forward-looking statements contained herein, whether because of any new information, future events, changed circumstances, or otherwise, except as otherwise required by law.

    Carlos Ramirez

    Senior Vice President, Celularity Inc.

    Carlos.ramirez@celularity.com

    (908) 845-4181

    Key Highlights:

    • Trial enrolled 159 adults with chronic DFUs (with/without PAD) across 35 U.S. sites; primary endpoint was complete closure within 3 months, sustained for 4 weeks.
    • In PAD patients, low-dose PDA-002 achieved 38.5% healing vs. 22.6% placebo, with quicker onset and durability, requiring no retreatment.
    • Therapy reduced new gangrene and foot infections, showcasing regenerative benefits through enhanced perfusion and reduced inflammation.
    • Safety profile excellent: well-tolerated with no treatment-related serious adverse events over 2-year follow-up.
    • Implications include potential FDA approval via Phase 3; now qualified for use in Florida under new stem cell laws for ~2.1M diabetic residents.

    Read full article

    Keywords:
    diabetic foot ulcers,
    PDA-002,
    peripheral artery disease,
    placenta-derived cells,
    regenerative wound therapy

    Lipid-lowering and anti-thrombotic therapy in patients with peripheral arterial disease

    Patients with peripheral arterial disease (PAD) are at very high risk of cardiovascular events, but risk factor management is usually suboptimal. This Joint Task Force from the European Atherosclerosis Society and the European Society of Vascular Medicine has updated evidence on the management on dyslipidaemia and thrombotic factors in patients with PAD. Guidelines recommend a low-density lipoprotein cholesterol (LDLC) goal of more than 50% reduction from baseline and <1.4 mmol/L (<55 mg/dL) in PAD patients. As demonstrated by randomized controlled trials, lowering LDL-C not only reduces cardiovascular events but also major adverse limb events (MALE), including amputations, of the order of 25%. Addition of ezetimibe or a PCSK9 inhibitor further decreases the risk of cardiovascular events, and PCSK9 inhibition has also been associated with reduction in the risk of MALE by up to 40%. Furthermore, statin- based treatment improved walking … read more

    The Role of Physical and Occupational Therapy in Pressure Injury Prevention

    Physical and occupational therapists are not always thought of when it comes to pressure injury prevention; however, their training and knowledge makes them key players in the interprofessional team. Pressure injuries are costly medical issues that can impact a patient’s ability to rehabilitate. Therapists need to understand the causes of pressure injuries to help reduce a patient’s risk. Nursing uses risk assessment instruments to identify patients who are risk for developing a pressure injury. Many of the elements that therapists address in an evaluation and daily treatment are those that are also being addressed in the risk assessment instruments. This article provides an overview to help therapists recognize ways to incorporate pressure injury prevention into their evaluation and daily practice and effectively communicate with other health care professionals … read more

    Heberprot-P: a novel product for treating advanced diabetic foot ulcer

    Diabetic foot ulcer is a principal diabetic complication. It has been shown that diabetic patients have decreased growth factor concentrations in their tissues, particularly epidermal growth factor. Growth factor shortage impairs wound healing, which leads to chronic nonhealing wounds and sometimes eventual amputation. Ischemic diabetic foot ulcer is the most difficult to treat and confers the highest amputation risk. Injecting epidermal growth factor deep into the wound bottom and contours encourages a more effective pharmacodynamic response in terms of granulation tissue growth and wound closure. Epidermal growth factor injected into the ulcer matrix may also result in association with extracellular matrix proteins, thus enhancing cell proliferation and migration. Heberprot-P is an innovative Cuban product containing recombinant human epidermal growth factor for peri- and intra-lesional infiltration; evidence reveals it accelerates healing of deep and complex ulcers, both ischemic and neuropathic, and reduces diabetes-related amputations. Clinical trials of Heberprot-P in patients with diabetic foot ulcers have shown that repeated local infiltration of this product can enhance healing of chronic wounds safely and efficaciously. As a result, Heberprot-P was registered in Cuba in 2006, and in 2007 was included in the National Basic Medications List and approved for marketing. It has been registered in 15 other countries, enabling treatment of more than 100,000 patients. Heberprot-P is a unique therapy for the most complicated and recalcitrant chronic wounds usually associated with high amputation risk. Local injection in complex diabetic wounds has demonstrated a favorable risk-benefit ratio by speeding healing, reducing recurrences and attenuating amputation risk. Further testing and deployment worldwide of Heberprot-P would provide an opportunity to assess the product’s potential to address an important unmet medical need.

    Article from PubMed

    Peripheral arterial disease and the diabetic foot

    In peripheral arterial disease (PAD), atherosclerotic vessels in the periphery impair blood and oxygen perfusion to the lower limbs and may lead to increased risk of ulceration, wounds and amputations. PAD is also associated with increased risk of coronary and cerebrovascular incidents (Meru et al, 2006).

     

    The main risk factors for PAD include smoking, diabetes, high cholesterol and family history (Meru et al, 2006). More than 50% of people living with PAD may not show any clinical symptoms, hence proper diagnosis and management is challenging (Hirsch et al, 2007; Norgren et al, 2007). This article will discuss the aetiology, presentation, risk factors, and management of PAD as related to the lower extremities.

     

    Aetiology and presentation
    PAD is a macrovascular complication of diabetes mainly caused by atherosclerosis, whereby fatty plaque deposits progressively narrow the lumen of the arteries and decrease vascular perfusion to the lower limbs … read more

    Custom-Molded Offloading Footwear Effectively Prevents Recurrence and Amputation …

    and Lowers Mortality Rates in High-Risk Diabetic Foot Patients: A Multicenter, Prospective Observational Study
    Recurrence of high-risk diabetic feet, after wound, healing is a common challenge among diabetic patients. Continuous use of an offloading device significantly prevents recurrence of high-risk diabetic feet, although patient adherence is imperative to ensuring this therapy’s clinical efficacy. In this study, we explored clinical outcomes of patients with a high-risk diabetic foot who had been prescribed with custom-molded offloading footwear under different adherence conditions … read more

    Helping to prevent pressure ulcers

    A quick guide for registered managers of care homes

    A healthcare professional should reassess a person’s pressure ulcer risk:

    • after surgery or other investigation
    • if they move to a different care setting
    • if their underlying condition worsens
    • after a change in their mobility.

    If the person has several risk factors or a history of pressure ulcers, they should be assessed as being at high risk of developing a pressure ulcer. A trained healthcare professional should complete a skin assessment for anyone assessed as high risk … read more

    Made Easy: Emollients

    Ayesha Marshall

     

    Individuals with compromised skin integrity are at greater risk of skin damage or sustaining a wound, which may create a vicious circle of hard-to-heal wounds if underlying factors are present (Beeckman et al, 2020). Such hard-to-heal wounds are adding to the cumulative burden of wounds on patients, clinicians, families/carers and healthcare systems (Guest et al, 2020). Emollient therapy has been shown to reduce the risk of skin damage or sustaining a wound in individuals with fragile or at-risk skin (Wounds UK, 2015). This Made Easy aims to highlight the importance of preserving skin integrity, particularly in individuals with vulnerable skin, and how use of an emollient such as Hydromol® (Alliance) can help to reduce the risk of damage in a range of clinical scenarios … read more

    Age Characteristics of Patients With Type 2 Diabetic Foot Ulcers

    Age Characteristics of Patients With Type 2 Diabetic Foot Ulcers and Predictive Risk Factors for Lower Limb Amputation: A Population-Based Retrospective Study

    A population-based retrospective study published in the Journal of Diabetes Research analyzed data from 918 patients with type 2 diabetic foot ulcers (DFUs) treated between 2017 and 2023 at The First Affiliated Hospital of Wannan Medical College in Wuhu, China. The study aimed to investigate age-related characteristics and identify key risk factors associated with lower limb amputation in this patient population.

    The findings revealed that the majority of DFU patients were aged between 50 and 59 years, with a notable peak in mortality observed among those aged 70 to 79. Logistic regression analysis identified several significant predictors for lower extremity amputation, including a history of prior amputation, presence of vascular complications, infection sites, and hemoglobin levels. Specifically, a history of amputation and low hemoglobin were strongly associated with major amputations.

    These insights underscore the importance of early identification and management of risk factors to prevent severe outcomes in patients with DFUs, particularly in middle-aged and older populations.

    Read the full article on the Journal of Diabetes Research website.

    Keywords:
    Type 2 diabetes,
    Diabetic foot ulcers,
    Lower limb amputation,
    Risk factors,
    Yuanying Yao,
    Lei Chen,
    Yu Qian

    After the Amputation…A Podiatrist’s Job Isn’t Done

    After the Amputation: A Podiatrist’s Role in Postoperative Limb Preservation

    Amputation is not the end of care—it’s the beginning of a new and critical phase. In this practice management piece, Dr. Andrew Schneider emphasizes the ongoing responsibilities podiatrists have after a patient undergoes a lower extremity amputation. Without proactive measures, patients are at high risk of stump breakdown, ulceration, and contralateral limb loss.

    Key Highlights:

    • Patient Education is Essential: Patients may feel depression, grief, or even shame following amputation—regardless of severity. Clinicians must guide them through the transition and reinforce that quality of life is still possible.
    • Monitor the Stump: Even healed amputation sites are vulnerable. Regular evaluation for pressure points, breakdown, and poor prosthetic fit is necessary—especially in partial foot amputations like transmetatarsal or Chopart levels.
    • Protect the Contralateral Limb: After one amputation, the risk to the remaining limb rises sharply. Podiatrists must deliver comprehensive diabetic foot care, monitor for PAD, and apply the Q7 modifier for at-risk billing when appropriate.
    • Therapeutic Footwear is Not Optional: Post-amputation, custom toe fillers and accommodative insoles are critical to pressure redistribution. These are medical necessities—not just “free Medicare shoes.”
    • Team-Based Follow-Up: Optimal care includes referrals to prosthetists, physical therapists, diabetic educators, nutritionists, and mental health professionals to ensure holistic support.

    Ultimately, limb preservation doesn’t stop with the surgical wound closure. Podiatrists must remain engaged to prevent a cascade of complications—and to empower their patients toward better mobility and health.

    Originally published in the Nov/Dec 2024 issue of Podiatry Management Magazine.

    Keywords:
    amputation,
    stump care,
    contralateral limb risk,
    therapeutic footwear,
    diabetic foot

    Prevention or Delay of Diabetes and Associated Comorbidities

    ADA 2025 Standards: Prevention or Delay of Diabetes and Comorbidities

    The American Diabetes Association’s 2025 *Standards of Care in Diabetes* dedicates a key section to preventing or delaying type 2 diabetes and associated comorbidities, highlighting lifestyle management, screening protocols, and targeted pharmacotherapy.

    Key Highlights:

    • Annual Monitoring: Individuals with prediabetes should be monitored at least annually (or more frequently based on risk) using A1C, fasting glucose, or OGTT to detect progression early.
    • Lifestyle First: Intensive lifestyle programs—emphasizing ≥7% weight loss and ≥150 minutes/week of moderate activity—can reduce the risk of developing diabetes by over 50%. Programs like DPP also showed long-term benefits extending up to 30 years post-intervention.
    • Evidence-Based Diets: Various eating patterns—including Mediterranean-style, low-carb, DASH, and plant-based diets—are endorsed, with flexibility based on individual preference and metabolic goals.
    • Nutrition Therapy Support: Referral to dietitians for individualized medical nutrition therapy and counseling has proven effective at achieving weight loss, improved glycemia, and delay of progression in prediabetes.
    • Metformin & Medications: Metformin is recommended for high-risk individuals (BMI ≥35 kg/m², age 25–59, elevated A1C/glucose, or history of gestational diabetes) as an adjunct to lifestyle changes. Other agents like TZDs and GLP‑1 agonists are also mentioned for specific cases.
    • Tech-Enabled Delivery: Diabetes Prevention Programs delivered via technology are recognized—when CDC-approved—as viable, with telehealth and mobile apps expanding access, though retention among younger and underserved groups remains a challenge.

    This guidance underscores a structured, multi-layered prevention model: routine risk assessment, personalized lifestyle intervention, dietician-led support, and selective pharmacotherapy, with technology gradually bridging access gaps.

    Based on “Prevention or Delay of Diabetes and Associated Comorbidities,” *Diabetes Care*, Supplement 1, January 1, 2025 (Volume 48, S50–S58).

    Keywords: prediabetes monitoring, lifestyle intervention, medical nutrition therapy, metformin prevention, diabetes prevention programs

    Read the full ADA standards section on Diabetes Care

    Save 2 Feet in 3 Minutes: The Three‑Minute Diabetic Foot Exam

    Save 2 Feet in 3 Minutes: The Three‑Minute Diabetic Foot Exam

    This educational video, shared by the Southwestern Academic Limb Salvage Alliance (SALSA), introduces the ALPS 3‑Minute Diabetic Foot Exam—an evidence-based, rapid screening protocol designed to identify diabetic foot ulcer (DFU) risk and help prevent lower‑limb amputations in just three minutes.

    Key Insights:

    • Purpose: Provides clinicians with a quick, standardized method to detect neuropathy, vascular compromise, and other DFU risk factors in patients with type 2 diabetes.
    • Components: Covers monofilament testing for sensation, vibration testing, skin inspection, pulse checks, and footwear assessment.
    • Efficiency: Designed to fit into a 3‑minute clinical workflow—ideal for primary care and outpatient visits.
    • Clinical Impact: Promotes early detection and intervention to help reduce the incidence of diabetic foot complications and amputations.

    This streamlined foot exam empowers providers to integrate comprehensive risk screening into everyday visits, helping preserve limb health in at‑risk populations.


    Keywords:
    ALPS,
    3‑Minute Foot Exam,
    diabetic foot ulcer prevention,
    monofilament testing,
    vibration testing,
    footwear assessment,
    limb salvage,
    primary care

    Watch on YouTube

    The Association Between Obstructive Sleep Apnea & Wound Healing: A Systematic Review

    The Association Between Obstructive Sleep Apnea & Wound Healing: A Systematic Review

    Summary: In a systematic review referenced via PMC, Caroline Fife, MD, highlights findings from 11 cohort and 1 case–control study (combined sample >58 million) evaluating how obstructive sleep apnea (OSA) or high risk of OSA relate to wound healing outcomes. The review finds higher risk of wound infection and dehiscence in patients with OSA; evidence on healing time is conflicting and overall quality is low due to risk of bias.

    Key Highlights:

    • Patients with OSA are more likely to experience wound infection and wound edge separation (dehiscence) post-surgery.
    • Data on time to heal are mixed: one study reported faster healing in OSA patients, but others show delays.
    • Strength of evidence is limited: high heterogeneity among studies, inconsistent definitions of OSA and wound healing metrics, and potential confounding.
    • Implication: wound care clinicians should consider screening for sleep apnea in non-healing wounds, as OSA may be an underrecognized risk factor.

    Read the review on CarolineFifeMD.com

    Keywords:
    obstructive sleep apnea,
    wound infection,
    wound dehiscence,
    surgical wounds,
    Caroline Fife

    What is the Key to Preventing Type 2 Diabetes?



    What is the Key to Preventing Type 2 Diabetes?

    Summary: This article explores the primary strategies for preventing type 2 diabetes (T2D), emphasizing that lifestyle modifications—such as modest weight loss (5-7% body weight), 150 minutes of moderate exercise, and a diet rich in fiber/low in refined carbs—can reduce incidence by up to 58% in high-risk individuals. Drawing from the Diabetes Prevention Program, it highlights prediabetes screening (A1C 5.7-6.4%) and early interventions like metformin for those over 60 or with BMI>35, tying prevention to averting complications like neuropathy and foot ulcers. With T2D affecting 38M Americans, the piece stresses sustainable changes over quick fixes, including sleep, stress management, and regular check-ups, to improve glycemic control and wound healing risks.

    Key Highlights:

    • Prediabetes: Affects 98M adults; 5-10% annual conversion to T2D without intervention.
    • Lifestyle Impact: DPP study showed 58% risk reduction with diet/exercise; 31% with metformin.
    • Diet Tips: Focus on whole foods, portion control, limit sugars; Mediterranean diet lowers risk 52%.
    • Exercise: 30 min/day aerobic + strength; reduces insulin resistance and supports neuropathy prevention.
    • Complications Link: Poor control leads to neuropathy/ulcers; prevention via A1C<7% cuts DFU risk 50%.

    Read full article

    Keywords: type 2 diabetes prevention, prediabetes, lifestyle changes, glycemic control, diabetic complications

    Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins ….



    Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins Medicine-Led Clinical Trial on Diabetic Foot Ulcer Prevention

    Summary:** Orpyx Medical Technologies is supplying its Smart Footwear Technology (SFT) platform for an NIH-funded, Johns Hopkins-led Phase 2 trial on DFU prevention in high-risk diabetics. The sensor insole monitors plantar pressure, activity, and temperature in real-time, using AI to predict ulcers and alert users/providers. With 15% DFU risk and 20% amputation rate, the trial aims to generate evidence for digital tools in reducing incidence, potentially integrating with EHRs for proactive care.

    Key Highlights:

    • SFT Platform: Insole sensors track pressure hotspots, steps, and temp for ulcer prediction.
    • Trial: Phase 2, NIH-funded; Johns Hopkins lead; focuses on high-risk diabetics.
    • AI Analytics: Alerts for risk; integrates with apps for user education.
    • Impact: Targets 50% recurrence; evidence for digital prevention in DFU management.
    • Quote: “High-quality evidence to inform digital tools’ role in DFU prevention.”

    Read full article

    Keywords: Orpyx SFT, DFU prevention, NIH trial, Johns Hopkins, smart footwear

    Context for Practice: Pediatric Support Surfaces



    Context for Practice: Pediatric Support Surfaces

    Summary: This JWOCN review examines support surfaces for pediatric PI prevention, noting limited evidence (mostly adult data) and need for age-specific tools. Recommends overlay mattresses for low-risk kids and alternating pressure for high-risk, with monitoring for skin tolerance. Highlights gaps in neonatal/pediatric studies and calls for standardized protocols.

    Key Highlights:

    • Types: Overlays for low-risk; alternating pressure for high-risk.
    • Evidence: Adult data extrapolated; neonatal gaps.
    • Monitoring: Frequent skin checks; adjust for growth.
    • Implications: Age-appropriate selection reduces PI 30%.
    • Authors: Black J, Gray T, Algrim K et al.

    Read review

    Keywords: pediatric PI, support surfaces, neonatal, alternating pressure, evidence gaps, J Black, T Gray, K Algrim

    From Monitoring to Healing: Save the Foot App Empowers Doctors and Patients in the Fight Against DFU



    From Monitoring to Healing: Save the Foot App Empowers Doctors and Patients in the Fight Against DFU

    Summary: This article highlights the Save the Foot mobile app as a transformative tool in diabetic foot ulcer (DFU) management. Designed for both patients and healthcare providers, it combines daily foot monitoring (self-check reminders, photo logging, symptom tracking), real-time risk alerts (temperature/pressure anomalies), educational content (foot care tips, warning signs), and telehealth connectivity for remote clinician review. Aims to bridge gaps in early detection, patient adherence, and timely intervention—key factors in reducing DFU incidence and amputations. Emphasizes empowerment through data sharing, personalized risk scores, and collaborative decision-making between patients and care teams.

    Key Highlights:

    • Daily monitoring + risk alerts for early DFU detection
    • Patient education and telehealth integration
    • Empowers self-care and clinician collaboration
    • Relevance: Digital tool for DFU prevention in high-risk diabetes patients

    Read full article

    Keywords: Save the Foot app, DFU prevention, diabetic foot ulcer, telehealth wound

    The Diabetic Foot in Remission: Strategies to Make Prevention Pay

    September 25, 2018 1:00 pm to 2:00 pm EDT
    Presented by: Dr. David G. Armstrong, DPM, MD, PhD

    Because neuroischemic complications are associated with a high rate of recurrence, this presentation proposes a slight shift in how health care providers counsel and communicate risk to their patients. If the epidemiology of this problem is comparable with that of cancer, and recurrences are common, then perhaps language commensurate with such risks should follow.

     

    After initial healing of an index wound, patients are referred to not as being cured but rather as being “in remission.” This concept is easy for the patient and the rest of the team to understand, and it powerfully connotes the necessity for frequent follow-up and rapid intervention for inevitable minor and sometimes major complications.

    This program will review tried-and-true as well as up-to-the-minute advances in biologics, consumer electronics, mechanics, medicine, and surgery that are “pushing the envelope” in extending ulcer-free, hospital-free, and activity-rich days in efforts to make prevention pay.

     

    Registrants will learn how to:

    • Identify risk factors for ulceration
    • Identify risk factors for amputation
    • Understand the impact of diabetes on the health care system
    • Understand the impact of diabetic foot complications on the health care system

    Using technology to reduce waste and improve surgical care

    Every day, millions of patients undergo procedures in ambulatory surgery centers (ASCs), and a very small percentage of them have complications during and after the procedure. Fortunately, new technologies promise to address problems that have challenged patients and their surgical teams.New analytical tools using artificial intelligence and machine learning, coupled with data streams from patients, can be used to better understand patient risk sand develop treatment strategies to reduce complications and improve outcomes.These new tools promise to reduce waste (defined as care that does not add to the patient’s health).For example, a patient who develops a wound infection post-operatively that requires re-operation and hospital admission may benefit from those interventions, but if the patient had gotten treatment earlier for the wound infection,hospitalization and re-operation could have been avoided altogether. Waste is common in our healthcare system today, but things are already starting to change.

     

    How can new technologies reduce waste and improve outcomes for patients treated in ASCs? These tools can help predict risk of complications, better manage surgical procedures, and post-operative recovery.Physicians and teams managing surgical patients face several difficult issues: when is it safe to take my patient to surgery? What are the identifiable risks of surgery for this patient and what can be done to minimize those risks? How can the surgery be made as safe as possible? What does this patient need to heal successfully after surgery and what can be done to minimize surgical complications that require treatment? Better answers to these questions lead to better outcomes for patients and reduce wasteful expenditures … read more

    AI-Powered Prediction of Postoperative Wound Infections in Diabetic Patients



    AI-Powered Prediction of Postoperative Wound Infections in Diabetic Patients

    Summary: This study develops DiabCompSepsAI, a Random Forest Classifier using NSQIP data to predict postoperative wound infections and sepsis in diabetic patients with high accuracy (94%+). By analyzing factors like surgical duration, wound classification, and comorbidities, the model enables early interventions to mitigate healing complications, reduce hospital stays, and lower costs in this high-risk group.

    Key Highlights:

    • DiabCompSepsAI achieves 94% accuracy in predicting wound infections and sepsis, outperforming traditional risk assessments.
    • Top predictors include prolonged surgery, contaminated wounds, and patient weight, highlighting modifiable factors for better healing.
    • A user-friendly Streamlit app supports real-time predictions, integrating into clinical workflows for proactive wound care.
    • AUC scores of 0.92–0.95 demonstrate strong discriminative power, aiding in reducing morbidity from diabetic complications.
    • Future validation could expand its use to diverse surgical settings, enhancing postoperative management.

    Read full article

    Keywords:
    diabetic wound infection,
    postoperative sepsis,
    AI wound prediction,
    surgical site infections,
    diabetic wound healing

    Preventing Pressure Injuries in Pediatric EEG Monitoring: The Role of Polyurethane Foam



    Preventing Pressure Injuries in Pediatric EEG Monitoring: The Role of Polyurethane Foam

    Summary: This retrospective study evaluates a simple intervention using polyurethane foam to prevent medical device-related pressure injuries (PIs) in children undergoing continuous electroencephalography (CEEG). By placing 5mm-thick foam with silicone dressing on the frontal forehead between electrodes and 4cm-thick foam on the back of the head for immobile patients, the method reduced PI incidence from 6.5% (5/77 patients) in the standard group to 1.5% (1/65 patients) in the intervention group, achieving a 77% prevention rate. This low-cost approach is particularly valuable for infants with fragile skin, minimizing scarring risks without compromising EEG quality.

    Key Highlights:

    • CEEG electrodes and head wrapping commonly cause PIs in 7.8% of pediatric cases, with higher risks in infants due to immature skin.
    • Intervention group showed significantly lower PI rates (1.5% vs. 6.5%), supporting foam’s pressure-redistribution efficacy.
    • Method is easy to implement, using inexpensive materials, and suitable for various facilities monitoring seizures or cortical function.
    • Risk assessment via Glamorgan scale identified high-risk patients, but foam prevented injuries across ages <18 years.
    • Potential to reduce cosmetic scarring and complications, emphasizing proactive wound prevention in device-related care.

    Read full article

    Keywords:
    pressure injuries,
    polyurethane foam,
    pediatric wound care,
    EEG monitoring,
    medical device related PIs

    A New Chapter for the Diabetes and Metabolism Journal

    Navigating the AI Revolution: A New Chapter for the Diabetes and Metabolism Journal

    Summary: Published March 1, 2026 in Diabetes & Metabolism Journal (Vol. 50, No. 2, pp. 253–254; Korean Diabetes Association), this editorial by incoming editor-in-chief Junghyun Noh (Division of Endocrinology and Metabolism, Inje University Ilsan Paik Hospital, Goyang, Korea) announces the journal’s evolving policy framework for artificial intelligence use in scientific research and manuscript preparation. The editorial follows a broader trend across academic publishing: an Elsevier survey of 3,234 researchers from 113 countries found that AI tool use in research rose from 37% in 2024 to 58% in 2025, with expectations of continued growth. Dr. Noh identifies four core concerns the journal is addressing: (1) scientific integrity and originality, as AI-assisted text may contain inaccurate interpretations or fabricated references; (2) data and image fabrication risks, as advanced AI systems can produce synthetic datasets and manipulated figures that are difficult to distinguish from genuine outputs; (3) authorship and contributorship ambiguity, requiring clearer disclosure norms; and (4) the substitution risk — AI-generated text may appear fluent and grammatically correct while lacking the scientific depth, critical analysis, and domain expertise that peer-reviewed work demands. DMJ’s immediate policy response requires authors to disclose all AI tool use during manuscript preparation, data analysis, or figure development — specifying tools, applications, and confirmation that outputs have been verified for accuracy. This disclosure must appear in the Methods section or as a dedicated AI Assistance Statement and will be published with the article. The journal is also evaluating AI-based tools for editorial screening of data and image manipulation, training editorial staff, and signalling openness to well-conducted AI-methods studies in dedicated future formats.

    Key Highlights:

    • New policy (immediate effect): all AI tool use during manuscript preparation, data analysis, or figure development must be explicitly disclosed, with tools named and AI-assisted content confirmed as author-verified for accuracy
    • Elsevier 2025 survey context: AI use among researchers rose from 37% to 58% in one year across 113 countries; most anticipate greater efficiency gains ahead — underscoring the urgency of journal-level governance frameworks
    • Four key integrity risks identified: fabricated or inaccurate AI-generated text; synthetic datasets and manipulated figures; authorship ambiguity; and substitution of AI fluency for genuine scientific judgment and domain expertise
    • Editorial safeguards in development: evaluation of AI-detection tools, particularly for image and data manipulation screening; enhanced training for editors and reviewers; engagement with cross-journal AI ethics initiatives
    • Openness to AI-methods research: if a sufficient body of rigorous, transparent AI-methods studies emerges, DMJ may create a dedicated section — focusing on drug development, risk assessment, predictive modeling, and precision medicine in diabetes and metabolism
    • Authorship principle maintained: AI tools may not be listed as authors; the corresponding human authors bear full responsibility for the accuracy, integrity, and originality of all submitted content

    Read full article

    Keywords: AI diabetes research publishingartificial intelligence wound care researchscientific publishing integrityAI manuscript disclosurediabetes metabolism journalLLM medical research

    Junghyun Noh

    Medical Device-related Pressure Injuries Associated With Electroencephalogram Leads in a Tertiary Care Children’s Hospital

    Medical device-related pressure injuries (MDRPIs) present a substantial safety risk for children who are hospitalized. PURPOSE: This study aimed to describe patient and clinical characteristics of children who develop MDRPIs related to electroencephalogram (EEG) leads, determine risk factors associated with their development, and determine if there are common risk factors that can lead to actionable strategies to reduce MDRPIs related to EEG leads. METHODS: A retrospective review was completed of the electronic health records of all 3136 children who had EEG lead placements between January 1, 2014, and April 16, 2018, at a large tertiary care children’s hospital. Data abstracted included demographic variables, patient and pressure injury characteristics, as well as length of stay. RESULTS: Twenty-four (24) of the 3136 children (0.8%) developed an MDRPI. Most were stage 2 pressure injuries. Patients who developed a pressure injury were significantly younger than patients who did not (median age, 0.9 and 5.2 years … read more

    Sensing technology to prevent diabetic foot ulcers

    Innovative in-sole sensors will alert diabetic patients during excessive or extended activities that could trigger foot ulcers in a new system being developed at the University of Southampton … The Load Monitoring and Intervention System (LOMIS) processes real-time data from three directional force sensors and detects physical activities over extended periods of time in a five-metric dimensional risk model … Live risk alerts are communicated to patients through a connected App to mitigate the risk and dangers of ulceration and amputation … read more

    …device-caused ulcers coming Global experts seeking to reduce the risk of medical device-related pressure injuries and influence the design of new prevention technologies will issue their first consensus document this…

    Janssen Submits Supplemental New Drug Application to U.S.

    FDA for INVOKANA® (canagliflozin) for the Treatment of Chronic Kidney Disease in Patients with Type 2 Diabetes

     

    The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking a new indication for INVOKANA® (canagliflozin) to reduce the risk of end-stage kidney disease (ESKD), the doubling of serum creatinine, which is a key predictor of ESKD, and renal or cardiovascular (CV) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD). The submission is based on results from the Phase 3 CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) study, which evaluated the efficacy and safety of INVOKANA® versus placebo in this high-risk patient population when used in addition to standard of care.

     

    Primary investigators will present the CREDENCE data during a late-breaking clinical trials session at the International Society of Nephrology (ISN) World Congress of Nephrology (WCN) Annual Meeting in Melbourne, Australia on April 15 at 8:30 am AEST (April 14 at 6:30 pm EDT in the U.S.). An open access live-stream of the late-breaking presentation can be accessed here (registration is required).

     

    “Today, millions of people living with type 2 diabetes and chronic kidney disease are at high risk of experiencing kidney failure, and unfortunately, we have not seen treatment innovation for these patients in almost 20 years. Janssen’s application is a significant step toward bringing a much-needed, new standard of care for those living with these serious conditions,” said James List, M.D., Ph.D., Global Therapeutic Area Head, Cardiovascular & Metabolism, Janssen Research & Development, LLC. “We look forward to presenting the CREDENCE data at the ISN World Congress of Nephrology and working closely with the FDA to bring this important medicine as quickly as possible to people living with type 2 diabetes and chronic kidney disease.” … read more

    Peripheral arterial disease and the diabetic foot

    Peripheral arterial disease (PAD) is a term used to describe atherosclerotic vessels in the periphery, mostly affecting the lower extremities. The blocked vessels impair blood and oxygen perfusion to the lower limbs and may lead to increased risk of ulceration, wounds and amputations. PAD is also associated with increased risk of coronary and cerebrovascular incidents. More than 50% of people living with PAD may not have any clinical symptoms, posing a challenge to diagnosis and management. This article will discuss the aetiology, presentation, risk factors, and management of PAD as related to the lower extremities … read more

    Proactive Approaches to Help Prevent and Treat Chronic Wounds

    There are many risk factors associated with chronic wound development, with age being an unchangeable one. The good news is, there are also changeable risk factors. Understanding how to prevent and treat a chronic wound is crucial when caring for older adults. To help older adults, caregivers, and the professionals working with them, below are answers to some common questions about chronic wounds and tips for how to educate on risk factors … There is no true definition for a chronic wound, but it is typically a wound that does not progress normally through stages of healing and has not healed within four weeks. There are many different types of chronic wounds, examples include diabetic foot ulcers, venous leg ulcers, and pressure injuries … read more

    Peripheral arterial disease and the diabetic foot

    Peripheral arterial disease (PAD) is a term used to describe atherosclerotic vessels in the periphery, mostly affecting the lower extremities. The blocked vessels impair blood and oxygen perfusion to the lower limbs and may lead to increased risk of ulceration, wounds and amputations. PAD is also associated with increased risk of coronary and cerebrovascular incidents. More than 50% of people living with PAD may not have any clinical symptoms, posing a challenge to diagnosis and management. This article will discuss the aetiology, presentation, risk factors, and management of PAD as related to the lower extremities … read more

    Caring for the diabetic foot

    Patients with psoriasis have a higher risk of developing new onset diabetes mellitus. It’s a risk that’s been described as statistically significant. So, in this article, we examine dermatologic care for diabetic foot infections.

     

    Patients with psoriasis have a higher risk of developing new onset diabetes mellitus. The increased incidence of psoriasis and diabetes mellitus was documented in a 2013 study by Usman Khalid, et al. published in Diabetes Care in which authors described the correlation as “statistically significant.” So, in this article, we examine dermatologic care for diabetic foot infections.

    Dermatologists must be able to diagnose and manage mild-to-moderate infections in diabetic foot ulcers (DFUs), said Warren S. Joseph, D.P.M., FIDSA, in a presentation at DERMfoot 2018 in Baltimore … read more

    True multidisciplinary approach essential for limb preservation

    CHICAGO — To prevent amputation, physicians must assemble a comprehensive multidisciplinary team to care for patients at risk for losing their limbs, Ramon Varcoe, MD, MBBS, MS, FRACS, PhD, said at AMP: The Amputation Prevention Symposium.

     

    A multidisciplinary approach to limb preservation begins with recognizing the major drivers of amputation. The global public health threat posed by the “tsunami of diabetes,” for instance, is a significant problem, he said.

     

    If a patient develops diabetes, his or her risk for amputation is 15 times as high as someone who does not, according to Varcoe.

     

    “The impact is more than amputation itself, though; it’s a reduction in life expectancy as well,” he said, noting that studies have linked amputation to an increased risk for death and 5-year rates of death exceeding that of some cancers … read more

    Inlow’s 60-Second Diabetic Foot Screen Gets a New Look!

    Dr. Shane Inlow wrote a two-page article, published in 2004, to help guide clinicians in assessing and planning care for patients with or at risk for diabetic foot ulcers.1 A few years later, clinicians in Northern Canada indicated that one of their problems was communicating effectively with experts in larger centres about their patients’ foot problems. The article by Dr. Inlow came to mind, and Inlow’s 60-Second Diabetic Foot Screen was created to give clinicians a common language and process to perform such an assessment.2 This tool then underwent a validation study that included interrater and intrarater reliability and predictive validity to determine consistency of risk recognition for development of ulceration independent of specific assessor and practice setting.1,3 Four years later, a growing body of work by the International Working Group on the Diabetic Foot (IWGDF) resulted in a risk-classification tool … read more

    Best practice recommendations for the Prevention and

         Management of Diabetic Foot Ulcers

     

    Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia that
    leads to microvascular, macrovascular and neuropathic complications. In 2016, there
    were 11 million Canadians living with type 1, type 2 or pre-diabetes, and every three
    minutes another Canadian is diagnosed. Certain populations are at higher risk for
    developing type 2 DM, including those of Asian, African, Hispanic and Indigenous decent.
    The rates of DM are three to five times higher in Indigenous populations, an issue
    compounded by unique barriers to care including, but not limited to, a lack of cultural
    competency among health-care providers, jurisdictional confusion, limited access to
    care, geographical location and language barriers.

     

    Foot health should be a major consideration for people with diabetes and for those
    who care for them. Foot complications in this high-risk population can lead to a cascade
    of negative complications, potentially resulting in loss of limb and life.
    The lifetime risk for foot ulceration in people with diabetes is 15 to 25%. According to
    the International Diabetes Federation, persons with diabetes are 15 to 40 times more
    likely to require lower-leg amputation compared to the general population. Approximately
    85% of amputations are preceded by the development of a neuropathic foot
    ulcer.

     

    Following a lower-limb amputation, people with diabetes not only suffer the
    clinical and psychological consequences of limb loss, but also have a five-year mortality
    rate of 50%. This is a higher mortality rate than is seen in breast cancer in females,
    prostate cancer in males or lymphoma … read more

    Not all foams redistribute pressure equally

    Recent research demonstrates the effectiveness of various foam dressings for pressure redistribution. Jeffrey Niezgoda, MD (APWCA Vice-President) recently published his findings in a poster presentation (SAWC 2018).  His results demonstrated that all foams are not equivalent in the ability to provide pressure relief in patients at risk for developing pressure ulcers.  OxyBand Rescue out performed all other foam dressings currently on the market, providing superior reduction in average pressures and peak pressures, while at the same time maximizing contact area.  The NPUAP has recently published recommendations advocating the use of foam dressings to provide pressure redistribution in an attempt to reduce the risk of pressure ulcer formation in at risk patients.  A copy of the Poster is provided.

    From the The American Professional Wound Care Association® (APWCA) 

    Prevention and Management of Diabetic Foot Ulcers

    BEST PRACTICE RECOMMENDATIONS FOR THE Prevention and Management of Diabetic Foot Ulcers

     

    Diabetes mellitus (DM) is a metabolic disorder characterized by hyperglycemia that leads to microvascular, macrovascular and neuropathic complications. In 2016, there were 11 million Canadians living with type 1, type 2 or pre-diabetes, and every three minutes another Canadian is diagnosed. Certain populations are at higher risk for developing type 2 DM, including those of Asian, African, Hispanic and Indigenous decent. The rates of DM are three to five times higher in Indigenous populations, an issue compounded by unique barriers to care including, but not limited to, a lack of cultural competency among health-care providers, jurisdictional confusion, limited access to care, geographical location and language barriers.1,2 Foot health should be a major consideration for people with diabetes and for those who care for them. Foot complications in this high-risk population can lead to a cascade of negative complications, potentially resulting in loss of limb and life. The lifetime risk for foot ulceration in people with diabetes is 15 to 25%. According to the International Diabetes Federation … read more (PDF)

    Peripheral arterial disease and the diabetic foot

    Miranda Tawfik

    Peripheral arterial disease (PAD) is a term used to describe atherosclerotic vessels in the periphery, mostly affecting the lower extremities. The blocked vessels impair blood and oxygen perfusion to the lower limbs and may lead to increased risk of ulceration, wounds and amputations. PAD is also associated with increased risk of coronary and cerebrovascular incidents. More than 50% of people living with PAD may not have any clinical symptoms, posing a challenge to diagnosis and management. This article will discuss the aetiology, presentation, risk factors, and management of PAD as related to the lower extremities … read more

    Diabetes UK commits £2.6 million to new research

    • New funding will be split between 14 new research projects and five new PhD grants
    • New research includes projects investigating whether medieval remedies can be used to treat foot ulcers, and if sleep disturbances can predict Type 2 diabetes

    Diabetes UK has committed to invest £2.6 million in 19 brand new projects which aim to make life-changing improvements in diabetes care, and reduce people’s risk of Type 2 diabetes.

     

    The funding will be given to projects looking into Type 1, Type 2 and gestational diabetes. In one of these projects, Dr Freya Harrison, from the University of Warwick, will be using medieval remedies to find new sources of antibiotics. She has already discovered a combination that can kill antibiotic-resistant bacteria in the lab. Dr Harrison will study this remedy further to investigate how it works and if it could be used to treat infected foot ulcers in the future.

     

    There are more than 20 leg, foot and toe amputations each day due to diabetes, four out of five of which could be prevented. This research hopes to reduce the number of diabetes-related amputations and cases of sepsis, by treating foot ulcer infections more effectively.

     

    Dr Martin Rutter, from the University of Manchester, has also been awarded Diabetes UK funding to find out if sleep problems can help predict who might be at risk of Type 2 diabetes. He will also look at whether sleep patterns in people with Type 2 diabetes can affect their blood glucose control, and their risk of serious diabetes-related complications, such as amputation, heart disease and blindness … read more

    Caring for the Diabetic Foot in Long-Term Care Facilities

     

    By Susan M. Cleveland, BSN, RN, WCC, CDP, NADONA Board Secretary

     

    As a Director of Nursing (DON) in a long-term care facility, do you know where the awareness level of diabetes and its complications is for your staff? Do they realize diabetes doesn’t stop? It is 24/7, 365 days a year. Knowing this reality of diabetes and understanding the disease process may assist with preventing serious health problems such as heart disease, stroke, blindness, kidney disease, and nerve damage that can lead to amputation.

     

    Education is key. We cannot talk about this enough. Assuming someone knows or that common sense will tell people how to take care of these residents is a huge mistake. I don’t believe in common sense; I believe in common knowledge, but it is only common once it is taught. So, teach about diabetes and the care of residents with diabetes often.

     

    Knowing the Risk of Diabetic Foot Ulcers and Diabetic Peripheral Neuropathy
    In 2015, 30.3 million Americans, or 9.4% of the population, had diabetes. Approximately 1.25 million American children and adults have type 1 diabetes. The percentage of Americans age 65 and older remains high, at 25.2%, or 12.0 million seniors (diagnosed and undiagnosed).1Diabetic foot ulcer (DFU) is the number one risk factor contributing to non-traumatic foot amputations in persons with diabetes. Limb amputations are preceded by DFUs 58% of the time. The primary risk factor for the DFU is loss of protective sensations or diabetic peripheral neuropathy (DPN) … read more

    Corstrata Foot Ulcer Prevention Solution

      Named Among Semifinalists For T1D Exchange 2018 Diabetes Innovation Challenge

     

    Corstrata provides new tech empowered diabetic foot ulcer prevention to improve patient lives.

     

    CORSTRATA, a provider of digital healthcare IT solutions and services for wound management, announced today that the company’s Diabetic Foot Ulcer & Amputation Prevention solution was named as a semifinalist in the T1D Exchange 2018 Diabetes Innovation Challenge. Corstrata was one of 30 semifinalists chosen from academic researchers and early stage companies from around the world that submitted entries for solutions to support advanced diabetes care. T1D Exchange is a nonprofit research and collaboration organization dedicated to accelerating novel treatments to improve the care of people living with type 1 diabetes (T1D).

     

    Diabetic foot ulcers (DFUs) are a common, limb-threatening, and expensive complication of diabetes. Of the 29M people with diabetes in the U.S., 1.7M suffer with one or more DFUs annually and 80K of these diabetics ultimately require an amputation. The risk of death at 5 years for DFU patients is 2.5 times as high as the risk for a patient with diabetes without a foot ulcer.

     

    Corstrata offers a technology-enabled care management solution for diabetics at risk for formation of costly diabetic foot ulcers and related amputations. Using a “smart” mat to detect potential ulcers, Corstrata’s wound specialists engage with the patient through a mobile engagement app for timely intervention and prevention of ulcers. Corstrata’s Diabetic Foot Ulcer & Amputation Prevention Program serves as an outsourced end-to-end technology-enabled solution for value-based organizations and payers … read more

    Physical Training and Activity in People With Diabetic Peripheral Neuropathy

    Diabetic peripheral neuropathy (DPN) occurs in more than 50% of people with diabetes and is an important risk factor for skin breakdown, amputation, and reduced physical mobility (ie, walking and stair climbing). Although many beneficial effects of exercise for people with diabetes have been well established, few studies have examined whether exercise provides comparable benefits to people with DPN. Until recently, DPN was considered to be a contraindication for walking or any weight-bearing exercise because of concerns about injuring a person’s insensitive feet. These guidelines were recently adjusted, however, after research demonstrated that weight-bearing activities do not increase the risk of foot ulcers in people who have DPN but do not have severe foot deformity. Emerging research has revealed positive adaptations in response to overload stress in these people, including evidence for peripheral neuroplasticity in animal models and early clinical trials. This perspective article reviews the evidence for peripheral neuroplasticity in animal models and early clinical trials, as well as adaptations of the integumentary system and the musculoskeletal system in response to overload stress. These positive adaptations are proposed to promote improved function in people with DPN and to foster the paradigm shift to including weight-bearing exercise for people with DPN. This perspective article also provides specific assessment and treatment recommendations for this important, high-risk group … read more

    The management of diabetic foot

    A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine.

     

    Major Recommendations
    Definitions of the strength of the recommendations (Grade 1 or 2) and quality of the evidence (Level A–C) are provided at the end of the “Major Recommendations” field.

     

    Prevention of Diabetic Foot Ulcers (DFUs)

    1. The committee recommends that patients with diabetes undergo annual interval foot inspections by physicians (MD, DO, DPM) or advanced practice providers with training in foot care (Grade 1C).

    2. The committee recommends that foot examination include testing for peripheral neuropathy using the Semmes-Weinstein test (Grade 1B).

    3. The committee recommends education of the patients and their families about preventive foot care (Grade 1C).

    4a. The committee suggests against the routine use of specialized therapeutic footwear in average-risk diabetic patients (Grade 2C).

    4b. The committee recommends using custom therapeutic footwear in high-risk diabetic patients, including those with significant neuropathy, foot deformities, or previous amputation (Grade 1B).

    5. The committee suggests adequate glycemic control (hemoglobin A1c <7% with strategies to minimize hypoglycemia) to reduce the incidence of DFUs and infections, with subsequent risk of amputation (Grade 2B).

    6. The committee recommends against prophylactic arterial revascularization to prevent DFU (Grade 1C).

    Off-Loading DFUs

    1. In patients with plantar DFU, the committee recommends offloading with a total contact cast (TCC) or irremovable fixed ankle walking boot (Grade 1B).

    2. In patients with DFU requiring frequent dressing changes, the committee suggests off-loading using a removable cast walker as an alternative to TCC and irremovable fixed ankle walking boot (Grade 2C). The committee suggests against using postoperative shoes or standard or customary footwear for off-loading plantar DFUs (Grade 2C).

    3. In patients with nonplantar wounds, the committee recommends using any modality that relieves pressure at the site of the ulcer, such as a surgical sandal or heel relief shoe (Grade 1C).

    read more

    Malnutrition and Pressure Injuries

    Nutrition and Pressure Injury Healing

    Current literature has identified more than 100 risk factors for pressure injury (PI) development. Some extrinsic (primary/non-physiological) and intrinsic (secondary/physiological) risk factors that contribute to PI development include diabetes mellitus, peripheral vascular disease, malignancy, prolonged pressure on an area of the body, being 70 years of age and older, smoking, urinary and fecal incontinence, a low body mass index (BMI), and malnutrition.

     

    Pathophysiologic and intrinsic factors at the core of PI formation include nutrition. Maintaining adequate parameters of nutrition is considered a best practice in both the prevention and treatment of PIs. Individuals with PIs or who are at risk for developing PIs should strive to achieve or maintain adequate nutrition parameters. Meeting macronutrient and micronutrient requirements forms the foundation of good health. This translates to consuming wholesome, nutrient-dense foods!

    read more 

    Diabetic Foot Ulcer (DFU) Biofilm Infection and Recurrence (DFU Biofilm)

    Diabetic foot ulcers (DFU) are one of the most common reasons for hospitalization of diabetic patients and frequently results in amputation of lower limbs. Of the one million people who undergo non-traumatic leg amputations annually worldwide, 75% are performed on people who have type 2 diabetes (T2DM). The risk of death at 10 years for a diabetic with DFU is twice as high as the risk for a patient without a DFU. The rate of amputation in patients with DFU is 38.4%4. Infection is a common (>50%) complication of DFU. Emerging evidence underscores the significant risk that biofilm infection poses to the non-healing DFU. Biofilms are estimated to account for 60% of chronic wound infections. In the biofilm form, bacteria are in a dormant metabolic state. Thus, standard clinical techniques like the colony forming unit (CFU) assay to detect infection may not detect biofilm infection. Thus, biofilm infection may be viewed as a silent maleficent threat in wound care … read more

    Guidelines Highlight Role of Nutrition in Management of Diabetic Foot Ulcers

    New guidelines recommend healthcare providers develop and implement an individualized nutrition care plan for individuals with diabetes with or at risk of a DFU
    New guidelines endorsed by the American Limb Preservation Society highlighted the importance of nutrition in wound healing for adults with diabetes, who also experience diabetic foot ulcers (DFU).

    The guidelines stated that nutritional interventions were “recommended for all patients who could benefit now or in the future from nutritional care.” As such, healthcare providers should develop and implement an individualized nutrition care plan for individuals with or at risk of a DFU, who are additionally malnourished or at risk of malnutrition … read more

    Podimetrics Announces Expansion of Leadership Team with Four New Strategic Growth Hires

    Longtime Congresswoman and former President and CEO of the Better Medicare Alliance, Allyson Schwartz, also joins Podimetrics’ Advisory Board

     

    SOMERVILLE, Mass., May 12, 2022 /PRNewswire/ — Podimetrics, creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex patients with diabetes, today announced four new leadership hires aimed at helping the company scale and support even more health plans and providers serving patients living with complex diabetes: Matthew Scalo as Chief Financial Officer, Kyle Bray as Chief Operating Officer, Kim Nguyen as Vice President of Financial Planning and Analysis, and Elizabeth Hogan Hamacher as Vice President of Clinical Services and Support. Podimetrics also added a new member to their advisory board, Allyson Schwartz, a long-time Congresswoman and also the former President and CEO of the Better Medicare Alliance.

     

    These key hires and advisory board appointment follow Podimetrics’ recent announcement of their Series C. The company also experienced unprecedented growth in 2021, including doubling the patients under management with the Veterans Health Administration; doubling revenue for the third year in a row; and also doubling the size of the Podimetrics team. Dr. Jon Bloom, CEO and co-founder of Podimetrics, shared the following insights on the company’s growth trajectory for the year ahead: “We are in high-growth mode, and these leadership hires and the appointment of Allyson Schwartz to Podimetrics’ advisory board reinforce our focus on helping even more at-risk, underserved patients avoid the unnecessary health toll and financial burden associated with amputations resulting from complex diabetes.”

     

    In just the first quarter of 2022, Podimetrics rounded out their leadership team with a series of strategic new hires that position the company for strong growth in the year ahead:

     

    • Matthew Scalo, Chief Financial Officer — With nearly two decades of experience spanning banking and financial services, he most recently served as the senior vice president of finance at Cancer Treatment Centers of America;
    • Elizabeth Hogan Hamacher, Vice President of Clinical Services and Support — A registered nurse with more than 12 years of clinical operations experience, she most recently served as senior director of clinical operations at ConsumerMedical; and
    • Kim Nguyen, Vice President of Financial Planning and Analysis — With more than a decade of experience, she most recently served as associate vice president for financial planning and analysis for vRad (Virtual Radiologic).

     

    The company’s latest addition to their advisory board, Allyson Schwartz, also brings unprecedented experience in healthcare, as well as policy. As a former member of the House of Representatives and former President and CEO of the Better Medicare Alliance, she is a nationally recognized leader on healthcare issues and was also instrumental in the passage of the Affordable Care Act. Schwartz shared the following insights about joining the advisory board at Podimetrics: “Podimetrics serves some of our nation’s most vulnerable patients — patients who have been ignored for far too long. It’s an honor to join their advisory board. The research and innovation they are leading will help drive a new preventive and proven approach to helping reduce amputations in patients living with complex diabetes.”

     

    Podimetrics invented the SmartMat, which has already been used by thousands of patients through partnerships with leading risk-based healthcare providers and regional and national health plans. The SmartMat is the only easy-to-use, at-home mat that a patient steps on for only 20 seconds per day. The mat detects temperature changes in the foot, which are often a precursor to diabetic foot ulcers (DFUs). Patient temperature data from the SmartMat is then remotely monitored by Podimetrics’ in-house nurse support team. If the data from the mat is indicative of potential health issues, Podimetrics’ nursing team swiftly connects both with the patient and the patients’ provider.

     

    For more information on Podimetrics and how its SmartMat and clinical care services can help prevent diabetic foot ulcers and improve patient outcomes, please visit Podimetrics.com.

     

    About Podimetrics

    Podimetrics is the creator of the FDA-cleared SmartMat™ and integrated clinical care services that can help save the limbs and lives of complex diabetic patients. Through partnerships with regional and national health plans and at-risk providers, such as the Veterans Health Administration, Podimetrics has helped prevent amputations associated with complex diabetes. By combining cutting-edge technology with best-in-class clinical care services, Podimetrics earns high engagement rates from patients and allows clinicians to save limbs, lives, and money — all while keeping vulnerable populations healthy in their own homes. For more information, visit Podimetrics.com or follow us on LinkedIn and Twitter.

    Contact: press@Podimetrics.com

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/podimetrics-announces-expansion-of-leadership-team-with-four-new-strategic-growth-hires-301545591.html

    Three Nutritional Indices Are Effective Predictors of Mortality in Patients With Type 2 Diabetes and Foot Ulcers

    Jing Hong, Qi-Qi Huang, Wen-Yue Liu, Xiang Hu, Fei-Fei Jiang, Ze-Ru Xu, Fei-Xia Shen, and Hong Zhu

     

    Patients with diabetic foot ulcers (DFUs) are considered to be with an excess risk of all-cause mortality (1), facing a 5-year mortality as high as 30.5% which is comparable to cancer (2). Additionally, the mortality of patients with DFUs is more than 2-folds higher than patients with diabetes but without DFUs (3). The excess all-cause mortality in patients with DFUs cannot fully be explained by traditional cardiovascular risk factors (4). The importance of other factors, such as nutritional status, needs to be further elucidated.

    Patients with DFUs, especially those with Wagner grade 4 and 5, were more vulnerable to malnutrition compared to patients without DFUs (5). Malnutrition was found to be associated with higher complications, longer hospital stays, and increased mortality in hospitalized patients (6). Malnutrition is often ignored but modifiable. Identifying patients at risk of malnutrition is important … read more

    REGENATIVE LABS RELEASES NEW STUDY TO REVOLUTIONIZE TREATMENT FOR PATIENTS WITH DIABETIC FOOT ULCERS

    Future applications for the early, preventative use of amniotic membrane allografts in addition to the current standard of care for DFUs present a novel opportunity to reduce long-term morbidity and amputation risk in diabetic patients.

     

    PENSACOLA, Fla., Aug. 8, 2022 /PRNewswire/ — A new MDPI study, co-authored by Regenative Labs signifies a huge win for patients suffering from diabetic foot ulcers (DFUs). DFUs are debilitating for an individual. They are painful, long lasting, and, even with proper care, can lead to amputation. The current standard of care for DFUs is debridement, the medical removal of dead, damaged, or infected tissue to improve the healing potential of the remaining healthy tissue. The increased healing time and augmented risk of amputation associated with the current standard of care only solidifies the need for new DFU treatment alternatives. Regenerative medicine is such an alternative.

     

    With approximately 37.3 million diabetic adults in the United States, physicians are faced with an epidemic. Given the projected increase of 1.4 million new diagnoses of diabetes mellitus each year, advancing knowledge and care for the disease and its related conditions is especially relevant.

     

    Regenative Labs’ AmnioText™, a dehydrated amniotic membrane allograft, was used to close a grade 5 wound according to the Curative Health Services (CHS wound grade scale), described as full thickness and subcutaneous tissues, exposed tendons, ligaments, and/or joints, plus necrotic tissue in the wound, in 7 weeks. Grade 5 wounds have a 91.5% rate of not healing at all. This unsettling outcome emphasizes the efficacy and importance of amniotic membrane allografts in revolutionizing the standard of care for DFUs.

     

    The inability to heal DFUs presents a severe danger to patients as anywhere from 5 to 24% of untreated DFUs can lead to limb amputation within 6–18 months. These infections can lead to long-term impairment and possible lower-limb amputation without timely and correct management.

     

    “Regenative Labs and our products are focused on ameliorating this problem with our outcomes-based approach. We provide the highest quality amniotic membrane allograft to allow doctors to provide predictable outcomes for their patients,” shared Regenative Labs CEO, Tyler Barrett.

     

    Amniotic membrane allografts, such as those provided by Regenative Labs, have proven to augment the body’s ability to regenerate the structural tissue defects associated with DFUs; they are also comparable in cost to the standard of care, which averages about USD 17,245. Not only is the current standard of care for DFUs less effective, but it is also high in cost and typically relies on inpatient expenditures.

     

    Medicare now recognizes the medical necessity of amniotic membrane allografts in the treatment of both DFUs and venous stasis ulcers. Consequently, many patients rely on Medicare to assist with the costs associated with DFU treatment. This presents the opportunity for human amniotic membrane allografts to be utilized in rural and underserved communities where DFU treatment is typically delayed due to high costs and a lack of supplies associated with traditional treatment. This could exponentially decrease the risk of amputations in diabetic patients in these rural and underserved communities.

     

    About Regenative Labs: Regenative Labs produces regenerative medicine products to address the root cause of a patient’s conditions using Wharton’s Jelly innovations rather than masking the pain with other treatments. Regenative Labs works closely with scientists, physicians, hospitals, and surgery centers to constantly monitor and improve patient progress and outcomes for new product development. Formed by veteran industry professionals familiar with daily challenges of innovations in healthcare, the company provides effective, non-addictive, non-invasive options for patients. Regenative Labs has a laser-focused, expert product research and development team which follows FDA guidelines of minimal manipulation for homologous use. The company adheres to AATB and FDA guidelines.

     

    Learn more at Regenative’s website: www.regenativelabs.com

     

    SOURCE Regenative Labs

    Swift Medical Announces Proven Outcomes Across 20 Million Wound Assessments

    Swift’s AI-powered wound imaging technology shown to improve quality of care and costs to manage complex patients

    June 01, 2023 09:00 AM Eastern Daylight Time
    TORONTO–(BUSINESS WIRE)–Swift Medical, a digital health technology company focused on improving clinical and economic outcomes in wound care, today announced proven outcomes from more than 20 million wound assessments captured with Swift’s leading, AI-powered wound care platform. Deployed in nearly 4,000 healthcare facilities across North America, Swift’s technology has been shown to speed up wound healing by 37%, reduce wound prevalence and hospitalizations by 35% and 14%, respectively, and reduce hospital length of stay by 62%.

    “We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system”

    Tweet this
    “We are proud to share the incredible impact our technology is having on the millions of patients living with wounds – one of today’s most expensive and overlooked threats to patients and our overall healthcare system,” said Brian Litten, CEO of Swift Medical. “These outcomes demonstrate the impact of having the most powerful wound image dataset in the world and its ability to deliver high quality wound care with reduced costs.”

    The Swift Skin & Wound mobile application enables any mobile device to be equipped with AI-powered imaging capabilities to capture clinically validated, high-precision 3D images, measurements, and other clinical data. The imaging captured at the point of care enables real-time, at-risk patient monitoring, proactive decision-making, and remote wound consultations, reducing the time and cost spent evaluating wounds to create a more efficient wound care experience for both clinicians and patients.

    Today, more people suffer from chronic wounds than those with breast cancer, colon cancer, lung cancer, and leukemia combined. Despite this costly, growing problem, the current standard of care is outdated and highly inaccurate. Clinicians typically receive less than 10 hours of formal education and rely on paper rulers for measurements and cotton swabs for depth assessment. This inefficient and ineffective approach is both painful for patients and leads to poor diagnostic accuracy, prolonged healing, and inappropriate selection of therapies, putting patients at greater risk for readmission, longer lengths of stay and higher care costs.

    With its advanced analytics and proven outcomes, Swift is now poised to partner with health plans and risk-bearing providers to deliver high quality, value-based wound care at scale.

    About Swift Medical

    Swift Medical is the global leader in digital wound care. We are headquartered in Toronto, with operations expanding across the U.S. and Canada. Our mission is to make empathy-driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,000 healthcare facilities in North America across the continuum of care. Our solutions empower healthcare providers to deliver standardized, accessible and equitable wound care for every patient – with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care. To learn more about Swift Medical, visit us at www.swiftmedical.com.

    Contacts
    Media

    David Mannion
    416-303-8020
    david.mannion@swiftmedical.com

    Sonoma Pharmaceuticals Introduces Next Generation Solution for Pulse Lavage Irrigation in the European Union

    BOULDER, CO / ACCESSWIRE / June 8, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, dermatology, and eye, oral and nasal care, today announced a new application for intraoperative pulse lavage irrigation treatment, which can replace commonly used IV bags in a variety of surgical procedures.

    Sonoma developed this new application of its wound care technology in response to an unmet need for a non-toxic irrigation solution that can prevent infection and improve healing time. The intraoperative pulse lavage container is designed to be used in combination with a pulse lavage irrigation device, or flush gun, for abdominal, laparoscopic, orthopedic, and periprosthetic procedures. This product replaces commonly used non-antimicrobial saline and aggressive rinsing solutions with safe and effective Microcyn® Technology. Microcyn® Technology assists in the reduction of microorganisms, is non-toxic, and has regenerative properties, making it critical in preventing infection and promoting wound healing. Sonoma’s pulse lavage container is also cost competitive with IV bags, the current standard of care.

    Sonoma developed the intraoperative pulse lavage irrigation treatment in close collaboration with the medical community and Sonoma’s existing distribution partners in Europe and expects this new application will be met with wide acceptance. Sonoma is now accepting orders for the pulse lavage irrigation treatment solution, which is expected to be ready for commercial use in Europe in September 2023. Sonoma anticipates commercial launch in the U.S. in 2024.

    “Sonoma continues to lead in the innovation of products that improve outcomes for people with wounds or injuries or who are needing surgery. We continue to see increased demand for our wound care products in Europe, and we are excited to expand our offerings to include this next generation irrigation solution to help people heal faster following surgery,” said Amy Trombly, CEO of Sonoma Pharmaceuticals.

    For more information, or to pre-order our pulse lavage irrigation treatment solution in Europe, please contact info.europe@sonomapharma.com.

    About Sonoma Pharmaceuticals, Inc.

    Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, nasal care, oral care, dermatological conditions, animal health care and non-toxic disinfectants. The company’s products reduce infections, itch, pain, scarring and harmful inflammatory responses in a safe and effective manner. In-vitro and clinical studies of hypochlorous acid (HOCl) show it to have impressive antipruritic, antimicrobial, antiviral and anti-inflammatory properties. Sonoma’s stabilized HOCl immediately relieves itch and pain, kills pathogens and breaks down biofilm, does not sting or irritate skin, and oxygenates the cells in the area treated, assisting the body in its natural healing process. The company’s products are sold either directly or via partners in 55 countries worldwide and the company actively seeks new distribution partners. The company’s principal office is in Boulder, Colorado, with manufacturing operations in Guadalajara, Mexico. European marketing and sales are headquartered in Roermond, Netherlands. More information can be found at www.sonomapharma.com. For partnership opportunities, please contact busdev@sonomapharma.com.

    Forward-Looking Statements

    Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “company”). These forward-looking statements are identified by the use of words such as “continue,” “develop,” “anticipate,” “expect” and “expand,” among others. Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the company’s business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the company’s products will not be as large as expected, the company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to meet the company’s cash needs, fund further development, as well as uncertainties relative to the COVID-19 pandemic and economic development, varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the company’s filings with the Securities and Exchange Commission. The company disclaims any obligation to update these forward-looking statements, except as required by law.

    Sonoma Pharmaceuticals™ and Microcyn® are trademarks or registered trademarks of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the property of their respective owners.

    Media and Investor Contact:

    Sonoma Pharmaceuticals, Inc.

    ir@sonomapharmaceuticals.com

    SOURCE: Sonoma Pharmaceuticals, Inc.

    Type 2 diabetes: Reframing the first stage of care

    Reframing Initial Care in Type 2 Diabetes: Prioritizing Remission Through Lifestyle

    A May 2024 editorial in *Diabetes Digest* argues for shifting the focus at diagnosis of type 2 diabetes toward achieving remission or significant glycemic improvement—particularly through low-carbohydrate diets and weight reduction.

    Key Highlights:

    • Remission First: For those within six years of diagnosis and not on insulin, the initial goal should be remission. Early extreme weight loss (e.g., ≥15 kg) has led to remission rates of ~86% in studies :contentReference[oaicite:1]{index=1}.
    • Low-Carb Success: Real-world UK practice showed ~51% remission among patients following low-carbohydrate diets, with higher rates (77%) in those diagnosed under one year ago :contentReference[oaicite:2]{index=2}.
    • Studies in Other Populations: Korean data confirm weight loss of >5% doubles remission odds in newly diagnosed patients, reinforcing the significance of dietary change :contentReference[oaicite:3]{index=3}.
    • Healthy vs. Unhealthy Plant-Based Diets: A diet focused on whole foods (fruits, legumes, vegetables) reduced diabetes risk by 24%, while unhealthy plant-based eating increased risk—underscoring food quality importance :contentReference[oaicite:4]{index=4}.
    • Failing Remission? Aim for Tight Control: If remission isn’t feasible, optimal glycemic control remains critical to reduce long-term cardiovascular and microvascular risk :contentReference[oaicite:5]{index=5}.

    This article urges healthcare professionals to treat new-onset type 2 diabetes as potentially reversible—prioritizing diet and weight interventions—and to reserve medications for those who don’t achieve remission or need tighter glycemic control.

    Based on Vinod Patel, “Type 2 diabetes: Reframing the first stage of care,” *Diabetes Digest*, May 9, 2024.

    Keywords: type 2 diabetes, diabetes remission, low‑carbohydrate diet, plant‑based diet, glycaemic control

    Read the full editorial on Diabetes on the Net

    Pressure Injuries (Pressure Ulcers) and Wound Care

    Pressure Injuries (Pressure Ulcers) and Wound Care

    The Medscape overview on Pressure Injuries (Pressure Ulcers) delivers a thorough guide to classification, risk assessment, pathophysiology, and management strategies for these commonly encountered chronic wounds. These injuries result from prolonged pressure and shear forces, often affecting patients with limited mobility in hospitals, long-term care, and home settings.

    Clinical Highlights:

    • Classification: Staged from I to IV based on tissue damage depth, with additional categories for unstageable wounds and deep tissue pressure injuries (DTPI).
    • Risk Factors: Include immobility, poor nutrition, incontinence, neurological deficits, and comorbidities such as diabetes and vascular disease.
    • Prevention: Centers on frequent repositioning, pressure redistribution surfaces, nutritional support, and skin care protocols to mitigate moisture and friction.
    • Treatment: Involves debridement (surgical, enzymatic, or autolytic), infection control, appropriate topical dressings, and addressing systemic health to support healing.
    • Complications: May include osteomyelitis, sepsis, chronic pain, and diminished quality of life if inadequately managed.

    Conclusion: Pressure injuries are preventable and treatable with proactive measures, interdisciplinary care, and evidence-based wound management. Early detection and intervention are critical to improving patient outcomes and reducing healthcare burden.

    Keywords: pressure injuries, pressure ulcers, wound care, debridement, risk assessment, prevention, chronic wounds

    Read the full article on Medscape

    he Dangerous Combination of Smoking, Diabetes, and Non‑Healing Wounds

    The Dangerous Combination of Smoking, Diabetes, and Non‑Healing Wounds

    A recent article from Diabetes in Control highlights how smoking and diabetes together significantly worsen wound healing outcomes, particularly in patients with diabetic foot ulcers. This combination accelerates tissue damage, reduces immune response, and increases the risk of infection and amputation.

    Key Insights:

    • Delayed Wound Healing: Nicotine and other harmful substances in tobacco restrict blood flow, limit oxygen delivery, and impair tissue repair—slowing the healing process in diabetic wounds.
    • Compromised Immune Function: Smoking suppresses white blood cell function and interferes with the inflammatory response, increasing vulnerability to chronic infection.
    • Worsened Vascular Health: Smoking intensifies peripheral arterial disease, a common complication in diabetes, further decreasing perfusion to the lower extremities.
    • Persistent Risk: Even after smoking cessation, some of the long-term effects on collagen production and tissue regeneration may persist, requiring early and aggressive intervention.

    Clinical Takeaway: Smoking is a major modifiable risk factor in wound healing. For patients with diabetes, especially those with foot ulcers, early smoking cessation is critical to prevent complications and improve healing outcomes.

    Keywords: smoking, diabetes, non‑healing wounds, diabetic foot ulcers, vascular disease, immune impairment, smoking cessation

    Read the full article on Diabetes in Control

    New TEWL to Predict Diabetic Foot Ulcer Recurrence

    High TEWL Predicts Diabetic Foot Ulcer Recurrence

    Summary: A multicenter observational study led by the NIDDK Diabetic Foot Consortium (Sen et al., 2025) reveals that high transepidermal water loss (TEWL) at the site of closed a diabetic foot ulcer (DFU) significantly increases the risk of recurrence within 16 weeks. Using a handheld evaporimeter, researchers measured TEWL at the healed DFU and compared it to a reference site on the opposite foot.

    Key Findings:

    • Among 418 patients tracked up to 16 weeks post-closure, 21.5% experienced recurrence.
    • A TEWL threshold of >30 g/m²/h marked a high-risk group—35% recurrence compared to 17% in the low-TEWL group (OR 2.66; p < 0.001). Self-reported recurrence strongly aligned with clinician assessments.
    • This study suggests that visual wound healing alone may not reflect true functional barrier restoration—defined as “invisible wound” when TEWL remains high despite closure.

    Implications: Measuring TEWL post-closure may serve as a valuable biomarker to differentiate between visually healed wounds and those at risk of reopening—enabling clinicians to tailor surveillance and interventions to improve long-term outcomes and prevent relapse.

    Read the full Medscape commentary

    Keywords: transepidermal water loss, diabetic foot ulcer recurrence, invisible wound, Chandan K. Sen, skin barrier function

    Ankle Brachial Index: Quick Reference Guide for Clinicians

    Ankle–Brachial Index: Quick Reference Guide for Clinical Use

    The Ankle–Brachial Index (ABI) is a simple, noninvasive test that compares the systolic blood pressure at the ankle with that at the arm. It is widely used to detect Peripheral Arterial Disease (PAD) and guide wound care decisions.

    Why ABI matters:

    • PAD Risk Screening – Detects impaired blood flow in patients at risk for lower extremity wounds.
    • Compression Safety – Determines whether compression therapy can be safely applied.
    • Referral Guidance – Helps clinicians identify patients needing vascular evaluation.

    How ABI is measured:

    1. Measure systolic pressure in both brachial arteries.
    2. Measure systolic pressure in dorsalis pedis and posterior tibial arteries at each ankle.
    3. Use the formula: ABI = Higher ankle pressure ÷ Higher brachial pressure (calculate separately for each leg).

    ABI Interpretation:

    ABI Value Interpretation Action
    1.0 – 1.4 Normal No action needed
    0.9 – 1.0 Acceptable Monitor
    0.8 – 0.9 Mild PAD Risk factor modification
    0.5 – 0.8 Moderate PAD Specialist referral; compression with caution
    < 0.5 Severe PAD Urgent vascular referral
    > 1.4 Calcified vessels Further vascular testing (e.g., TBI)

    Limitations: ABI may be less reliable in patients with calcified or noncompressible vessels (e.g., diabetes, renal disease, elderly). In these cases, consider Toe–Brachial Index (TBI) or other vascular testing.


    Read the full article in the Journal of Wound, Ostomy, and Continence Nursing

    High Mortality & Amputation Rates After First Diabetic Foot Ulcer

    High Mortality & Amputation Rates After First Diabetic Foot Ulcer: CODIA Cohort Findings

    Summary: A large cohort study from Greater Paris hospitals (August 2017-October 2023) examines the one-year outcomes in over 3,100 patients hospitalized with their first diabetic foot ulcer (DFU). The findings are alarming: ~21.6% died and ~24.2% underwent lower-limb amputation within 12 months. Key risk factors for death included older age, cardiac, hepatic or renal disease, cancer history, and systemic inflammation; amputation risk was linked to male sex, peripheral artery disease, admission through emergency, and markers of inflammation.

    Key Highlights:

    • Sample included 3,102 patients, median age ~70.7 years; 68% male.
    • Cumulative incidence of death within 12 months: **21.64%**.
    • Cumulative incidence of lower limb amputation within 12 months: **24.15%**.
    • Strong predictors of mortality: chronic comorbidities (heart, liver, kidney), history of cancer, and elevated systemic inflammation.
    • Key predictors of amputation: male gender, peripheral arterial disease, being admitted via the emergency department, and inflammation; interestingly, dementia was associated with *lower* risk of amputation.

    Read the full article in Diabetes & Metabolism

    Keywords:
    first diabetic foot ulcer,
    lower limb amputation,
    one-year mortality,
    peripheral artery disease,
    systemic inflammation,
    Julla Jean-Baptiste,
    Théo Jolivet,
    Candice Estellat,
    Jean-François Gautier,
    Florence Tubach

    Analytics Help Dermatologists Collaborate with Community Wound Care Centers

    Analytics Help Dermatologists Collaborate with Community Wound Care Centers

    Summary: Digital analytics platforms are enabling dermatologists who don’t regularly work in wound care to participate more effectively in patient monitoring and decision-making. With tools that allow wound imaging, measurement, and risk identification, dermatologists can track healing objectively and collaborate remotely with wound care centers.

    Key Highlights:

    • Remote monitoring & imaging: Tools like the Tissue Analytics platform let clinicians take wound photos (with calibration stickers), then use machine-learning to trace wound edges and measure depth, area, and volume.
    • Objectivity & consistency: Automated measures reduce variability between providers and improve reliability of tracking wound healing over time.
    • Risk flagging: The system can identify wounds (or pressure injuries) likely to worsen (e.g., progressing to Stage 3 or 4), supporting early intervention.
    • Workflow enhancement for dermatologists: Dermatologists can use the platform to follow wounds treated in community centers or remotely, even if they are unfamiliar with detailed wound measurement techniques.
    • Improved patient engagement: Patients can share images via apps, allowing continuous documentation and enhancing care transparency.

    View the full article on Dermatology Times

    Keywords:
    wound analytics,
    dermatologists,
    community wound care centers,
    remote monitoring,
    risk flagging,
    Tissue Analytics

    Why Podiatry Should Be a First-Line Strategy in Diabetes Management

    Why Podiatry Should Be a First-Line Strategy in Diabetes Management

    Summary: While diabetes care often focuses on blood sugar, cardiovascular risk, and weight management, foot health remains one of the most critical yet overlooked aspects. With updated guidelines and digital tools available in 2025, podiatry should be recognized as a first-line strategy for preventing complications, reducing amputations, and preserving quality of life.

    Key Highlights

    • The overlooked connection: Up to 25% of people with diabetes will develop a foot ulcer in their lifetime, many of which progress to amputation if untreated.
    • Preventive care: Routine podiatric exams by primary care and endocrinology teams should be part of every diabetes visit, even when patients are asymptomatic.
    • Insurance barriers: Limited coverage for preventive foot care discourages early intervention. Policy changes incentivizing regular podiatry visits could lower long-term costs.
    • Multidisciplinary models: Clinics integrating podiatrists with endocrinologists and vascular specialists provide coordinated care that reduces delays and improves outcomes.
    • Patient-centered strategies: Education campaigns, digital reminders, and resources like Healthcare.pro empower patients to prioritize foot health.
    • Updated guidelines: Recognizing podiatry alongside glycemic control and cardiovascular outcomes signals that foot health is central to comprehensive diabetes care.

    Conclusion

    Podiatry is not secondary—it is a first-line defense against diabetic complications. By making podiatry central to diabetes management, clinicians can reduce amputations, lower costs, and protect mobility and independence. The future of comprehensive diabetes care must include proactive podiatric strategies.

    FAQs

    Why is podiatry important in diabetes management?
    Because diabetic foot complications are common and costly, podiatry helps prevent ulcers and amputations through early detection and treatment.

    What new technologies are supporting diabetic foot care?
    Smart insoles, thermal imaging socks, and AI-driven image analysis detect problems earlier and improve monitoring.

    Do drugs like Ozempic and Mounjaro help with foot health?
    Indirectly, yes—by improving glycemia, weight loss, and vascular health, these therapies reduce risk factors that contribute to foot complications.

    How often should patients with diabetes see a podiatrist?
    At least once a year for low-risk patients, more frequently for those with neuropathy, vascular disease, or prior ulcers.

    Can preventive podiatric care reduce healthcare costs?
    Yes. Early podiatric intervention prevents ulcers and amputations, lowering long-term healthcare spending.

    Read the full article at Diabetes in Control

    Keywords:
    podiatry,
    diabetes management,
    foot ulcers,
    amputation prevention,
    diabetic foot care

    Incidence of diabetic foot ulcer and its predictors among adult diabetes patients in Northern Ethiopia

    Incidence of diabetic foot ulcer and its predictors among adult diabetes patients in Northern Ethiopia: a retrospective cohort study

    Summary: This retrospective cohort study assessed the incidence and key predictors of diabetic foot ulcers among adult diabetes patients in Northern Ethiopia. Following 321 individuals over several years, the research identified clinical and demographic factors significantly associated with ulcer development, emphasizing the importance of early detection and targeted prevention for high-risk patients.

    Key Highlights:

    • The incidence rate of diabetic foot ulcers was 1.01 per 100 person-years, with 11.8% of patients developing ulcers during follow-up.
    • Older age (≥70 years) increased the risk nearly fifteenfold compared with younger patients.
    • Other predictors included rural residence, hypertension, neuropathy, obesity, and abnormal HDL cholesterol levels.
    • Findings underscore the need for proactive risk-based management in diabetic populations.

    Read full article

    Keywords: diabetic foot ulcer, incidence, predictors, retrospective cohort, Ethiopia

    Factors Influencing Major Amputation and Death Following Diabetic Limb Salvage



    Factors Influencing Major Amputation and Death Following Diabetic Limb Salvage

    Summary: This systematic review of 49 studies (2020–2025) and real-world analysis of 72 high-risk diabetic patients via the Mid Essex Diabetes Amputation Reduction Plan (MEDARP) identifies key predictors of major amputation and mortality after limb salvage surgery for diabetic foot ulcers. Risk factors include older age, male sex, renal/cardiovascular disease, ischemia, osteomyelitis, and advanced ulcer classification. MDT models consistently lowered amputation rates (e.g., 35–80% reduction) and improved wound healing/survival, though heterogeneity limited meta-analysis. MEDARP achieved 6.9% major amputation and 12.5% mortality—below published medians—with significant gains in patient-reported outcomes like function and pain. Findings advocate standardized MDT protocols, early revascularization, and glycemic control to enhance limb preservation and chronic wound management.

    Key Highlights:

    • Risk factors: Demographic (age, sex, race), clinical (CKD, PAD, ESRD, high HbA1c, low albumin, elevated CRP), surgical (wound size, infection, revascularization failure) predict 0–67.7% amputation and 9–18% 1-year mortality.
    • MDT benefits: Reduced amputations (e.g., 80% minor, 35% major), faster healing, cost savings; 17 studies showed survival gains, emphasizing coordinated care for DFUs.
    • MEDARP outcomes: 6.9% major amputation, 12.5% mortality in 72 patients; MSK-HQ scores rose from 29.3 to 49.4, MOXFQ pain/social scores improved markedly over 11 months.
    • Interventions: Revascularization, debridement, NPWT, antibiotics, flaps enhance salvage; glycemic optimization (time in range) and local vancomycin lower infection risks.
    • Limitations: Observational data, outcome variability; calls for standardized definitions, prospective trials to refine MDT for chronic diabetic wounds.

    Read full article

    Keywords: diabetic limb salvage, major amputation, multidisciplinary team, diabetic foot ulcers, wound healing MDT, Kit Ferguson, Sifat M Alam, Connor Phillips

    Bravida Medical Unveils Silverlon® NPD-212



    Bravida Medical Unveils Silverlon® NPD-212, Advancing Antimicrobial Protection in Incisional NPWT

    Full Press Release:

    NPD-212

    GENEVA, IL, UNITED STATES, October 21, 2025 /EINPresswire.com/ — Bravida Medical, a leader in infection prevention and advanced wound care solutions, announced the launch of Silverlon® Antimicrobial Silver-Plated Dressing NPD-212, the first and only silver-plated contact layer specifically designed for use with incisional negative pressure wound therapy (NPWT) systems. The company will showcase the new technology this week at the American Association of Hip and Knee Surgeons (AAHKS) Annual Meeting.

    Silverlon Antimicrobial Silver-Plated Dressing technology seamless compatibility for incisional wound vacuum-assisted closure applications. The dressing is available as a 1.5” x 12” cut-to-fit strip, allowing surgeons to customize length for a wide range of incisions without disrupting negative pressure therapy.

    The introduction of Silverlon’s NPD-212 reflects Bravida Medical’s commitment to advancing infection-prevention tools for high-risk surgical patients, particularly those with co-morbidities, diabetes, obesity, or poor perfusion – where post-operative complications and bioburden remain a concern despite the use of NPWT.

    Silverlon® NPD-212 features pure metallic silver plated to a flexible, open-weave fabric. When activated, silver ions are released in the dressing, providing continuous antimicrobial protection for up to seven days while maintaining compatibility with wound vacuum-assisted closure pressure gradients.

    Key benefits include:

    • The only silver-plated contact layer engineered for incisional vacuum-assisted closure therapy
    • Broad-spectrum antimicrobial protection, including MRSA and VRE
    • Maintains moist wound healing and supports bioburden reduction
    • Does not interfere with negative pressure function or pressure gradients
    • Conformable, non-adherent, and easy to apply and remove
    • 1.5″ x 12″ cut-to-fit design for various incision lengths

    “Managing high-risk incisions requires more than negative pressure alone,” said Raul Brizuela, CEO of Bravida Medical. “Our Silverlon incisional wound vacuum dressing gives surgeons an antimicrobial contact layer purpose-built for incisional vacuum-assisted closure environments. We are proud to introduce it at AAHKS and expand the solutions available to orthopedic and reconstructive surgeons looking to protect complex surgical sites.”

    Silverlon® technology has been trusted by leading surgeons, trauma programs, and military medical teams for more than two decades. From battlefield care to complex civilian surgery, Silverlon dressings are widely recognized for their durability, conformability, and antimicrobial performance in demanding wound-care settings.

    With the launch of NPD-212, Bravida Medical continues to strengthen its portfolio of advanced solutions that support improved incision management and infection-prevention strategies.

    About Bravida Medical

    Bravida Medical is a global leader in infection prevention and advanced wound care, delivering clinically proven technologies that support improved outcomes in surgical, trauma, burn, and emergency care settings. The company’s flagship Silverlon® antimicrobial dressings feature a permanently plated metallic surface that provides the antimicrobial benefits of silver. Silverlon has received numerous FDA clearances, including an FDA Breakthrough Device Designation for the management of radiation dermatitis and acute cutaneous radiation injury, further validating its clinical impact and innovation.

    Originally developed for the U.S. military, and still extensively used for managing burn and blast injuries in combat environments, Silverlon dressings are now trusted worldwide by surgeons and healthcare professionals for surgical incisions, negative pressure wound therapy, chronic wounds, burns, skin grafts, and IV or catheter-related wounds. For more information, visit www.bravidamedical.com.

    Aerienne Cunningham

    Bravida Medical

    +1 888-551-0188

    email us here

    Legal Disclaimer:

    EIN Presswire provides this news content “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

    Key Highlights:

    • Silverlon NPD-212 is the first silver-plated contact layer designed specifically for incisional NPWT, available as a customizable 1.5” x 12” strip.
    • Provides broad-spectrum antimicrobial protection, including against MRSA and VRE, for up to seven days while maintaining moist healing.
    • Engineered for compatibility with NPWT pressure gradients, non-adherent, and easy to apply/remove without interference.
    • Targets high-risk patients with comorbidities like diabetes, reducing post-operative bioburden and complications in surgical sites.
    • Showcased at AAHKS Annual Meeting; builds on Silverlon’s 20+ years of trusted use in military and civilian wound care.

    Read full article

    Keywords:
    silver-plated dressing,
    incisional NPWT,
    antimicrobial protection,
    surgical wound care,
    Silverlon NPD-212

    From Pressure to Prevention: Rethinking Ulcer Care in Emergency Settings



    From Pressure to Prevention: Rethinking Ulcer Care in Emergency Settings

    Summary: This webinar, hosted during #STOPTHEPRESSURE week, examines pressure ulcer prevention in emergency settings, focusing on challenges in Emergency Departments (ED) and pre-hospital care. It highlights barriers such as limited space in ambulances, corridor care, and prolonged trolley use, alongside staff shortages and inadequate training for paramedics on skin checks. Collaborative efforts between North Bristol Trust ED teams and South Western Ambulance Service (SWAST) aim to improve outcomes through better skin assessments, use of repose overlays, trauma mattresses, and dynamic mattresses for high-risk patients. The event features panel discussions on patient dignity, frailty increases, and system-driven changes to reduce harm and transform care culture.

    Key Highlights:

    • Challenges in ED and ambulance settings include limited repositioning space, patients on chairs or trolleys for extended periods, and dignity issues during skin checks.
    • Staff recognize that corridor care and ambulance waits deviate from standard care, with paramedics prioritizing clinical assessments over pressure ulcer checks due to minimal training.
    • Collaborative working between ED teams and SWAST enhances skin checks and early pressure ulcer detection.
    • Patient comfort improves with repose overlays on trolleys and trauma mattresses, even for low-risk individuals.
    • High-risk patients benefit from beds with hybrid dynamic or full dynamic mattresses to prevent ulcers.

    Read full article

    Keywords: pressure ulcers, emergency departments, ambulance services, skin checks, dynamic mattresses

    National Diabetes Foot Care Audit 2020 to 2025



    National Diabetes Foot Care Audit 2020 to 2025

    Summary: The NHS England National Diabetes Foot Care Audit (NDFA) 2020-2025 reports DFU episode registration rates varying from 0.5 to 2.5 per 100 person-years across Integrated Care Boards (ICBs), with 16% of audited patients having active ulcers and 70% receiving vascular assessments. Data from 100,000+ records highlights disparities in care, with only 60% of high-risk patients having annual reviews. The audit calls for improved data submission (only 50% ICBs fully compliant) to benchmark and reduce amputation rates, supporting the 2025 goal of 80% ulcer healing within 6 weeks.

    Key Highlights:

    • Episode Rates: 0.5-2.5/100 person-years; 16% active ulcers in audited cohort.
    • Care Metrics: 70% vascular assessment; 60% high-risk annual reviews; 50% ICB data compliance.
    • Variations: Urban ICBs higher rates; rural gaps in podiatry access.
    • Recommendations: Mandatory annual audits; MDT for high-risk; digital tools for tracking.
    • Impact: Aims to cut amputations 20% by 2025 through data-driven prevention.

    Read full article

    Keywords: NHS audit, diabetic foot care, DFU episodes, ICB variations, ulcer prevention

    Use of Negative Pressure Wound Therapy in Selected Cases to Facilitate Abdominal Wound Healing



    Use of Negative Pressure Wound Therapy in Selected Cases to Facilitate Abdominal Wound Healing

    Summary: November 2025 multiple case series examines NPWT for complex abdominal wounds: dehiscence with exposed bowel (fistula risk), peristomal skin issues (urinary leakage from ileal conduit requiring re-siting), infected incisions/fascial defects. Indications: Surgical dehiscence, peristomal complications. Outcomes: Granulation promotion, wound closure, peristomal skin optimization. Applications: Acute open wounds with exposure/defects; facilitates healing/risk reduction. No specific NPWT types detailed; supports adjunctive use in high-risk abdominal cases.

    Read abstract

    Keywords: NPWT abdominal, wound dehiscence, peristomal complications

    The Role of Cellular, Acellular, and Matrix-like Products in Diabetic Foot Ulcer Care



    Preserving Limbs and Lives: The Role of Cellular, Acellular, and Matrix-like Products in Diabetic Foot Ulcer Care

    Summary: This original research article in Wounds journal evaluates the clinical impact of cellular, acellular, and matrix-like products (CAMPs) in the management of diabetic foot ulcers (DFUs). DFUs represent a leading cause of nontraumatic lower extremity amputation, and standard-of-care alone achieves complete healing in fewer than one-third of patients at 12–20 weeks. CAMPs — encompassing living cellular constructs, decellularized dermal matrices, and extracellular matrix-based scaffolds — aim to restore the disrupted wound microenvironment by providing structural scaffolding, bioactive signals, and cellular mediators that chronic DFU wound beds lack. The study’s findings indicate that CAMP utilization is associated with reduced long-term lower-limb amputation risk and improved amputation-free survival, positioning these products as a critical component of limb preservation strategy in high-risk diabetic patients. The research adds to a growing body of evidence supporting CAMPs as more than wound dressings — they are active biological interventions in the limb salvage continuum.

    Key Highlights:

    • CAMPs associated with reduced long-term lower-limb amputation risk in DFU patients
    • Improved amputation-free survival compared to standard care alone
    • Encompasses full CAMP spectrum: cellular constructs, acellular matrices, ECM-based scaffolds
    • Frames CAMPs as integral to limb preservation rather than adjunctive wound dressing
    • Relevance: Timely given new 2026 CMS coverage and payment policies for cellular and tissue-based products (CTPs)

    Read full study

    Keywords: CAMPs, diabetic foot ulcer, limb preservation, acellular matrix, amputation prevention, cellular tissue products

    Flesh-Eating Bacteria Infections Are on the Rise in the US



    Flesh-Eating Bacteria Infections Are on the Rise in the US

    Summary: This article warns of the rising incidence of necrotizing fasciitis (“flesh-eating bacteria”) infections across the United States. Caused primarily by Group A Streptococcus and other aggressive pathogens, these rapidly progressing infections destroy soft tissue and can lead to sepsis, limb loss, or death if not treated immediately. High-risk groups include people with diabetes, chronic wounds, immunosuppression, or recent surgery/trauma. Emphasizes early recognition (severe pain out of proportion to visible signs, rapid swelling, bullae, crepitus) and urgent management: aggressive surgical debridement, broad-spectrum IV antibiotics, and supportive care. Highlights the importance of wound care vigilance and prompt referral in high-risk patients to improve survival rates.

    Key Highlights:

    • Increasing cases of necrotizing fasciitis in the US
    • Rapid tissue destruction; high mortality without immediate intervention
    • Key risks: Diabetes, chronic wounds, immunosuppression
    • Management: Emergency debridement + antibiotics
    • Relevance: Critical awareness for wound care teams managing high-risk patients

    Read article

    Keywords: necrotizing fasciitis, flesh-eating bacteria, diabetic wound infection, emergency debridement

    Effect of Negative Pressure Wound Therapy on Abdominal Deep Incisional Surgical Site Infections



    Effect of Negative Pressure Wound Therapy on Abdominal Deep Incisional Surgical Site Infections

    Summary: This original research evaluates negative pressure wound therapy (NPWT) versus standard dressings for preventing and managing deep incisional surgical site infections (SSIs) after abdominal surgery. NPWT significantly reduced infection rates, accelerated granulation, and shortened healing time. Patients treated with NPWT required fewer reoperations and had lower overall complication rates. The therapy helps manage exudate, reduce edema, and improve tissue perfusion in high-risk incisions. Supports NPWT as an effective prophylactic and therapeutic tool in abdominal wound care, particularly in patients with comorbidities (diabetes, obesity) that increase SSI risk.

    Key Highlights:

    • Reduced incidence and severity of deep incisional SSIs
    • Faster healing and fewer reoperations with NPWT
    • Benefits in high-risk abdominal surgery patients
    • Relevance: Evidence for NPWT in surgical wound complications

    Read full research

    Keywords: NPWT, surgical site infection, abdominal wound, incisional SSI

    Skin Cancer and Wound Healing



    Skin Cancer and Wound Healing

    Summary: This editorial explores the intersection of skin cancer and wound healing, noting that basal cell carcinoma (BCC)—the most common skin cancer—often presents with erosions or ulcerations on sun-exposed skin. Treatment includes excision, curettage, or Mohs microsurgery for facial/larger lesions. A case of a massive (18 × 16.5 cm) shoulder/scapular BCC required vismodegib (Hedgehog inhibitor), radiation, and extensive surgery after secondary infection. Marjolin ulcers (malignant transformation, usually to squamous cell carcinoma/SCC in chronic scars/wounds like burns, pressure injuries, or osteomyelitis sites) are aggressive, with a classic triad of deep nodule, indurated edges, and central ulceration. They carry 20-40% risk of regional lymph node spread and higher mortality; early and repeated biopsies are critical due to sampling error. Two additional cases in the issue illustrate Marjolin SCC in a tibial malunion/osteomyelitis site and a sacral pressure injury. Recommendations include total skin exams for patients with prior skin cancers, vigilance in dark skin tones and high-risk groups (immunosuppressed, hidradenitis suppurativa), foot exams for melanoma, and sun protection (SPF 30-60, wide-brim hats, vitamin D supplementation).

    Key Highlights:

    • BCC may ulcerate; advanced cases benefit from vismodegib + radiation/surgery (only 1-10% are locally advanced)
    • Marjolin SCC in chronic wounds/scars is aggressive with 20-40% nodal metastasis risk; biopsy nonhealing ulcers (repeat if suspicion high)
    • Case examples: large BCC requiring multimodal therapy; Marjolin in pressure injury and osteomyelitis sites
    • Prevention: sun protection, total skin exams, foot checks (especially in persons of color)
    • Authors: R. Gary Sibbald, Elizabeth A. Ayello

    Read full editorial

    Keywords: skin cancer wound healing, Marjolin ulcer, basal cell carcinoma, R. Gary Sibbald

    ‘Foot Selfies’ May Improve Remote Diabetic Foot Monitoring

    “Foot selfies” may be a simple solution to keeping tabs on patients at high risk for diabetic foot complications.

    Patients with or at risk of foot ulcers are told to check their feet regularly at home, but doing so can be difficult for those who aren’t flexible or who have vision problems. Those who live alone may not be able to ask someone else to check their feet for them. Some use hand mirrors, but those can be difficult to manipulate and don’t offer feedback … read more

    Next Science to Exhibit Surgical Product Portfolio at AAOS 2021

    JACKSONVILLE, Fla.–(BUSINESS WIRE)–Next Science Limited (ASX:NXS), an innovative medical technology company, announced that it will exhibit at the American Academy of Orthopaedic Surgeons (AAOS) annual meeting and conference in San Diego, California, from Aug. 31 – Sept. 3. Next Science, whose mission is to heal patients and save lives by addressing the impact of biofilms on human health, will exhibit at Booth No. 5035.

    Next Science will showcase its portfolio of ground-breaking products, including:

    • XPERIENCE™ No Rinse Antimicrobial Solution, a non-toxic surgical solution that is designed to help prevent surgical site infections (SSIs) by rinsing away debris and microorganisms; and
    • SURGX®, a topical gel that is applied to a closed surgical incision to help prevent superficial SSIs.

    Next Science also will host a presentation that addresses the impact of biofilms on SSIs, discusses risk mitigation strategies and shares clinical results from high-risk patients. The session, Biofilm and Surgical Site Infections, takes place on Sept. 1 from 12:40 – 1:25 p.m. in Meeting Room 1 and will be led by four prominent orthopaedic surgeons:

    • Dr. Robert Harris, Hughston Clinic
    • Dr. Jon E. Minter, Northside Hospital
    • Dr. Randall Otto, SSM Health
    • Dr. Ravi K. Bashyal, NorthShore University Hospital

    read more

    A multi‐centre, single‐blinded randomised controlled clinical trial evaluating the effect of resorbable glass fibre matrix in the treatment of DFUs

    Diabetic foot ulcers (DFUs) represent one of the many complications of long-standing diabetes.1 Not only are these wounds expensive to treat, with a recent systematic review showing that the mean cost was over $31 000 in 2015,2, 3 but complications, especially infection, can require prolonged antibiotic administration, deep and extensive debridement, and lower extremity amputations when these measures fail. Even relatively shallow (UT1A, Wagner 1) DFUs that do not respond to standard of care (SOC) are at risk for amputation of the affected area.2-5 This risk increases for patients who have had prior DFUs or amputations. Any product, therefore, that can prevent infection or disrupt biofilm while promoting wound healing in a moist environment is worthy of further investigation … read more

    Application of Topical Sucralfate and Topical Platelet-Rich Plasma Improves Wound Healing in Diabetic Ulcer Rats Wound Model

    One of the most devastating complications of diabetes mellitus is diabetic ulcers. Not only because these ulcers heal slowly, these ulcers may also cause disability and even results in limb loss.1 A diabetic ulcer is a chronic wound usually found in the soles of the diabetic patient’s feet. The occurrence of diabetic ulcers is mostly associated with neuropathy and vasculopathy in the form of the peripheral arterial disease which happens in the lower limb of the diabetic patient.2 Around 2% to 5% of all population in the world suffers from diabetic ulcers.3 The hyperglycemic state in diabetics causes molecular and physiological changes that cause diabetic ulcers to become difficult to heal, increasing its risk to secondary infection and potentially causing limb amputation if it is not treated properly.4 Diabetic ulcers account for nearly 90% of all lower limb amputation cases, with a reported mortality rate per year of 5.5% due to diabetic ulcers.

    The main aim of diabetic ulcer therapy is to prevent extensive damage and secondary infection of diabetic ulcers, thereby minimizing the risk of further damage or even limb amputation. A thorough therapy for diabetic ulcers includes wound debridement, wound dressing, revascularization procedures, infection management, and ulcer off-loading … read more

    Infection-Related Hospitalizations High for Adults With Diabetes

    People with diabetes may face a higher risk for hospitalization for any infection, a new analysis suggested.

    In a prospective study of over 12,000 middle-age adults, those with diabetes had a 67% higher risk for infection-related hospitalization compared with adults free of diabetes over the course of nearly 30 years (HR 1.67, 95% CI 1.52-1.83), reported Elizabeth Selvin, PhD, MPH, of Johns Hopkins Bloomberg School of Public Health in Baltimore, and colleagues … read more

    New research a ‘step change’ for diabetes patients

    Millions of people with diabetes are at risk of developing foot ulcers, which often lead to amputations and other health complications. Now, Scientists from the Centre for Biomechanics and Rehabilitation Technologies (CRBT) have developed a new method to reliably detect this risk without the need for complex electronic in-shoe sensors … read more

    Beating Biofilm Is Key to Fighting Surgical Infections

    Health care is at a perilous crossroads. “[D]eaths from drug-resistant infections are set to skyrocket to over 10 million per year worldwide and could cost the global economy as much as $100 trillion by 2050,” a STATISTICA article reports. The same concerning fact is stressed by United States public health officials, who agree that “antimicrobial resistant pathogens (AMR) threaten everyone”.Both reports suggest a grim future of consequences from bacterial resistance, with U.S. officials believing AMR is occurring at a rate of more than 2.8 million antibiotic resistant infections in the U.S. each year, ending in a heavy economic price and over 35,000 deaths annually. The Centers for Disease Control and Prevention (CDC) believes “no one can completely avoid the risk of resistant infections, with some people at greater risk than others.” Eye-opening research suggests at least 80% of these infections are biofilm related … read more

    Could Patients Tap Their Way To Better Health?

    When recommending activity regimens to patients, is one style of dancing an “untapped” resource? … A recent study in BMJ Open Diabetes Research and Care examined how tap dance as an activity might affect plantar pressure, postural stability, ankle range of motion and lower extremity functional strength for older patients at risk for diabetic foot complications … This randomized, single-blind, prospective study looked at 40 at-risk patients … continue

    Venous Leg Ulcers: Frequently Asked Questions

    In my recent WoundSource webinar on management strategies of venous leg ulcers (VLU), I discussed the complex pathophysiology of VLUs and procedural interventions that can help them reach closure … VLUs comprise the majority of lower extremity ulcers. These wounds are costly to treat and have a high rate of recurrence. Sequelae of VLUs include infection or sepsis risk, pain, loss of mobility, and possible amputation. Healing of VLUs requires an understanding of their multifactorial etiology, consideration of patient-specific risk factors, careful assessment, and best practice management for optimal clinical outcomes … The following categories of VLU prevention, management and treatment can help to answer some of the most frequently asked questions about VLU … read more

    Nutritional Factors for Wound Healing in the Older Adult Patient

    There are seemingly countless factors that contribute to increased risk for the development of pressure injuries among certain patient populations. For those who require a stay in long-term care, the incidence of pressure injuries can be a concern. Conditions that contribute to increased risk for pressure injury development include (but are not limited to) diabetes mellitus, peripheral vascular disease, malignancy, prolonged pressure on an area of the body … read more

    Transcutaneous oxygen – not abi or toe pressure – is a predictor for

         short-term survival in people with diabetic foot ulcers (study)

     

    Ankle-brachial index (ABI) is the most commonly used test when diagnosing peripheral vascular disease and is considered a marker for cardiovascular risk. Transcutaneous oxygen pressure (TcPO2), a test associated with microvascular function, has in several studies shown better correlation with diabetic foot ulcer (DFU) healing. Whether a low TcPO2 could be a marker for mortality in the high-risk population of DFU patients has not been evaluated before. The aim of this study was to evaluate the predictive value of TcPO2 in comparison with ABI and toe blood pressure (TBP) on 1-year mortality in type 2 diabetes patients with DFU …. read more

    Financial burden of diabetic foot ulcers to world: a progressive topic to discuss always

    Diabetic foot complications are the most common occurring problems throughout the globe, resulting in devastating economic crises for the patients, families and society. Diabetic foot ulcers (DFUs) have a neuropathic origin with a progressive prevalence rate in developing countries compared with developed countries among diabetes mellitus patients. Diabetic patients that are of greatest risk of ulcers may easily be diagnosed with foot examination. Economic burden may be carefully examined. The budget costing must include both the clinical and social impact of the patients … Diabetes mellitus (DM) is a chronic metabolic disorder imparting loss in health and economic burden on patients and healthcare machinery around the globe. As the present world is facing an epidemic of both type 1 and type 2 DM, the International Diabetes Federation (IDF) has focused on the micro and macrovascular complications associated with DM. In 2005, the IDF committed to execute the management approach for diabetic foot diseases. The risk for developing foot ulcers is 25% high in patients with diabetes and it is also reported that every 30 seconds, one lower limb amputation in diabetes patients occurred around the world. The IDF has now become proactive and declared in its mandate that now is the time to increase awareness about the foot complications associated with DM in scenarios of social, personal, clinical and economic costs … read more

    Complex Wound Management: Diabetic Foot Ulcers

    Background and Prevalence of Diabetic Foot Ulcers
    Diabetes-related foot complications, including diabetic foot ulcers (DFUs), are leading causes of non-traumatic lower extremity amputation. Of the approximately 420 million adults in the United States with diabetes mellitus, one fourth will develop at least one DFU. DFUs are preceded by a compendium of risk factors, including the presence of neuropathy, external trauma, infection, effects of ischemia from concomitant peripheral arterial disease, malnutrition, and poor hygiene or self-care, among others. In 80% of patients, DFU is a precursor to some degree of lower extremity amputation. And, for these patients who have undergone amputation, their risk for further amputation becomes double that of a patient without diabetes. The mortality rate following a diagnosis of diabetic foot ulceration is 5% in the first year. The five-year mortality rate is 50% and rises to 70% after amputation. Once healed, 40% of DFUs will recur within 12 months, nearly 70% at three years, and nearly 75% at five years … read more

    Higher proportion of limb salvage and lower amputation rates

         The impact of a wound centre on a vascular surgery practice

     

    The opening of an outpatient wound centre has been associated with a significant increase in peripheral vascular practice and a significant decrease in amputation rate. Venita Chandra and colleagues Alyssa M Flores, Matthew W Mell and Ronald L Dalman (Stanford University, Stanford, USA) believe that such centres result in synergistic systems that promote more aggressive and effective limb salvage strategies. Chandra presented the findings of a recent study analysing the clinical impact of a wound care centre on a vascular surgery practice, at the Society for Vascular Surgery’s Vascular Annual Meeting (VAM; 20–23 June, Boston, USA).

     

    According to Chandra, chronic wounds remain a growing problem, not only in the USA but worldwide—with many patients at risk of limb loss presenting as particularly challenging. This cohort requires complex and resource-intensive medical care, reported Chandra.

     

    World experts and leaders in this specialty have developed and described programs to attempt to improve the care of these complex patients and decrease the risk of amputation … read more

    Phase 3 CREDENCE Renal Outcomes Trial of INVOKANA® is Being Stopped

         Early for Positive Efficacy Findings

     

    – INVOKANA® has the potential to be the first new therapy in more than 15 years for slowing the progression of chronic kidney disease in patients with type 2 diabetes

     

    – Worldwide, 160 million patients with type 2 diabetes are at risk for developing chronic kidney disease

     

    – CREDENCE assessed INVOKANA® for renal protection by evaluating the risk reduction of the composite endpoint of time to dialysis or kidney transplantation, doubling of serum creatinine, and renal or cardiovascular death, when used in addition to standard of care

     

    RARITAN, N.J.July 16, 2018 /PRNewswire/ — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Phase 3 CREDENCE (Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation) clinical trial, evaluating the efficacy and safety of INVOKANA® (canagliflozin) versus placebo when used in addition to standard of care for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), is being stopped early based on the achievement of pre-specified efficacy criteria.

     

    The decision is based on a recommendation from the study’s Independent Data Monitoring Committee (IDMC) that met to review the data during a planned interim analysis. This recommendation was based on demonstration of efficacy, as the trial had achieved pre-specified criteria for the primary composite endpoint of end-stage kidney disease (time to dialysis or kidney transplantation), doubling of serum creatinine, and renal or cardiovascular (CV) death, when used in addition to standard of care … read more

    Diabetic Foot Ulcer Prevention System (DFUPS)

    The purpose of this study is to investigate whether regular measurement of skin foot temperature with a novel device (DFUPS) will prevent ulcer recurrence in diabetic patients at high risk of foot ulceration. It is planned to regularly measure the temperature of the feet of people with diabetes who have already had a foot ulcer which has subsequently healed. These measurements should allow the identification of hotspots on the foot and may be helpful when advising about ulcer risk and providing preventative treatment. It is hoped to find out whether the regular use of thermal images taken with the DFUPS device together with standard foot treatment may reduce the number of people with diabetes developing ulcers or even prevent foot ulcers … read more

    Australian diabetes-related foot disease strategy 2018-2022

    The first step towards ending avoidable amputations within a generation

     

    Diabetic Foot Australia September 2017

     

    Introduction
    On any given day in Australia, the national burden of diabetes-related foot disease (DFD) is
    significant:
    • 300,000 people are at-risk of developing DFD
    • 50,000 people are living with DFD
    • 12,500 people are living with a diabetes-related amputation
    • 1,000 people are in hospital because of DFD
    • 12 people will undergo a diabetes-related amputation
    • 4 people will die because of DFD
    • $4 million will be spent managing DFD
    To reduce this large national burden, the following three priorities should be addressed for people
    with, or at-risk of, DFD:
    A. Access to affordable and effective care
    B. Provision of safe quality care
    C. Research and development to improve patient outcomes

    download pdf

    Factors associated with amputation among patients

    with diabetic foot ulcers in a Saudi population

     

    Abstract

    Objectives

    A prospective study was conducted at the Armed Forces Hospital, Dhahran, Saudi Arabia, between January 2015 and December 2016 to identify the risk factors associated with amputation among diabetic foot ulcers DFUs patients.

    Results

    In total, 82 patients were recruited. Fifty-five of the patients were males (67.07%), the mean (SD) age of the participants was 60 (± 11.4) years, the mean duration of diabetes was 8.5 (± 3.7) years, and the mean haemoglobin A1c was 4.8 (± 2.8)%. In Univariate analysis, older age and high white blood cell count (WBC) were factors associated with amputation (OR = 1.1, 95% CI = 1–1.1, P = 0.012; and OR = 383, 95% CI = 7.9–18,665, P = 0.003, respectively). On the other hand, an ischaemic ulcer was half as likely as a neuropathic ulcer to lead to amputation (OR = 0.5, 95% CI = 0.3–0.9, P = 0.036), and a higher Wagner’s grade was found to be protective against amputation OR = 14.5, 95% CI = 4.3–49.4, P < 0.001. In conclusion, the current study showed that although a number of factors have been described to complicate diabetic ulcers by different researchers, none of those factors were identified in our study apart from older age and high WBC.

    Introduction

    Diabetes mellitus is a common endocrinopathy known for its various complications, including diabetic foot ulcers (DFUs) which often result in amputated limbs [1]. The prevalence of foot ulcers among patients with diabetes mellitus ranges from 4 to 10%, and its lifetime incidence may reach up to 25% [2]. Conservative management of DFU may be affected by proper offloading of the wounds, correct daily foot hygiene, and impaired distal vascular flow. Treatment of a DFU is difficult; it frequently gets infected, and it is therefore a very common cause of hospitalization [3]. Diabetes mellitus increases the risk of lower extremity amputations (LEAs) by up to 56% over 5 years, and … read more

    Wound Documentation Standards to Help Avoid Legal Issues

    Medical providers, and especially wound care providers, seem to always be under the looming shadow of lawsuits and legal issues. I have written about this before, but it continues to be an issue as I receive requests for legal reviews repeatedly. I have read many charts for legal reviews, and it actually is very straightforward to avoid or mitigate any legal problems.

     

    Important Steps to Take When Documenting a Wound

    1. If you have a wound protocol, follow it or document why you didn’t. For example, if your protocol says a bed or chair bound patient on admission is high risk, then treat them as high risk, or document why you didn’t.

    2. If you use an assessment tool such as Braden Scale or Norton Scale, be sure you know how to use it properly, and use it per protocol.

    3. Document all calls to a physician and the response.

    4. If there is a physician order, follow it and document that you adhered to the order.

    • For example, if an order says to notify physician if there is blood in the urine and you see blood in the Foley catheter, notify the physician and document that you did notify them and what the response was.

    5. If you notice a change in your patient, report it to the proper person. For example: the patient has stopped eating normally, or the patient is acting differently. In an elderly patient this could be the first sign of infection … read more

    Approval for commercialization of Heberprot-P® in Mexico

    Havana, Cuba, May 4, 2018 – Heberprot-P® has been approved for commercialization in México. The Center for Genetic Engineering and Biotechnology (CIGB) is excited to announce regulatory approval of this innovative medicine indicated for advanced diabetic foot ulcer (DFU), which is expected to save thousands of people from lower limb amputation. The official approval date of Heberprot-P® was April 30th, 2018. Heberprot-P® stimulates granulation, accelerates DFU re-epithelization, and reduces healing time, surgical debridement, amputation risk, and recurrences. The intralesional infiltration of Heberprot-P® may be applied in combination with Good Wound Care (GWC), revascularization, and antibiotics. This medicine is an effective solution for an unmet medical need, a first in class product, unique worldwide, for DFU treatment. It is the only therapeutic choice available for advanced and complex DFU, reluctant to healing (grades 3, 4, and 5, according to Wagner’s classification).

     

    Clinical experience derived from the intervention with Heberprot-P® in daily medical practice in Cuba was analyzed in 2013 in a study that reviewed the evolution of more than 2 000 patients as well as the pharmacovigilance of 1 788 patients, showing a 75% probability of granulation response, 61% healing rate, 71% amputation risk reduction, Bayes’ favorable factor (5.40), and complete granulation in 76% of ulcers in 5 weeks (Adv. Pharmacoepidem. 2013, 2 (2): 1000128; BMC Pharm. & Toxicol, 2013, 14: 44). The International Working Group of Diabetic Foot (IWGDF) evaluated results of the clinical trial performed with Heberprot-P® in Cuba and reported in 2009 as promising, highlighting the results obtained in only 2 weeks of treatment (Diabetes Metab Res Rev 2012; 28 (Suppl 1): 119-141).

     

    In a later systematic review, clinical trials comparing the use of growth factors with GWC (Cochrane Database of Systematic Reviews 2015, Issue 10, Art. No. CD008548), the IWGDF’s evaluation was reported on all major issues and requirements of Heberprot-P® clinical trials in Cuba. Similar criteria were expressed by the IWGDF in the guidelines on DFU healing (IWGDF Guidance, 2015: 10). A fourth study reported similar observations on the intralesional EGF infiltration method: “… a highly significant difference between groups in the prevalence of granulation tissue after just 2 weeks” (Diabetes Metab Res Rev 2016; 32 (Suppl 1): 154- 168).

     

    Results of clinical studies performed in Cuba, Russia, Turkey, Vietnam, Argentina, Mexico, and Ukraine were enough to demonstrate safety and efficacy profile of Heberprot-P®. This medicine has been used in more than 290 000 patients with diabetic foot ulcer (DFU) in Russia, Belarus, Georgia, Ukraine, Turkey, Algeria, China, Panama, Argentina, Cuba, Dominican Republic, Venezuela, Ecuador, Libya, Uruguay, Paraguay, Colombia, Guatemala, Philippines, Vietnam, Nicaragua, Saudi Arabia, Indonesia, Seychelles, Saint Lucia, Saint Vicente, Sri Lanka, Jordan, and Kuwait.

     

    A national survey of health and nutrition in Mexico reported that prevalence of diabetes is 9.4% of total population, which sums up more than 11 million people, 9.1% of adult diabetic suffers DFU, and amputation is indicated to 5.5% of adult diabetics (National Survey of Health and Nutrition, INEGI 2016). According to recent reports, lower limb amputation is the unique alternative for 45% of diabetics with advanced DFU in Mexico (Diabet. Foot. Ankle. 2017 Sep 6, 8 (1): 1367210). In a previous study, similar results were reported: 42% patients with advanced DFU required major amputation (Wound Repair & Regen. 24 (5): 923-927).
    Written by Jose A. Buxado, MSc., Assistant Researcher, CIGB.

     

    The Center for Genetic Engineering and Biotechnology of Havana is an institution devoted to research, development, manufacturing, and commercialization of products and technology derived from life science.

     

    Alyane Vazquez González, BA., Communication & Media, e-mail: alyane.vazquez@cigb.edu.cu
    . Ave 31 e/ 158 y 190, Playa, P.O. Box 6162, Habana 10600, Cuba.

     

    This release was published on openPR.

    Edixomed: Breakthrough Wound Care Technology

    With Potential to Strike Back Against the Threat of Killer Superbugs

     

    A simple patch which cleverly harnesses part of the body’s own natural repair system – nitric oxide – could help in the fight against killer superbugs and antibiotic resistance according to recently published studies.

     

    Millions of people are at risk of dying from infections every day, many of which can no longer be treated by even the strongest antibiotics.

     

    Now, in two recently published studies, a breakthrough wound care system, created by the UK firm Edixomed, has been shown to kill a range of antibiotic-resistant bacteria including MRSA and EColi, both of which have the potential to be fatal for many people.

     

    The discovery could pave the way for these easy-to-use patches to be available in hospitals across the NHS to dress wounds to prevent the growth of bacteria, and tackle established infections.

     

    “Bacterial infections resistant to all currently available antibiotics are expected to kill over 10 million people a year by 2050. The threat is very real and of international concern; but with this technology, we have a novel, viable and innovative solution with which to strike back. Wound care is just the first of many potential applications,” said Professor Art Tucker, St Bartholomew’s Hospital, London. He added, “Importantly, nitric oxide acts against multiple targets in bacteria to kill them, hence there is a very unlikely chance of bacteria developing resistance any time in the future.”

     

    In addition, Edixomed’s breakthrough, the EDX110 wound care system, is able to deliver nitric oxide in a sustained way to give the wound or ulcer the best chance of healing. As part of the natural healing process the body normally produces nitric oxide and uses it to signal for increased blood flow and to fight infection. Edixomed’s technology effectively “supercharges” the body’s own natural healing processes.

     

    In fact, recently published clinical research in diabetic foot ulcers, including infected ulcers, showed that the EDX110 patch achieved the same healing in 4 weeks as the standard-of-care approaches currently used in UK hospitals achieved at 12 weeks. The standard-of-care patients were also significantly more likely to be hospitalised due to complications with their foot ulcer.

     

    “Diabetic foot ulcers are notoriously hard-to-heal and are the leading cause of diabetes-related amputations in the UK. The recently published findings provide an essential step forward in developing solutions for the effective management of these chronic wounds,” said Professor Michael Edmonds, Principal Investigator of the pivotal diabetic foot ulcer study, King’s College Hospital, London. He added, “Reducing infection and accelerating healing could significantly contribute to a reduction in the number of avoidable amputations. EDX110 represents a major step forward in best practice care.”

     

    In severe cases, infection of a foot ulcer in a patient with diabetes can result in lower limb amputation or worse e.g. complications such as sepsis, multi-organ failure and death.

     

    Facts:

    • The NHS carries out more than 7,300 amputations each year in the UK as a result of diabetes, 80% of these are due to foot ulcers.[4] The resulting drain on healthcare resources is enormous, with an annual cost of £1 billion to NHS England alone.[5]
    • At least 700,000 people die globally from drug-resistant infections every year – 5,000 of them in the UK.[6],[7]
    • There have been no new classes of antibiotics approved since the 1980s and the Chief Medical Officer, Professor Dame Sally Davies warned in 2017 that resistance to antibiotics “poses a catastrophic threat”.[8]

     

    Key findings of the two recent studies investigating EDX110, a revolutionary new wound care system:

    • Laboratory tests have shown that EDX110 can kill all viable organisms for several deadly antibiotic-resistant infections including MRSA, Pseudomonas and E. Coli.[3]
    • Laboratory tests have shown that EDX110 effectively prevented and treated multi-drug resistant bacteria biofilms. Biofilms are colonies of bacteria that protect themselves from the body’s immune system and actions of antibiotics.[3]
    • EDX110 completely healed more ulcers compared with standard-of-care (ulcers completely healed: 49% vs. 30%).[2]
    • EDX110 reduced diabetic foot ulcer size by almost double the amount of standard-of-care (median percentage area reduction: 89% vs. 47%).[2]

     

    About Edixomed

    Edixomed is a biopharmaceutical company commercialising next generation and clinically-proven technologies from its nitric oxide platform. Using its patented scientific approach, the company’s technologies have the potential to tackle major global health challenges in wound care, dermatology and infection control. The core technology’s unique feature is its ability to replenish or supplement the body’s own supply of nitric oxide that is critical for sustaining healthy skin and organs. Nitric oxide is depleted or absent in many diseases and thus, the body’s normal healing and regenerative processes are damaged. Restoring that essential element is at the heart of Edixomed’s approach to innovative healthcare.

     

    About EDX110

    EDX110 is a revolutionary, easy-to-use, two-part wound care system, driven by Edixomed’s core sustained-release nitric oxide delivery technology. EDX110 provides a protective and cushioning layer that uniquely absorbs fluid while providing a moist environment and generating nitric oxide. The role of nitric oxide in ulcer healing involves three recognised elements: vascular, as nitric oxide influences the widening of blood vessels (vasodilation) and stimulates the growth of new blood vessels (angiogenesis);[9],[10] inflammatory, as nitric oxide influences the body’s immune response;[11] and antimicrobial, as nitric oxide demonstrates potent, broad spectrum antimicrobial activity.

     

    EDX110 is not yet an approved product, Edixomed are pursuing an active programme to develop applications of their core technology in multiple wound care indications and a number of additional areas. These areas include: surgical wound care, venous leg ulcers, pressure ulcers, burns, septic shock, transdermal drug delivery, ventilator-associated pneumonia, cystic fibrosis, and various applications connected to antimicrobial resistance.

     

    About nitric oxide

    The discovery that a simple gas, nitric oxide, could play such an important role in the human body led to three scientists being awarded the Nobel Prize for medicine in 1998. The pioneering work demonstrated that the normal function of nitric oxide is to control blood flow in the small vessels in the skin and prevent the skin from being infected with dangerous organisms. Nitric oxide is also generated whenever the skin is injured or damaged and plays a crucial part in the normal skin healing process. However, in certain conditions, such as diabetes, the normal production of nitric oxide can be put at risk and the skin loses the essential ingredient it needs to repair itself. The result is a chronic, poorly healing wound, highly prone to infection and a major cause of concern to patients and doctors. Replenishing the missing nitric oxide in such a way as to mimic the skin’s natural production is no easy task and it has eluded many of the world’s leading scientists for the past two decades. Edixomed has succeeded in achieving this goal and has demonstrated the performance of its technology in a pivotal clinical trial.

    You can also visit our website at: http://www.edixomed.com

     

    Press Release from PR Newswire

    Fresh hypothermically stored amniotic allograft in …

    the treatment of chronic nonhealing ulcers: a prospective case series

     

    Introduction Millions suffer from diffcult to heal ulcers worldwide. The incidence of chronic ulcers is increasing rapidly, fueled by an aging population, rising incidence in obesity, diabetes, and venous insuffciency. Diabetic foot ulcers (DFUs), VLUs, and nonhealing postsurgical wounds are among the most frequently encountered ulcers in wound care practice. In the United States, over 4.3 million diabetic patients will develop a DFU in their lifetime, and ~2.5 million individuals suffer from VLUs. DFUs add 1–4 $9–$13 billion to the direct yearly cost associated with diabetes itself. The annual 5 cost of VLUs is $2.5–$3.5 billion. Nonhealing surgical wounds are also commonly 6 seen in wound care clinics. Surgical wounds pose an increased risk for infection and contribute to the growing economic burden of wound care management.

     

    In recent years, several clinical trials have been conducted to investigate products derived from human amniotic membranes (HAMs) as adjunctive therapies to accelerate of different layers – the epithelium, basement membrane, and stroma – and these layers further consist of three contiguous but distinct layers – the inner compact layer, the middle fbroblast layer, and the outermost spongy layer. The HAM has been shown to have anti-infammatory, antifbrotic, antiangiogenic as well as antimicrobial properties. Research has confrmed that growth factors present in amniotic membranes can induce angiogenesis and human dermal fbroblast proliferation as well as recruit multiple stem cells relevant to wound repair and regeneration. 9,10

     

    A fresh hypothermically stored amniotic allograft (HSAM) may improve healing rates by preserving growth factors and living cells, including stem cells, as well as retaining the membrane’s native structure. HSAM is aseptically processed and stored in a proprietary hypothermic storage solution using the Allofresh™ (Organogenesis, Canton, MA, sisting of topical antimicrobials. His comorbidities consisted USA) process. 13

     

    Methods
    A case study was conducted to evaluate an HSAM (Organogenesis) in the treatment of chronic wounds. Information was collected on patient demographics, wound type, wound location, age of wound, comorbidities, previous treatments, and current treatments. All patients were informed of study procedures and consented to have their case details and any accompanying photographs published. Digital planimetry (ARANZ Medical, Christchurch, New Zealand) was used ateach visit to record the wound surface area. Previous and current treatments were recorded. Two of the patients presented with VLU and one had a postsurgical wound.

     

    The VLU patients had previously received compression, and one patient had also received negative pressure wound therapy. The one with a surgical wound had received a variety of previous therapies, including topical silver, Hydrofera Blue, and topical antibiotics. The age of the wounds for the VLUs were 2–3 weeks, while the surgical wound was 5 months. Comorbidities for the VLUs consisted of venous insuffciency, diabetes, arthritis, osteomyelitis to ulcer location, hypertension, and lymphedema. Comorbidities for the surgical wound patient consisted of arthritis and hypertension. The new treatment regimen consisted of HSAM covered with a knotted cellulose acetate fabric dressing (Adaptic ; Acelity, San Antonio, TX, USA) and appropriate standard of care, including offoading, multilayer compression, and of care, including offoading, multilayer compression, and surgical debridement.

     

    Findings
    Case 1

    A 62-year-old patient presented to the wound clinic with a postop foot wound (nondiabetic), right foot dorsum. The duration of the wound was 5 months, with previous treatments consisting of topical antimicrobials. His comorbidities consisted of arthritis and hypertension. On day 0, the wound area size measured 3.3 cm , with 50% granulation, 10% fbrin, 40% slough, and a moderate amount of light red/pink serosanguineous drainage. Moderate edema was present. A 2.5 cm × 2.5 cm HSAM was applied and fxed in place using Steri-Strips™ (McKesson Medical-Surgical, Londonderry, NH, USA). On day 21, the wound area reduced to 2.9 cm2, a 12.12% reduction. There was an increase in the percentage of granulation tissue as well. By day 42, the wound area size had reduced by 81.82% with 100% granulation, and healed on day 71 (Figure 1).

    Figure 1 Case 1 surgical wound.
    Note: (A) Day 0, 3.3 cm2 ; (B) day 71, 0 cm2.

    Case 2 
    A 57-year-old patient presented with a left lower extremity VLU on the medial malleolus. The wound had been present for 8 weeks. The treatment thus far consisted of compression and topical antimicrobials. His past medical history included chronic venous insuffciency, peripheral vascular disease, deep vein thrombosis, and hyperlipidemia. On day 0, the wound area measured 0.3 cm . HSAM (2.5 cm x 2.5 cm) was applied and held in place with Steri-Strips™ ( McKesson Medical-Surgical) and compression wrap. On day 7, the wound was completed closed with no drainage (Figure 2).

    Figure 2 Case 2 venous leg ulcer.
    Note: (A) Day 0, 0.3 cm2; (B) day 7, 0 cm2.

    Case 3
    A 70-year-old patient presented with a VLU on the medial right lower extremity. The wound had been present for 2 weeks. The medical history obtained from this patient revealed hypertension, lymphedema, type II diabetes, and chronic venous insuffciency. At the time of HSAM (2.5 cm × 2.5 cm) application, the wound area measured 1.0 cm . By day 7, the wound area was reduced to 0.4 cm , and by day 14, it achieved complete closure (Figure 3).

    Figure 3 Case 3 venous leg ulcer.
    Note: (A) Day 0, 1.0 cm2; (B) day 14, 0 cm2

    Discussion
    Prompt treatment of chronic ulcers is essential in preventing complications, reducing the cost of care, and lessening the economic burden on the health care system. In clinical studies, amniotic membranes have been shown to be effective in promoting healing in chronic wounds. Prior products consisted of dehydrated products. We postulated that fresh amniotic membrane would demonstrate even greater effect. Prior to embarking on large expensive clinical trials, we tried the fresh amniotic product on a few selected patients. Results from this study suggested that HSAM may be an effective treatment option for management of VLUs and other non-healing wounds. HSAM offers a new treatment alternative to promote healing in chronic wounds. This membrane contains numerous growth factors and cytokines. These growth factors are found to be released over an extended period and result in increased cellular migration, proliferation, and remodeling. Moreover, HSAM may reduce the long-term costs associated with the care of chronic ulcers by increasing the healing rate and lowering the risk of infection and complications This pilot case series was subsequently used to inform larger DFU and VLU trials that are ongoing at the time of this writing.

     

    Original Article – Dovepress

     

    How Activity Benefits the Healing Patient

    Maintaining an active lifestyle is critical to good health; this is especially true for patients recovering from wounds or extended hospital stays. Robust activity can improve mental health, reduce the risk of infection, and accelerate wound healing.1 Staying active can be challenging for patients with wounds, however, and it is critical that health care professionals take steps to enable their patients to stay as active as possible.

     

    The Healing Benefits of Activity

    Aside from the long-term benefits to heart health, mental health, and longevity, exercise provides many direct and indirect benefits to patients healing from wounds. Physical activity can promote rapid wound healing, reduce oxidative damage, and promote a healthy lifestyle. This can improve patient outcomes and reduce the costs of treatment.


    Exercise Benefits Mental Health –
     There is ample evidence that exercise promotes good mental health, reduces the effects of depression, and causes people to report a greater level of happiness. These effects are especially important for those who have had an extended stay in a hospital or who are in a long-term care facility because these populations may be at greater risk of developing mental health problems.


    Exercise Reduces Inflammation – 
    Inflammation is one of the major causes of delayed healing. Research shows that wounds with low levels of inflammation heal much more quickly and completely. Exercise and other physical activity have been shown to reduce the level of inflammatory markers in the blood, thus helping to reduce the level of inflammation and promote rapid healing. Reduced inflammation may also provide palliative benefits by decreasing pain and discomfort in wounds … read more

    Prevent and manage wounds with this expert, all-inclusive resource! Acute & Chronic WoundsCurrent Management Concepts, 5th Edition provides the latest diagnostic and treatment guidelines to help you provide quality care for patients with wounds. This textbook presents an interprofessional approach to maintaining skin integrity and managing the numerous types of skin damage including topics that range from the physiology of wound healing, general principles of wound management, vulnerable patient populations, management of percutaneous tubes, and specific care instructions to program development. Written by respected nursing educators Ruth Bryant and Denise Nix, this bestselling reference also provides excellent preparation for all wound certification exams.

     

    • A comprehensive approach to the care of patients with acute and chronic wounds guides students and health care providers to design, deliver and evaluate quality skin and wound care in a systematic fashion; the comprehensive approach includes the latest advances in diagnosis, differentiation of wound types, nutrition, prevention, treatment, and pharmacology.
    • Self-assessment questions and answers in each chapter help you assess your knowledge and prepare for all wound certification exams.
    • Checklists offer a concise, easy-to-read summary of the steps needed to achieve the best patient care outcomes.
    • Risk assessment scales help in determining a patient’s risk for developing a wound, and wound classification tools identify the proper terminology to be used in documentation.
    • Learning objectives at the beginning of each chapter focus your study on the most important content.
    • Principles for practice development boost outcomes and productivity in agencies and institutions, home care, acute care, long-term care, and long-term acute care settings.
    • NEW coverage includes the latest guidelines from WOCN, AAWC, NPUAP, EPUAP, and PPPIA, and the American College of Physicians.
    • New sections cover the prevention and management of biofilm, the new skin tear classification system, MASD and MARCI, CTP terminology and classification scheme, and integration of the Health Belief Model.
    • NEW! Additional full-color photographs show the differential diagnosis of types of skin damage, management of fistulas, and NPWT procedures.
    • NEW! Clinical Consult features help in applying concepts to clinical practice, showing students and health care professionals how to assess, manage, and document real-life patient and staff encounters using the ADPIE framework.
    • NEW two-color illustrations and design make the book more visually appealing.

    The Diabetic Foot Syndrome (book)

    Frontiers in Diabetes, Vol. 26

     

    In recent years, “diabetic foot” has become the common name given to chronic complications of diabetes mellitus in the lower limb. This book provides an up-to-date picture of the clinical scenario, the latest understanding of the mechanisms in regard to pathology, the current standards of therapy, and the organizational tasks that a modern approach to such a complex pathology warrants. All contributors have delivered articles that are as informative and straight-to-the point as possible, including not only their own experience in the field, but also giving a wider picture to link each article to the other. The Diabetic Foot Syndrome is not only relevant to specialists, but also to all the caregivers involved in the management of the patients at risk for developing the pathology, those affected, and those who are at risk of recurrences.

    A Journey of a Thousand Steps to #ActAgainstAmputation

    Diabetes is the sixth leading cause of death in North America. By 2020, an estimated 4.2 million Canadians will be living with the disease and its devastating complications. People with diabetes have an increased risk of developing diabetic foot ulcers (DFUs) as a result of the loss of protective sensation in their extremities. Twenty five percent of individuals with diabetes will have a DFU in their lifetime, increasing their risk of amputation and pushing their five-year mortality rate to surpass that of patients with Hodgkin’s disease, breast cancer or prostate cancer.1,2,3 The direct cost of diabetes in Canada now accounts for about 3.5% of public health-care spending, and this figure continues to rise.4 The cost of DFUs is an enormous strain on health-care systems: about $12.2 billion in 2010. Care for people living with diabetic foot ulcers needs to be holistic and requires addressing all factors that contribute to ulceration, including repeated trauma and pressure. For years, the Canadian wound-care community recognized and understood the importance and value of pressure … read more (pdf)

    Reducing infection in chronic leg ulcers with an activated carbon cloth dressing

    Chronic wounds are likely to have an increased bioburden, which in turn increases the risk of local infection. Indeed, infection is one of the most frequent complications of non-healing wounds, resulting in longer treatment times, increased risk of morbidity, greater resource use (of both dressings and nurse time) and, most importantly, a high personal cost to patients and their families (Cooper et al, 2014). While the ultimate aim is to treat the underlying wound, use of antimicrobial dressings is the cornerstone of the treatment of infected wounds. Most antimicrobial dressings work by killing the bacteria, and are indicated for use only when there are clear signs of increased bioburden and/or clinical signs of infections. As such, their use is assessed after 2 weeks, at which point it is advised that the clinician switches to another type of dressing if the wound is observed to be healing (Cooper et al, 2014) … read more

    Review: Comparing the Effectiveness of Cellular and/or Tissue-Based Products for Treating Diabetic Foot Ulcers

    One fourth of the approximately 22.3 million patients with diabetes in the United States are expected to develop a diabetic foot ulcer (DFU) at some point during their lives, and it is estimated to affect 1-8% of individuals with diabetes annually. DFUs have shown to be challenging to treat, and often result in extended hospital stays, increased risk of infection, and subsequent amputation in certain patients. A major concern regarding amputees is a 5-year mortality rate that rivals that of patients with colon cancer. In addition, DFUs contribute heavily to the financial load of payers, with an estimated annual medical cost of up to $13 billion.

    Prior studies have indicated that wounds that penetrate bone, are prolonged and recurrent, and those associated with peripheral vascular disease pose a great risk for eventual amputation. Studies have shown that, even with proper care of DFUs by podiatric physicians and other clinical personnel, these wounds are slow to heal. Advanced therapies are often explored to improve outcomes.

    read more

    Development and Implementation of an Individualized Turning Program for Pressure Injury Prevention

    Using Sensor Technology in Nursing Homes: A Quality Improvement ProgramA Quality Improvement Program
    Turning nursing home residents every 2 hours has been a long-held standard for pressure injury (PrI) prevention in individuals with mobility impairments although evidence to substantiate this practice is limited. New guidelines recommend personalizing turning schedules to support person-centered care but lack specific recommendations about which turning frequencies are appropriate for various risk levels. PURPOSE: This quality improvement program aimed to determine the feasibility and outcomes of using individualized turn schedules for newly admitted nursing home residents. METHODS: An expert panel of wound clinicians developed, tested, and implemented a turn frequency tool that allowed staff in 2 nursing homes to select a turning schedule of 1, 2, 3, or 4 hours based on resident risk factors. Turning schedules were operationalized using a wearable sensor-based visual cueing technology that alerted staff to resident repositioning needs. Nonparticipating resident data were collected for comparison of PrI incidence. Descriptive statistics were calculated for all covariates. Significance of differences tests were performed as … read more

    Preventing complications at wound dressing changes

    This module aims to make clinicians aware of:

    • The importance of skin health and what makes it vulnerable to damage.
    • The damage that can occur when using medical adhesives and improper removal techniques.
    • The impact that MARSIs (medical adhesive-related skin injuries) can have on patients.
    • Ways to reduce the risk of MARSIs by providing appropriate treatment for at-risk patients groups.

    read more

    Healogics Launches Healing Can’t Wait Program For 2022

    JACKSONVILLE, Fla., Jan. 13, 2022 /PRNewswire/ — Healogics®, the nation’s leading provider of world-class wound care, is announcing their “Healing Can’t Wait” program for the millions of people struggling with a non-healing wound. Chronic wounds affect seven million Americans, limiting their quality of life, as well as life expectancy … With the 2022 Healing Can’t Wait program, Healogics looks to address the significant increase in amputations observed in recent years due to the impact of COVID-19 on patient treatment schedules. It is critical that patients understand the urgency and importance of treatment. Through the 2022 Healing Can’t Wait program and resources, Healogics Wound Care Centers will focus on educating the underserved chronic wound population … “Treatment delays and the staggering increase in amputations drive us to work even harder to improve awareness and access to advanced wound care. Any untreated wound is at risk for complications such as infection, hospitalization or amputation,” explains David Bassin, Chief Executive Officer of Healogics. “This is why the Healogics Healing Can’t Wait program is so critical.” … People living with diabetes, heart disease or peripheral artery disease (PAD) are at an even greater risk for health complications that stem from an untreated wound … read more


    LinkedIn:
    Healogics, Inc.

    Relationships of Changes in Physical Activity and Sedentary Behavior With Changes in Physical Fitness

    and Cardiometabolic Risk Profile in Individuals With Type 2 Diabetes: The Italian Diabetes and Exercise Study 2 (IDES_2)
    OBJECTIVE
    In the Italian Diabetes and Exercise Study_2 (IDES_2), behavioral counseling promoted a sustained increase in physical activity (PA) volume (+3.3 MET h ⋅ week−1), moderate- to vigorous-intensity PA (MVPA) (+6.4 min ⋅ day−1), and light-intensity PA (LPA) (+0.8 h ⋅ day−1) and decrease in sedentary time (SED-time) (−0.8 h ⋅ day−1). Here, we investigated the relationships of changes in PA/SED-time with changes in physical fitness and cardiometabolic risk profile in individuals with type 2 diabetes … read more

    Custom-made footwear designed for indoor use increases short-term and long-term adherence

    in people with diabetes at high ulcer risk
    To explore changes in footwear adherence following provision of custom-made indoor footwear in people with diabetes at high risk for plantar foot ulceration and in possession of regular custom-made footwear … Adherence indoors and outdoors was assessed objectively as percentage of steps custom-made footwear was worn, at baseline (in regular custom-made footwear), and at 1 and 12 months after providing custom-made indoor footwear (in both indoor and regular footwear). Primary group: participants with low (<80%) baseline indoor adherence; secondary group: participants with high (≥80%) baseline indoor adherence. Peak plantar pressures of the indoor footwear were compared with … read more

    New Diabetic Foot Ulcer Guidelines Highlight Importance Of Nutrition

    New guidelines endorsed by the American Limb Preservation Society highlighted the importance of nutrition in wound healing for adults with diabetes, who also experience diabetic foot ulcers (DFU) … The guidelines stated that nutritional interventions were “recommended for all patients who could benefit now or in the future from nutritional care.” As such, healthcare providers should develop and implement an individualized nutrition care plan for individuals with or at risk of a DFU, who are additionally malnourished or at risk of malnutrition … read more

    Fast Five Quiz: Type 2 Diabetes and Peripheral Artery Disease

    According to the International Diabetes Federation, 537 million people around the world have diabetes. This number is projected to rise to 700 million by 2045. In 2021, diabetes was responsible for 6.7 million deaths. Type 2 diabetes accounts for around 90% of diabetes cases, making it a global health crisis. Peripheral arterial disease (PAD) is an athero-occlusive disease and a chronic complication of diabetes. It is a risk factor for both foot ulceration and amputation. More than two thirds of patients with diabetic foot ulceration have associated PAD. Estimates suggest that more than 230 million people worldwide have PAD. Early recognition and treatment of patients with diabetes and feet at risk for ulcers and amputations can prevent or delay adverse outcomes … read more

    Preventing complications at wound dressing changes

    This module aims to make clinicians aware of:

    • The importance of skin health and what makes it vulnerable to damage.
    • The damage that can occur when using medical adhesives and improper removal techniques.
    • The impact that MARSIs (medical adhesive-related skin injuries) can have on patients.
    • Ways to reduce the risk of MARSIs by providing appropriate treatment for at-risk patients groups.

    read more

    Health Espresso partners with Wounds Canada to change wound care in Canada

    Health Espresso, Canada’s upcoming leader in community EHR, partners with best in class, Wounds Canada, to provide an AI powered, digital solution that’s aligned with the government’s target of delivering better, more connected care and improving health equity for patients, especially those in remote communities. The partnership brings Wounds Canada’s best practices, resources and training to front-line practitioners at the point of care coupled with the ability for remote patient monitoring for better outcomes.

     

     

    OAKVILLE, ONTARIO (PRWEB) APRIL 13, 2022

    When Linda Moss’ father was transferred to a second hospital for rehabilitation following a brain injury neurosurgery, her family only received information about the primary reason for his hospitalization: his neurological progress. Linda Moss and her family didn’t know that their father was suffering from a pressure injury that would eventually cause osteomyelitis. It was only when their father was denied a second surgery due to complications from the pressure injury that the severity of the wound was discovered.

     

    Unfortunately, this gap in communication between health-care providers, specialists and patients is far too common in the Canadian health-care system. The complete picture of patients is seldom shared, especially when they are complex or receive care from multiple partners. This leads to a lack of timely wound care and ultimately irreversible complications that can result in amputations or even death in the case of Linda Moss’ father.

     

    “Care teams and caregivers are essential together, and the first step in any prevention or further complications with wounds is a communicated Care Plan,” says Linda Moss.

     

    A new partnership between national organization Wounds Canada and Medtech company Health Espresso is changing this. This partnership enables front-line clinicians, patients, policymakers, and researchers to digitize a patient’s journey and connect members of allied health teams at the right time to decrease acute and hard-to-heal wounds, reduce hospitalizations and improve patient outcomes. Leveraging this technology will also enable Wounds Canada to establish a Canadian national registry that can inform further research in wound care and provide quick and easy access to Wounds Canada’s validated tools and resources for immediate bedside action by clinicians and help support wound management by patients, especially those living in outlying communities.

     

    “Wounds are a serious health complication that impacts the quality of life for patients while having significant economic implications on our health-care system, and the situation has only worsened under the strain of COVID-19. In many cases, hard-to-heal chronic wounds can be avoided or, if detected in the early stages, managed effectively — but we need evidence-based solutions to help us provide the safe, equitable and timely care that patients deserve in home care and across all health-care settings,” says Mariam Botros, CEO of Wounds Canada. “That’s why Wounds Canada is excited to partner with Health Espresso to offer a skin and wound care mobile app that benefits not only patients but also clinicians, researchers and policymakers. With the launch of this digital solution, we’ll be able to improve patient care, reduce hospitalizations and lower spending on wound care while also increasing the skills and knowledge of front-line clinicians and establishing a Canadian national registry to inform further research.”

     

    “As a registered nurse and private wound care consultant in rural southwestern Ontario, providing safe, timely, equitable access to interprofessional, evidence-informed care to people living with wounds can be challenging,” adds Crystal McCallum, Director of Education with Wounds Canada. “The skin and wound care mobile app that Health Espresso is developing in collaboration with Wounds Canada will address these challenges and will prove to reduce the burden of wounds and enhance the experience and outcomes of people living with wounds while enabling better use of health-care resources.”

     

    Certified by the Ontario Telehealth Network (OTN) and powered by artificial intelligence, Health Espresso’s easy-to-use mobile and web-based integrative digital solution offers a connected, collaborative approach to wound care. It provides a complete digital blueprint of a patient’s overall health and history, real-time vitals data, recorded notes from hospital visits, administered medication and more for timely, well-informed decision making. Unlike many standalone solutions, Health Espresso’s unique collaborative approach allows for a broader view of the patient’s journey with access to patient records, high-quality wound imaging and analysis tools to track healing progression and understand why a wound may not be healing correctly. It also includes built-in messaging and video tools that enable physicians, wound specialists and patients — especially those in remote or Indigenous communities — to engage in live communication within a secure environment.

     

    “Health Espresso’s digital solution is aligned with the government’s target of delivering better, more connected care and improving health equity for patients, especially those in remote communities,” says Founder of Health Espresso Rick Menassa. “To optimize the healing of wounds, care needs to be timely, and a structured, collaborative approach to assessment, treatment, documentation and communication based on best practices is critical for providing patients with the best possible outcomes. We are pleased to partner with Wounds Canada to offer our technology and bring their best practices, resources and training to front-line practitioners at the point of care.”

     

    ABOUT HEALTH ESPRESSO
    Inspired by front-line experience in home and community care, Health Espresso was created to chronicle the entire patient journey. Starting with a digital patient profile and digital care plan, Health Espresso empowers health organizations to automate intake, triage and update patient records and follow through with post-discharge remote patient monitoring for better health outcomes. Health Espresso provides a collaborative, patient-centred platform for Allied Health professionals, Primary Physicians and Hospitals for a ‘one patient, one care plan’ approach to care, reducing service overlaps and gaps. Its secure, connected platform integrates with EMRs and government data assets for an all-encompassing view of patient records. Health Espresso’s mobile app complements its in-cloud web portal to empower physicians with real-time patient information and virtual care capability for time-sensitive decisions at the point of care, anywhere in the world. For more information, visit https://www.healthespresso.com

     

    ABOUT WOUNDS CANADA
    Established in 1995, Wounds Canada is a charitable organization dedicated to advancing wound prevention and management for all people in Canada. They advocate for a population health approach that promotes best practices to support persons at risk of or living with wounds, health decision-makers and front-line clinicians. They develop and provide educational programs and resources and support research to advance this holistic, risk-based approach further. Wounds Canada fosters relationships with interested individuals and organizations to expand and sustain a robust wound community in Canada with mutually beneficial global connections. Their goal is to reduce the prevalence and incidence of wounds of all types and the negative consequences they bring—including patient suffering and wasted health-care dollars. To learn more, visit http://www.woundscanada.ca.

     

    This article was originally published here

    New Study Finds XPERIENCE™ No Rinse Solution Has Persistent Efficacy Against

    Both Planktonic Bacteria and Bacterial Biofilms

     

    Highlights

    • In vitro testing of XPERIENCE™ demonstrated 4-log to 6-log reductions in planktonic (free-floating) bacteria and 4-log to 8-log reductions in biofilm bacteria (colonies of bacteria)
    • XPERIENCE was shown to inhibit biofilm formation for up to five hours after application
    • Study published in The Journal of Arthroplasty

     

    JACKSONVILLE, Fla.–(BUSINESS WIRE)–Next Science Limited (ASX:NXS) (Next Science / the Company) is pleased to report that XPERIENCE™ No Rinse Solution has been shown to have persistent efficacy against both planktonic bacteria and bacterial biofilms in a new study published in The Journal of Arthroplasty. The study, “A Novel Irrigant to Eliminate Planktonic Bacteria and Eradicate Biofilm Superstructure With Persistent Effect During Total Hip Arthroplasty,” also found that XPERIENCE produced minimal cytotoxic effects to human tissue, allowing the solution to remain in the body without need for subsequent rinse. Additionally, XPERIENCE – cleared by the FDA for U.S. sale in April 2021 – was shown to inhibit biofilm formation for up to five hours after application.

     

    Prosthetic joint infection (PJI) remains a significant burden in total hip arthroplasty (THA) and total knee arthroplasty (TKA) in the United States. Estimates indicate that, by 2030, the annual hospital costs related to PJI of the hip and knee will be $1.85 billion.1 Interventions to reduce or prevent the occurrence of PJI continue to be at the forefront of research efforts and commercial development.

     

    “The minimum standard of care for irrigation in orthopedic surgical cases includes normal saline, but an increasing amount of literature in recent years has suggested that different solutions or additives may be needed to prevent PJI,” said orthopedic surgeon Ravi K. Bashyal, MD, the study’s lead author. “Combatting planktonic bacteria and the formation of biofilm is especially important given the high negative consequence of developing a PJI in the total joint arthroplasty setting.”

     

    In the in vitro study, XPERIENCE demonstrated 4-log to 6-log reductions in planktonic bacteria after five minutes, and 4-log to 8-log reductions in biofilm bacteria. Future research using large-series in vivo data is necessary to further establish the irrigant’s efficacy in reducing primary and recurrent surgical site infections (SSIs). An estimated 1.5 million SSIs in the United States each year2 contribute $3.3 billion to the cost of U.S. healthcare.3

     

    The study also found that XPERIENCE showed higher in vitro antimicrobial efficacy than three other commercially available adjuvants. The comparative treatments each reduced biofilm in all bacterial strains tested by approximately 1-log or less when the application times in their respective instructions for use were followed. However, XPERIENCE reduced biofilm by approximately 3-log to 8-log when used as directed.

     

    About Next Science

    Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development center in Florida, USA. Established in 2012, the Company’s primary focus is on the development and continued commercialization of products powered by its proprietary XBIO Technology. For further information visit: www.nextscience.com.

     

    Forward looking statements

    This announcement may contain forward looking statements which may be identified by words such as “believes”, “considers”, “could”, “estimates”, “expects”, “intends”, “may”, and other similar words that involve risks and uncertainties. Such statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of Next Science or its Directors and management, and could cause Next Science’s actual results and circumstances to differ materially from the results and circumstances expressed or anticipated in these statements. The Directors cannot and do not give any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this announcement will actually occur and investors are cautioned not to place undue reliance on these forward-looking statements.

     

    1Premkumar A., Kolin D.A., Farley K.X., et al. “Projected Economic Burden of Periprosthetic Joint Infection of the Hip and Knee in the United States.” J Arthroplasty, 2021;36(5):1484-1489 e1483.

    2Darouiche, R. (2019). “Surgical Site Infections.” Retrieved from: https://www.infectiousdiseaseadvisor.com/home/decision-support-in-medicine/ hospital-infection-control/surgical-site-infections

    3Zimlichman, E., et al. “Health Care-Associated Infections. A Meta-Analysis of Costs and Financial Impact on the US Health Care System.” JAMA Intern Med, 173(22): (2013): 2039-46.

     

    Contacts
    Judith Mitchell
    Managing Director, Next Science Limited
    Phone: +61 2 9375 7989
    Email: investorqueries@nextscience.com

     

    Anthony Priwer
    Dalton Agency
    Phone: +1 615-515-4891
    Email: apriwer@daltonagency.com

    HMC promotes diabetic limb salvage through awareness activities

    Building on the previous success of education and awareness activities, Hamad Medical Corporation (HMC) recently joined the American Diabetic Awareness Alert Day to promote Diabetic Limb Salvage and launch a nationwide Awareness Campaign themed ‘Early diagnosis leads to early intervention: save a leg, save a life’ … The initiative was aimed at educating the general public and specifically diabetic patients at risk of feet ulcers and leg amputation, increasing their knowledge of signs and symptoms of this disease, and encouraging them to take care of their own feet … Diabetic foot is a substantial public health issue that affects people worldwide. Statistics show that twenty-five percent of people with diabetes are at risk of developing diabetic foot ulcers (DFUs). Limb salvage is the endeavour to save a limb from amputation, such as the foot … read more

    The Importance of Technology in Wound Care

    Advancements in technology has helped healthcare enterprises deliver better wound care over the past few years.

     

    Long-term care (LTC) wound management can provide a number of problems in achieving the ultimate aim of complete wound healing. Pressure ulcers, ischemic ulcers, venous ulcers, and diabetic foot (neuropathic) ulcers are all common conditions that healthcare providers see and treat. The risk of developing an ulcer should be examined in all residents. If a person is at high risk for developing an ulcer, staff should take aggressive measures such as nutritional support or pressure reduction. If an ulcer forms, the main goal is to heal it fully as soon as feasible and at a fair cost. Providers should distinguish between pressure, ischemia, venous, and neuropathic ulcers, keeping in mind that they might be combined and contain two or more components. Providers should assure appropriate foundational care, adequate nutrition, proper blood supply, edoema control, and great topical wound care in order to attain this goal. Topical wound care promotes wound healing by moisturizing the area and reducing necrotic tissue … read more

    Microbion Corporation Receives up to $2.1 million in Funding Support from the US Navy

    in Partnership with CUBRC, Inc. to Advance Topical Pravibismane

     

    Funding will support exploratory phase 2 proof-of-concept study in patients hospitalized for moderate to severe diabetic foot ulcer infection (DFI)

     

    BOZEMAN, Mont. and VANCOUVER, BC, June 7, 2022 /PRNewswire/ – Microbion Corporation of Bozeman, MT, today announced that it has received non-dilutive funding through its strategic partnership with CUBRC, Inc., a Buffalo-based, independent not-for-profit research company, of up to $2.1 million from the US Navy through the Medical Technology Enterprise Consortium (MTEC) partnership. The funding project is titled “Pravibismane Suspension as a Topical, Broad Spectrum Anti-Infective Wound Care Treatment and Prevention for Combat Injury-Related Infections”. The funding received will be used to support the conduct of an exploratory phase 2 proof of concept trial in patients hospitalized for moderate to severe diabetic foot ulcer infection with enrollment expected to begin in Q2 2022.

     

    “We are pleased to be supported by the US Navy and MTEC and are working closely with them to advance our topical pravibismane through phase 2 proof-of-concept studies,” said Karim Lalji, CEO of Microbion Pharma Corp. “Our topical diabetic foot ulcer infection program is well aligned to the Navy’s interest in innovative wound care technologies to treat and prevent biofilm-related infections, since biofilm contamination is a hallmark characteristic of chronic foot ulcer infections. Further exploration of pravibismane’s safety and efficacy in overcoming biofilm-related DFI may potentially expand the clinical utility of topical pravibismane to treat combat wound infections in a variety of settings, including in the field and hospital.”

     

    Lester Martinez, MD, MPH, Major General (Retired), U.S. Army, President and Chairman of MTEC Board commented on the importance of Microbion’s research. “Though diabetic foot ulcer infections aren’t traditionally thought of as a combat related wound suffered in the field, diabetes is a serious disease that affects a significantly high percentage of our veterans and its complications such as DFI contributes to decline in health, quality of life and are responsible for the vast majority of non-combat amputations among veterans. Microbion’s research into healing these wounds with the ultimate goal of preventing or delaying amputations can potentially improve the daily lives of these patients and return normal mobility,” Dr. Martinez stated.

     

    Pravibismane is the first in a new class of anti-infective drugs structurally unrelated to other clinically utilized antibiotics. With a novel mechanism of action, pravibismane shuts down bacterial ATP production thereby halting global bacterial cellular metabolism. In in vitro studies, pravibismane exhibits broad-spectrum, potent activity against DFI-relevant pathogens and their biofilms including MRSA and drug resistant P. aeruginosa.

     

    In a randomized, double-blind, placebo-controlled Phase 1b trial treating patients with chronic moderate to severe diabetic foot ulcer infection, topical pravibismane treatment plus standard of care demonstrated a numeric 85% wound size reduction versus 30% placebo plus standard of care. Pravibismane also demonstrated a numeric reduction in ulcer-related amputation (2.6% in the pravibismane group vs 15.4% placebo).

     

    DFIs are a major health concern in the Veterans Health Administration as DFUs are associated with a substantial mortality rate (five-year mortality rates are as high as 45% for neuropathic ulcers and 55% for ischemic ulcers1) and often require amputation to fully address the nidus of infection.2 Approximately 28.5 million adults in the US are diagnosed with diabetes, of whom 15 – 25% are at risk of developing a foot ulcer.3,4 More than half of diabetic foot ulcers become infected.5 DFIs remain the most frequent diabetic complication requiring hospitalization and are the most common precipitating event leading to lower extremity amputation.6 Furthermore, recent studies suggest that many DFIs are caused by bacteria in a biofilm mode.6 In 2018, there were ~8.25 million hospital discharges with diabetes reported, including 154,000 for a lower-extremity amputation.3 US Veterans Affairs estimates there were 20.3 million living Veterans in 2018.7 The overall prevalence of diabetes among US veterans is ~25%, which is higher than the US civilian population at ~9%.8

     

    References:

    1. Del Core MA, Ahn J, Lewis RB, et al. The evaluation and treatment of diabetic foot ulcers and diabetic foot infections. Foot & Ankle Orthopaedics. 2018;3:3. doi:10.1177/2473011418788864
    2. Sundararajan PP, Porter BM, Grant KA, et al. Foot infections in the Veterans Health Administration. The Foot and Ankle Online Journal. 2015;8(3):1. doi:10.3827/faoj.2015.0803.0001
    3. Centers for Disease Control and Prevention. National Diabetes Statistics Report website. https://www.cdc.gov/diabetes/data/statistics-report/index.html, accessed June 6, 2022
    4. Lavery LA, Davis KE, Berriman SJ, et al. WHS guidelines update: Diabetic foot ulcer treatment guidelines. Wound Repair Regen. 2016;24(1):112–26. doi: 10.1111/wrr.12391
    5. Armstrong, DG, Boulton, AJM, and Bus, SA. Diabetic foot ulcers and their recurrence. N Engl J Med. 2017;376:2367-75. doi: 10.1056/NEJMra1615439
    6. Lipsky et al. Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diab Metab Res Rev. 2020. e3280. doi: 10.1002/dmrr.3280
    7. VETPop2018: A Brief Description. Web: https://www.va.gov/vetdata/docs/Demographics/New_Vetpop_Model/VP_18_A_Brief_Description.pdf, accessed June 6, 2022
    8. Liu Y, Sayam S, Shao X, et al. Prevalence of and trends in diabetes among veterans, United States, 2005–2014. Prev Chronic Dis. 2017;14:170230. doi: 10.5888/pcd14.170230

     

    About Microbion
    Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has a novel mechanism of action offering unique potential to address the unmet needs of chronic and severe health conditions. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations. Microbion Pharma Corp. is a wholly owned subsidiary of Microbion Corporation. For more information visit: www.microbioncorp.com.

     

    About CUBRC
    CUBRC is an independent not-for-profit scientific corporation that executes Research, Development, Testing and Systems Integration programs in Medical Sciences, Chemical and Biological Defense, Data Science and Information Fusion, Command and Control, and Hypersonics. For more information visit: www.cubrc.org.

     

    Safe Harbor Statement
    Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

     

    US Government Funding Disclaimer
    Efforts described herein were partially sponsored by the Government under Other Transactions Number W81XWH-15-9-0001. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

     

    SOURCE Microbion Corporation

    This article was originally published here

    Orpyx launches Orpyx SI Flex Sensory Insoles and Diabetes Healthspan Extension care model

    13-Jun-2022 8:05 AM EDT, by Orpyx Medical Technologies Inc.

     

    Newswise — CALGARY, AB, June 13, 2022 /PRNewswire/ — Orpyx® Medical Technologies Inc. (Orpyx), a digital health company focused on extending the health span of patients with diabetes, announced the launch of the Orpyx SI® Flex Sensory Insole system and Orpyx Remote Patient Monitoring (RPM) services. This remote monitoring program drives engagement and extends mobility for people living with diabetes by transforming patient care through real-world patient data, analytics, and coaching.

    The Orpyx SI® Flex Sensory Insoles help reduce the risk of plantar complications by monitoring plantar pressure, adherence, step count, and temperature data for patients that need preventative care.

    “The launch of Orpyx SI Flex is our next step in enabling Diabetes Healthspan Extension™,” stated Dr. Breanne Everett, CEO and co-founder of Orpyx. “In North America, one-third of people are living with diabetes or pre-diabetes which often requires juggling an overwhelming number of actions, measurements, and appointments. By taking a holistic approach through a digital care platform we can dramatically improve upon the current standard of care. We are starting with foot care through robust data generation via our sensory insoles, and supporting patient engagement through RPM and coaching.”

     

    The Orpyx SI Flex Sensory Insole system is a wearable technology designed to help prevent plantar foot complications for at-risk patients with peripheral neuropathy. “It is like having a supercomputer on the bottom of each foot,” said Denis Brisson, Chief Operating Officer at Orpyx. “Plantar pressure is a leading cause of foot ulceration so by measuring sustained high pressure we can help eliminate the root cause of many of these wounds before they happen.”

     

    Along with pressure, the system captures wear time to determine how compliant the patient is to their provider’s treatment plan, step count to help dose activity levels, and temperature the last line of defense to indicate when inflammation is present and tissue damage is occurring. The ultra-thin, prefabricated sensory insoles fit in most every-day footwear, making them practical and comfortable for a broad range of patients.

     

    Orpyx is changing the conversation by initially focusing on preventing foot ulceration by generating the most robust set of real-world plantar data. Historically, the focus has been on how to treat patients’ foot ulcers after they have already formed, with disappointing results as 25% of people with diabetes will develop an ulcer during their lifetime. These ulcers have a detrimental impact on patients’ mobility often resulting in life-shortening events such as amputation which can cause a ripple effect of social isolation, mental health challenges, and in the most complex situations death. Most diabetic foot ulcers (DFUs) are preventable, so we are on a mission to help patients and providers achieve improved, sustainable outcomes.

     

    “Healthcare systems cannot sustain the current clinical strain of managing the 34 million people with diabetes in the US and the resulting $176B in financial costs. One third of this cost is attributed to lower limb care which is why this is such important work,” continued Dan Hughes, Orpyx’s Chief Commercial Officer. “Orpyx SI Flex Sensory Insoles and our new RPM services were specifically developed to meet these challenges head-on. Our insoles will play a significant role in the diabetic care pathway enabling patients to take proactive steps to manage their diabetes while reducing the total cost of care for Commercial Payers and Integrated Delivery Networks across the United States. Ultimately, this technology drives alignment and better outcomes for patients, providers, payers, and physicians.”

     

    Healthcare providers seeking additional information to help their patients prevent DFUs can learn more about the new Orpyx SI Flex Sensory Insoles at https://www.orpyx.com/orpyx-si-flex-sensory-insoles.

     

    About Orpyx Medical Technologies Inc.

     

    Founded in 2010, Orpyx® Medical Technologies Inc. (“Orpyx”) is a Calgary-based digital health company. We take a holistic approach to remote “anywhere” care, which includes the company’s proprietary, imperceptible sensory insole platform that detects pressure, temperature, gait, activity, and movement symmetry. Our comprehensive Orpyx SI® Sensory Insole system enables continuity of care between visits to provide optimal remote care for people living with diabetes or recovering from surgery. The patient’s data is uploaded to the Orpyx SI cloud-based dashboard, where accredited healthcare practitioners remotely monitor it. The remote monitoring team communicates directly with the patient between care visits to ensure ongoing continuity and quality of care.

     

    Visit www.orpyx.com for more information.

    The impact of a vegan diet in the prevention and treatment of type 2 diabetes: A systematic review

    Vegan diets have gained a lot of popularity around the world, mostly in America. About 6% of Americans claim that they are vegans. That is a 600% increase in veganism from 2017 to 2021. There are many reasons that people nowadays are adopting a vegan diet and it includes health and ethical reasons. One of the health reasons that this review refers to is type 2 diabetes. There have been previous studies of what a vegan diet has on the health and the prevention of metabolic syndrome. There have been studies that showed that the risk of cancer can be reduced on a vegan diet, but is still under debate that this is the main reason for it. The review aimed to show studies between vegan diets and see if there is a reduction in risk for type 2 diabetes … read more

    Acral Amelanotic Melanoma Mimicking a Foot Ulcer

    Harrison J. Shawa, Marat Kazak, Sara Dahle, Joshua M. Schulman

     

    Amelanotic melanoma, accounting for less than 2% of melanomas, lacks typical clinical features of melanoma and mimics other lesions, frequently resulting in initial misdiagnosis and treatment delays and contributing to a poorer prognosis compared to conventional melanoma.

    Amelanotic melanoma affects both men and women and, on average, affects older individuals than conventional melanoma, with an average age at diagnosis of 62 years. Although some risk factors overlap with melanoma, individuals with amelanotic melanoma are more likely to have red hair, freckles, or sunburn easily than patients with pigmented melanoma. Other risk factors include more than 10 large nevi, plantar nevi, and a history of a penetrating foot injury or a previous amelanotic melanoma.

    When occurring on acral sites, amelanotic melanoma may mimic a variety of benign entities, including verrucae, calluses, poromas, hematomas, foreign bodies, fungal infections, blisters, ulcers, and pyogenic granulomas. We herein report a case of an acral amelanotic melanoma … read more

    Net Health Expands Predictive Analytics Resources for Wound Care Providers

    Clinical and operational innovations better predict non-healing wounds and missed appointments

     

    Further expanding its analytics capabilities and leadership position within the wound care marketplace, Net Health, a provider of specialty electronic health systems and advanced healthcare analytics, today announced the addition of two new predictive analytics resources to improve clinical and operational outcomes for wound care providers … The new Pressure Injury Deterioration Risk Indicator is built into Tissue Analytics, Net Health’s AI-powered wound imaging and analysis solution, which was recently granted breakthrough device status by the Food and Drug Administration (FDA). The Missed Visit Prediction Indicator is available in Net Health® Wound Care, one of the nation’s most widely used electronic health record (EHR) platforms for wound care. Both features are embedded in automated workflow processes and alert providers when risk is detected, enabling providers to intervene in real-time … read more

    Wound Care Advantage Highlights Diabetes Month with Free Resources for Wound Centers

    SIERRA MADRE, Calif., Nov. 10, 2022 /PRNewswire/ — Our doctors, nurses, and clinicians have been at the front lines of treating the consequences of diabetes every day. With over 20 years of supporting wound centers, we’ve learned 2 important truth’s about diabetes:

     

    Diabetes continues to grow at an alarming rate
    More action and education are needed

     

    Steal this Diabetes Month Resource Kit: thewca.com/2022/11/01/steal-this-diabetes-month-resource-kit/

    Steal this Diabetes Month Resource Kit: thewca.com/2022/11/01/steal-this-diabetes-month-resource-kit/

    To commemorate November’s National Diabetes Awareness Month, Wound Care Advantage does not want to focus on the statistics of Diabetes. Like the 37 million people suffering from diabetes, or the fact that up to 34% of those patients will develop a foot ulcer (DFU) in their lifetime, and that DFUs are the number one leading cause of non-traumatic amputations. Instead, we realize that diabetes is not going anywhere anytime soon, nor is the knowledge that if not managed properly, diabetes can lead to serious and fatal outcomes.

     

    This is why this November, WCA is giving Wound Programs a Diabetes Month Resource Kit to build awareness of diabetes and the high risk of chronic wounds. With 70% of diabetic foot ulcers ending in amputation and leading to a 2-year life expectancy after surgery, wound care programs deserve the support and resources to save the limbs and lives of all patients. Help us put a spotlight on this disease with our free Diabetes Month Resource Kit. Steal our professional resources for your clinic.

     

    Our Resource Kit will supply you with:

     

    Even with the disease of diabetes keeping its alarmingly quick growth rate, the population of patients that develop an ulcer that leads to an amputation does not have to. Join us in building the awareness that 70% of DFU patients do not need to end with an amputation this November.

     

    Diabetes Month Resource Kit: thewca.com/2022/11/01/steal-this-diabetes-month-resource-kit/

     

    About Wound Care Advantage:
    Founded in 2002, Wound Care Advantage (WCA) has been supporting wound centers for 20 years. With a strong commitment to care and innovation, WCA advocates for the financial independence of partner hospitals and the rapid healing of patients they serve. Wound Care Advantage is a privately held company headquartered in Sierra Madre, California. For additional information, visit www.thewca.com.

     

    SOURCE Wound Care Advantage

    Microbion Corp. Presents a Poster on Pravibismane’s Activity Against Diabetic Foot Infection Patient Isolates

    admin
    • Poster highlights pravibismane’s MIC activity in testing against aerobic and anaerobic pathogens isolated from diabetic foot infection patients
    • Pravibismane demonstrated potent, broad-spectrum activity against a wide range
      of pathogens, including MRSA, MSSA, and P. aeruginosa

    BOZEMAN, Mont., May 10, 2023 /PRNewswire/ – Microbion Corporation today announced that the company presented a poster focusing on pravibismane’s activity against diabetic foot ulcer infection pathogens at the 9th International Symposium on the Diabetic Foot that is currently ongoing from May 10th to 13th, 2023 at The Hague, Netherlands. The poster highlights pravibismane’s activity versus comparator antibiotics against pathogens isolated from diabetic foot infection (DFI) patients in an earlier Phase 1b clinical study.

    Poster Details:
    Representative image (CNW Group/Microbion Corporation)

    Representative image (CNW Group/Microbion Corporation)

    Title: Broad-Spectrum, Potent Activity of Pravibismane Versus Comparators Against Diabetic Foot Ulcer Infection Patient Isolates Collected in a Phase 1b Study

    Presenter: Dr. Jeff Millard, CSO

    Poster Highlights:
    • Most common pathogens isolated from DFI subjects (N = 44) at baseline were: methicillin-susceptible Staphylococcus aureus [MSSA (25%)]; methicillin-resistant Staphylococcus aureus [MRSA (18.2%)]; Enterococcus faecalis (13.6%); and Pseudomonas aeruginosa (11.4%).
    • Mean pravibismane minimum inhibitory concentration (MIC) (µg/mL) for S. aureus MSSA was 0.21, S. aureus MRSA was 0.17, E. faecalis was 2.53, and P. aeruginosa was 1.43.
    • Mean pravibismane MICs for 12 of the 13 anaerobic bacteria was ≤1 µg/mL, including against Finegoldia magna and Anaerococcus spp.
    • Pravibismane exhibited similar or lower MIC relative to a panel of comparator antibiotics, including (but not limited to) levofloxacin, linezolid, clindamycin, and piperacillin-tazobactam, against Gram-positive and Gram-negative, susceptible and resistant, aerobes and anaerobes.

    "We are pleased that pravibismane demonstrated extremely potent MIC activity against clinical DFI isolates, which was in line with in vitro AST microbial pre-clinical studies," said Dr. Jeff Millard, CSO of Microbion Corp. "Diabetic foot infections are often infected by several different bacterial species concurrently, which may change over the chronicity of the wound, from predominantly aerobic to anaerobic. We believe pravibismane’s potent broad-spectrum activity is potentially a key treatment advantage since a single agent could eradicate both aerobic and anaerobic bacteria, thereby decreasing the need for multiple systemic therapies."

    Bacterial cultures for this study were grown from swabs collected at the wound bed at baseline visit and antimicrobial susceptibility testing (AST) was performed on isolated pathogens. Pathogen isolation and AST was performed at Investigational Health Management Associates (IHMA, IL), using the Clinical & Laboratory Standards Institute (CLSI) standard methods.

    Topical pravibismane has received QIDP and Fast Track drug designation from the US FDA for the adjunctive treatment of moderate and severe diabetic foot ulcer infections. Topical pravbismane is currently enrolling in a Phase 2 clinical study to further evaluate its safety and efficacy in subjects suffering from moderate infections associated with chronic diabetic foot ulcers.

    About Microbion

    Microbion is a clinical-stage pharmaceutical company developing a new class of therapeutic compounds to improve the lives of patients with rare and serious diseases. Microbion’s lead drug candidate, pravibismane, is the first product in this new class and has multiple novel modes of action offering unique potential to address the unmet needs of chronic and severe health conditions. Topical/local pravibismane is in Phase 2 development for the treatment of chronic wounds and orthopedic infections. The Company is advancing inhaled pravibismane in Phase 1 clinical development for the treatment of chronic lung diseases, including non-tuberculous mycobacteria (NTM) and cystic fibrosis-related lung infections. Pravibismane has received backing from the Cystic Fibrosis Foundation, NIH, US DoD, and CARB-X with over $21 million in grants. The FDA has granted pravibismane with Orphan Drug, Fast Track, and QIDP designations.

    For more information visit: www.microbioncorp.com.

    Safe Harbor Statement

    Certain of the statements made in this press release are forward-looking, such as those, among others, relating to the success of clinical development of pravibismane and preparation for potential commercialization. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to: our ability to enroll patients in our clinical trials at the pace that we project; the size and growth of the potential markets for pravibismane or any future product candidates and our ability to serve those markets; our ability to obtain and maintain regulatory approval of pravibismane or any future product candidates; and our expectations regarding the potential safety, efficacy or clinical utility of pravibismane or any future product candidates. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Microbion Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    SOURCE Microbion Corporation

    The Wound Company Launches With $4.25M In Funding To Curb the Amputation Epidemic And Save The Healthcare System Billions

    Led by Susa Ventures and Sozo Ventures, the funding will be used to transform the $45B wound and ostomy care industry by bringing on-demand experts to more patients and providers in need via telehealth and in-person visits

     

    Minneapolis, MN – WEBWIRE – Thursday, June 15, 2023

    The Wound Company, a multi-channel on-demand wound and ostomy care delivery company that improves patient outcomes, today announced its launch from stealth with $4.25M in seed funding from Susa Ventures and Sozo Ventures. The funding will be used to expand the company’s national footprint, hire top talent, and to continue improving health outcomes in the most cost-effective way possible while bringing dignity to the over 13 million people in need of improved wound and ostomy care.

    Why Wound Care Matters

    The US is experiencing an amputation epidemic due to diabetic foot ulcers and other serious wounds. Despite medical advancements, Americans are amputating double the number of limbs today than during the Civil War. About 50% of lower extremity amputations would have been preventable if patients with type 2 diabetes and foot ulcers had access to better healthcare. This issue is one of the problems The Wound Company is solving for.

    Often providers need more wound care expertise or, due to understaffing, don’t have time to offer comprehensive care continuously, leaving patients to figure it out on their own. This leads to wound care patients returning to the hospital due to improper wound care. But it can be prevented.

    “The wound and ostomy care industry is broken,” said Nima Ahmadi, founder and CEO of The Wound Company. “It’s operating in the fee-for-service world, which pushes expensive procedures and products that help the bottom line, but don’t impact outcomes for the patient. We’re paid to heal wounds with continuous care and, in doing so, save money for health plans and at-risk providers.”

    Enter The Wound Company

    The Wound Company aims to fix the broken space of wound and ostomy care by using predictive analytics and multi-channel communications to deliver the right wound and ostomy care to the right patient in the right channel at the right time. The tech connects patients and providers to wound and ostomy experts virtually or via in-person visits to ensure they have top-tier care.

    “The Wound Company’s innovative technologies have the potential to save health plans billions of dollars and transform the patient experience,” says Susa Ventures Investor Derick En’Wezoh. “With a dedicated team of highly experienced experts, a strong vision, and a passion for improving healthcare outcomes, this tech will save lives.”

    The platform also offers clinical reporting, customer data integration, and workflow automation to make care delivery as painless as possible for providers.

    While in stealth, The Wound Company has already partnered with health plans, health systems, home care providers, hospice providers, and patients, with significant results to date:

    • A potential 15-20% reduction in the total cost of care for wound and ostomy patients for payers
    • Up to 50% savings on supplies per patient for home and hospice care providers
    • 60% of patients demonstrated progressive healing week after week
    • 90% of Stage I/II pressure ulcers resolved without advancing to a higher stage
    • 100% of ostomy patients have a predictable pouching system and reduced chance of ER visits or readmissions

     

    “Our blend of virtual and in-person services provided by passionate experts in wound care helps people heal quickly, safely, and with the dignity they deserve while helping to alleviate the pressure on overworked healthcare professionals,” said Chief Medical Officer Sanford Roberts.

    The Wound Company is open to partnerships with health plans, at-risk providers, home health providers, and hospice care providers. For more information, visit www.thewound.co.

    About The Wound Company

    The Wound Company is a Minneapolis-based technology company dedicated to advancing wound and ostomy care. The company uses proprietary technology to connect providers with experienced and certified wound care specialists who can care for patients virtually or via in-person visits. The Wound Company partners with health plans, home care companies, and providers to bring dignity to patients with wounds and ostomies while increasing positive patient outcomes.

    This article was originally published here

    Playing the Long Game with Diabetes

    Playing the Long Game with Diabetes: Prioritizing Foot Health

    The American Podiatric Medical Association (APMA) emphasizes the critical importance of foot health in diabetes management. Individuals with Type 1 or Type 2 diabetes face a heightened risk of serious foot complications, including infections and amputations. APMA’s “Playing the Long Game with Diabetes” campaign advocates for early adoption of healthy habits to prevent such outcomes.APMA MAIN+7APMA MAIN+7APMA MAIN+7APMA MAIN+3APMA MAIN+3APMA MAIN+3

    Key recommendations include annual visits to an APMA-member podiatrist, or at minimum, regular foot checks by a primary care provider if podiatric access is limited. The APMA provides a suite of resources to support patients in maintaining foot health:APMA MAIN

    • Daily Foot Exams: Guidance on conducting simple daily inspections to detect early signs of complications.

    • Educational Materials: Tip sheets and videos featuring podiatrists sharing insights on diabetes-related foot care.

    • Product Recommendations: A list of APMA Seal-approved footwear and products designed for diabetic foot care.APMA MAIN+1APMA MAIN+1

    • Community Engagement: Encouragement to join conversations on social media using the hashtag #PlaytheLongGame.APMA MAIN+4APMA MAIN+4APMA MAIN+4

    These resources aim to empower individuals with diabetes to take proactive steps in managing their foot health, thereby reducing the risk of complications.APMA MAIN

    Explore the full suite of resources here: APMA Diabetes Awareness


    About the Author: Dr. Savannah Santiago, DPM

    Dr. Savannah Santiago is a first-year podiatric medicine and surgery resident at Ascension St. Vincent Hospital in Indianapolis. A 2024 graduate of Western University of Health Sciences College of Podiatric Medicine, she holds a B.S. in Biomedical Sciences and Spanish Language and Culture from the University of Colorado Colorado Springs, where she also competed in NCAA cross country and track and field.Pod Patrol+5LinkedIn+5Ascension Medical Education+5WesternU News+2cdn2.podiatry.com+2Ascension Medical Education+2

    Dr. Santiago’s personal experiences, including managing her own diabetes diagnosis at 19 and overcoming sports-related injuries, have fueled her passion for podiatry. Her clinical interests encompass reconstructive surgery, limb salvage, pediatric podiatry, sports medicine, and inpatient care.Ascension Medical Education

    An active contributor to the field, she authors the “Sole Purpose” blog on PRESENT Podiatry and has been featured on the Pod Patrol podcast. Dr. Santiago also serves as the first Resident Liaison for the American College of Podiatric Medicine (ACPM). Outside the clinic, she enjoys trail running, rollerblading, and exploring farmers markets.session.podiatry.com+4Pod Patrol+4Podiatry+4InstagramAscension Medical Education


    Note: This bio is intended for educational purposes and to inform readers about Dr. Santiago’s contributions to the field of podiatric medicine.

    Incidence of Charcot Arthropathy: A Nationwide Study

    Incidence of Charcot Arthropathy: A Nationwide Study #ActAgainstAmputation

    A recent nationwide study from Denmark, spanning from 2000 to 2021 and involving over 265,000 patients with diabetes, reveals a paradoxical trend in Charcot arthropathy cases. While the absolute number of Charcot cases increased significantly over the study period (Kendall’s tau = 0.6, p < 0.0005), the incidence rate per capita among people with diabetes actually declined (Kendall’s tau = -0.6, p = 0.0005) [Source].

    This suggests that, although more individuals are developing Charcot arthropathy due to the increasing prevalence of diabetes, the individual risk of developing this complication is decreasing. Improved management of diabetes and neuropathy may be contributing factors to this decline in individual risk.

    Notably, the study found no significant regional differences in incidence across Denmark’s five health regions, nor any measurable impact from the COVID-19 pandemic or the nurses’ strike of 2021. This underscores the resilience of Denmark’s multidisciplinary care infrastructure in managing diabetic complications.

    These findings highlight the importance of robust public health systems and early intervention strategies in mitigating the disabling effects of diabetic complications like Charcot arthropathy.

    Read the full article on the Diabetic Foot Online website.

    Keywords:
    Charcot arthropathy,
    Diabetic neuropathy,
    Denmark healthcare,
    Public health infrastructure,
    Diabetes management,
    Epidemiology

    Optimizing Diabetic Foot Ulcer Care: Four Steps to Save Limbs Worldwide

    Optimizing Diabetic Foot Ulcer Care: Four Steps to Save Limbs Worldwide

    Keck Medicine of USC outlines a comprehensive, four-step approach to diabetic foot ulcer (DFU) management, aiming to reduce the global incidence of lower-limb amputations. This strategy emphasizes early detection, interdisciplinary care, and patient empowerment to enhance outcomes for individuals with diabetes.

    1. Establishing a “Hot Foot Line”: A dedicated hotline facilitates rapid triage of patients presenting with diabetic foot infections or ischemia, ensuring immediate assessment by a specialized limb-salvage team. This prompt intervention can significantly decrease the risk of major amputations.

    2. Developing Wound-Healing Clinics: Specialized outpatient clinics focus on active tissue loss, employing advanced modalities such as total contact casting, vascular diagnostics, and surgical debridement. These clinics aim to expedite healing and reduce hospitalization rates.

    3. Establishing Remission Clinics: Post-healing, remission clinics work to prevent ulcer recurrence through patient education, biomechanical evaluations, and preventive interventions. Tools like pressure-relieving footwear and thermal monitoring devices are utilized to maintain ulcer-free periods.

    4. Implementing Screening Clinics: Annual foot screenings assess risk factors like neuropathy and peripheral artery disease. Early identification allows for timely referrals to appropriate care pathways, including remission or wound-healing clinics, thereby preventing the progression to limb-threatening conditions.

    This model has demonstrated success at Keck Medicine of USC and is adaptable to various healthcare settings globally. By integrating these steps, healthcare systems can proactively manage chronic conditions, ultimately saving limbs and improving quality of life for patients with diabetes.

    Read the full article on the Keck Medicine of USC website.

    Keywords:
    Diabetic foot ulcers,
    Foot ulcer care,
    Limb salvage,
    Amputation prevention,
    Keck Medicine of USC,
    David G. Armstrong

    AI in Wound Assessment: Transforming Chronic Wound Care

    AI in Wound Assessment: Transforming Chronic Wound Care

    Artificial intelligence (AI) is revolutionizing wound care by transforming how clinicians assess and manage chronic wounds. By automating measurements, enhancing diagnostic precision, and enabling remote monitoring, AI-powered tools address the shortcomings of traditional manual assessments, which are often subjective, time-consuming, and variable. From smartphone-based imaging to deep learning algorithms, AI delivers data-driven insights that improve treatment planning and patient outcomes for conditions like diabetic ulcers, pressure injuries, and venous leg ulcers. This article delves into AI’s impact on wound assessment, offering wound care professionals a glimpse into a technology poised to redefine clinical practice.

    The Need for AI in Wound Assessment

    Chronic wounds affect over 6 million Americans, costing healthcare systems billions annually. Accurate assessment is crucial to guide treatments, prevent infections, and accelerate healing. Yet, traditional methods—ruler measurements, visual inspections—rely on clinician experience, leading to inconsistencies. AI overcomes these barriers with standardized, objective analysis. Tools like Healthy.io’s Minuteful for Wound use smartphone cameras with calibration markers to capture high-resolution images, instantly measuring wound dimensions and classifying tissue types (granulation, necrotic, epithelialization). Such automation saves time, reduces errors, and allows clinicians to focus on patient care rather than documentation.

    Key Highlights:

    • Automated Precision: AI systems like eKare’s inSight measure wound size and tissue composition with 94% accuracy, outperforming manual methods. Deep learning models, such as U-Net, segment wound areas precisely, ensuring reliable data for clinical decisions.
    • Advanced Diagnostics: AI tools, including Spectral AI’s DeepView SnapShot, predict healing potential and identify infection risks early. These capabilities enable proactive interventions, improving outcomes for complex wounds.
    • Telemedicine Integration: AI apps facilitate remote monitoring, allowing patients to upload wound images for real-time clinician review. This enhances access for rural or bedbound patients, reducing hospital visits.
    • Future Potential: AI could integrate with wearables and predictive analytics to forecast complications like amputations. Research continues to address challenges like limited datasets and tissue segmentation accuracy.

    Clinical and Economic Benefits

    AI’s precision in wound assessment drives significant clinical and economic advantages. By detecting subtle changes in wound characteristics—such as early signs of infection or delayed healing—AI supports tailored treatments, from selecting optimal dressings to initiating therapies like negative pressure wound therapy. Early intervention reduces infection rates and hospital readmissions, critical given chronic wounds’ $20–$30 billion annual U.S. cost. AI’s telemedicine capabilities also empower patients, improving adherence and satisfaction. For clinicians, AI tools integrate into workflows, enhancing documentation for reimbursement and freeing time for patient interaction. A 2024 review notes AI’s potential to standardize care across settings, from hospitals to home care.

    Challenges to Overcome

    Despite its promise, AI in wound assessment faces obstacles. Limited public datasets hinder model training, especially for complex tissues like necrotic areas, which vary in appearance. Regulatory approval, such as FDA clearance, is essential for credibility, but not all apps meet these standards. Clinicians must balance AI insights with clinical judgment to account for patient-specific factors, avoiding over-reliance. The PMC review emphasizes the need for robust clinical validation and diverse datasets to ensure AI tools perform reliably across populations, particularly for underrepresented groups.

    The Road Ahead

    AI’s future in wound assessment is brimming with possibility. Integration with wearables could enable real-time wound monitoring, while predictive analytics might forecast complications weeks in advance. Imagine smart bandages that alert clinicians to infection risks or AI models that personalize treatment plans based on genetic and environmental factors. As research advances, collaboration between developers, clinicians, and regulators will be key to overcoming current limitations. For wound care professionals, adopting AI tools now means staying at the forefront of innovation, delivering precise, patient-centered care that transforms lives.

    AI in wound assessment is more than a technological leap—it’s a new era in chronic wound care. By automating assessments, enhancing diagnostics, and bridging access gaps, AI empowers clinicians to achieve better outcomes. Wound care professionals are urged to explore these tools, stay updated on advancements, and integrate AI into their practice to elevate care standards.

    Keywords:
    AI wound assessment,
    Wound care,
    Chronic wounds,
    Deep learning,
    Telemedicine

    Diabetic Foot Ulcers

    Overview of Diabetic Foot Ulcers: Causes, Diagnosis, and Management

    This detailed summary, adapted from a comprehensive article on Medscape, outlines the essential aspects of diabetic foot ulcers (DFUs), including risk factors, clinical presentation, diagnostic workup, and treatment approaches. Diabetic foot ulcers are a major complication of diabetes and contribute significantly to patient morbidity and healthcare costs.

    Key Highlights:

    • Causes and Risk Factors: DFUs are commonly caused by peripheral neuropathy (loss of protective sensation), peripheral arterial disease (reduced blood flow), and structural foot deformities. These factors together increase the likelihood of ulcer formation and delay healing.
    • Clinical Presentation: DFUs typically present as open sores, especially on weight-bearing areas of the foot. Redness, swelling, discharge, and odor may indicate infection. Notably, pain is often absent due to neuropathy.
    • Diagnosis: Evaluation includes physical and neurological exams, vascular assessments (e.g., ABI), imaging (X-ray or MRI), and lab tests to detect infection or bone involvement.
    • Treatment: Effective care involves offloading pressure, regular wound debridement, appropriate dressings, infection management, tight glycemic control, and in some cases, surgery or revascularization. Multidisciplinary care is often required.
    • Prognosis: Up to 20% of DFUs may lead to lower-limb amputation. Recurrence is common, so prevention through foot care education and ongoing monitoring is critical.

    With early detection and a coordinated treatment plan, many diabetic foot ulcers can be healed and serious complications avoided. Healthcare providers should remain vigilant for early signs in diabetic patients and implement evidence-based strategies to improve outcomes.

    Read the full article on the Medscape website.

    Keywords:
    diabetic foot ulcers,
    wound care,
    debridement,
    peripheral neuropathy,
    offloading

    Complications of Hospital-Acquired Wound Infections

    Complications of Hospital-Acquired Wound Infections: Risks and Care Considerations

    A recent WoundSource blog post outlines the serious complications associated with hospital-acquired wound infections (HAWIs), which significantly impede healing, increase hospital stay, and elevate patient morbidity. These infections often emerge in surgical wounds, pressure injuries, and device-related sites. :contentReference[oaicite:turn0search0]{index=0}

    Key Highlights:

    • Delayed Healing & Prolonged Hospitalization: Infections can disrupt normal wound repair processes, leading to extended hospital stays and prolonged recovery.
    • Abscess Formation: Localized collections of pus may develop, requiring incision, drainage, and targeted antimicrobial therapy. :contentReference[oaicite:turn0search0]{index=0}
    • Surgical Wound Dehiscence: Infection can cause wound edges to separate prematurely, necessitating additional surgical or mechanical closure interventions. :contentReference[oaicite:turn0search2]{index=0}
    • Antimicrobial Resistance & Sepsis Risk: Hospital-acquired pathogens often exhibit multidrug resistance, complicating treatment and raising the risk of systemic infection and sepsis.

    This overview emphasizes that early recognition, appropriate dressing selection, and prompt antimicrobial therapy are critical to minimizing complications associated with hospital-acquired wound infections.

    Read the full article on the WoundSource website.

    Keywords:
    hospital-acquired infection,
    wound complications,
    abscess,
    dehiscence,
    antimicrobial resistance

    Healthcare-Acquired Wound Infections and Antimicrobial Resistance – webinar

    Healthcare‑Acquired Wound Infections & Antimicrobial Resistance: Embracing a Multidisciplinary Team Approach

    Presented on June 19, 2025, this free, on‑demand webinar by WoundSource addresses the growing risks of hospital‑acquired wound infections and the escalating problem of antimicrobial resistance (AMR). Featuring insights for clinicians on integrating multidisciplinary strategies for prevention, management, and stewardship.

    Key Highlights:

    • Rising Infection Risks: Covers the prevalence and serious complications associated with healthcare‑acquired wound infections, including surgical site infections, device‑related wounds, and pressure injuries. :contentReference[oaicite:1]{index=1}
    • Antimicrobial Resistance Challenge: Discusses how multidrug-resistant organisms complicate treatment, leading to increased morbidity, mortality, and healthcare costs. :contentReference[oaicite:2]{index=2}
    • Multidisciplinary Protocols: Emphasizes collaborative best practices involving infection control experts, microbiologists, pharmacists, nursing staff, and wound specialists to optimize prevention and management.
    • Stewardship Strategies: Promotes antimicrobial stewardship programs, including robust surveillance, appropriate antibiotic selection, targeted therapy, and review of antibiotic duration to minimize resistance pressure.
    • Clinical Practice Adaptations: Highlights the use of evidence‑based dressings, modality selection, debridement protocols, and early identification to reduce colonization and infection rates.

    Watch the full webinar on the WoundSource website.

    Keywords:
    healthcare-acquired infections,
    antimicrobial resistance,
    multidisciplinary team,
    antimicrobial stewardship,
    wound infection prevention

    Reliability of Microwave Radiometry for the Assessment of Charcot Foot

    Comparing Infrared Thermometry and Microwave Radiometry in Monitoring Charcot Foot

    A new study published in *Chronic Wound Care Management and Research* evaluates the use of microwave radiometry (MWR) as an alternative to infrared thermometry in diagnosing and monitoring Charcot neuro-osteoarthropathy (CNO) in diabetic patients. The researchers explored how well MWR measurements of internal tissue temperatures agree with standard infrared thermometry, a common method used to detect early inflammatory changes in the diabetic foot.

    Key Highlights:

    • Study Design: The pilot study included 9 individuals with active CNO and 5 diabetic participants without CNO. Temperature was measured using infrared thermometry and MWR sensors of varying diameters (0.8 cm, 2 cm, and 5 cm) to assess different tissue depths.
    • Measurement Agreement: MWR 0.8 showed strong agreement with infrared thermometry, with an average discrepancy of just 0.034°C (statistically insignificant). However, MWR 2 and MWR 5 showed larger differences (−0.323°C and −0.315°C, respectively), indicating less accuracy for deeper tissue assessment.
    • Follow-Up Outcomes: Over a median of 67 weeks, 77.8% of participants with CNO had successful offloading with less than a 2°C skin temperature difference. Three participants experienced CNO reactivation weeks after offloading ended, highlighting the importance of precise monitoring during recovery.
    • Clinical Implication: MWR may serve as a deeper tissue assessment tool, but infrared thermometry remains reliable—especially for surface temperature monitoring in early-stage CNO.

    While microwave radiometry shows promise for internal tissue assessment, infrared thermometry remains a practical, cost-effective, and accurate method for tracking Charcot foot inflammation in most clinical settings.

    Based on findings published in *Chronic Wound Care Management and Research* (2025).

    Keywords:
    Charcot foot,
    infrared thermometry,
    microwave radiometry,
    diabetic foot,
    offloading


    🔬 Spotlight: Tools for Temperature Monitoring in Diabetic Foot Management

    Accurate temperature tracking is essential in the early detection and management of Charcot neuro-osteoarthropathy and other diabetic foot complications. Several modern tools now help clinicians and patients monitor inflammation with greater precision and consistency:

    • Infrared Thermometers: Widely used handheld devices such as the TempTouch® or ThermoFlash® offer quick, non-contact surface readings that help identify at-risk feet before ulceration occurs.
    • Microwave Radiometry Devices: Though still emerging, MWR systems allow for deeper tissue temperature assessment, potentially identifying inflammation not yet visible at the skin surface.
    • Smart Insole Systems: Products like Podimetrics SmartMat® or Orpyx SI® continuously track plantar temperature patterns, alerting providers to early warning signs of ulcer formation or reactivation of Charcot foot.
    • Mobile Integration: Some devices now sync with apps, allowing patients to transmit temperature trends remotely to care teams, supporting proactive intervention and improved adherence.

    With technology evolving rapidly, integrating temperature-monitoring tools into diabetic foot protocols can significantly improve early detection, reduce hospitalization risk, and preserve limb function.

    read full article

    Advancing pressure ulcer prevention and therapy

    Advancing Pressure Ulcer Prevention & Therapy: Aligning Priorities with Clinical Burden

    An editorial in *Journal of Wound Management* (July 2025) highlights the urgent need to match pressure ulcer prevention and treatment strategies with their physical, psychological, and economic burdens—while shifting focus toward strategic, patient-centered approaches.

    Key Highlights:

    • High Burden, High Priority: Pressure ulcers cause substantial patient distress and healthcare costs, underscoring the need for practices aligned with their varied impacts.
    • Need for Strategic Action: Authors advocate for multidisciplinary collaboration, outcome measurement, and integrating prevention efforts into routine care pathways.
    • Education & Engagement: Highlighted studies show that patient and family education—including interactive tools like web-based games—can increase awareness, responsibility, and empathy in prevention efforts.
    • Data-Informed Planning: Use of risk assessment tools, financial impact tracking, and evaluation of preventative versus treatment costs can help prioritize effective interventions.
    • Dynamic Guidelines Still Essential: As evidence evolves, expert-driven and living clinical guidelines remain foundational for adapting strategies across care settings.

    The editorial urges healthcare systems to view pressure ulcers through a strategic lens—driven by burden, guided by data, and supported by education—ensuring prevention and therapy efforts are patient-focused and outcomes-oriented.

    Based on Grešš Halász & Pokorná, “Advancing pressure ulcer prevention and therapy – from clinical burden to strategic priorities,” *Journal of Wound Management*, Volume 26, Issue 2, July 2025.

    Keywords: pressure ulcer prevention, clinical burden, patient education, risk assessment, data-informed care

    Read the full editorial on Journal of Wound Management

    User experiences of patients’ relatives with a computer game about pressure ulcer prevention

    User Experiences with a Pressure Ulcer Prevention Game: A Qualitative Study

    A June 2025 descriptive qualitative study published in *Journal of Wound Management* explores user experiences of a computer-based pressure ulcer prevention game—designed for patients and relatives to build awareness, improve self-care, and reduce caregiver burden.

    Key Highlights:

    • Engaging Format: The interactive game uses real-world scenarios to teach posture shifts, cushion selection, skin inspection, and risk factors in a narrative-based format.
    • Positive Reception: Players described the game as enjoyable, educational, and easy to navigate—reporting improved confidence in identifying risk factors and prevention strategies.
    • Emotional Impact: Users appreciated the immersive storytelling that fostered empathy and motivation, with some citing a greater sense of responsibility for loved ones’ care.
    • Areas for Improvement: Participants suggested enhancements such as adaptive difficulty levels, more personalized scenarios, multilingual support, and mobile access to increase reach.
    • Caregiver Benefit: Family members noted that shared gameplay created meaningful discussions about pressure ulcer prevention and even empowered them to participate in repositioning routines more confidently.

    This study supports the role of gamified digital tools in patient and caregiver education, offering an engaging way to improve preventative behavior and promote collaborative care efforts.

    Based on Nielsen & Krabbe Sørensen, “User experiences of a computer game about pressure ulcer prevention: descriptive qualitative study,” *Journal of Wound Management*, Volume 26, Issue 2—June 2025.

    Keywords: pressure ulcer game, patient education, caregiver engagement, gamification, qualitative study

    Read the full study on Journal of Wound Management

    Thermal Imaging Predicts Healing in Diabetic Foot and Venous Leg Ulcers

    Thermal Imaging Predicts Healing in Diabetic Foot and Venous Leg Ulcers

    Recent research highlights the growing role of thermal imaging—combined with advanced analytics—as a non-contact tool to predict healing trajectories in diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), offering promise for early intervention in home and clinical settings.

    Key Insights:

    • Early Identification in DFUs: A pilot study from RMIT University, University of Melbourne, and Austin Health showed that changes in the isothermal area of new DFUs measured by thermal imaging can predict healing status at week 4—potentially allowing clinicians to identify non-healing wounds earlier than traditional methods.
    • Non-Contact Home Monitoring: For VLUs, thermal texture analysis—focusing on changes in pixel patterns over two weeks—was better at distinguishing between healed and unhealed wounds by week 12 than conventional area-based thermal measurements, and didn’t require strict imaging conditions like temperature or angle control.
    • Benefits Over Standard Imaging: Unlike RGB photography or planimetry—which need consistent conditions and physical contact—thermal texture methods are more resilient to environmental variations and avoid infection risks, making them suitable for remote patient monitoring.
    • AI & Future Direction: Advances in AI-powered thermal platforms may enhance risk prediction and preventive care. Early alerts based on temperature or texture shifts can enable tailored interventions, reducing reliance on in-person assessments.

    In sum, texture-focused thermal imaging offers a fast, objective, remote-friendly method to flag wounds at risk of delayed healing—potentially transforming wound surveillance, especially for vulnerable patients in home care settings.

    Keywords:
    thermal imaging,
    diabetic foot ulcer,
    venous leg ulcer,
    non-contact monitoring,
    AI wound assessment

    Read the full article on Wound Care Advisor

    Management of an open crush fracture to the foot from a lawnmower injury: A case report

    Management of an Open Crush Fracture to the Foot from a Lawnmower Injury: Case Report

    This case report from *The Foot & Ankle Online Journal* (December 2020) details the clinical journey of a patient sustaining a high-energy open crush fracture to the mid- and forefoot—caused by a lawnmower. The report highlights key steps in surgical, infection-control, and rehabilitation management within an evidence-based framework.

    Case Overview:

    • Injury Description: The patient presented with an open fracture involving multiple metatarsals and cuneiforms, with accompanying soft-tissue loss and heel pad damage—characteristic of high-energy lawnmower trauma.
    • Initial Management Steps: Following Advanced Trauma Life Support principles, the patient underwent emergent irrigation and debridement, broad-spectrum intravenous antibiotics within one hour, tetanus prophylaxis, and limb stabilization with Kirschner-wires and external fixation.
    • Surgical Reconstruction: Multiple staged procedures addressed wound cleaning, fracture alignment, and repair of soft tissue avulsions, using a combination of hardware and meticulous technique to preserve tissue viability and prevent infection.
    • Infection Prevention Strategy: Aggressive decontamination, serial debridement, and appropriate antimicrobial coverage for both anaerobic and aerobic pathogens—including Pseudomonas and Staph aureus—were employed to reduce osteomyelitis risk.
    • Rehabilitation Approach: A structured physiotherapy program was initiated early, focusing on range-of-motion, strengthening, edema control, and gradual weight-bearing to restore function and reduce stiffness.

    Clinical Takeaways:

    • High-risk open crush injuries require immediate, protocol-driven intervention to minimize complications like infection and non-union.
    • Staged surgical treatment—balancing infection control, mechanical stability, and soft tissue preservation—is essential for optimal outcomes.
    • Early rehabilitation plays a key role in functional recovery and reducing long-term morbidity.

    This illustrative case underscores the critical value of a multidisciplinary, evidence-based approach when managing severe foot trauma from lawnmower injuries.

    Keywords: open fracture, crush injury, lawnmower trauma, debridement, Kirschner‑wire fixation, antibiotic prophylaxis, physiotherapy rehabilitation

    Read the full case report on FAOJ

    Associations Between Diabetes Mellitus and Neurodegenerative Diseases

    Exploring the Link Between Diabetes and Neurodegenerative Diseases

    A growing body of research reveals a strong association between diabetes mellitus (DM)—particularly type 1 and type 2—and major neurodegenerative disorders. This review explores how insulin resistance, hyperglycemia, and impaired glucose metabolism may contribute to the pathogenesis of diseases such as Alzheimer’s, Parkinson’s, Huntington’s, and ALS.

    Key Highlights:

    • Widespread Impact: Type 2 diabetes and cognitive impairment are the most common chronic conditions in adults over 60. The global burden of both is rising rapidly, with DM prevalence projected to reach 783 million by 2045, and dementia cases exceeding 150 million by 2050.
    • Shared Mechanisms: Suggested mechanisms linking DM and neurodegenerative diseases include impaired insulin signaling, mitochondrial dysfunction, oxidative stress, glial cell dysregulation, and chronic inflammation—all of which may accelerate neuronal damage and cognitive decline.
    • Alzheimer’s Disease: T2DM patients show up to a 65% increased risk of developing Alzheimer’s. Insulin-treated individuals face an even greater risk (up to 4.3-fold). Hyperglycemia may exacerbate memory deterioration by damaging pyramidal neurons in key hippocampal areas.
    • Parkinson’s & Huntington’s: Both diseases involve progressive neuronal loss in regions highly sensitive to metabolic dysfunction. For example, dopaminergic neuron degeneration in Parkinson’s is thought to be influenced by insulin resistance and impaired glucose uptake.
    • Vascular Dementia & ALS: Studies show diabetic individuals have elevated risks of vascular dementia, with abnormal insulin levels contributing to cerebrovascular damage. ALS and other rare NDs also share metabolic links with diabetes in emerging research.

    Although mechanisms remain under investigation, it is increasingly clear that poor glycemic control and insulin dysfunction not only harm peripheral organs but may also accelerate brain aging and neurodegeneration. Further research could lead to shared treatment pathways and early interventions targeting both metabolic and cognitive health.

    Keywords:
    diabetes mellitus,
    type 1 diabetes,
    type 2 diabetes,
    Alzheimer’s disease,
    Parkinson’s disease,
    Huntington’s disease,
    ALS,
    neurodegenerative disease,
    insulin resistance,
    cognitive decline

    Read the full article on PubMed Central

    Diagnosis & Management of Diabetic Foot Complications

    Diagnosis & Management of Diabetic Foot Complications

    Originally published in a 2018 American Diabetes Association compendium, this review by Andrew J.M. Boulton, David G. Armstrong, and Robert S. Kirsner offers a comprehensive roadmap for addressing diabetic foot complications, with a focus on prevention, timely diagnosis, and limb preservation.

    Key Insights:

    • Prevalence & Burden: Diabetic foot ulcers (DFUs) affect up to 34% of people with diabetes in their lifetime. DFUs are the leading cause of lower-extremity amputations, many of which are preventable with early intervention.
    • Risk Factors: Peripheral neuropathy, peripheral artery disease, foot deformity, infection, and poor glycemic control significantly increase DFU and amputation risk.
    • Screening & Diagnosis: The authors emphasize regular foot exams, monofilament testing, vascular assessment, and the use of classification tools like the Wagner or University of Texas systems.
    • Management Strategies: Effective treatment includes offloading, sharp debridement, infection control, vascular evaluation, and referral to a multidisciplinary team when necessary.
    • Advanced Therapies: Adjunctive approaches include growth factors, skin substitutes, stem cell-based products, hyperbaric oxygen therapy, and negative pressure wound therapy—especially for non-healing or complex wounds.
    • Charcot Neuroarthropathy: Often underdiagnosed, Charcot foot requires early recognition and prolonged offloading to prevent collapse and ulceration.

    This ADA compendium remains a foundational resource for clinicians working to reduce DFU incidence and preserve limbs through coordinated, evidence-based care.

    Keywords:
    Andrew J.M. Boulton,
    David G. Armstrong,
    Robert S. Kirsner,
    diabetic foot ulcer,
    Charcot foot,
    offloading,
    hyperbaric oxygen therapy,
    negative pressure wound therapy,
    limb preservation

    Read the full article on ResearchGate

    Wound Progression and Healing in Patients With Moisture-Associated Skin Damage

    Wound Progression and Healing in Patients With Moisture-Associated Skin Damage

    A retrospective observational study published in the Journal of Wound, Ostomy, and Continence Nursing (July 2025) examined the relationship between moisture-associated skin damage (MASD) and wound healing outcomes. The research team, led by Laura R. Sibbald, investigated how MASD affects wound progression in patients receiving care at a Canadian community hospital system.

    Study Highlights:

    • Patient Cohort: The study analyzed 236 patients with MASD and 236 matched controls without MASD using electronic medical records.
    • Wound Progression: Patients with MASD were more likely to experience delayed wound healing and wound deterioration compared to those without MASD.
    • Contributing Factors: Increased moisture from incontinence, sweat, and wound exudate was associated with worsening skin integrity and inflammation, leading to prolonged healing timelines.
    • Clinical Implications: The findings highlight the importance of early identification and management of MASD as a risk factor for poor wound healing outcomes in vulnerable populations.

    Conclusion: MASD significantly impairs wound healing and increases the risk of wound progression. Clinical strategies focused on moisture control and barrier protection are essential to prevent complications and support recovery.

    Keywords: Laura R. Sibbald, moisture-associated skin damage, wound healing, wound progression, MASD, skin integrity

    Read the full study in JWOCN

    Surgical Options for Advanced Pressure Injuries

    Surgical Options for Advanced Pressure Injuries

    The August 2025 issue of Advances in Skin & Wound Care features an in-depth review on surgical approaches to managing advanced pressure injuries. The article examines current indications, patient selection, and procedural strategies for debridement, tissue reconstruction, and long-term wound closure in patients with stage 3 or stage 4 pressure injuries.

    Key Points Covered:

    • Indications for Surgery: Persistent non-healing wounds despite optimal conservative care, exposure of bone or tendon, and recurrent infections.
    • Surgical Techniques: Sharp debridement, negative pressure wound therapy with instillation, and flap-based reconstructions such as myocutaneous and fasciocutaneous flaps.
    • Pre-Op Considerations: Nutritional status, infection control, patient mobility, and psychosocial support all impact surgical eligibility and outcomes.
    • Outcomes and Challenges: Surgical success rates are improved with multidisciplinary care and patient adherence to post-op offloading and follow-up protocols. However, recurrence remains a risk in high-pressure zones like the sacrum and ischial areas.

    Clinical Relevance: Surgical intervention is not appropriate for all patients with pressure injuries, but for carefully selected individuals, it can offer faster healing and reduced infection risk. The article advocates for collaborative care planning between surgeons, wound care nurses, physical therapists, and nutritionists.

    Keywords: pressure injuries, surgical debridement, flap reconstruction, wound surgery, negative pressure wound therapy, multidisciplinary wound care

    Read the full article in Advances in Skin & Wound Care

    What is the Diabetes Capital of the World?

    What Is the Diabetes Capital of the World?

    Summary: This Diabetes in Control post explores the oft-used label “diabetes capital of the world,” a moniker commonly applied to India due to its exceptionally high absolute number of adults living with diabetes. The piece touches on why the burden is so large—genetic susceptibility to insulin resistance, rapid urbanization, dietary shifts, and reduced physical activity—and why this matters for public health and complication prevention.

    Key Points:

    • Why the label sticks: In global comparisons, India consistently ranks at or near the top for total diabetes cases. Concentrated urban growth and lifestyle changes have accelerated incidence and prevalence.
    • Risk drivers and disparities: Central obesity at relatively lower BMI, high-carbohydrate dietary patterns, and physical inactivity contribute to risk. Urban areas typically show higher prevalence than rural regions.
    • Implications for wound care: A higher diabetes burden translates into more neuropathy, PAD, and foot ulcers—raising the stakes for prevention, screening (e.g., annual foot exams), and early intervention.
    • What helps: Population-level strategies—nutrition counseling, structured physical activity, tobacco cessation, glycemic and blood pressure control—combined with primary-care screening and multidisciplinary limb-preservation programs.

    Read the post on Diabetes in Control

    Keywords:
    India,
    diabetes prevalence,
    type 2 diabetes,
    insulin resistance,
    urbanization and health,
    diabetic foot complications,
    prevention and screening,
    lifestyle interventions

    Artificial Intelligence in Wound Care: Help or Hindrance?

    Artificial Intelligence in Wound Care: Help or Hindrance?

    Summary: An editorial published by Wounds International examines the emerging role of artificial intelligence (AI) in wound care, weighing its potential benefits in clinical decision-making, risk prediction, and workflow efficiency against challenges such as bias, data quality, and the risk of overreliance on algorithms.

    Key Highlights:

    • AI technologies show promise in wound assessment, image analysis, and early detection of complications.
    • Concerns remain regarding data security, accuracy across diverse patient populations, and clinician accountability.
    • The authors emphasize that AI should complement—not replace—clinician expertise, maintaining patient-centered care as the core priority.
    • Successful adoption will require robust validation, ethical oversight, and integration into multidisciplinary workflows.

    Read the full article in Wounds International

    Keywords:
    artificial intelligence,
    wound care technology,
    digital health,
    clinical decision support,
    ethics

    Balancing Costs, Access, and Innovation in Wound Healing: A Logical Approach?

    Balancing Costs, Access, and Innovation in Wound Healing: A Logical Approach? #CAMPs #ActAgainstAmputation

    Summary: In a critical commentary on the DF Blog at DiabeticFootOnline, David G. Armstrong reflects on recent CMS reform proposals targeting reimbursement for cellular and acellular products (CAMPs). Citing new research led by Bill Tettelbach (published in the Journal of Wound Care), the piece argues that blunt reimbursement cuts risk increasing inequity, threatening innovation, and harming vulnerable patients.

    Key Highlights:

    • In 2023, just 3% of nonfacility providers accounted for nearly 64% of Medicare’s CAMP spending, with average per-patient costs dramatically higher than typical providers.
    • While aiming to limit waste and fraud, flat-rate reimbursement models risk penalizing ethical, resource-limited, or rural providers—limiting patient access to life-saving therapies.
    • Dramatic reductions in CAMP availability could lead to higher downstream costs through more amputations, hospitalizations, and poorer outcomes.
    • Policy proposals include smarter, AI-assisted oversight, targeted intervention on high-use providers, equitable reimbursement tied to clinical complexity, and sustained support for innovation and vulnerable care settings.

    Read the full post on DF Blog (DiabeticFootOnline)

    Keywords:
    CMS reform,
    CAMPs,
    wound healing innovation,
    health equity,
    David G. Armstrong,
    Bill Tettelbach

    Preventing Surgical Wound Infections: Key Nursing Interventions

    Preventing Surgical Wound Infections: Key Nursing Interventions

    Summary: A recent blog post on WoundSource highlights essential nursing interventions to prevent surgical incision infections, emphasizing early attention, meticulous hygiene, and post-operative wound care.

    Key Highlights:

    • Hands and forearms should be washed thoroughly with antiseptic soap and a nail brush for at least five minutes before contact with the incision.
    • Strict hand hygiene and aseptic technique are critical in minimizing the risk of introducing bacteria during dressing changes and wound care.
    • Effective nursing strategies include early identification of high-risk patients, ongoing inspection for subtle signs of infection, and prompt intervention when abnormalities arise.
    • Continuity of care—especially during handoffs between surgical and post-op teams—ensures consistent infection prevention practices.

    Read the full post on WoundSource

    Keywords:
    surgical wound infections,
    nursing interventions,
    hand hygiene,
    aseptic technique

    From Healing to Remission: A Clinician’s Guide to Managing Diabetic Foot Ulcers

    From Healing to Remission: A Clinician’s Guide to Managing Diabetic Foot Ulcers

    Summary: A new article on Medscape reframes diabetic foot ulcer (DFU) care by encouraging clinicians to view a healed ulcer not as an endpoint, but as a remission state—one that demands ongoing prevention, monitoring, and patient education. The piece outlines proactive strategies to reduce ulcer recurrence, preserve limb function, and sustain long-term patient engagement.

    Key Highlights:

    • Language shift: Using the term “in remission” instead of “healed” helps patients stay aware that DFU is a chronic condition with high risk of recurrence.
    • Structured limb-preservation plans: Follow-ups every 1-3 months in the first year post-healing, plus risk-based intervals afterward, with regular vascular assessments especially up through 18 months post-closure.
    • Prevention tools: Thermometry, remote monitoring of temperature/exudate/pressure/moisture, and protective footwear become central components of follow-up care.
    • Self-management: Patients (or caregivers) should perform daily inspections, recognizing early signs, even in the absence of overt sores; lifestyle moderators like glucose, lipids, and BP control also critical.
    • Psychosocial support: Screening for depression, social isolation, and other mental health or socio-economic factors that otherwise undermine preventive behaviors and healing maintenance.
    • Implementation challenges: Shifting to a remission model requires clinic protocol changes, multidisciplinary coordination, and policies that recognize the long-term burden of DFUs and CLTI (chronic limb threatening ischemia).

    Read the full article on Medscape

    Keywords:
    diabetic foot ulcer,
    remission model,
    limb preservation plan,
    thermometry,
    patient self-care,
    psychosocial support

    Determinants of Delayed Wound Healing in Postoperative Patients: Insights From a Prospective Study

    Determinants of Delayed Wound Healing in Postoperative Patients: Insights From a Prospective Study

    Summary: A prospective study published in Wounds investigated the risk factors associated with **delayed wound healing (DWH)** in postoperative patients at a tertiary hospital in South India. The research identified multiple preoperative, intraoperative, and postoperative determinants that clinicians can target to improve outcomes and reduce complications.

    Key Highlights:

    • Older age, diabetes, anemia, and malnutrition were strong preoperative predictors of DWH.
    • Longer surgical duration and emergency procedures were linked to poorer healing trajectories.
    • Postoperative infection and poor wound care compliance significantly increased the likelihood of delay.
    • Multivariate analysis underscored diabetes and wound infection as the most powerful predictors.
    • Authors recommend integrated preoperative optimization, meticulous surgical technique, and rigorous postoperative monitoring to mitigate risk.

    Read the full study in Wounds

    Keywords:
    delayed wound healing,
    postoperative patients,
    wound infection,
    South India study

    Silent and Sinister: High Prevalence of Silent, Severe Coronary Ischemia in Patients with Diabetic Foot Ulcers

    Silent and Sinister: High Prevalence of Silent, Severe Coronary Ischemia in Patients with Diabetic Foot Ulcers

    Summary: A recent study published in *Journal of Vascular Surgery* (Monahan et al., 2025) found that a large portion of patients with diabetic foot ulcers (DFUs), even without prior known coronary artery disease or symptoms, have **silent but severe coronary ischemia** detectable on advanced imaging. This suggests underrecognized cardiovascular risk in the DFU population and possible need to integrate cardiac screening into comprehensive care.

    Key Highlights:

    • Among selected DFU patients who underwent coronary CT angiography (cCTA), more than half showed functional evidence of severe coronary disease via CT-derived fractional flow reserve (FFRct ≤ 0.75).
    • Some patients required coronary intervention following catheterization despite no history of cardiac disease or symptoms.
    • Suggests that DFU should be treated not only as a local wound issue but as a marker of systemic vascular disease.

    Read the full article on DiabeticFootOnline

    Keywords:
    diabetic foot ulcer,
    coronary ischemia,
    silent ischemia,
    CT-angiography,
    Monahan et al.,
    vascular risk

    Association of Inflammation and Nutrition-Based Indicators With Diabetic Foot Ulcers

    Association of Inflammation and Nutrition-Based Indicators With Diabetic Foot Ulcers

    Summary: A new combined cross-sectional and retrospective study from China (Hua Chen, Yu Zhou, Jiezhi Dai) examines multiple inflammation and nutrition biomarkers and their association with prevalence of diabetic foot ulcers (DFUs). Using a large US dataset (NHANES) plus a clinical retrospective arm, the team finds strong links between DFU presence and indicators such as neutrophil-albumin, monocyte-albumin, red cell distribution width-albumin, HALP, and PNI.

    Key Highlights:

    • Data from ~31,126 participants in NHANES (1999–2004) and clinical data comparing DFU vs non-DFU patients.
    • Higher tertiles of NAR, MAR, and RAR (ratios combining inflammatory cells or red-cell width with albumin) correlate with increased odds of DFU.
    • Higher HALP (hemoglobin-albumin-lymphocyte-platelet) and Prognostic Nutritional Index (PNI) are inversely correlated with DFU – i.e. better nutrition/inflammation status associated with lower DFU risk.
    • Non-linear relationships found, especially for RAR, showing risk climbs sharply at higher levels.

    Read the full article in Frontiers in Endocrinology

    Keywords:
    inflammation biomarkers,
    nutrition indices,
    diabetic foot ulcer prevalence,
    NHANES,
    Hua Chen,
    Yu Zhou,
    Jiezhi Dai

    Machine Learning to Diagnose Complications of Diabetes

    Machine Learning to Diagnose Complications of Diabetes

    Summary: A recent manuscript in Journal of Diabetes Science & Technology (2025) from Scheideman et al. surveys how machine learning (ML) is being used to detect and predict complications of diabetes—including foot ulcers, retinopathy, nephropathy, autonomic dysfunction, and neuropathy. The review highlights both existing successes and current limitations in bringing AI/ML into clinical workflows.

    Key Highlights:

    • Deep learning models are already in use for retinopathy screening through fundus images; future systems are pushing toward multimodal risk prediction and smartphone-based deployment.
    • For diabetic foot ulcers, thermal imaging combined with convolutional neural networks is showing promise in earlier risk detection than conventional clinical examination.
    • Wearables, ECG, and corneal imaging are being explored to detect peripheral and autonomic neuropathy earlier.
    • Challenges remain: dataset diversity, labeling quality, external validation, explainability, and seamless integration into clinical care.

    Read the full review on DiabeticFootOnline

    Keywords:
    machine learning,
    diabetic foot ulcer,
    retinopathy,
    nephropathy,
    wearable sensors,
    thermal imaging,
    Scheideman,
    David G. Armstrong

    Systematic Review: Polyhexanide vs Other Dressings — Safety and Efficacy in Various Wound Types

    Systematic Review: Polyhexanide vs Other Dressings — Safety and Efficacy in Various Wound Types

    Summary: A forthcoming systematic review & meta-analysis (ahead of print) in *Wound Practice and Research* compared polyhexanide (a biguanide antiseptic) dressings against other dressing types across multiple wound types. Results suggest polyhexanide dressings are generally safe, with comparable or improved healing rates, and with lower local irritation in some cases.

    Key Highlights:

    • Polyhexanide showed better or equal effectiveness for healing across diabetic, venous, pressure, and mixed aetiology wounds compared to wound dressings without polyhexanide.
    • Safety profile good: less cytotoxicity, lower risk of pain or stinging in patients, some favorable tolerability.
    • Meta-analysis indicates that polyhexanide may help particularly in wounds with moderate bioburden or infection risk.
    • Limitations: heterogeneity of wound types, variations in application frequency and adjunct therapies; many studies still small sample size.

    Read ahead-of-print meta-analysis in *Wound Practice & Research*

    Keywords:
    polyhexanide dressings,
    antiseptic dressings,
    wound safety,
    wound healing comparison

    Evidence Review & Consensus: Dialkylcarbamoyl Chloride (DACC)–Coated Wound Dressings

    Evidence Review & Consensus: Dialkylcarbamoyl Chloride (DACC)–Coated Wound Dressings

    Summary: A Wounds International expert consensus document evaluates the clinical role of DACC-coated wound dressings, which bind microorganisms through hydrophobic interactions rather than releasing active antimicrobial agents. This mode of action reduces resistance risk and preserves host tissue, offering a unique option for wounds at risk of infection.

    Key Highlights:

    • Mechanism: DACC attracts and irreversibly binds hydrophobic microbes, physically removing them when the dressing is changed, rather than killing them chemically.
    • Evidence base: Systematic reviews and clinical studies support effectiveness in reducing bioburden and promoting healing in diabetic foot ulcers, pressure ulcers, venous leg ulcers, surgical wounds, and burns.
    • Safety: No cytotoxicity; suitable for fragile tissue. Dressings are biocompatible and safe across a wide range of wound types and patient populations.
    • Consensus: The panel positions DACC dressings as a valuable first-line tool for infection prevention and adjunctive therapy in wounds with high microbial burden or delayed healing.
    • Health economics: By reducing infection rates and antibiotic use, DACC dressings may contribute to lower overall treatment costs and improved antimicrobial stewardship.

    Read the full consensus document on Wounds International

    Keywords:
    DACC wound dressing,
    antimicrobial stewardship,
    bioburden control,
    diabetic foot ulcer,
    venous leg ulcer,
    pressure ulcer

    Prevention and Management of Skin Tears in Aged Skin

    Prevention and Management of Skin Tears in Aged Skin

    Summary: A Wounds International “Made Easy” article authored by Karen Ousey, Corey Heerschap, Debra Thayer, and Emmy Nokaneng outlines updated ISTAP best practice guidelines for preventing and managing skin tears. These traumatic wounds are increasingly common in aged populations and require gentle, evidence-based care strategies.

    Key Highlights:

    • Risk assessment: Updated ISTAP tools help identify patients at high risk, particularly older adults with fragile skin and comorbidities.
    • Prevention: Regular moisturisation, use of pH-balanced cleansers, avoidance of adhesives, and caregiver education reduce incidence.
    • Management: When skin tears occur, preserve and reposition flaps, avoid traumatic dressings, and minimize disturbance during healing.
    • Dressing selection: Silicone and non-adherent dressings support “undisturbed healing” and can lower costs and complications.

    Read the full article on Wounds International

    Keywords:
    skin tears,
    aged skin,
    ISTAP,
    Karen Ousey,
    wound prevention

    Embracing the New Braden Scale II

    Embracing the New Braden Scale II

    Summary: Pressure injuries remain a major concern in healthcare, especially among patients with limited mobility. The original Braden Scale, developed in the 1980s, has long been used to identify patients at risk. The newly released Braden Scale II addresses limitations of the original version, offering enhanced accuracy, expanded assessment criteria, and better alignment with evidence-based practice.

    Key Highlights:

    • Expanded components: In addition to sensory perception, moisture, activity, mobility, nutrition, and friction/shear, the Braden Scale II introduces a subcategory in the activity component: “ability to change and control body position.”
    • Updated scoring: Criteria for each category have been reevaluated to align with current clinical knowledge and provide a more accurate risk assessment.
    • Sensory perception: Expanded to include cognitive abilities, recognizing how impairments affect a patient’s ability to perceive or respond to discomfort.
    • Clinical benefits: The Braden Scale II improves precision, ensures comprehensive evaluation, and enhances prevention strategies against pressure injuries.
    • Hospital implementation: Successful use requires staff training, integration into electronic health records, and a collaborative approach across disciplines.
    • Education focus: Hospitals should prioritize ongoing education to ensure consistency in applying the Braden Scale II and interpreting scores.

    Read the full article on Wound Care RN

    Keywords:
    Braden Scale,
    Braden Scale II,
    pressure injury prevention,
    wound assessment,
    hospital implementation,
    patient outcomes

    Timing of Rehabilitation and Pressure Ulcers Requiring Treatment During Acute Hospitalization in …

    Timing of Rehabilitation and Pressure Ulcers Requiring Treatment During Acute Hospitalization in Patients With Cervical Spinal Cord Injuries

    Summary: A retrospective cohort study from Japan analyzed whether initiating rehabilitation within two days of surgery reduced pressure ulcer risk among patients with acute cervical spinal cord injuries. The research found that early rehabilitation was linked to shorter hospital stays, but did not significantly decrease the incidence of pressure ulcers requiring treatment.

    Key Highlights:

    • Study population: 5,162 patients with acute cervical spinal cord injury who underwent spinal surgery within three days of admission (2010–2022).
    • Rehabilitation timing: Early rehabilitation began within two days post-surgery; non-early rehabilitation started three or more days after surgery.
    • Pressure ulcer outcomes: Early rehabilitation showed no significant reduction in pressure ulcers requiring treatment after statistical adjustment.
    • Hospital stay: Patients receiving early rehabilitation had hospital stays shortened by about 7.4 days compared to the non-early group.
    • Implications: Early rehabilitation may improve hospital efficiency but does not appear to directly impact pressure ulcer risk in this patient population.

    Read the full article in Spinal Cord / Nature

    Keywords:
    spinal cord injury,
    pressure ulcers,
    rehabilitation timing,
    acute hospitalization,
    length of stay

    8 Dermatology Headlines You Missed in September 2025

    8 Dermatology Headlines You Missed in September 2025

    Summary: This monthly roundup from HCPLive compiles eight notable dermatology developments from September 2025. Topics include new FDA approvals (e.g., remibrutinib for chronic spontaneous urticaria, guselkumab for pediatric psoriasis, ruxolitinib cream in children), label expansions for therapies in epidermolysis bullosa, and research linking maternal diet and biologic therapy to dermatologic outcomes.

    Key Highlights:

    • FDA approved **remibrutinib** for chronic spontaneous urticaria, offering a new oral option.
    • **Guselkumab (Tremfya)** received pediatric approval for plaque psoriasis in children age 6 and above.
    • **Ruxolitinib cream** was approved for atopic dermatitis in children aged 2-11.
    • **Beremagene geperpavec-svdt (Vyjuvek)** label updated to allow use from birth in dystrophic epidermolysis bullosa.
    • Studies showed **maternal dietary diversity** is associated with reduced childhood eczema risk.
    • A report pointed to **biologic therapy in psoriasis** correlating with lower malignancy risk.
    • **Rocatinlimab** trials showed promising early results for treating atopic dermatitis.
    • **Narrowband UVB phototherapy** was found effective for psoriasis in skin of color when other therapies weren’t tolerated.

    Read the full article on HCPLive

    Keywords:
    Tim Smith,
    Abigail Brooks,
    dermatology headlines,
    FDA approvals dermatology,
    skin disease research

    The impact of diabetes on the outcomes of lower extremity arterial disease in patients ….

    The impact of diabetes on the outcomes of lower extremity arterial disease in patients with vascular surgical interventions in Kosovo

    Summary: This observational study in Kosovo evaluated how type 2 diabetes affects outcomes in patients undergoing vascular surgery for lower extremity arterial disease (LEAD). Among patients treated between November 2023 and April 2024, the study found high amputation risk, significant complication rates, and identified clinical factors associated with poorer outcomes.

    Key Highlights:

    • Patient demographics: Most were between ages 62–71; ~63% male; nearly all (96.3%) were managed with insulin.
    • Adverse events: Toe gangrene requiring amputation occurred in ~25.9% of cases; arterial thrombosis was a common preoperative complication.
    • Hospital stay and treatment: Typical duration was 6–10 days; combined antiplatelet, antidiabetic, and antibiotic therapy used in ~81.5% of patients.
    • Clinical implications: Diabetes markedly worsens surgical outcomes for LEAD, underscoring the need for aggressive risk factor control, tailored perioperative management, and close follow-up.

    Read the full article in the Italian Journal of Medicine

    Keywords:
    Dion Haliti,
    Dea Haliti,
    Laura Leci Tahiri,
    Nora Shabani-Behrami,
    Elena Hajdari,
    Naim Haliti,
    Ragip Shabani,
    Fehim Haliti,
    Qenan Maxhuni,
    Rrahman Ferizi,
    type 2 diabetes mellitus,
    lower extremity arterial disease,
    vascular surgery outcomes

    Development and validation of a nomogram for predicting moderate-to-severe diabetic foot ulcers in type 2 diabetes

    Development and validation of a nomogram for predicting moderate-to-severe diabetic foot ulcers in type 2 diabetes

    Summary: This study developed and validated a nomogram model to predict the risk of moderate to severe diabetic foot ulcers (DFUs) in patients with type 2 diabetes. Using retrospective data from 499 hospitalized patients, the authors identified 9 independent predictors and demonstrated that their model had excellent discrimination, calibration, and clinical utility.

    Key Highlights:

    • Study cohort: 499 patients with type 2 diabetes hospitalized between January 2021 and December 2023.
    • Predictors included: Diabetic kidney disease (DKD), diabetic peripheral neuropathy (DPN), diabetic retinopathy (DR), peripheral angiopathy (PAD), D-dimer, K-time, total cholesterol (TC), LDL-C, and HDL-C.
    • Model performance: The nomogram achieved an AUC of 0.977 (95% CI 0.965–0.989) in the training set and 0.977 (95% CI 0.958–0.996) in the validation set.
    • Calibration & validation: Calibration curves showed strong agreement between predicted and observed outcomes. Decision curve and clinical impact analyses supported its clinical usefulness.
    • Novel biomarkers: Inclusion of coagulation markers (K-time and D-dimer) with microvascular and lipid metrics enhances predictive capability.
    • Implications: The nomogram can guide early identification of high-risk patients, enabling preventive strategies to reduce ulcer progression and limb loss.

    Read the full article in Frontiers in Endocrinology

    Keywords:
    Jinying Zhang,
    Jing Lin,
    Lizhen Wu,
    Jiayu Lin,
    nomogram,
    diabetic foot ulcer prediction,
    type 2 diabetes,
    coagulation markers,
    DKD,
    DPN,
    PAD

    Clinical Evidence and Cost-Effectiveness: Advanced Cellular Tissue Products for Diabetic Foot Ulcers



    Clinical Evidence and Cost-Effectiveness: Advanced Cellular Tissue Products for Diabetic Foot Ulcers

    Summary: This article provides a comprehensive review of the clinical evidence and cost-effectiveness of advanced cellular/tissue products (CTPs) for diabetic foot ulcers (DFUs), focusing on FDA-approved options like Apligraf and Dermagraft. It demonstrates their superiority over standard care in achieving higher healing rates, shorter closure times, and reduced complications such as infections and amputations, while delivering significant long-term cost savings despite initial expenses. The discussion underscores the urgent need for early intervention in DFU management amid rising diabetes prevalence.

    Key Highlights:

    • CTPs like Apligraf (human skin equivalent) and Dermagraft (dermal skin substitute) promote faster wound closure and lower amputation risks in chronic DFUs unresponsive to standard care.
    • Randomized trials show up to twice the healing rates with CTPs, supported by real-world data and meta-analyses confirming reduced hospitalization and infection risks.
    • Economic analyses reveal per-patient savings of $5,253–$6,991 over 18 months, offsetting upfront costs through fewer emergency visits and inpatient stays.
    • Challenges include high DFU recurrence (50% within 1 year) and the need for prompt adjunctive therapies to prevent 1 in 6 cases from leading to amputation.

    Read full article

    Keywords:
    diabetic foot ulcers,
    cellular tissue products,
    Apligraf,
    Dermagraft,
    cost-effective wound care

    Factors Influencing Dressing Choice in Wound Care: A Discussion


    Factors Influencing Dressing Choice in Wound Care: A Discussion

    Summary: This discussion outlines how wound type, exudate level, infection risk, and cost considerations guide dressing selection. It stresses evidence-based choice, patient comfort, and regular reassessment to optimize healing outcomes.

    Key Highlights:

    • Explains how exudate and infection risk drive dressing selection.
    • Highlights cost and patient comfort as clinical factors.
    • Encourages evidence-based individualized care.
    • Recommends ongoing evaluation during wound healing.

    Read full article

    Keywords:
    dressing choice,
    wound assessment,
    clinical decision,
    wound management

    Negative Pressure Wound Therapy for Complicated Diabetic Foot Wounds



    Negative Pressure Wound Therapy for Complicated Diabetic Foot Wounds

    Summary: This retrospective case series assesses negative pressure wound therapy (NPWT) in 30 diabetic patients with complicated foot or lower limb infections over 15 years. Following initial debridement and antibiotics, NPWT at -125 mmHg for 7-12 days promoted granulation and healing in 80% of cases, preventing major amputations despite high-risk features like ischemia and polymicrobial infections (e.g., MRSA, E. coli). Five patients (16.6%) required major amputations, and one died. No associations were found with standard classifications (WIFI, IWGDF, TPI). A literature review supports NPWT as an adjunct for faster healing and reduced amputations in selected DFUs, though guidelines caution its use in active infections. The study highlights NPWT’s potential in real-world settings but calls for larger RCTs to confirm benefits.

    Key Highlights:

    • NPWT achieved limb preservation in 80% of high-risk diabetic wounds, with 20% fully healing via grafts or sutures.
    • Common pathogens like MRSA and E. coli were managed effectively post-debridement, reducing infection persistence.
    • Average NPWT duration was 9 days, with hospital stays of 25 days, underscoring its feasibility in clinical practice.
    • Challenges include guideline limitations for infected wounds and need for multidisciplinary approaches to optimize outcomes.
    • Literature shows NPWT halves amputation risks compared to standard care in some trials, supporting its innovative role.

    Read full article

    Keywords:
    diabetic foot ulcers,
    negative pressure wound therapy,
    wound healing innovations,
    diabetic wound infections,
    limb salvage in diabetes

    Choice of Primary Repair in Animal Bite Wounds: A Novel Management Strategy



    Choice of Primary Repair in Animal Bite Wounds: A Novel Management Strategy

    Summary: This article introduces a novel management strategy for animal bite wounds, primarily from dogs and cats, which pose significant risks especially to children due to potential infections from oral bacteria. Challenging the standard practice of surgical debridement followed by delayed primary closure, the study evaluates criteria for safe primary repair, demonstrating reduced infection rates, better cosmetic results, and shorter healing times in low-risk cases like facial bites with thorough irrigation and antibiotics.

    Key Highlights:

    • Animal bites often lead to polymicrobial infections; primary repair is feasible in clean, low-risk wounds after aggressive debridement and prophylactic antibiotics.
    • Facial bites in children benefit most from primary closure to prevent scarring and functional impairment.
    • Prospective evaluation shows infection rates under 2% with the novel protocol, compared to 5-10% in delayed closure.
    • Emphasizes multidisciplinary assessment including wound location, depth, and patient factors for decision-making.
    • Calls for updated guidelines to incorporate this strategy, reducing unnecessary delays in healing.

    Read full article

    Keywords:
    animal bite wounds,
    primary repair,
    delayed closure,
    wound infection prevention,
    pediatric wound management

    Harnessing Molecular Medicine to Accelerate Wound Healing



    Harnessing Molecular Medicine to Accelerate Wound Healing

    Full Press Release: TAICEND – advancing the science of wound healing to cut recovery time by more than half.

    KAOHSIUNG CITY, Taiwan, Oct. 17, 2025 /PRNewswire/ — TAICEND will present its five major wound healing product series at the 2025 MEDICA Fair in Germany, including the Postoperative Care Series, Acute & Chronic Wound Series, Pressure Relief Series, Skin Protection & Prevention Series, and the Trauma Series.

    With molecular medicine as the foundation of its R&D, TAICEND integrates cellular concepts into the wound healing process, providing in-depth insights into cellular activity at each stage of healing and mapping these mechanisms to product applications. This approach highlights the company’s commitment to delivering a complete and protocol-driven clinical value in wound care.

    In the Postoperative Care Series, TAICEND addresses the needs of patients recovering from procedures such as cesarean sections and orthopedic surgeries. The products help keep wounds clean, reduce the risk of infection, stabilize wound sites, alleviate pain, and minimize scar formation.

    The Acute & Chronic Wound Care Series targets difficult-to-heal wounds such as pressure ulcers. TAICEND’s standardized wound healing SOP has been clinically shown to accelerate healing speed by more than 50%, making it highly suitable for home healthcare and long-term care facilities.

    The Pressure Relief & Prevention Series is specifically designed to address skin injuries caused by medical devices or prolonged immobility. Common scenarios include facial pressure from BiPAP masks, skin damage from drainage tubes or nasogastric tubes, and localized pressure injuries in bedridden patients. This series provides effective solutions to redistribute pressure and minimize friction-related skin damage, offering a reliable preventive care option for patients.

    The Skin Protection & Prevention Series will feature a new product for Incontinence-Associated Dermatitis (IAD) prevention and care. With a simple two-step protocol, it provides an effective and convenient solution for managing skin health in elderly and bedridden patients.

    Within the Emergency & Trauma Series, TAICEND will unveil a range of products designed for emergency and battlefield applications, including emergency bandages, tourniquets, and chest seals. These products are engineered to provide rapid, life-saving interventions in critical injury scenarios, underscoring TAICEND’s dedication to delivering comprehensive wound care solutions—from clinical settings to frontline emergencies.

    We warmly invite you to visit the TAICEND booth at MEDICA 2025 in Germany, where you can explore more of our products and technologies with in-depth professional insights.

    Booth number: Hall6 #H66-1

    Join us on this journey of innovation in wound healing!

    Contact:

    Tsumin Huang

    +886 7 6955313

    401603@email4pr.com

    Cision

    View original content:https://www.prnewswire.com/news-releases/harnessing-molecular-medicine-to-accelerate-wound-healing-302586308.html

    SOURCE TAICEND TECHNOLOGY CO., LTD.

    Copyright 2025 PR Newswire

    Key Highlights:

    • TAICEND’s molecular medicine-driven products accelerate wound healing by over 50%, targeting postoperative, chronic, and trauma scenarios.
    • Postoperative Care Series reduces infection risk and scarring in surgical recovery.
    • Acute & Chronic Wound Series ideal for pressure ulcers in home and long-term care.
    • Pressure Relief Series prevents device-related injuries in immobile patients.
    • New IAD prevention product in Skin Protection Series simplifies elderly skin care.
    • Emergency & Trauma Series includes battlefield-ready tools like tourniquets and chest seals.

    Read full article

    Keywords:
    molecular medicine wound healing,
    postoperative wound care,
    chronic wound series,
    pressure ulcers,
    trauma series

    Breathable Revolution: Medical Non-Woven Tape Transforming Wound Care



    Breathable Revolution: Medical Non-Woven Tape Transforming Wound Care

    Summary: This article highlights the transformative role of medical non-woven tape in wound care, driven by innovations from Hangzhou Econ Nonwoven New Materials Co., Ltd. Engineered with ultra-soft viscose fibers and patented low-trauma adhesives, the tape offers enhanced breathability to prevent maceration, hypoallergenic properties to minimize allergies, and biodegradability for eco-friendly disposal. Outperforming traditional woven tapes, it accelerates healing in post-surgical, geriatric, pediatric, and sports medicine applications, meeting surging global demand for smart, patient-centered materials that reduce pain and complications.

    Key Highlights:

    • Superior breathability from viscose fibers prevents moisture buildup, reducing maceration risks and speeding healing in sensitive skin areas.
    • Low-trauma adhesive ensures secure bonding yet painless removal, ideal for fragile or hairy skin in pediatric oncology and sports injuries.
    • Hypoallergenic design lowers infection and irritation risks, making it suitable for chronic wound management in geriatric care.
    • Hydrolytic degradation technology allows 100% biodegradability, supporting sustainable practices without compromising performance.
    • Global market shift toward non-woven solutions emphasizes clinical efficiency, with clinicians adopting for faster recovery and fewer interventions.

    Read full article

    Keywords:
    medical non-woven tape,
    breathable wound dressings,
    hypoallergenic tape,
    low-trauma adhesive,
    wound care innovation

    Predicting Diabetic Neuropathy: ML Model for Early Detection in T2DM

    Predicting Diabetic Neuropathy: ML Model for Early Detection in T2DM

    Summary: This retrospective study analyzes data from 1,001 T2DM patients in Xinjiang, China, to build and validate machine learning models for diagnosing diabetic peripheral neuropathy (DPN), a key precursor to foot ulcers and amputations. Using SVM-RFE and LASSO, seven risk factors (age, diabetes duration, 2hPG, LDL-C, blood urea, eGFR, urinary uric acid) were identified. The Random Forest model excelled with an external validation AUC of 0.953, supporting precision screening in high-risk regions to mitigate wound complications through timely interventions.

    Key Highlights:

    • Random Forest model achieved top performance (training AUC 1.000, external AUC 0.953), outperforming GBM, GLM, and SVM for DPN prediction.
    • Key risks include age (≥50 years elevates odds), prolonged diabetes duration, and renal markers like reduced eGFR, linking to neuropathy progression.
    • External validation on 123 patients confirmed accuracy (86.3%), sensitivity (93.0%), and no overfitting via bootstrapping and calibration.
    • Model addresses Xinjiang’s high DPN prevalence, enabling early detection to prevent painless ulcers and non-traumatic amputations in T2DM.
    • Limitations: Single-center data; future needs include multicenter trials and integration of genetic/dietary factors for broader applicability.

    Read full article

    Keywords:
    diabetic peripheral neuropathy,
    DPN prediction,
    machine learning diabetes,
    T2DM complications,
    foot ulcer prevention

    Big Pharma and Big Food’s Grip on the American Heart Association

    The Hidden Hands: Big Pharma and Big Food’s Grip on the American Heart Association

    In a recent YouTube video that has sparked heated discussions among health enthusiasts and skeptics alike, emergency medicine physician Dr. Suneel Dhand pulls no punches. Titled “Big Pharma’s Influence on the American Heart Association,” the 15-minute rant dissects what he calls the “insane” new blood pressure guidelines from the AHA and its partner, the American College of Cardiology (ACC). Dhand, a vocal advocate for metabolic health, accuses the organizations of being puppets in a “clown world” of corporate medicine, where strict thresholds—labeling systolic readings as low as 124 mmHg as “elevated”—push millions toward unnecessary medications, risking side effects like falls and cognitive impairment in the elderly. His critique isn’t isolated; it’s a flare-up in a long-simmering debate about how industry giants—Big Pharma and Big Food—exert outsized influence over one of America’s most trusted health nonprofits.

    The American Heart Association, founded in 1924 as a modest group of 12 physicians, has ballooned into a $1 billion-plus behemoth, funding research, shaping public policy, and issuing guidelines that guide everything from doctor’s offices to grocery aisles. With heart disease killing nearly one in five Americans, the AHA’s voice carries immense weight. Yet, as Dhand points out, its evolution from a volunteer-driven entity to a corporate-funded powerhouse raises red flags. Historical ties to Procter & Gamble (P&G) in the 1940s—allegedly a $2 million donation (over $20 million today) that kickstarted vegetable oil endorsements—set the stage for today’s entanglements. Fast-forward to fiscal year 2023-2024, and the AHA’s disclosures reveal a web of relationships with pharmaceutical behemoths and food conglomerates that could subtly—or not so subtly—tilt the scales toward profit over public health.

    This article dives deep into these influences, drawing on AHA’s own financial reports, expert critiques, and the broader context of guideline development. We’ll explore how Big Pharma’s dollars fund research and endorsements that favor drugs, while Big Food’s forum membership shapes nutrition advice in ways that cozy up to processed products. The result? Guidelines that often sideline root causes like insulin resistance and ultra-processed diets, perpetuating a cycle of chronic illness.

    A Brief History: From Grassroots to Corporate Ally

    The AHA’s origins were pure: a response to skyrocketing heart disease rates in the early 20th century. But by the mid-1940s, as Dhand recounts, P&G—a maker of Crisco shortening and other hydrogenated fats—stepped in with a transformative gift. In exchange for branding vegetable oils as “heart-healthy,” the AHA received funding that propelled it from obscurity to national prominence. This wasn’t mere philanthropy; it aligned with P&G’s marketing push against animal fats, a narrative that endures in low-fat dogma despite mounting evidence of vegetable oils’ inflammatory risks.

    Decades later, the AHA’s revenue streams diversified, but corporate support remains a cornerstone. In FY 2023-2024, total revenue topped $1.1 billion, with corporate contributions—pharma, devices, and food—accounting for roughly 15-20%. The AHA insists this is dwarfed by individual donations (over 80%), and its conflict-of-interest (COI) policy mandates disclosures and recusal for guideline authors. Yet critics, including Dhand, argue that even “negligible” percentages translate to hundreds of millions, creating a quid pro quo where funders get a seat at the table—and a say in the menu.

    Big Pharma’s Billions: Funding Research, Shaping Guidelines

    Pharmaceutical companies aren’t shy about their AHA ties. The organization’s FY 2023-2024 Pharma Disclosure List reveals a who’s who of industry titans, from statin makers to device innovators. Here’s a snapshot of the 42 listed entities:

    • Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Sanofi: These pharma heavyweights dominate cardiovascular drug markets, funding AHA initiatives from $100,000 to multimillion-dollar grants for research, education, and events.
    • Device and Biotech Players: Abbott (again, for stents), Boston Scientific, Edwards Lifesciences, Medtronic, and Stryker pour resources into device trials and training programs.
    • Emerging Biotech: Alnylam, BridgeBio, Cytokinetics, Ipsen, Kiniksa, Lantheus, Lexicon, Milestone, Regeneron—niche players in gene therapies and rare heart conditions, often sponsoring targeted symposia.

    Collectively, these partners contributed an estimated $150-200 million in FY 2023-2024, per AHA breakdowns—funds earmarked for “scientific programs” but often tied to product promotion. The AHA’s IRS Form 990 underscores this, noting robust COI safeguards, yet a 2024 study in the Journal of the American Heart Association found that 40% of Japanese cardiology guideline authors had pharma ties—mirroring U.S. patterns.

    Guideline Goldmines: Statins, BP, and Beyond

    Pharma’s fingerprints are most evident in treatment recommendations. Take statins: The AHA/ACC’s 2018 cholesterol guidelines expanded their use to 30 million Americans, including low-risk groups—a boon for Pfizer (Lipitor) and others, whose patents may have lapsed but generics still rake in billions. Critics like Dhand argue this ignores lifestyle fixes, echoing a 2023 BMJ analysis showing guideline panels with industry funding are 3.5 times more likely to recommend sponsor drugs.

    Dhand’s video zeros in on the 2023 BP guidelines, co-authored by AHA/ACC, which lowered “normal” to under 120 mmHg—potentially medicating 100 million more adults. Funded by trials from AstraZeneca and Novartis (ACE inhibitors, ARBs), these shifts, per Dhand, exemplify “Big Pharma’s paradigm” of over-treatment. “Why reclassify normal as elevated?” he asks, linking it to insulin resistance from poor diets—unaddressed in favor of pills.

    Device influence is subtler but real. Medtronic and Boston Scientific sponsor AHA’s electrophysiology sessions, where guidelines endorse ICDs and pacemakers—devices generating $10 billion annually. A 2024 AHA policy paper admits evaluating “non-financial relationships” for COI, but enforcement relies on self-reporting.

    The Ripple Effect: Research and Public Messaging

    AHA-funded studies often align with funders. A 2023 Regeneron-backed trial on PCSK9 inhibitors (Repatha) showed cardiovascular benefits, influencing 2022 update endorsements. Public campaigns, like “Life’s Essential 8,” integrate pharma messaging—subtly promoting adherence to medicated lifestyles over metabolic resets.

    Dhand’s frustration peaks here: “Consensus means financed by Big Pharma.” He calls for debate, decrying ignored root causes like carbs and sugar, which fuel 90% of hypertension via insulin spikes.

    Big Food’s Forum: Certifying Convenience Over Caution

    If Pharma pushes pills, Big Food sweetens the deal with “heart-healthy” labels. The AHA’s Industry Nutrition Forum (INF), launched in 2021, convenes “multi-sector dialogue” on food systems. Its nine members read like a processed-food hall of fame:

    • Aramark, Cargill, General Mills, Kroger Health, PepsiCo: Giants in institutional catering, meat processing, cereals, groceries, and snacks.
    • CanolaInfo, McCormick Science Institute, National Dairy Council, United Soybean Board: Trade groups promoting canola oil, spices, dairy, and soy—echoing that 1940s P&G pivot.

    These partners fund INF initiatives, including the Heart-Check mark, which certifies over 800 products as low-sat-fat, low-cholesterol options. Cheerios? Check. Low-fat yogurt? Check. But critics blast it as a “pay-to-play” seal, where companies tweak formulations minimally for endorsement—boosting sales without addressing ultra-processed pitfalls.

    Nutrition Guidelines: Low-Fat Legacy Meets Processed Pals

    AHA’s 2021 Dietary Guidance prioritizes “whole foods” but hedges on saturated fats and sugars, aligning with INF sponsors. A 2025 advisory on ultra-processed foods (UPFs) warns of cardiometabolic risks—yet Heart-Check includes UPFs like flavored oats if they meet nutrient thresholds. PepsiCo’s INF role? It lobbies for “reformulated” snacks, while Cargill pushes soy/canola amid debates on seed oils’ omega-6 inflammation.

    Dhand ties this to metabolic neglect: Guidelines harp on salt (2% effective) but ignore carbs driving insulin resistance. A 2022 PMC review notes AHA recs misalign with UPF evidence, potentially influenced by forum funding.

    The 2024 “US Health and the Future of Food” report, co-authored with INF, calls for “nutrition security” but spotlights affordable processed options over whole-food access—convenient for Kroger and General Mills.

    The Toxic Tango: Pharma Meets Food in Heart Health

    Pharma and Food aren’t silos; they converge in AHA’s ecosystem. Statin guidelines pair with low-fat diets—endorsing canola (CanolaInfo) while prescribing Lipitor (Pfizer). This synergy sustains chronicity: Poor diets breed disease; drugs manage symptoms; repeat.

    A 2025 AAFP piece on pediatric obesity guidelines flags similar COIs, where AAP authors received pharma payments—paralleling AHA’s statin/BP panels. Dhand’s video encapsulates the fallout: Rising heart disease despite AHA’s $1B war chest, as metabolic health crumbles under carb-heavy, medicated norms.

    Public health toll? $400B+ annually in U.S. cardiovascular costs, with guidelines potentially overprescribing $20B in unnecessary BP meds alone.

    Calls for Accountability: Transparency or Overhaul?

    AHA’s COI policy is robust on paper—disclosures, recusal, federal compliance—but enforcement lags. The 2023-2024 Form 990 affirms board approval, yet no independent audits of guideline funding.

    Dhand demands debate: “Communicate with me… I could beat you with logic.” Broader voices, like Nina Teicholz’s “The Big Fat Surprise,” echo historical biases. Solutions? Mandate zero corporate funding for guidelines, crowdsource research, prioritize metabolic metrics.

    A Heart for the People: Reclaiming Independence

    The AHA does good—$3B in research since 1949, CPR training for millions. But as Dhand warns, “Your time is up” for the Pharma-Food paradigm. True heart health demands ditching donors for data: Guidelines rooted in unbiased trials, nutrition advice favoring whole foods over certified junk, and a return to Hippocratic basics—”first, do no harm” via lifestyle, not labels or labs.

    Until then, consumers beware: That Heart-Check stamp or BP script might serve shareholders more than your ticker. As Dhand urges, wake up, cut the carbs, and question the consensus. Your heart—and wallet—will thank you.

    University Health Opens Clinic Aimed at Preventing Diabetic Amputations



    University Health Opens Clinic Aimed at Preventing Diabetic Amputations

    Summary: University Health has launched a new Limb Salvage Clinic at the Texas Diabetes Institute in San Antonio to combat the rising tide of diabetes-related foot ulcers and amputations in Bexar County, where 15% of residents (up to 239,000 people) live with diabetes—higher than state and national averages. Led by interventional cardiologist Dr. Anand Prasad, the clinic offers comprehensive, one-stop services including podiatric wound monitoring, debridement, minimally invasive vascular procedures like angioplasty with dissolvable stents, and preventive care for peripheral artery disease (PAD) and neuropathy. Highlighting the urgency, the facility treated its first patient, 50-year-old Charlie Treviño, a diabetic construction worker with a recent foot ulcer post-heart surgery, aiming to restore blood flow and promote healing to avoid limb loss. By integrating podiatry, cardiology, and vascular surgery, the clinic addresses rapid wound progression—potentially infecting within days—and underserved needs in high-risk Hispanic and Black communities, targeting 20+ patients weekly for faster, multidisciplinary intervention.

    Key Highlights:

    • Bexar County diabetes prevalence: 15% (239,000 people), with some zip codes over 20%; lifetime foot ulcer risk for diabetics: 25-33%; U.S. annual diabetic amputations: >100,000.
    • Clinic location: Texas Diabetes Institute, South Zarzamora Street, San Antonio; services include wound debridement, offloading, vascular angioplasty, and collaborative podiatry-cardiology care.
    • First patient case: Charlie Treviño received immediate podiatric evaluation and planned stent procedure to improve leg/foot circulation, emphasizing early intervention for non-healing ulcers.
    • Expert insights: Dr. Michael Sobolevsky calls San Antonio the “diabetic foot capital of the world”; Dr. Ivana Akinyeye stresses single-visit efficiency as “time is of the essence” for ulcers.
    • Broader impact: Addresses PAD/neuropathy causing poor healing; aims to reduce lifelong disability in underserved areas, with plans for vascular surgery integration and expanded staffing.

    Read full article

    Keywords: limb salvage clinic, diabetic foot ulcers, amputation prevention, peripheral artery disease, multidisciplinary wound care

    Early Clinical Experience with a Topical Desiccating Agent for Wound Bed Preparation in Diabetic Foot Ulcers



    Early Clinical Experience with a Topical Desiccating Agent for Wound Bed Preparation in Diabetic Foot Ulcers

    Summary: This retrospective case series evaluates the clinical outcomes of a novel topical desiccating agent (TDA) used under a compassionate-use protocol for wound bed preparation in 67 patients with hard-to-heal (chronic) diabetic foot ulcers (DFUs) treated between 2020 and 2023. The TDA, applied topically, facilitated effective debridement and promoted granulation tissue formation, leading to granulation in 88.1% of cases (mean time: 44.3 days) and complete re-epithelialization in 85.1% of patients. No adverse events were reported, and the agent was well-tolerated in this high-risk population, suggesting its potential as a safe, non-invasive adjunct to standard care. Further prospective studies are recommended to confirm these promising results.

    Key Highlights:

    • Patient cohort: 67 adults with chronic DFUs; treated under institutional ethics-approved compassionate-use protocol from 2020-2023.
    • Granulation achievement: 88.1% of patients (mean time to granulation: 44.3 days), indicating rapid wound bed preparation.
    • Healing outcomes: 85.1% reached complete re-epithelialization, highlighting TDA’s efficacy in promoting full closure.
    • Safety profile: No adverse events reported; well-tolerated across all applications, suitable for high-risk diabetic populations.
    • Implications: TDA offers a novel, clinic-applicable chemical debridement option; supports further evaluation in controlled trials for DFU management.

    Read full article

    Keywords: topical desiccating agent, diabetic foot ulcers, wound bed preparation, chemical debridement, granulation tissue, Johannes P Snels, Bart J Q van Luijk, Arjan C Assendelft

    The Charcot Foot: A Missed Diagnosis Can Cost a Limb



    The Charcot Foot: A Missed Diagnosis Can Cost a Limb

    Summary: This article explores Charcot neuroarthropathy, a destructive condition primarily in diabetic patients first described in 1883, which can lead to severe deformities, ulcers, and amputations if misdiagnosed as cellulitis or osteomyelitis. Affecting 0.08-13% of diabetics, acute Charcot presents with painless swelling, erythema, and warmth, progressing to chronic “rocker bottom” deformities increasing plantar pressure and ulceration risk. Diagnosis relies on clinical suspicion, radiographs (often normal early), and MRI for bone marrow edema patterns distinguishing it from infection. Treatment emphasizes immobilization and early referral to prevent limb-threatening complications, underscoring the role of wound care providers in recognizing this mimic to preserve function and reduce amputation rates.

    Key Highlights:

    • Prevalence: 0.08% in general diabetics to 13% in high-risk clinics; often underestimated due to misdiagnosis as infection.
    • Acute symptoms: Edema, erythema, warmth (3+°C higher than contralateral foot), mild pain from neuropathy; chronic: Rocker bottom deformity, hyperkeratotic ulcers from pressure.
    • Diagnosis: MRI most accurate (periarticular edema in Charcot vs. intraosseous in osteomyelitis); three-phase bone scan 93% sensitive; elevation test differentiates from cellulitis (resolves in 10 min).
    • Treatment: Immobilization like fractures; avoid unnecessary I&D or antibiotics; early intervention prevents degeneration and ulceration cycle.
    • Expert quote: “Early diagnosis of Charcot foot and proper treatment are critical to preventing long-term consequences.”

    Read full article

    Keywords: Charcot foot, diabetic neuropathy, wound misdiagnosis, rocker bottom deformity, limb preservation

    Use of Subatmospheric Pressure Systems in Diabetic Foot Ulcers



    Use of Subatmospheric Pressure Systems in Diabetic Foot Ulcers

    Summary: This review explores the application of subatmospheric pressure systems, or negative pressure wound therapy (NPWT), in managing diabetic foot ulcers (DFUs), a major complication of diabetes mellitus affecting millions globally due to neuropathy, vascular disease, and infection risks. Drawing from PubMed, Elsevier, and Scielo databases (2011 onward), it presents case studies demonstrating NPWT’s efficacy in accelerating healing by enhancing tissue perfusion, reducing edema and bacterial load, and stimulating granulation. At pressures of -60 to -125 mmHg, NPWT achieved 50-100% wound closure in 15-35 weeks, often with adjunct debridement and grafts, offering a non-surgical, cost-effective option that improves patient satisfaction and reduces amputation risks.

    Key Highlights:

    • Case 1: 47-year-old woman with full-thickness DFU; NPWT at -125 mmHg reduced depth 50% by week 5, full epithelialization by week 15.
    • Case 2: 43-year-old woman with infected wound; NPWT at -60 to -100 mmHg enabled complete healing with skin graft.
    • Case 3: 34-year-old man with 3.8 cm² ulcer; NPWT at -125 mmHg with biweekly debridement achieved 91% area reduction by day 35.
    • Benefits: Shortens treatment duration, lowers microbial load, promotes granulation; safe with mild complications like maceration.
    • Implications: NPWT as adjunct/alternative to surgery for DFUs; further studies needed for first-line use in chronic wound care.

    Read full article

    Keywords: negative pressure wound therapy, diabetic foot ulcers, NPWT, granulation tissue, wound perfusion

    Prevention of Infection in Peripheral Arterial Reconstruction of the Lower Limb



    Prevention of Infection in Peripheral Arterial Reconstruction of the Lower Limb

    Summary: This Cochrane review synthesizes evidence from 40 RCTs and quasi-RCTs involving 7970 participants on pharmacological and non-pharmacological interventions to prevent infections after lower limb peripheral arterial reconstruction. Prophylactic antibiotics likely reduce surgical site infections (SSIs) and graft infections (low-certainty evidence), but no clear differences exist between short- vs. long-duration regimens or antibiotic types (very low-certainty). Closed incision negative pressure therapy (ciNPWT) may lower SSI and graft infection risks compared to standard closure (very low-certainty), while other methods like dressings or sutures show little benefit. The review highlights the need for standardized trials to guide wound care protocols in vascular surgery, where infections complicate healing and increase amputation risks.

    Key Highlights:

    • Antibiotics vs. none: Reduced SSIs (RR 0.20, 95% CI 0.11-0.34; NNT 9) and graft infections (RR 0.19, 95% CI 0.06-0.63; low-certainty).
    • Short vs. long antibiotics: No difference in SSIs (RR 0.75, 95% CI 0.40-1.40) or graft infections (very low-certainty).
    • ciNPWT vs. standard: Possible reduction in SSIs (RR 0.49, 95% CI 0.27-0.86) and graft infections (RR 0.55, 95% CI 0.19-1.59; very low-certainty).
    • No effects on mortality, re-intervention, or amputation across comparisons (very low- to low-certainty evidence).
    • Implications: Suggest antibiotics for prevention; ciNPWT promising for high-risk surgical wounds; more research needed for dressings and techniques.

    Read full article

    Keywords: peripheral arterial reconstruction, surgical site infection, prophylactic antibiotics, closed incision NPWT, vascular wound care

    Diabetic Foot Care: New Tech & Preventing Amputations


    Diabetic Foot Care: New Tech & Preventing Amputations

    Summary: With 1 in 5 diabetics facing foot ulcers and up to 20% leading to amputation (costing >$30,000/case), this article explores innovations like AI for early detection, bioengineered skin substitutes, hyperbaric oxygen therapy (HBOT), phage therapy, and telehealth to improve outcomes and accessibility. Emphasizing prevention through daily inspections, proper footwear, and glycemic control, it highlights tools like Podimetrics’ remote monitoring and community education to enhance adherence, ultimately reducing mobility loss and long-term healthcare burdens.

    Key Highlights:

    • Stats: 15% lifetime DFU risk; 25-33% amputation rate; $9B+ annual U.S. cost.
    • AI Detection: Analyzes gait/genetics for risk prediction; Podimetrics uses images/patient data for proactive care.
    • Wound Tech: Stem cells/platelet-rich plasma accelerate healing; bioengineered scaffolds support growth; HBOT boosts perfusion; phage targets resistant bacteria.
    • Telehealth: Remote consults cut amputations (e.g., VA programs); challenges: equity, privacy.
    • Prevention: Foot checks, smoking cessation, BMI control; peer support for adherence.

    Read full article

    Keywords: diabetic foot care, amputation prevention, AI prediction, phage therapy, telehealth wounds

    Diabetes Breakthrough: Sound Waves Offer New Hope for Foot Ulcers



    Diabetes Breakthrough: Sound Waves Offer New Hope for Foot Ulcers

    Summary:** Non-invasive sound wave therapy accelerates diabetic foot ulcer (DFU) healing by stimulating tissue regeneration and blood flow, considered an adjunct to standard wound care like debridement. While details on trial size/methods are limited, it reduces infection risks and may lessen surgery needs, improving quality of life and amputation prevention in diabetics. The approach builds on sound wave applications in medicine, positioning it as a safe, non-invasive option for chronic ulcers.

    Key Highlights:

    • Mechanism: Sound waves enhance circulation and cellular repair in stalled DFUs.
    • Role: Adjunct to debridement/dressings; considered free of side effects.
    • Outcomes: Faster healing; potential to cut amputation risks in diabetics.
    • Expert View: Considered adjunct, not replacement; complements traditional care.
    • Implications: Improves mobility/QoL; broader medical applications for sound waves.

    Read full article

    Keywords: sound wave therapy, diabetic foot ulcers, non invasive, amputation prevention, adjunct therapy

    Wound Care Transformation in Wales – Digital Empowerment and the Skin Tone Tool



    Wound Care Transformation in Wales – Digital Empowerment and the Skin Tone Tool

    Summary:** Wales is transforming wound care through digital tools and the Skin Tone Tool, addressing disparities in pressure ulcer and DFU assessment. The tool—integrated into e-health records—standardizes skin color-inclusive evaluation, reducing misdiagnosis in darker tones and improving prevention via real-time risk alerts. Early adopters report 20% better detection rates and 15% fewer incidents, aligning with NHS Wales’ digital strategy for equitable care.

    Key Highlights:

    • Skin Tone Tool: 6-tone scale in digital charts for accurate pressure ulcer/DFU assessment.
    • Digital Integration: Alerts for risk; training for 90% staff; 20% improved detection.
    • Impact: Reduces disparities in darker skin; 15% fewer ulcers via early intervention.
    • Policy: NHS Wales mandates for 2025; supports pressure ulcer prevention protocols.
    • Future: National rollout; links to telemedicine for remote wound monitoring.

    Read full article

    Keywords: skin tone tool, digital wound care, pressure ulcer, inclusive assessment, Wales NHS

    A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency



    A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis

    Summary: This narrative review examines the multifactorial pathogenesis of diabetic foot ulcers (DFUs), affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, peripheral neuropathy, hyperglycemia-induced immune defects, and microbial dysbiosis with biofilms. It discusses diagnostic tools (ABI, TCOM, biopsy) and evidence-based therapies from offloading/compression (TCCs 80% efficacy) to advanced interventions like HBOT (50% closure), growth factors, stem cells, and bioengineered skins (50-70% rates). Microbial shifts (Staphylococcus dominance) exacerbate inflammation; the review advocates personalized, multidisciplinary strategies with AI diagnostics and nanotech antimicrobials to mitigate global burden and enhance limb salvage.

    Key Highlights:

    • Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection in 60% of cases.
    • Immune Dysbiosis: Hyperglycemia promotes M1 macrophages; biofilms resist antibiotics in 50% of infected DFUs.
    • Therapies: Offloading (TCCs 80%); HBOT (50% closure); bioengineered skins (70% in RCTs).
    • Future: AI for risk prediction; microbiome modulation with phages; nanotech for targeted delivery.
    • Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading cuts risk 50%.

    Read full article

    Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins, Abdullah Al-Rubaish, Mohammed Al-Rubaish, Ahmad Al-Rubaish

    PGIMER Marks World Diabetes Day with Special Patient Awareness Programme



    PGIMER Marks World Diabetes Day with Special Patient Awareness Programme

    Summary: On World Diabetes Day 2025, PGIMER Chandigarh hosted an awareness program for 100+ patients, focusing on diabetic foot ulcers (DFUs) as a major complication. Experts like Dr. Prabhat Rijal discussed hypoglycemia risks and DFU prevention through daily foot checks, proper footwear, and HbA1c <7%. The event highlighted multidisciplinary care (endocrinologists, surgeons, podiatrists) to reduce 15-25% DFU incidence and 20% amputation rate, with calls for community screening to address India's 77M diabetics.

    Key Highlights:

    • DFU Risks: Neuropathy/circulation issues cause 15-25% incidence; 50% recur without care.
    • Prevention: Daily inspections, offloading, glycemic control; early referral cuts amputations 50%.
    • Event: 100+ attendees; sessions on hypoglycemia, DFU management; free screenings.
    • Expert: Dr. Rijal: “DFUs from poor sensation/healing; education saves limbs.”
    • Impact: Targets India’s 77M diabetics; promotes MDT for 80% 6-week healing.

    Read full article

    Keywords: World Diabetes Day, diabetic foot ulcers, PGIMER, amputation prevention, patient education

    Advances in Skin & Wound Care – November/December 2025 Issue



    Advances in Skin & Wound Care – November/December 2025 Issue

    Summary: Volume 38, Issue 10 features pediatric support surfaces (extrapolating adult data for low-risk overlays vs alternating pressure), a QI project reducing hospital-acquired PIs 35% via bundles (Braden q-shift, turning q2h), and policy on surgical wounds (dehiscence risks, NPWT). Additional: Awareness on global burden ($148B U.S. spend), original research on EV scar reduction, and clinical consults on MDRPI.

    Key Highlights:

    • Pediatric: Overlays for low-risk kids; gaps in neonatal evidence.
    • QI: 35% PI drop; 60% compliance ↑ via PDSA cycles.
    • Policy: CMS doubles skin substitute apps; lymphedema coverage saves $1.3B.
    • Research: EVs ↓ scar thickness 25%; biofilms via SEM-Weka.
    • Editors: Ayello EA, Sibbald RG; 500+ pages.

    Browse issue

    Keywords: ASWC issue, pediatric surfaces, PI QI, surgical policy, EV scars, EA Ayello, RG Sibbald

    Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know



    Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know

    Summary: Medical device-related pressure injury (MDRPI) results from sustained pressure/shear at skin-device interfaces, often device-shaped over bony prominences. Incidence varies (critical care highest); risks include immobility, poor fit, and inconsistent checks. Prevention bundles: structured assessments, prophylactic dressings (silicone foam), microclimate management, offloading, and interprofessional collaboration (respiratory/nursing/PT). Early detection via infrared/ultrasound reduces complications; protocols essential across settings.

    Key Highlights:

    • Risks: Patient (immobility, edema), device (rigid, tight), care (delayed escalation).
    • Bundles: Frequent checks under devices, silicone dressings, moisture wicking, repositioning.
    • Tech: Infrared/ultrasound for subclinical detection; AI predictions emerging.
    • Roles: Respiratory for fit, nursing for monitoring, PT for positioning.
    • Outcomes: Bundles cut incidence 30-50%; education with photos/audits key.

    Read full guide

    Keywords: MDRPI, pressure injury, prevention bundles, device interfaces, interprofessional, Matthew Davis

    Diabetes Care in Nigeria: Closing the Gaps, Charting a Way Forward


    Diabetes Care in Nigeria: Closing the Gaps, Charting a Way Forward

    Summary: Aljazirahnews long-form piece highlights Nigeria’s exploding diabetes burden (estimated 11–15 million cases) and the catastrophic downstream effect on diabetic foot ulcers. A patient vignette describes a woman who nearly lost her leg after a minor injury escalated while walking barefoot at home — a common cultural practice. Late presentation with Wagner 3–4 ulcers is the norm, leading to high amputation rates (up to 50% in some centers).

    Key Points:

    • Only ~30% of diabetics diagnosed; most present only when complications arise
    • Barefoot walking at home cited as major preventable risk factor
    • Few multidisciplinary foot clinics; most care still surgeon-led with delayed offloading
    • Call for national screening, subsidised footwear, and podiatry training

    Read full article →

    Keywords: Nigeria, diabetic foot ulcers, barefoot risk, late presentation, amputation crisis

    $45 Million Settlement Medicare Fraud in Wound Care Billing

    $45 Million Settlement: Vohra Wound Physicians and Its Founder Agree to Pay for Alleged Medicare Fraud in Wound Care Billing

    November 25, 2025 – The U.S. Department of Justice announced today that Vohra Wound Physicians Management LLC, the nation’s largest multispecialty wound-care physician group serving skilled-nursing facilities, and its founder and owner, Dr. Ameet Vohra, have agreed to pay $45 million to resolve allegations of systematic Medicare fraud spanning more than a decade (2012–2024).


    The settlement is one of the largest False Claims Act recoveries ever involving wound-care services and the first major public enforcement action targeting aggressive upcoding and unnecessary surgical debridement in the post-acute and long-term care space.

    Core Allegations (as outlined in the DOJ settlement agreement)

    1. Medically Unnecessary Excisional Debridement
      Physicians were allegedly pressured to perform — or document as performed — sharp excisional debridement (CPT 11042–11047 series) on wounds that were clean, granulating, or required only conservative management.
    2. Deliberate Upcoding of Routine Wound Care
      Routine cleansing, dressing changes, and non-excisional conservative management were allegedly billed as “surgical debridement” or higher-level evaluation-and-management codes.
    3. Non-Reimbursable E/M Billing
      Vohra physicians allegedly billed separate E/M services on the same day as facility-mandated wound rounds, which Medicare does not reimburse when performed in SNFs.
    4. EHR and Billing-System Manipulation – the most explosive claim
      The company’s proprietary EHR and billing software was allegedly programmed to automatically default to the most lucrative debridement and E/M codes, override physician selections, and prevent lower-level codes from being submitted — even when the treating clinician deliberately chose them.
    5. Training and Incentive Structure
      Internal training materials and compensation plans allegedly rewarded physicians whose “productivity” (measured almost exclusively in RVUs from debridement codes) exceeded certain thresholds, creating what the government called a “culture of overutilization.”

    Settlement Breakdown and Corporate Integrity Agreement

    • Civil settlement: $45,000,000
    • Five-year Corporate Integrity Agreement (CIA) with mandatory independent audits, annual risk assessments, EHR transparency requirements, and physician-level billing monitoring
    • No admission of liability (standard in most FCA settlements)
    • Ability-to-pay analysis was not cited, indicating the company had sufficient liquidity to pay the full amount

    Why This Case Matters to the Entire Wound-Care Ecosystem

    1. Signal to the SNF Wound-Care Industry
      Vohra is the dominant player in the SNF wound physician space (approximately 3,000 facilities nationwide). This settlement puts every similar group — and the SNFs that contract with them — on notice.
    2. EHR Manipulation as an Enforcement Priority
      The DOJ and OIG explicitly called out the deliberate programming of EHRs to drive fraudulent billing — a tactic that is difficult to detect in routine audits but devastating when uncovered.
    3. Whistleblower Involvement
      Multiple former Vohra physicians and billing staff filed qui tam suits (sealed until today). They will share an undisclosed relator’s award, likely in the $7–9 million range.
    4. Ripple Effects on Medicare Advantage and Commercial Plans
      Because many Vohra contracts are capitated or bundled, private payers are already launching their own audits and clawbacks based on the same patterns identified by Medicare.
    5. Clinical Implications
      Unnecessary sharp debridement carries real patient risk: pain, bleeding, delayed healing, and infection. Several whistleblowers alleged that residents with stable, granulating wounds were routinely subjected to aggressive procedures solely to generate revenue.

    Industry Reaction (early statements as of Nov 25, 2025)

    • Alliance for Wound Care Stakeholders: “We support appropriate enforcement but are concerned that legitimate, evidence-based debridement will now be second-guessed.”
    • American Professional Wound Care Association (APWCA): Issued a call for clearer CMS guidance on excisional vs selective debridement documentation.
    • Major SNF chains (Genesis, Ensign, ProMedica): Declined comment or stated they are “reviewing contracts and internal audits.”

    What Happens Next

    • Expect a wave of OIG and Medicare contractor (MAC/UPIC) audits targeting debridement claims in SNFs nationwide.
    • EHR vendors serving the wound space are likely to face subpoenas regarding default settings and hard-coded billing rules.
    • Private whistleblower suits against other large wound-physician groups have already been filed under seal.

    This settlement marks a turning point in how Medicare views aggressive wound-care billing in the nursing-home setting. For clinicians, it is a stark reminder that documentation, medical necessity, and patient-centered decision-making must always supersede financial or productivity metrics — no matter how cleverly the software is designed to hide it.


    Sources
    U.S. Department of Justice – Office of Public Affairs (Nov 25, 2025)
    Settlement Agreement and Corporate Integrity Agreement (publicly available on OIG website)
    Multiple sealed qui tam complaints unsealed today in the Eastern District of Texas and Southern District of Florida

    Stay tuned — this story is far from over.

    Exploration of an Intelligent ICU Pressure Ulcer Skin Assessment System Based on a …



    Exploration of an Intelligent ICU Pressure Ulcer Skin Assessment System Based on a Dynamic Reward Adaptive Framework

    Summary: The system integrates a dual-path intelligent training framework with a dynamic reward mechanism, using an adaptive detector to classify limited samples into true and fake categories. A training auxiliary module generates synthetic data to augment the dataset, addressing data scarcity. Challenges include data scarcity, low-quality images, and dynamic risk changes. Results show 89.7% accuracy on CP-LFW dataset, outperforming SenseTime (76.2%) and MIT EmoPainNet (82.1%). Enables accurate analysis of limited skin lesion images, supports real-time risk prediction, and facilitates personalized nursing decisions, improving care efficiency and outcomes in ICU settings.

    Key Highlights:

    • Framework: Dual-path training, dynamic rewards, synthetic data gen.
    • Challenges: Scarce high-quality images, low-res, dynamic risks.
    • Results: 89.7% accuracy (CP-LFW); beats SenseTime (76.2%), EmoPainNet (82.1%).
    • Implications: Real-time ICU assessment, personalized care.
    • Authors: Han J, Lei Y, Qiu Q.

    Read full paper

    Keywords: pressure ulcer, ICU assessment, dynamic reward, data scarcity, synthetic data, intelligent assessment

    Long-Term Outcomes of Surgical Mesh in Abdominal Wall Reconstruction



    Long-Term Outcomes of Surgical Mesh in Abdominal Wall Reconstruction: A 5-Year Prospective Study

    Summary: Prospective 5-year follow-up (n=300 abdominal hernia repairs) evaluated synthetic mesh complications, finding 15% wound-related events (infection 8%, seroma 4%, recurrence 3%). Infection risk highest in contaminated fields (OR 4.5); prophylactic antimicrobials reduced rates 40%. Mesh type (absorbable vs permanent) showed no difference in long-term hernia recurrence (12% both). Recommends routine surveillance for early intervention in high-risk patients.

    Key Highlights:

    • Complications: 15% at 5 years; infection OR 4.5 in contaminated cases.
    • Antimicrobials: Reduced infections 40%; no impact on recurrence.
    • Mesh Types: Absorbable vs permanent: similar 12% recurrence.
    • Method: Prospective; Kaplan-Meier for time-to-event.
    • Authors: Garcia M, Patel R, Thompson L et al.

    Read prospective study

    Keywords: surgical mesh, abdominal wounds, long term outcomes, infection, recurrence, M Garcia, R Patel, L Thompson

    The “Comfort Paradox”: Why Feeling Good Might Be Bad for the Diabetic Foot



    The “Comfort Paradox”: Why Feeling Good Might Be Bad for the Diabetic Foot

    Summary: This blog post discusses the “Comfort Paradox” in diabetic neuropathy: patients select shoes based on comfort/fit, but loss of protective sensation means they cannot detect harmful friction/pressure. Up to 82% wear improper footwear (33-43% too short, 46% too narrow), increasing DFU risk. Cites Carral-Sota et al. review emphasizing therapeutic shoes reduce ulcers/amputations. Recommends “Goldilocks” fit (1-2 cm toe clearance), rigid/rocker soles for offloading over soft cushioning; avoid sandals. Structured shoes > comfort priority for prevention.

    Key Highlights:

    • Paradox: Comfort perception unreliable without sensation.
    • Stats: 33-82% improper fit; ↑ DFU risk.
    • Recommendations: Rigid/rocker soles, extra depth, professional fitting.
    • Cited: Carral-Sota review (J Clin Med 2025).
    • Contributors: ALPSlimb, Keck School USC; #ActAgainstAmputation.

    Read full post

    Keywords: comfort paradox, neuropathy, diabetic footwear, offloading, DFU prevention

    Patient, Disability and Clinician Groups Condemn CMS “Dangerous Experiment” With …



    Patient, Disability and Clinician Groups Condemn CMS “Dangerous Experiment” With Ostomy, Urological, and Tracheostomy Supplies

    Summary: WOCN and allied patient/disability/clinician groups issued a joint statement condemning CMS’s November 28, 2025, final DMEPOS rule fast-tracking ostomy, tracheostomy, and urological supplies into Medicare Competitive Bidding Program as early as 2026. Groups call it a “dangerous experiment” ignoring warnings: supplies are life-sustaining prosthetics needing individual tailoring, not commodities; bidding slashes choice to mail-order contractors, overriding clinicians; risks leaks, infections, hospitalizations; Congress protected these items—CMS circumvents administratively. Urge immediate halt, collaboration for targeted fraud solutions without harming access.

    Key Highlights:

    • Rule: Adds supplies to bidding; ignores stakeholder warnings.
    • Risks: Leaks/infections/hospitalizations; loss of choice/clinical override.
    • Criticism: Undermines CMS principles; shifts costs to ERs/clinics.
    • Call: Halt implementation; work with patients/clinicians/Congress.
    • Signatories: WOCN + patient/disability groups.

    Read full statement

    Keywords: CMS supplies, competitive bidding, ostomy, urological, WOCN

    Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know



    Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know

    Summary: Comprehensive guide to medical device-related pressure injuries (MDRPI): device-shaped ulcers from sustained pressure/shear (masks, tubes, collars). Risks: patient (immobility/edema), device (rigid/tight), care (delayed checks). Prevention bundles: structured assessments, prophylactic silicone foams, microclimate control, repositioning, interprofessional input (RT/nursing/PT). Emerging: infrared/ultrasound for subclinical detection. Incidence highest ICU; bundles ↓ 30-50%.

    Key Highlights:

    • Risks: Patient/device/care factors; ICU highest.
    • Bundles: Inspections under devices, foams, offloading.
    • Roles: RT fit, nursing monitor, PT position.
    • Tech: Infrared/ultrasound early detection.
    • Outcomes: Bundles ↓ incidence 30-50%; education key.

    Read full guide

    Keywords: MDRPI, pressure injury, prevention bundles, device interfaces, interprofessional

    NPIAP Webinar | Pressure Injury Prevention Update



    January 21st Webinar: Open for Registration

    Summary: NPIAP webinar January 21, 2026: “Pressure Injury Prevention: Current Guidelines and Best Practices.” Covers updated staging, risk assessment tools, support surfaces, nutrition, and multidisciplinary prevention bundles. Free registration; 1 CE credit available.

    Key Highlights:

    • Date: Jan 21, 2026; virtual.
    • Topics: Staging, risk tools, bundles, nutrition.
    • CE: 1 credit.
    • Registration: Open to all.

    Register

    Keywords: NPIAP webinar, pressure injury, prevention, guidelines

    The Role of Artificial Intelligence in Wound Care



    The Role of Artificial Intelligence in Wound Care: Applications, Evidence and Future Directions

    Summary: Comprehensive review of AI in wound care: imaging analysis (92% accuracy bacterial detection), risk prediction (75-93% PI/DFU recurrence), smart dressings (sensor-integrated), telehealth monitoring. Evidence: high concordance with experts, faster assessments, reduced errors. Challenges: data bias, validation; future: personalized algorithms, integrated systems, ethical frameworks.

    Key Highlights:

    • Applications: Imaging, prediction, dressings, telehealth.
    • Evidence: 92% bacterial accuracy; 75-93% risk prediction.
    • Benefits: Faster, objective, remote care.
    • Future: Personalized, bias-mitigated, regulatory standards.
    • Authors: Not specified in summary.

    Read review

    Keywords: AI wound care, imaging, prediction, smart dressings, telehealth

    Every 20 Seconds A Limb Is Lost: Indian AI Targets 80% Preventable Diabetes Amputations



    Every 20 Seconds A Limb Is Lost: Indian AI Targets 80% Preventable Diabetes Amputations

    Summary: January 10, 2026 article on massive diabetes amputation burden (every 20 seconds globally; >100K major lower-limb cases yearly in India), with ~80% preventable via early screening—yet only 3.5% get full foot exams. Spotlights StrideAid’s affordable AI-powered D-PoC system for rural/Tier-2 detection (thermal imaging, pressure mapping, neuropathy/ABI checks), classifying risk and guiding interventions. Pilots show 35-40% amputation reduction; complements advanced treatments like synthetic matrices for ulcers that form.

    Key Highlights:

    • Stats: 80% preventable; high mortality (70% within 5 years post-amputation); ₹1.5L DFU cost.
    • Tool: D-PoC AI (20-min screening, risk profiling, multilingual StrideGPT).
    • Outcomes: 35-40% amputation drop in targeted areas; >8,500 screenings.
    • Implications: Early prevention focus to reduce ulcers/amputations globally.

    Read article

    Keywords: diabetes amputations, preventable amputations, StrideAid, DFU, AI screening